Third Report on Human Biomonitoring of Environmental Chemicals in Canada

(PDF Version - 5,190 K)

Erratum

Introduction - New Chemical Count Error

The "Introduction" stated that 19 new environmental chemicals were measured in cycle 3. The number has been corrected to 15.

Selection of Environmental Chemicals - Table Errors

Under "Selection of Environmental Chemicals", in the table titled "Chemicals measured in individual respondents in the Canadian Health Measures Survey cycle 3 (includes chemicals introduced for cycle 3 and carried forward from cycles 1 and 2)", the entries for Inorganic mercury in cycle 1, t,t-MA (trans,trans-Muconic acid) in cycle 2, and S-PMA (S-Phenylmercapturic acid) in cycle 2 erroneously stated "No" for their inclusion in these cycles. The table has been corrected to "Yes" for these entries. The entry for Arsenocholine in cycle 2 erroneously stated "Yes" for its inclusion in this cycle and has been corrected to "No". The entry for Arsenobetaine has been corrected to Arsenobetaine and arsenocholine.

Cotinine - Symbol Error

In the "Cotinine" summary, the text originally included an equal sign in the phrase "with detectable cotinine concentrations (=1.1 µg/L)". This has been corrected to a greater than or equal to sign as follows "with detectable cotinine concentrations (=1.1 µg/L)".

Polycyclic Aromatic Hydrocarbon Metabolites: Overview - CASRN Error

In the "Overview" summary for Polycyclic Aromatic Hydrocarbon Metabolites, the table titled "Hydroxylated PAH metabolites measured in the Canadian Health Measures Survey cycle 3 and their parent PAH compounds" listed the CASRN for 3-hydroxyfluoranthene as 206-44-0. The CASRN was corrected to 17798-09-3.

Styrene, Xylenes - Statement Removal

In the "Styrene" and "Xylenes" summaries, the text originally included the statement "However, in 1995, the Federal-Provincial Advisory Committee on Environmental and Occupational Health published a guidance report on residential indoor air quality that provides a general guideline for levels of VOCs in outdoor and indoor air (Health Canada, 1995)." The document "Indoor Air Quality in Office Buildings: A Technical Guide" has been removed from the Health Canada Indoor Air website.  Health Canada considers that this publication requires updating but that this task does not fall within the current mandate of the Indoor Air program. The guide was originally published when Health Canada was responsible for responding to requests for air quality investigations in federal buildings. This activity is now carried out by Public Works and Government Services Canada. This statement has now been removed from these summaries.

Trihalomethanes - Reference Error

In the "Trihalomethanes" summary, the reference to Health Canada's "Guidelines for Canadian drinking water quality: Guideline technical document - Trihalomethanes" cited the year 2009 with an in text citation of "Health Canada, 2009g". The reference has been corrected with the year 2006 and the in text citation is now "Health Canada, 2006c".

Appendix A - Lab Group Removal

Under "Appendix A", the ALS Laboratory Group was included in the list of analytical laboratories that performed analyses of environmental chemicals and creatinine. However ALS Laboratory Group analyses were not included in this report. The reference to ALS Laboratory Group has been removed from this report.

Table of Contents

• Introduction
• Objectives
• Survey Design
  • Target Population
  • Sample Size and Allocation
  • Sampling Strategy
    • Sampling of Collection Sites
    • Dwelling and Participant Sampling
  • Selection of Environmental Chemicals
  • Ethical Considerations
• Fieldwork
• Laboratory Analyses
  • Acrylamide
  • Environmental Phenols
  • Metals and Trace Elements
    • Arsenic
    • Cadmium, Lead, and Total Mercury
    • Fluoride
    • Inorganic Mercury
    • Methylmercury
  • Nicotine Metabolite
  • Polycyclic Aromatic Hydrocarbon Metabolites
  • Volatile Organic Compounds
    • Benzene Metabolites
  • Creatinine
• Statistical Data Analyses
• Considerations for Interpreting the Biomonitoring Data
• Summary and Results for Acrylamide
  • Acrylamide
• Summaries and Results for Environmental Phenols
  • Bisphenol A
  • Triclosan
• Summaries and Results for Metals and Trace Elements
  • Arsenic
  • Cadmium
  • Fluoride
  • Lead
  • Mercury
• Summary and Results for Nicotine Metabolite
  • Cotinine
• Summaries and Results for Polycyclic Aromatic Hydrocarbon Metabolites
  • Overview
  • Benzo[a]pyrene
  • Chrysene
  • Fluoranthene
  • Fluorene
  • Naphthalene
  • Phenanthrene
  • Pyrene
• Summaries and Results for Volatile Organic Compounds
  • Benzene and Benzene Metabolites
  • Ethylbenzene
  • Styrene
  • Tetrachloroethylene (Perchloroethylene)
  • Toluene
  • Trichloroethylene
  • Trihalomethanes
  • Xylenes
• References
• Appendix A: Limits of Detection
• Appendix B: Conversion Factors
• Appendix C: Creatinine

Introduction

These data tables present national data on concentrations of environmental chemicals in Canadians. These data were collected as part of the Canadian Health Measures Survey (CHMS), an ongoing national direct health measures survey. Statistics Canada, in partnership with Health Canada and the Public Health Agency of Canada, launched the CHMS in 2007 to collect health and wellness data and biological specimens on a nationally representative sample of Canadians. Biological specimens were analyzed for indicators of health status, chronic and infectious diseases, nutritional status, and environmental chemicals.

The CHMS biomonitoring component measures many environmental chemicals and/or their metabolites in blood and urine of survey participants. An environmental chemical can be defined as a chemical substance, either human-made or natural, that is present in the environment and to which humans may be exposed through media such as air, water, food, soil, dust, or consumer products.

The first Report on Human Biomonitoring of Environmental Chemicals in Canada was published in August 2010 and included baseline data for 92 environmental chemicals measured in cycle 1 (Health Canada, 2010a). Data for cycle 1 of the CHMS were collected between March 2007 and February 2009 from approximately 5,600 Canadians aged 6 to 79 years at 15 sites across Canada. The Second Report on Human Biomonitoring of Environmental Chemicals in Canada was published in April 2013 (Health Canada, 2013a). Data for cycle 2 were collected between August 2009 and November 2011 from approximately 6,400 Canadians aged 3 to 79 years at 18 sites across Canada. Cycle 2 included 91 environmental chemicals, 42 of which were also measured in cycle 1.

The data for cycle 3 were collected between January 2012 and December 2013 from approximately 5,800 Canadians aged 3 to 79 years at 16 sites across Canada. Cycle 3 included 48 environmental chemicals measured in individual samples, 33 of which have been measured in previous cycles.

A summary of the environmental chemicals measured in cycle 1, cycle 2, and cycle 3 of the CHMS is presented in the table below.

Summary of chemicals measured in cycle 1 (2007-2009), cycle 2 (2009-2011), and cycle 3 (2012-2013) of the Canadian Health Measures Survey

Chemicals	Cycle 1	Cycle 2	Cycle 3
Organochlorines	Yes	No	No
Polybrominated flame retardants	Yes	No	No
Polychlorinated biphenyls	Yes	No	No
Chlorophenols	Yes	Yes	No
Perfluoroalkyl substances	Yes	Yes	No
Phthalate metabolites	Yes	Yes	No
Pesticides	Yes	Yes	No
Environmental phenols	Yes	Yes	Yes
Metals and trace elements	Yes	Yes	Yes
Nicotine metabolite	Yes	Yes	Yes
Polycyclic aromatic hydrocarbons	No	Yes	Yes
Volatile organic compounds: Benzene metabolites	No	Yes	Yes
Volatile organic compounds	No	No	Yes
Acrylamide	No	No	Yes
Trihalomethanes	No	No	Yes

Collection for cycle 4 of the CHMS began in January 2014 and will be completed in late 2015. Planning for future cycles is under way.

The general CHMS survey design and implementation are described on the Health Canada website, with emphasis on the biomonitoring component. The website also contains descriptive summaries for each chemical, outlining the chemical's identity, common uses, occurrence in the environment, potential sources of exposure in the human population, toxicokinetics in the body, health effects, regulatory status, and existing Canadian biomonitoring data.

Data tables specific to each chemical are provided below the relevant text; the tables are broken down by age group and sex, and contain descriptive statistics on the distribution of blood and/or urine concentrations in the sample population. For the 15 new environmental chemicals measured in cycle 3, tables present baseline data for the Canadian population. For chemicals that were also measured in previous cycles, data from all cycles are presented together in tables to allow for ease of comparison. Data for chemicals that were only measured in cycle 1 and/or cycle 2 can be found in the first Report on Human Biomonitoring of Environmental Chemicals in Canada (Health Canada, 2010a) or the Second Report on Human Biomonitoring of Environmental Chemicals in Canada (Health Canada, 2013a).

Objectives

The primary purpose of the biomonitoring component of the Canadian Health Measures Survey (CHMS) is to provide human biomonitoring data to scientists and health and environment officials to aid in assessing exposure to environmental chemicals and in developing policies to reduce exposure to toxic chemicals for the protection of the health of Canadians.

Some specific uses of the CHMS biomonitoring data include the following:

• to establish baseline concentrations of chemicals in Canadians that could allow for comparisons with subpopulations in Canada and with other countries
• to establish baseline concentrations of chemicals to track trends in Canadians over time
• to provide information for setting priorities and taking action to protect the health of Canadians and to protect Canadians from exposure to environmental chemicals
• to assess the effectiveness of health and environmental risk management actions intended to reduce exposures and health risks from specific chemicals
• to support future research on the potential links between exposure to certain chemicals and specific health effects
• to contribute to international monitoring programs, such as the Stockholm Convention on Persistent Organic Pollutants

Survey Design

The Canadian Health Measures Survey (CHMS) was designed as a cross-sectional survey to address important data gaps and limitations in existing health information in Canada. Its principal objective is to collect national-level baseline data on important indicators of Canadians' health status, including those pertaining to exposures to environmental chemicals. This information is important in understanding exposure to risk factors, detecting emerging trends in risk factors and exposures, and advancing health surveillance and research in Canada. Detailed descriptions of the CHMS rationale, survey design, sampling strategy, and mobile examination centre (MEC) operations and logistics for cycle 3 have been published (Labrecque and Quigley, 2014; Statistics Canada, 2015).

Target Population

Cycle 3 of the CHMS targets the population aged 3 to 79 years living at home and residing in the 10 provinces. The following groups are excluded from the survey's coverage: persons living in the three territories; persons living on reserves and other Aboriginal settlements in the provinces; full-time members of the Canadian Forces; the institutionalized population, and residents of certain remote regions. Altogether, these exclusions represent approximately 4% of the target population.

Although the CHMS is not able to provide representative data for the entire Canadian population, there are a number of surveys and research projects carried out in partnership with Health Canada that directly target some of these population gaps.

The First Nations Biomonitoring Initiative (FNBI) is a survey carried out by the Assembly of First Nations and Health Canada that seeks to establish baseline biomonitoring data for First Nations people living on-reserve south of the 60° parallel (AFN, 2013). Between 2009 and 2011, the FNBI measured the levels of 97 environmental chemicals in blood and urine samples collected from 503 participants living in 13 First Nation communities across Canada. The  complete report has been published by the Assembly of First Nations.

In addition, numerous biomonitoring studies have been undertaken in Canada's North through the Northern Contaminants Program (NCP). The NCP, which is managed by federal government departments, provincial and territorial agencies, and Aboriginal organizations, was established in 1991 to respond to concerns about human exposure to contaminants in traditional diets of Northern Aboriginal peoples. The NCP provides funding for numerous individual studies undertaken in various regions of the North, including the Northwest Territories, Nunavut, and Nunavik (Quebec's North). More detailed information and results from these studies have been summarized in the Canadian Arctic Contaminants Assessment Reports (CACAR) and numerous scientific articles.

Sample Size and Allocation

To meet the objective of producing reliable estimates at the national level by age group and sex, cycle 3 of the CHMS required a minimum sample of at least 5,700 participants. The participants were distributed among six age groups (3-5, 6-11, 12-19, 20-39, 40-59, and 60-79 years) and sex (except for 3-5 years), for a total of 11 groups. For the 3- to 5-year age group, the survey was not designed to provide estimates for the individual sexes.

Sampling Strategy

To meet the requirements of the CHMS, a multi-stage sampling strategy was used.

Sampling of Collection Sites

The CHMS required participants to report to a MEC and be able to travel to the centre within a reasonable period of time. For cycle 3, the 2011 Census geography was used to create 360 collection sites across the country. A geographic area with a population of at least 10,000 and a maximum participant travel distance of 75 kilometres (50 kilometres in urban areas and 75 kilometres in rural areas) were required for the location of collection sites. Areas not meeting these criteria were excluded.

A larger number of collection sites would have optimized the precision of the estimates. However, the logistical and cost constraints associated with the use of MECs restricted the number of collection sites to 16. The 16 collection sites were selected from within the five standard regional boundaries used by Statistics Canada (Atlantic, Quebec, Ontario, the Prairies, and British Columbia); they were allocated to these regions in proportion to the size of the population. Although not every province in Canada had a collection site, the CHMS sites were chosen to represent the Canadian population in all 10 provinces, east to west, including larger and smaller population densities. The collection sites selected for cycle 3 of the CHMS are listed in the table below.

Canadian Health Measures Survey cycle 3 collection sites

Dwelling and Participant Sampling

Within each site, dwellings with known household composition at the time of the 2011 Census, updated with the most recent information from administrative files, were stratified by age of household residents at the time of the survey, with the six age-group strata corresponding to the CHMS cycle 3 age groups (3-5, 6-11, 12-19, 20-39, 40-59, and 60-79 years). Within each site, a simple random sample of dwellings was selected in each stratum. Each selected dwelling was then contacted and asked to provide a list of current household members; this list was used to select the survey participants. One or two people were selected, depending on the household composition.

Selection of Environmental Chemicals

The process to determine the list of environmental chemicals to be included in cycle 3 of the CHMS built upon the existing consultation process used for cycle 2. The primary mechanism of consultation for cycle 2 was through a questionnaire distributed to key stakeholders with expertise or interest in human biomonitoring of environmental chemicals; the purpose was to define specifically what should be measured in blood and urine samples in the Canadian population. Key participants included various internal Health Canada branches and programs as well as a number of external groups, including other federal departments, provincial/territorial health and environment departments, industry groups, environment and health non-governmental organizations, and academics. Through this consultation, over 310 different chemicals and metabolites were nominated.

Selection was based on health risks; evidence of human exposure; existing data gaps; commitments under national and international treaties, conventions, and agreements; availability of standard laboratory analytical methods; and current and anticipated health policy development and implementations.

The following criteria were used as a general guide for identifying and selecting the environmental chemicals to include in the CHMS:

• seriousness of known or suspected health effects related to the substance
• need for public health actions related to the substance
• level of public concern about exposures and possible health effects related to the substance
• evidence of exposure of the Canadian population to the substance
• feasibility of collecting biological specimens in a national survey and associated burden on survey participants
• availability and efficiency of laboratory analytical methods
• costs of performing the test
• parity of selected chemicals with other national and international surveys and studies

Because less than 2 years had passed between the selection processes for cycle 2 and cycle 3, it was determined that an entirely new consultation was unnecessary; rather, the existing priority list from cycle 2 was used as the starting point for cycle 3. Chemicals that were included in the cycle 2 priority list, which could not previously be included for various reasons, were given highest priority for inclusion in cycle 3. In addition, environmental chemicals from cycles 1 and 2 considered to be high priorities were carried forward into cycle 3. Ultimately, the list was narrowed by the volume of biospecimens available from survey participants to conduct the analyses. Blood volume is generally limited; it is also required for analyses of chronic and infectious diseases and nutritional biomarkers. Thus, fewer environmental chemicals were measured in blood than in urine.

A full list of the chemicals measured in individual respondents in CHMS cycle 3 is presented in the table below.

Chemicals measured in individual respondents in the Canadian Health Measures Survey cycle 3 (includes chemicals introduced for cycle 3 and carried forward from cycles 1 and 2).

Chemicals	Cycle 1	Cycle 2	Cycle 3
Metals and trace elements
Cadmium	Yes	Yes	Yes
Lead	Yes	Yes	Yes
Mercury (total)	Yes	Yes	Yes
Methylmercury	No	No	Yes
Inorganic mercury	Yes	No	Yes
Fluoride	No	Yes	Yes
Arsenic (speciated)
Arsenate	No	Yes	Yes
Arsenite	No	Yes	Yes
DMA (Dimethylarsinic acid)	No	Yes	Yes
MMA (Monomethylarsonic acid)		Yes	Yes
Arsenocholine	No	No	Yes
Arsenobetaine and arsenocholine	No	Yes	Yes
Environmental phenols
Bisphenol A	Yes	Yes	Yes
Triclosan	No	Yes	Yes
Nicotine metabolite
Cotinine	Yes	Yes	Yes
PAHs (polycyclic aromatic hydrocarbons)
Benzo[a]pyrene metabolite
3-Hydroxybenzo[a]pyrene	No	Yes	Yes
Chrysene metabolites
2-Hydroxychrysene	No	Yes	Yes
3-Hydroxychrysene	No	Yes	Yes
4-Hydroxychrysene	No	Yes	Yes
6-Hydroxychrysene	No	Yes	Yes
Fluoranthene metabolite
3-Hydroxyfluoranthene	No	Yes	Yes
Fluorene metabolites
2-Hydroxyfluorene	No	Yes	Yes
3-Hydroxyfluorene	No	Yes	Yes
9-Hydroxyfluorene	No	Yes	Yes
Naphthalene metabolites
1-Hydroxynaphthalene	No	Yes	Yes
2-Hydroxynaphthalene	No	Yes	Yes
Phenanthrene metabolites
1-Hydroxyphenanthrene	No	Yes	Yes
2-Hydroxyphenanthrene	No	Yes	Yes
3-Hydroxyphenanthrene	No	Yes	Yes
4-Hydroxyphenanthrene	No	Yes	Yes
9-Hydroxyphenanthrene	No	Yes	Yes
Pyrene metabolite
1-Hydroxypyrene	No	Yes	Yes
Volatile organic compounds
Benzene metabolites
t,t-MA (trans,trans-Muconic acid)	No	Yes	Yes
S-PMA (S-Phenylmercapturic acid)	No	Yes	Yes
Benzene	No	No	Yes
Ethylbenzene	No	No	Yes
Styrene	No	No	Yes
Tetrachloroethylene	No	No	Yes
Toluene	No	No	Yes
Trichloroethylene	No	No	Yes
Trihalomethanes
Bromodichloromethane	No	No	Yes
Dibromochloromethane	No	No	Yes
Tribromomethane	No	No	Yes
Trichloromethane	No	No	Yes
Xylenes
m-Xylene & p-Xylene	No	No	Yes
o-Xylene	No	No	Yes
Acrylamide
Acrylamide haemoglobin adduct	No	No	Yes
Glycidamide haemoglobin adduct	No	No	Yes

Owing to the high cost of laboratory analyses, some environmental chemicals were not measured for all CHMS participants. The majority of the environmental chemicals were measured in a subsample of 2,500 participants aged 3 to 79 years, with the following exceptions: lead, cadmium, total mercury, and cotinine were measured in all participants; methylmercury was measured in 1,000 participants aged 20 to 79 years; and trihalomethanes and volatile organic compounds were measured in 2,500 participants aged 12 to 79 years. Further details on the subsampling for environmental chemicals are available in Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015) and in Sampling documentation for cycle 3 of the Canadian Health Measures Survey (Labrecque and Quigley, 2014).

Environmental chemicals measured by age group

Measure	Matrix	Target sample size	Age (years)
			3-5	6-11	12-19	20-39	40-59	60-79
Metals and trace elements	Urine, blood	5,700	Yes	Yes	Yes	Yes	Yes	Yes
Methylmercury	Blood	1,000	No	No	No	Yes	Yes	Yes
Arsenic	Urine	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Fluoride	Urine	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Acrylamide	Blood	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Benzene metabolites	Urine	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Environmental phenols	Urine	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Nicotine metabolite	Urine	5,700	Yes	Yes	Yes	Yes	Yes	Yes
PAH metabolites	Urine	2,500	Yes	Yes	Yes	Yes	Yes	Yes
Volatile organic compounds	Blood	2,500	No	Yes	Yes	Yes	Yes	Yes

Ethical Considerations

Personal information collected through the CHMS is protected under the federal Statistics Act (Canada, 1970-71-72). Under the Act, Statistics Canada is obliged to safeguard and to keep in trust the information it obtains from the Canadian public. Consequently, Statistics Canada has established a comprehensive framework of policies, procedures, and practices to protect confidential information against loss, theft, unauthorized access, disclosure, copying, or use; this includes physical, organizational, and technological measures. The steps taken by Statistics Canada to safeguard the information collected in the CHMS have been described previously (Day et al., 2007).

Ethics approval for all components of the CHMS was obtained from the Health Canada and Public Health Agency of Canada Research Ethics Board. Informed written consent for the MEC portion of the CHMS was obtained from participants older than 14 years of age. For younger children, a parent or legal guardian provided written consent, and the child provided assent. Participation in this survey was voluntary, and participants could opt out of any part of the survey at any time.

A strategy was developed to communicate results to survey participants with the advice and expert opinion of the CHMS Laboratory Advisory Committee, the Physician Advisory Committee, l'Institut national de santé publique du Québec (the reference laboratory performing some of the environmental chemical analyses), and Health Canada's Research Ethics Board (Day et al., 2007). For the environmental chemicals, only results for lead and mercury were actively reported to participants. However, participants could receive all other test results upon request to Statistics Canada. More information on reporting to participants, including the ethical challenges encountered, can be found in Haines et al. (2011).

Fieldwork

Fieldwork for the Canadian Health Measures Survey (CHMS) cycle 3 took place over a period of 2 years from January 2012 to December 2013. Data were collected sequentially at 16 sites across Canada. The sites were ordered to take into account seasonality by region and the temporal effect, subject to operational and logistical constraints.

Statistics Canada mailed an advance letter and brochure to households that were selected as outlined in the Dwelling and Participant Sampling section. The mailing informed potential participants that they would be contacted for the survey's data collection.

Data were collected from consenting survey participants through a household personal interview, using a computer-assisted method, and a visit to a mobile examination centre (MEC) for physical measures and biospecimen collection. The field team consisted of household interviewers and the CHMS MEC staff, including trained health professionals who performed the physical measures testing (Statistics Canada, 2015).

Participants were first administered a household questionnaire in their home. Using a computer application, the interviewer randomly selected one or two participants and conducted separate 45- to 60-minute health interviews (Statistics Canada, 2015). The interviews collected demographic and socio-economic data and information about lifestyle, medical history, current health status, the environment, and housing conditions. At this time, the collection protocol for the indoor air and tap water component of the survey was also initiated. Within approximately 2 weeks after the home visit, participants visited the MEC. Each MEC consisted of two trailers linked by an enclosed pedestrian walkway. One trailer was for reception and contained an administration area and an examination room; the other trailer contained additional examination rooms and a laboratory. The MEC operated 7 days a week in order to complete approximately 350 visits at each site over 5 to 6 weeks and to accommodate participants' schedules (Statistics Canada, 2015). MEC appointments averaged about 2.5 hours. A parent or legal guardian accompanied children under 14 years of age. To maximize response rates, participants who were unable or unwilling to go to the MEC were offered the option of a home visit by members of the CHMS MEC staff to perform some of the physical measures and the biospecimen collection portion of the survey (Statistics Canada, 2015).

At the start of the MEC visit, participants signed consent/assent forms prior to any testing and in most cases provided a urine sample immediately thereafter. For logistical purposes, spot samples were collected rather than 24-hour urine samples. The urine samples were collected using the first-catch urine, as opposed to the mid-stream urine collected in cycle 1. Guidelines were provided to participants asking them to abstain from urinating 2 hours prior to their MEC visit. Samples were collected in 120 mL urine specimen containers. Trained health professionals took physical health measurements such as height, weight, blood pressure, lung function, and physical fitness. A series of screening questions were administered to participants to determine their eligibility for the various tests, including phlebotomy (blood collection), based on pre-existing exclusion criteria (Statistics Canada, 2015). Blood specimens were drawn by a certified phlebotomist; the maximum amount depended upon the age of the participant. The approximate volume drawn from participants aged 3-5 years was 22.0 mL; 6-11 years, 28.5 mL; 12-13 years, 48.8 mL; 14-19 years, 52.8 mL; and 20-79 years, 72.8 mL.

All blood and urine specimens collected in the MEC were processed and aliquoted in the MEC. Biospecimens were stored temporarily in temperature-monitored freezers at -30ºC until shipping, with the exception of blood samples collected for volatile organic compound analysis; these were refrigerated. Once a week, the specimens were shipped on dry ice or in monitored refrigerated conditions to the reference laboratory for analyses. Standardized operating procedures were developed for the collection of blood and urine specimens, processing and aliquoting procedures, as well as for shipping biospecimens to ensure adequate data quality and to standardize data collection. A priority sequence for laboratory analyses was established in the event that an insufficient volume of biospecimen was collected for complete analyses of the environmental chemicals as well as for analyses of infectious diseases, nutritional status, and chronic diseases. Details on the collection tubes, aliquot volumes, and priority testing are presented in the table below.

Urine and blood collection procedure for the environmental chemicals

Measure	Matrix	Collection Tube (size and typeTable A footnote a)	Optimal VolumeTable A footnote b
Acrylamide	Whole Blood	4.0, 6.0 or 10mLTable A footnote c Lavender EDTATable A footnote d	1.5 mL
Metals			1.0 mL
Methylmercury			1.8 mLTable A footnote e
Volatile organic compounds (VOCs)	Whole Blood	10 mL Washed Grey	10 mL
Creatinine	Urine	120 mL urine specimen container	0.5 mL
Fluoride			0.8 mL
Arsenic (speciated)			1.0 mL
Nicotine metabolite			0.8 mL
Inorganic mercury			1.5 mL
Environmental phenols			0.8 mL
Polycyclic aromatic hydrocarbon metabolites (PAHs) and benzene metabolites			12 mL
Specific gravity			0.3 mL
Table A footnote a Becton Dickinson Vacutainers were used for the collection of blood; VWR urine specimen containers were used for the collection of urine Return to Table A footnote a referrer Table A footnote b Optimum sample volume sent to the reference laboratory Return to Table A footnote b referrer Table A footnote c 4.0 mL tubes used for respondents aged 3-5 years; 6.0 mL tubes used for respondents aged 6-11 years; 10 mL tubes used for respondents aged 20-79 years Return to Table A footnote c referrer Table A footnote d EDTA: ethylenediaminetetraacetic acid Return to Table A footnote d referrer Table A footnote e Methylmercury only collected in respondents aged 20 to 79 years Return to Table A footnote e referrer

To maximize the reliability and validity of the data and to reduce systematic bias, the CHMS developed quality assurance and quality control protocols for all aspects of the fieldwork. Quality assurance for the MEC covered staff selection and training, instructions to respondents (pre-testing guidelines), and issues related to data collection. All staff had appropriate education and training for their respective positions. To ensure consistent measurement techniques, procedure manuals and training guides were developed in consultation with, and reviewed by, experts in the field. Quality control samples were done at each site, consisting of three field blanks per site (deionized water for most analytes), blind replicates (three pairs per site except blood VOCs and cotinine), and blind control samples (approximately six per site).

The quality control samples were sent to the laboratory with regular specimen shipments. Results were sent to Statistics Canada's CHMS headquarters, along with all other respondent results, where they were assessed to determine the accuracy of the methodology based on the defined analyte concentration. The replicates were used to assess the precision of the analysis in pre-established acceptable ranges. If required, feedback was provided quickly to the reference laboratory for review and remedial action.

Beginning in cycle 2, a subsample of CHMS participants' households were selected for a component that involved sampling of indoor air over a 7-day period. A tap water sampling protocol was introduced in cycle 3 to complement the indoor air component. By sampling both indoor air and tap water in the home environment, where Canadians spend the majority of their time, two potential sources of exposure to environmental chemicals are captured.

Participants were asked to place the indoor air sampler in their household for 7 days in order to measure a number of VOCs. One indoor air sampler was given per selected household, along with a pencil, a postage-paid envelope, and an information sheet. After the 7-day collection period was over, participants mailed their indoor air sampler in the envelope provided to CASSEN Testing Laboratories where all indoor air analyses were performed.

The tap water sampling was carried out during the household interview by the interviewer and lasted for approximately 10 minutes. The objective of tap water collection was to determine the prevalence of and characterize the distribution of exposure to fluoride and to VOCs from tap water. Two samples were collected at each household and were shipped to the laboratories where the tap water analysis was performed. Fluoride samples were analyzed by the Laboratoire de santé publique du Québec whereas the VOC samples were analyzed by a Health Canada research laboratory.

Indoor air results were not reported back to respondents; however, the tap water test results were reported back to those who participated in both the household and the clinic portion of the survey. Reports included results for those chemicals for which either aesthetic quality or maximum acceptable concentration (MAC) guidelines have been established by the Federal-Provincial-Territorial Committee on Drinking Water. Aesthetic objectives address concentrations that could affect the taste, smell, or colour of water, while still being below the point at which health effects could appear whereas MACs are established on the basis of health considerations. Certain chemicals measured in the tap water sample do not have established guidelines; respondents were able to receive these results only upon request. If one or more of the tap water results was found to exceed a MAC, survey staff contacted the respondents to inform them of their result and to ask for their consent to share the result with provincial authorities.

A complete list of the substances measured in the indoor air and tap water samples is available in the Canadian Health Measures Survey (CHMS) Content summary for cycles 1 to 8 (Statistics Canada, 2013a). Further details on the indoor air study and tap water sampling are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available upon request by contacting Statistics Canada at info@statcan.gc.ca.

Detailed descriptions of the CHMS MEC operations and logistics have been described previously in Bryan et al. (2007) and are presented in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015).

Laboratory Analyses

Laboratory analyses of environmental chemicals and creatinine were performed at analytical laboratories within Health Canada, l'Institut national de santé publique du Québec (INSPQ), and the ALS Laboratory Group. Laboratories developed standardized operating procedures for the analytical methods used to measure environmental chemicals or their metabolites in biological samples. Analytical accuracy and precision of measurements were evaluated through rigorous method validation programs at each laboratory.

Internal quality control measures within each laboratory included the analysis of calibration standards, laboratory blanks, method blanks, and in-house quality control samples in each analytical batch. In addition, laboratories conducted periodical analyses of Standard Reference Materials/Certified Reference Materials when available. Quality assurance reviews were conducted on laboratory data on a regular basis to evaluate any issues in the batch processing and to identify inconsistencies in analytical results. Appropriate corrective measures were taken when required. As part of external quality control measures, laboratories participated in external quality control programs and inter-laboratory comparison studies when available. Tables are provided with limits of detection for each method (Appendix A). The methods used in the analyses of the environmental chemicals and creatinine are described below.

Acrylamide

Whole blood was thawed at room temperature and reacted with modified Edman reagent (pentafluorophenyl isothiocyanate) for 2 hours at 55°C. The sample was purified using solid phase extraction on Isolute HM-N sorbent. Analytes were then eluted with diisopropyl ether/ethyl acetate/toluene (50/40/10 v/v/v) and the extract was evaporated under a stream of nitrogen. The sample was reconstituted in methanol/water (40/60 v/v) and analyzed using a Waters Acquity ultraperformance liquid chromatograph (UPLC) system coupled to a Quattro Premier tandem mass spectrometer (Health Canada, 2014a).

Environmental Phenols

For the analysis of bisphenol A and triclosan, urine samples were subjected to enzymatic hydrolysis (ß-glucuronidase enzyme). The samples were then derivatized with pentafluorobenzyl bromide at 70ºC for 2 hours. The derivatized products were extracted with a mixture of dichloromethane-hexane. Evaporated extracts were dissolved in the appropriate solvent and analyzed using an Agilent 6890 or 7890 gas chromatographic system coupled to a Waters Quattro Micro gas chromatograph (GC) tandem mass spectrometer. The mass spectrometer was operated in the negative ion chemical ionization mode and the analytes were quantified using multiple reaction monitoring (MRM) (INSPQ, 2014a). Free and hydrolyzed forms of bisphenol A were measured together by this procedure.

Metals and Trace Elements

Arsenic

Urine samples were diluted in ammonium carbonate solution and analyzed for arsenite (As3+), arsenate (As5+), monomethylarsonic acid, dimethylarsinic acid, and the sum of arsenobetaine and arsenocholine using a Waters Acquity UPLC coupled to a Varian 820-MS inductively coupled plasma-mass spectrometer (ICP-MS) system (INSPQ, 2009a). For arsenocholine, urine was diluted with formic acid and acetonitrile solution and analyzed on Waters Acquity UPLC coupled to a TQ-S tandem mass spectrometer (INSPQ, 2009a).

Cadmium, Lead, and Total Mercury

Blood samples were diluted in a basic solution containing octylphenol ethoxylate and ammonia. They were analyzed for cadmium, lead, and total mercury using a Perkin Elmer Sciex Elan DRC II ICP-MS. Matrix matched calibration was performed using blood from non-exposed individuals (INSPQ, 2010).

Fluoride

Urine samples were diluted with ionic adjustment buffer and analyzed using an Orion pH meter with a fluoride ion selective electrode (Orion Research Inc.) (INSPQ, 2009b).

Inorganic Mercury

Urine was digested in nitric acid at 50°C, diluted, and analyzed for inorganic mercury on a Perkin Elmer FIMS 100 (cold vapour system). Matrix matched calibration was performed using urine from non-exposed individuals (INSPQ, 2009c).

Methylmercury

Methylmercury was extracted by sonication from whole blood using an L-cysteine acid solution. After centrifugation, proteins were precipitated using acetonitrile. The supernatant was extracted using an MCX solid phase extraction cartridge. The extract was evaporated to dryness, reconstituted in the appropriate solvent, and analyzed using a Water Acquity UPLC coupled to a Varian 820-MS ICP-MS (INSPQ, 2011).

Nicotine Metabolite

Free cotinine was recovered from urine samples by solid-phase extraction on an automated Janus workstation. Deuterated cotinine was used as the internal standard. The extract was redissolved in the mobile phase, and analyzed using a Waters Acquity UPLC coupled to a Waters Quattro Premier XE tandem mass spectrometer with an electrospray ionization source operating in positive ion mode. The analytes were quantified using MRM (INSPQ, 2009d).

Polycyclic Aromatic Hydrocarbon Metabolites

For the analysis of polycyclic aromatic hydrocarbon metabolites (3-hydroxybenzo[a]pyrene, 2-hydroxychrysene, 3-hydroxychrysene, 4-hydroxychrysene, 6-hydroxychrysene, 3-hydroxyfluoranthene, 2-hydroxyfluorene, 3-hydroxyfluorene, 9-hydroxyfluorene, 1-hydroxynaphthalene, 2-hydroxynaphthalene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, 4-hydroxyphenanthrene, 9-hydroxyphenanthrene, and 1-hydroxypyrene), urine samples were hydrolyzed using b-glucuronidase enzymatic solution and extracted with an organic solvent at neutral pH. The extracts were evaporated and derivatized with N-methyl-N-(trimethylsilyl)-trifluoroacetamide and analyzed using an Agilent 7890 gas chromatograph coupled to an Agilent 7000B triple-quad tandem mass spectrometer operating in electron impact ionization mode. Analytes were quantified using MRM (INSPQ, 2014b).

Volatile Organic Compounds

Whole blood samples were withdrawn using a previously cleaned air-tight syringe, transferred to a glass vial, and a mixture of isotopically labelled analogs was added. The vial was crimp-sealed and placed in a temperature-controlled autosampler tray. The samples were maintained at 40°C with continuous mixing. The analytes (benzene, toluene, ethylbenzene, m-xylene, o-xylene, p-xylene, chloroform, bromoform, bromodichloromethane, dibromochloromethane, trichloroethane, tetrachloroethene, and styrene) were extracted by inserting a solid phase microextraction fiber into the vial headspace. After extraction, the fiber was transferred to a heated gas chromatograph inlet where the analytes were rapidly desorbed off the fiber. The analytes were focused using a ThermoFisher Scientific Cryotrap (Cryotrap 915) and analyzed using a ThermoFisher Scientific TRACE Ultra gas chromatograph coupled to TSQ Quantum XLS mass spectrometer equipped with electron ionization source. The analytes were quantified in selected reaction monitoring mode (Health Canada, 2012a).

Benzene Metabolites

Benzene metabolites (trans,trans-muconic acid and S-phenylmercapturic acid) were extracted from urine using a hydrophilic-lipophilic-balanced solid-phase extraction cartridge on an automated Janus workstation. The extracts were evaporated to dryness, reconstituted in the mobile phase, and analyzed using a Waters Acquity UPLC coupled to a Waters Xevo TQ-S tandem mass spectrometer operated in negative ion mode (INSPQ, 2014c).

Creatinine

Creatinine was measured in urine using the colorimetric end-point Jaffe method. An alkaline solution of sodium picrate reacts with creatinine in urine to form a red Janovski complex using Microgenics DRI Creatinine-Detect reagents (#917). The absorbance was read at 505 nm on a Hitachi 917 chemistry autoanalyzer (INSPQ, 2008).

Statistical Data Analyses

Descriptive statistics on the concentrations of environmental chemicals in the blood and urine of Canadians, aged 3 to 79 years, were generated using the Statistical Analysis System software (SAS Institute Inc., version  9.2, 2008) and the SUDAAN® (SUDAAN Release 11.0.1, 2013) statistical software package.

The Canadian Health Measures Survey (CHMS) is a sample survey, meaning that the participants represent many other Canadians not included in the survey. In order for the results of the survey to be representative of the entire population, sample weights were generated by Statistics Canada and incorporated into all estimates presented in the data tables (e.g. geometric means). Survey weights were used to take into account the unequal probability of selection into the survey as well as non-response. Further, to account for the complex survey design of the CHMS, the set of bootstrap weights included with the data set was used to estimate the 95% confidence intervals (CIs) for all means and percentiles (Rao et al., 1992; Rust & Rao, 1996).

For each chemical measured in cycle 3, data tables are presented. Data from cycle 1 and cycle 2 are also provided within the tables for those substances measured in all cycles. In the first Report on Biomonitoring of Environmental Chemicals in Canada, all results were reported to two decimal places. For cycles 2 and 3 of the CHMS, the reporting protocol changed and the results were reported to two significant digits. For consistency, cycle 1 data were adjusted to two significant digits before generating the descriptive statistics and data from all cycles are presented to two significant digits. Therefore, the descriptive statistics presented for cycle 1 may differ from those presented in the first report. The differences are not significant and the values presented in the first report are still considered to be accurate.

The data tables include the sample size (n); percentage of results that fall below the limit of detection (LOD); geometric mean (GM); the 10th, 50th, 90th, and 95th percentiles; and associated 95% CIs. For each chemical, results are presented for the total population as well as by age group and sex. For each chemical that was measured in multiple cycles of the CHMS, a summary table is provided that compares results for the aggregate of all age groups common to all cycles and for that same aggregate population separated by sex. Measurements that fell below the LOD for the laboratory analytical method were assigned a value equal to half the LOD. If the proportion of results below the LOD was greater than 40%, GMs were not calculated. Percentile estimates that are less than the LOD are reported as <LOD. The appendices contain tables of LOD values for each chemical, specific to each cycle, and conversion factors to assist in the comparison of data from other studies that report different units (Appendices A and B).

Chemicals measured in whole blood are presented as weight of chemical per volume of whole blood (e.g. µg chemical/L blood).

For urine measurements, concentrations are presented as weight of chemical per volume of urine (e.g. µg chemical/L urine) and adjusted for urinary creatinine (e.g. µg chemical/g creatinine). Urinary creatinine is a chemical by-product generated from muscle metabolism; it is frequently used to adjust for urine concentration (or dilution) in spot urine samples because its production and excretion are relatively constant over 24 hours owing to homeostatic controls (Barr et al., 2005; Boeniger et al., 1993; Pearson et al., 2009). If the chemical measured behaves similarly to creatinine in the kidney, it will be filtered at the same rate, thus expressing the chemical per gram of creatinine helps adjust for the effect of urinary dilution as well as some differences in renal function and lean body mass (Barr et al., 2005; CDC, 2009; Pearson et al., 2009). Creatinine is primarily excreted by glomerular filtration; therefore, creatinine adjustment may not be appropriate for compounds that are excreted primarily by tubular secretion in the kidney (Barr et al., 2005; Teass et al., 2003). In addition, creatinine excretion can vary owing to age, sex, and ethnicity; therefore, it may not be appropriate to compare creatinine-adjusted concentrations among different demographic groups (e.g. children with adults) (Barr et al., 2005). Where urinary creatinine values were missing or <LOD, the estimate of that participant's creatinine-adjusted chemical was not calculated and was also set to missing.

Descriptive statistics are available for creatinine (mg/dL) (Appendix C). These include n; % <LOD; GM; the 10th, 50th, 90th, and 95th percentiles; and associated 95% CIs for the total population as well as by age group and sex. Measurements that fell below the LOD for the laboratory analytical method were assigned a value equal to half the LOD.

Specific gravity was also measured in all urine samples immediately following sample collection at the mobile examination centre. Urinary specific gravity is the ratio of densities between urine and pure water and can be used to adjust for variations in urine output, similar to urinary creatinine adjustment. Urinary specific gravity adjustment has not been presented for any of the chemicals; however, specific gravity data are available upon request by contacting Statistics Canada at info@statcan.gc.ca should researchers wish to perform this adjustment for their own data analyses.

Under the Statistics Act, Statistics Canada is required to ensure participant confidentiality. Therefore, estimates based on a small number of participants are suppressed. Following suppression rules for the CHMS, any estimate based on fewer than 10 participants is suppressed in the data tables. To avoid suppression, estimates at the 95th percentile require at least 200 participants, estimates at the 10th and 90th percentiles require at least 100 participants, estimates at the 50th percentile require at least 20 participants, and estimates of the geometric mean require at least 10 participants.

Estimates from a sample survey inevitably include sampling errors. Measuring the possible scope of sampling errors is based on the standard error of the estimates drawn from the survey results. To get a better indication of the size of the standard error, it is often more useful to express the standard error in terms of the estimate being measured. The resulting measure, called the coefficient of variation (CV), is obtained by dividing the standard error of the estimate by the estimate itself, and it is expressed as a percentage of the estimate. This report employs the following Statistics Canada guidelines for releasing estimates based on their CV:

• When a CV is between 16.6% and 33.3%, an estimate can be considered for general unrestricted release but is accompanied by a warning cautioning subsequent users of the high sampling variability associated with the estimate. These estimates are identified by the superscript letter E.
• When a CV is greater than 33.3%, Statistics Canada recommends not releasing the estimate because conclusions based on these data will be unreliable and most likely invalid. These estimates will not be published and will instead be replaced by the letter F.

Further details on the sample weights and data analysis are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015).

Considerations for Interpreting the Biomonitoring Data

The Canadian Health Measures Survey (CHMS) was designed to provide estimates of environmental chemical concentrations in blood or urine for the Canadian population as a whole. The first cycle of the survey covered approximately 96% of the Canadian population aged 6 to 79 years. The second and third cycles included children as young as 3 years of age and also covered approximately 96% of the Canadian population up to 79 years of age. The survey was not designed to permit breakdown of data by region, province, or collection site though some analysis is possible if data from more than one cycle are combined (see Instructions for Combining Multiple Cycles of CHMS Data). In addition, the CHMS design did not target specific exposure scenarios; consequently, it did not select or exclude participants on the basis of their potential for low or high exposures to environmental chemicals.

Biomonitoring can estimate how much of a chemical is present in a person, but it cannot say what health effects, if any, may result from that exposure. The ability to measure environmental chemicals at very low concentrations has advanced in recent years. However, the presence alone of a chemical in a person's body does not necessarily mean that it will cause a health effect. Factors such as the dose, the toxicity of the chemical, and the duration and timing of exposure are important to determine whether potential adverse health effects may occur. For chemicals such as lead or mercury, research studies have provided a good understanding of the health risks associated with different concentrations in blood. However, for many chemicals, further research is needed to understand the potential health effects, if any, from different blood or urine concentrations. Furthermore, small amounts of certain chemicals, such as manganese and zinc, are essential for the maintenance of good health and would be expected to be present in the body. In addition, the way in which a chemical will act in the body will differ among individuals and cannot be predicted with certainty. Certain populations (children, pregnant women, the elderly, or immuno-compromised people) may be more susceptible to the effects of exposure.

The absence of a chemical does not necessarily mean a person has not been exposed. It may be that the technology is not capable of detecting such a small amount, or that the exposure occurred at an earlier point in time allowing for the chemical to be eliminated from the person's body before measurement took place.

Biomonitoring cannot tell us the source or route of the exposure. The amount of chemical measured indicates the total amount that has entered the body through all routes of exposure (ingestion, inhalation, and skin contact) and from all sources (air, water, soil, food, and consumer products). The detection of the chemical may be the result of exposure to a single source or multiple sources. In addition, in most cases biomonitoring cannot distinguish between natural and anthropogenic sources. Many chemicals (lead, mercury, cadmium, and arsenic) occur naturally in the environment and are also present in human-made products.

While metals are measured in urine as the parent compounds, almost all other chemicals are measured as metabolites. For many chemicals, parent compounds may be broken down (i.e. metabolized) in the body into one or more metabolites. For example, the polycyclic aromatic hydrocarbon chrysene is broken down into several metabolites. Some metabolites are specific to one parent compound whereas others are common to several parent compounds. Several urinary metabolites are also formed in the environment (e.g. chlorpyrifos metabolites). Their presence in urine does not necessarily mean that an exposure to the parent chemical has occurred; rather, exposure could be to the metabolite itself in media such as food, water, or air.

Factors that contribute to the concentrations of chemicals measured in blood and urine include the quantity entering the body through all routes of exposure, absorption rates, distribution to various tissues in the body, metabolism, and excretion of the chemical and/or its metabolites from the body. These processes, also called toxicokinetics, depend on both the characteristics of the chemical, including its solubility in fat (or lipophilicity), its pH, its particle size, and the characteristics of the individual being exposed, such as age, diet, health status, and race. For these reasons, the way in which a chemical will act in the body will differ among individuals and cannot be predicted with certainty.

The CHMS biomonitoring data currently available include temporal data for substances measured in cycle 1 (2007-2009), cycle 2 (2009-2011), and cycle 3 (2012-2013), as well as baseline data for substances introduced to the survey in cycle 3. Results from future cycles can be compared with the baseline data from the CHMS in order to begin to examine trends in Canadians' exposures to selected environmental chemicals. It is important to note that there were some sampling and analytical modifications between cycles that may have contributed some variation in results for those substances measured in multiple cycles. The limits of detection (LOD) for certain analytical methods have changed from cycle to cycle. Although the LOD values did not change by a large margin, this difference should be noted when comparing data from multiple cycles. A list of LOD values from cycles 1, 2, and 3 is provided (Appendix A). In addition, the urine collection protocol and guidelines were changed in cycle 2, and this may have resulted in a shift in creatinine levels when cycle 1 data are compared with those from subsequent cycles. This, in turn, could affect creatinine-adjusted levels of some chemicals.

Urinary creatinine concentrations can also be affected by variables such as age, sex, and ethnicity resulting in differences among demographic groups within a single cycle (Mage et al., 2004). In particular, creatinine excretion per unit bodyweight increases substantially with increasing age in children (Aylward et al., 2011; Remer et al., 2002). As a result, it is acceptable to compare creatinine-adjusted concentrations among similar demographic groups (e.g. children with children, adults with adults, males with males) but not among two different demographic groups (e.g. children with adults, males with females) (Barr et al., 2005).

More in-depth statistical analyses of the CHMS biomonitoring data, including time trends, exploring relationships among environmental chemicals, other physical measures, and self-reported information are being published by researchers in the scientific literature. A  bibliography of publications using CHMS data is available. CHMS data are available to scientists through Statistics Canada's  Research Data Centres Program and are a resource for additional scientific analyses. Further information about the CHMS can be obtained by contacting Statistics Canada at info@statcan.gc.ca.

Summary and Results for Acrylamide

Acrylamide

Acrylamide (CASRN 79-06-1) is a chemical used primarily in the production of polymers such as polyacrylamides (ATSDR, 2012a). Polyacrylamides are used to clarify drinking water and treat effluent from water treatment plants and industrial processes (ATSDR, 2012a). They are also used as binding, thickening, or flocculating agents in grout, cement, pesticide formulations, cosmetics, food manufacturing, and soil erosion prevention (Environment Canada & Health Canada, 2009a). Polymers of acrylamide are also used in ore processing, food packaging, and plastic products (Environment Canada & Health Canada, 2009a). In Canada, polyacrylamide is used as a coagulant and flocculant for the clarification of drinking water, in potting soils, and as a non-medicinal ingredient in natural health products and pharmaceuticals (Environment Canada & Health Canada, 2009b). Acrylamide can also form naturally in certain foods during processing or cooking at high temperatures (Health Canada, 2009a). It is formed mainly in carbohydrate-rich plant-based foods such as potatoes and grains with the highest concentrations detected in potato chips and french fries (Health Canada, 2009a).

Entry into the environment may occur during production and industrial use (ATSDR, 2012a). Residual monomers may be released to drinking water during polyacrylamide treatment processes and are the main source of drinking water contamination by acrylamide (ATSDR, 2012a). Acrylamide is a component of cigarette smoke and may be released to indoor air as a result of smoking (NTP, 2005; Urban et al., 2006).

Acrylamide exposure in the general population occurs primarily through food and to a lesser degree through air, drinking water, and soil (Environment Canada & Health Canada, 2009a). Inhalation of tobacco smoke, including second-hand smoke, is also a major source of inhalation exposure for the general population (ATSDR, 2012a). Animal studies indicate that acrylamide is readily absorbed via oral and pulmonary routes, and to a lesser degree following dermal exposure (ATSDR, 2012a). Once absorbed, acrylamide is widely distributed throughout the body accumulating in red blood cells (ATSDR, 2012a). Acrylamide is metabolized to form the epoxide derivative, glycidamide, and both acrylamide and glycidamide react with haemoglobin in red blood cells forming adducts (ATSDR, 2012a). Absorbed acrylamide and its metabolites are rapidly eliminated in urine, primarily as mercapturic acid conjugates of acrylamide and glycidamide (ATSDR, 2012a). Acrylamide and glycidamide haemoglobin adducts are considered markers of exposure over the previous 120 days, the average life span of red blood cells (ATSDR, 2012a).

Exposure to acrylamide is known to cause a number of health effects in humans, including neurotoxicity. Inhalation exposure to acrylamide in occupational settings has been associated with peripheral neuropathy characterized by muscle weakness and numbness in hands and feet (Environment Canada & Health Canada, 2009b). Studies with laboratory animals have observed adverse reproductive and developmental effects and shown that acrylamide is genotoxic and carcinogenic (Environment Canada & Health Canada, 2009b; WHO, 2006). Reviews of existing epidemiological studies have found that there is inadequate evidence in humans to establish an association between acrylamide exposure and carcinogenicity (Health Canada, 2008a; IARC, 1999a). However, on the basis of evidence in experimental animals, the International Agency for Research on Cancer (IARC) and the U.S. Environmental Protection Agency (U.S. EPA) have classified acrylamide as probably carcinogenic to humans (EPA, 2010; IARC, 1999a). Further, on the basis of available evidence from animal studies, the Joint FAO/WHO Expert Committee on Food Additives determined that the estimated intake of acrylamide from certain foods may be a human health concern (FAO/WHO, 2006).

Health Canada and Environment Canada concluded, on the basis of carcinogenic potential, that acrylamide in Canada may constitute a danger to human life or health (Environment Canada & Health Canada, 2009b). Acrylamide is listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999). The Act allows the federal government to control the importation, manufacture, distribution, and use of acrylamide in Canada (Canada, 1999; Canada, 2011a). Health Canada's risk management strategy for acrylamide in food is focused on reducing foodborne exposure to acrylamide (Health Canada, 2009b). To reduce exposure to acrylamide from food sources, Health Canada suggests following the recommendations provided in Canada's Food Guide, thereby limiting consumption of carbohydrate-rich foods that are high in fat (such as potato chips and french fries), sugar, or salt (Health Canada, 2009a). However, occasional consumption of these products is not likely to be a health concern. Other suggestions for reducing exposure to acrylamide from certain foods include paying careful attention to oil and baking temperatures, following the manufacturer's cooking instructions, storing potatoes at a temperature above 8°C, washing or soaking cut potatoes in water prior to frying, and toasting bread or baked goods to the lightest colour acceptable (Health Canada, 2009a). Health Canada regularly reviews data on the concentrations of acrylamide in foods sold on the Canadian market; these results may be shared with industry, particularly if elevated levels of acrylamide are identified in certain products. Health Canada continues to encourage the food industry to further pursue reduction efforts for acrylamide in processed foods (Health Canada, 2012b). In order to obtain additional information demonstrating successful acrylamide reduction strategies on the part of food manufacturers, Health Canada initiated a one-year call for data in September 2013 seeking submissions of published and unpublished technical information on the occurrence of acrylamide in foods available for sale in Canada (Health Canada, 2013b). Health Canada has also amended the Food and Drug Regulations to permit the use of asparaginase in certain food products to reduce the formation of acrylamide during cooking (Canada, 2012a; Health Canada, 2013c). Acrylamide is included as a prohibited ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Health Canada, 2014b).

Because acrylamide-containing polymers are used in drinking water treatment, most Canadian jurisdictions have requirements to meet health-based standards for additives that limit the amount of acrylamide present in the treated drinking water (NSF International, 2013; NSF International, 2014). Health Canada has also set a maximum level for acrylamide in polyacrylamide-containing formulations used in natural health products in Canada (Environment Canada & Health Canada, 2009a; Health Canada, 2012c).

In a study carried out on Montreal Island to assess the levels of acrylamide in 195 non-smoking teenagers aged 10 to 17 years, the geometric mean concentrations of haemoglobin adducts of acrylamide and glycidamide were 45.4 pmol/g globin and 45.6 pmol/g globin, respectively (Brisson et al., 2014).

Acrylamide and its metabolite glycidamide were analyzed as adducts in whole blood of CHMS participants aged 3 to 79 years in cycle 3 (2012-2013). Data are presented in blood as pmol/g haemoglobin (Hb). Finding a measurable amount of acrylamide or glycidamide haemoglobin adducts in blood is an indicator of exposure to acrylamide and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for acrylamide and glycidamide haemoglobin adducts in the Canadian population.

Acrylamide haemoglobin adducts - Geometric means and selected percentiles of whole blood concentrations (pmol/g Hb) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 1 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	3 (2012-2013)	2492	0	73 (65 - 82)	35 (30 - 40)	64 (57 - 70)	190 (160 - 230)	240 (190 - 290)
Males	3-79	3 (2012-2013)	1225	0	79 (69 - 90)	36 (31 - 40)	68 (61 - 75)	200 (150 - 260)	270Table 1 footnote E (160 - 380)
Females	3-79	3 (2012-2013)	1267	0	68 (59 - 78)	35 (29 - 41)	60 (51 - 69)	180 (130 - 230)	210 (180 - 250)
Total	3-5	3 (2012-2013)	471	0	59 (55 - 64)	39 (35 - 43)	59 (55 - 63)	87 (73 - 100)	100 (82 - 120)
Total	6-11	3 (2012-2013)	505	0	61 (57 - 65)	37 (34 - 41)	62 (58 - 67)	100 (88 - 110)	110 (98 - 120)
Total	12-19	3 (2012-2013)	507	0	63 (59 - 67)	37 (31 - 42)	57 (53 - 61)	110 (87 - 130)	170Table 1 footnote E (96 - 240)
Total	20-39	3 (2012-2013)	348	0	80 (65 - 97)	34 (24 - 43)	74 (59 - 89)	190 (130 - 260)	260 (190 - 340)
Total	40-59	3 (2012-2013)	311	0	83 (67 - 100)	35 (24 - 47)	66 (49 - 82)	230 (180 - 290)	330 (210 - 450)
Total	60-79	3 (2012-2013)	350	0	63 (59 - 68)	34 (29 - 40)	62 (59 - 65)	130 (100 - 150)	160 (130 - 190)
Table 1 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 1 footnote a referrer Table 1 footnote E Use data with caution. Return to table 1 footnote E referrer

Glycidamide haemoglobin adducts - Geometric means and selected percentiles of whole blood concentrations (pmol/g Hb) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 2 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	3 (2012-2013)	2492	0.76	68 (62 - 75)	36 (34 - 38)	65 (59 - 70)	150 (120 - 180)	190 (150 - 220)
Males	3-79	3 (2012-2013)	1225	1.14	69 (62 - 77)	37 (35 - 38)	66 (58 - 74)	170 (120 - 210)	210 (160 - 260)
Females	3-79	3 (2012-2013)	1267	0.39	67 (60 - 74)	36 (32 - 40)	64 (57 - 71)	130 (100 - 160)	160 (120 - 200)
Total	3-5	3 (2012-2013)	471	0	80 (75 - 85)	51 (43 - 59)	78 (74 - 81)	120 (110 - 130)	140 (120 - 150)
Total	6-11	3 (2012-2013)	505	0	73 (70 - 77)	47 (45 - 48)	74 (68 - 81)	110 (97 - 120)	130 (110 - 150)
Total	12-19	3 (2012-2013)	507	1.18	62 (59 - 65)	35 (32 - 37)	60 (57 - 62)	110 (95 - 130)	160 (120 - 200)
Total	20-39	3 (2012-2013)	348	0.86	72 (60 - 86)	38 (30 - 46)	74 (62 - 86)	160 (130 - 190)	210 (160 - 260)
Total	40-59	3 (2012-2013)	311	1.29	71 (58 - 86)	36 (31 - 42)	62 (50 - 74)	180 (140 - 220)	230 (170 - 290)
Total	60-79	3 (2012-2013)	350	1.71	60 (53 - 67)	34 (29 - 39)	60 (50 - 70)	100 (90 - 110)	120 (110 - 130)
Table 2 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 2 footnote a referrer

Summaries and Results for Environmental Phenols

Bisphenol A

Bisphenol A (BPA; CASRN 80-05-7) is a synthetic chemical used as a monomer in the production of some polycarbonate plastics and as a precursor for monomers of certain epoxy-phenolic resins (EFSA, 2007). Polycarbonate is used in the manufacture of food and beverage containers such as repeat-use water bottles and storage containers; it was also used in infant bottles in Canada prior to 2010. Epoxy resins are used as an interior protective lining for food and beverage cans. Additional end-use products containing polycarbonate plastics and resins include medical devices, some dental fillings and sealants, sporting and safety equipment, electronics, and automotive parts (EFSA, 2007; NTP, 2007). BPA is also used in the paper industry to produce thermal paper used for various products including receipts, prescription labels, airline tickets, and lottery tickets (Geens et al., 2011).

BPA does not occur naturally in the environment (Environment Canada & Health Canada, 2008a). Entry into the environment may occur from industrial sources or from product leaching, disposal, and use (CDC, 2009).

The primary route of exposure to BPA for the general public is through dietary intake as a result of various sources, including migration from food packaging and repeat-use polycarbonate containers (Health Canada, 2008b). Health Canada has recently updated its dietary exposure estimates for BPA following the completion of a number of specific food surveys, including canned foods and beverages, liquid infant formula, and Total Diet samples (Health Canada, 2012d). Exposure can also occur from contact with environmental media, including ambient and indoor air, drinking water, soil, and dust, and from the use of consumer products (Environment Canada & Health Canada, 2008a). BPA exposure from dental fillings and sealants is short term and considered unlikely to contribute substantially to chronic exposure (WHO, 2011a). However, further clinical research would help to answer questions about the potential harms caused by the exposure to BPA from dental composite materials (CADTH, 2012).

In humans, BPA is readily absorbed and undergoes extensive metabolism in the gut wall and the liver (WHO, 2011a). Recent studies have also suggested that it may be absorbed and metabolized by the skin following dermal exposure to free BPA in products such as those made from thermal printing papers (Mielke et al., 2011; Zalko et al., 2011). Glucuronidation has been recognized as a major metabolic pathway for BPA, resulting in the BPA-glucuronide conjugate metabolite (EFSA, 2008; FDA, 2008). Conjugation of BPA to BPA-sulphate has been shown to be a minor metabolic pathway (Dekant & Völkel, 2008). The BPA-glucuronide metabolite is rapidly excreted in urine with a half-life of less than 2 hours (WHO, 2011a). Urinary levels of total BPA, including both conjugated and free unconjugated forms, are commonly used as biomarkers to assess recent exposures (Ye et al., 2005).

Characterization of the potential risk to human health from exposure to BPA includes key effects on the liver and on reproduction, including fertility and developmental effects (Environment Canada & Health Canada, 2008a; EU, 2010). Developmental neurotoxicity studies in laboratory animals have suggested that, at low levels of exposure in fetuses and newborns, BPA can affect neural development and behaviour (Environment Canada & Health Canada, 2008a; WHO, 2011a). An American prospective birth cohort study demonstrated affected behavioural and emotional regulation domains in 3-year-olds following gestational BPA exposure (Braun et al., 2011). The potential role of BPA and other environmental estrogens in the prevalence of obesity and related metabolic diseases, as well as certain types of cancer, is under intensive debate and investigation among scientific communities (Ben-Jonathan et al., 2009; Carwile & Michels, 2011; Newbold et al., 2009; Song et al., 2014; Soto et al., 2008).

The Government of Canada has conducted a scientific screening assessment of the impact of human and environmental exposure to BPA and determined that it is toxic to human health and the environment as per the criteria set out under the Canadian Environmental Protection Act, 1999 (CEPA 1999) (Canada, 1999; Canada, 2010a). Because of the uncertainty raised in some laboratory animal studies relating to the potential effects of low levels of BPA, a precautionary approach was applied when characterizing risk. Combining the highest potential exposure and subpopulations with potential vulnerability due to potential differences in the toxicokinetics and metabolism of BPA, the risk management strategy for health focused on decreasing exposure to newborns and infants (Environment Canada & Health Canada, 2008b). As of March 2010, under the Canada Consumer Product Safety Act, Health Canada has prohibited the manufacturing, advertisement, sale, or import of polycarbonate baby bottles that contain BPA (Canada, 2010b).

Health Canada has concluded that current dietary exposure to BPA through food packaging uses is not expected to pose a health risk to the general population, including newborns and young children (Health Canada, 2012d). However, the general principle of as low as reasonably achievable (ALARA) was applied to continue efforts on limiting BPA exposure from food packaging applications to infants and newborns, specifically from pre-packaged infant formula products as a sole source food. As part of this ALARA approach, Health Canada committed to supporting industry to reduce levels of BPA in infant-formula can linings (Health Canada, 2010b). In addition, Health Canada has assessed a number of proposed industry alternatives to BPA and deemed them acceptable for packaging of liquid infant-formula. Infant-formula manufacturers are now phasing out the use of BPA-containing packaging materials, and the can-coating industry has developed various BPA-free alternatives for can coatings currently available on the market. Health Canada will continue to review pre-market submissions for infant-formula packaging to ensure the lowest levels of BPA achievable (Health Canada, 2010b). BPA is also included as a prohibited ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Health Canada, 2014b). Risk management actions have also been developed under CEPA 1999 with the objective of minimizing releases of BPA in industrial effluents (Canada, 2012b).

The Maternal-Infant Research on Environmental Chemicals (MIREC) Study is a national-level prospective biomonitoring study carried out in pregnant women aged 18 years and older from 10 sites across Canada (Arbuckle et al., 2013). In the MIREC Study of 1,936 participants in their first trimester of pregnancy, the geometric mean and 95th percentile for total BPA in urine were 0.80 µg/L and 5.40 µg/L, respectively (Arbuckle et al., 2014). The First Nations Biomonitoring Initiative (FNBI) is a nationally representative biomonitoring study of adult First Nations peoples living on reserves south of the 60° parallel (AFN, 2013). It comprises 13 randomly selected First Nation communities in Canada with 503 First Nations participants aged 20 years and older. The geometric mean and 95th percentile for total bisphenol A in urine were 1.55 µg/L and 11.27 µg/L, respectively.

Urinary total BPA (including both free and conjugated forms) was analyzed in the urine of Canadian Health Measures Survey participants aged 6 to 79 years in cycle 1 (2007-2009), and 3 to 79 years in cycle 2 (2009-2011) and cycle 3 (2012-2013). Data from these cycles are presented as both µg/L and µg/g creatinine. Finding a measurable amount of BPA in urine is an indicator of exposure to BPA and does not necessarily mean that an adverse health effect will occur.

Bisphenol A (BPA) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 6-79 years ^{Table 3 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 3 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5476	9.26	1.2 (1.1 - 1.2)	Table 3 footnote F	1.3 (1.1 - 1.4)	4.6 (4.1 - 5.1)	6.9 (5.6 - 8.2)
Total	6-79	2 (2009-2011)	2036	5.26	1.2 (1.1 - 1.3)	0.27 (0.22 - 0.31)	1.2 (1.1 - 1.3)	4.5 (3.9 - 5.0)	6.7 (4.8 - 8.5)
Total	6-79	3 (2012-2013)	5149	8.00	1.1 (1.0 - 1.2)	0.29 (0.26 - 0.32)	1.1 (0.95 - 1.2)	4.2 (3.6 - 4.8)	6.6 (5.7 - 7.5)
Males	6-79	1 (2007-2009)	2659	7.67	1.3 (1.2 - 1.4)	0.23Table 3 footnote E (<LOD - 0.34)	1.4 (1.2 - 1.6)	4.4 (3.9 - 5.0)	6.7 (5.3 - 8.1)
Males	6-79	2 (2009-2011)	1021	4.90	1.3 (1.1 - 1.4)	0.27Table 3 footnote E (<LOD - 0.37)	1.3 (1.1 - 1.5)	4.6 (4.1 - 5.2)	7.3Table 3 footnote E (4.0 - 11)
Males	6-79	3 (2012-2013)	2566	7.21	1.2 (1.1 - 1.3)	0.35 (0.25 - 0.46)	1.2 (0.98 - 1.4)	4.4 (3.7 - 5.0)	6.5 (5.5 - 7.5)
Females	6-79	1 (2007-2009)	2817	10.76	1.0 (0.93 - 1.2)	<LOD	1.1 (0.94 - 1.3)	4.9 (4.2 - 5.5)	7.0 (5.3 - 8.6)
Females	6-79	2 (2009-2011)	1015	5.62	1.2 (1.0 - 1.3)	0.26 (0.21 - 0.32)	1.1 (0.98 - 1.3)	4.0 (2.9 - 5.2)	6.6 (4.8 - 8.4)
Females	6-79	3 (2012-2013)	2583	8.79	1.0 (0.88 - 1.2)	0.29 (<LOD - 0.38)	1.0 (0.90 - 1.1)	4.1 (3.2 - 4.9)	6.9 (5.3 - 8.5)
Table 3 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 3 footnote a referrer Table 3 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 3 footnote b referrer Table 3 footnote E Use data with caution. Return to table 3 footnote E referrer Table 3 footnote F Data is too unreliable to be published. Return to table 3 footnote F referrer

Bisphenol A (BPA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 6-79 years ^{Table 4 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 4 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5462	9.26	1.4 (1.3 - 1.5)	0.39 (0.30 - 0.49)	1.3 (1.2 - 1.5)	4.7 (4.0 - 5.4)	7.2 (6.4 - 8.0)
Total	6-79	2 (2009-2011)	2027	5.26	1.2 (1.1 - 1.2)	0.39 (0.34 - 0.44)	1.0 (0.96 - 1.0)	4.0 (3.5 - 4.5)	6.6 (4.8 - 8.5)
Total	6-79	3 (2012-2013)	5147	8.00	1.1 (1.0 - 1.2)	0.40 (0.35 - 0.44)	0.98 (0.92 - 1.0)	3.3 (2.9 - 3.7)	5.7 (4.2 - 7.2)
Males	6-79	1 (2007-2009)	2650	7.67	1.3 (1.2 - 1.4)	0.38 (0.28 - 0.48)	1.2 (1.0 - 1.4)	3.9 (3.5 - 4.3)	6.0 (5.3 - 6.7)
Males	6-79	2 (2009-2011)	1018	4.90	1.0 (0.94 - 1.2)	0.36 (0.24 - 0.48)	0.99 (0.90 - 1.1)	3.5 (2.6 - 4.3)	5.8Table 4 footnote E (3.4 - 8.3)
Males	6-79	3 (2012-2013)	2566	7.21	1.0 (0.94 - 1.1)	0.38 (0.31 - 0.45)	0.97 (0.87 - 1.1)	3.0 (2.6 - 3.4)	4.8 (3.5 - 6.2)
Females	6-79	1 (2007-2009)	2812	10.76	1.5 (1.4 - 1.6)	<LOD	1.5 (1.3 - 1.6)	5.9 (4.9 - 6.9)	8.5 (6.9 - 10)
Females	6-79	2 (2009-2011)	1009	5.62	1.3 (1.2 - 1.4)	0.48 (0.39 - 0.57)	1.1 (0.89 - 1.3)	4.5 (3.4 - 5.5)	6.8 (4.5 - 9.2)
Females	6-79	3 (2012-2013)	2581	8.79	1.2 (1.1 - 1.3)	0.41 (0.37 - 0.45)	0.99 (0.92 - 1.1)	3.9 (2.9 - 4.8)	6.9Table 4 footnote E (4.1 - 9.7)
Table 4 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 4 footnote a referrer Table 4 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 4 footnote b referrer Table 4 footnote E Use data with caution. Return to table 4 footnote E referrer

Bisphenol A (BPA) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 5 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 5 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	2560	5.04	1.2 (1.1 - 1.3)	0.27 (0.22 - 0.31)	1.2 (1.1 - 1.3)	4.5 (4.0 - 5.0)	6.7 (4.8 - 8.6)
Total	3-79	3 (2012-2013)	5670	7.80	1.1 (1.0 - 1.2)	0.29 (0.27 - 0.32)	1.1 (0.95 - 1.2)	4.2 (3.6 - 4.8)	6.6 (5.8 - 7.5)
Males	3-79Table 5 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	1281	4.84	1.3 (1.1 - 1.5)	0.27 (<LOD - 0.36)	1.3 (1.1 - 1.5)	4.6 (4.1 - 5.2)	7.9Table 5 footnote E (4.3 - 11)
Males	3-79	3 (2012-2013)	2826	6.97	1.2 (1.1 - 1.4)	0.35 (0.25 - 0.46)	1.2 (0.99 - 1.4)	4.4 (3.7 - 5.0)	6.4 (5.2 - 7.7)
Females	3-79Table 5 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	1279	5.24	1.2 (1.0 - 1.3)	0.26 (0.21 - 0.32)	1.1 (0.98 - 1.3)	4.1 (3.0 - 5.1)	6.6 (4.9 - 8.4)
Females	3-79	3 (2012-2013)	2844	8.61	1.0 (0.88 - 1.2)	0.29 (<LOD - 0.39)	1.0 (0.91 - 1.1)	4.1 (3.3 - 4.9)	6.9 (5.4 - 8.4)
Total	3-5Table 5 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	524	4.20	1.4 (1.1 - 1.8)	0.30Table 5 footnote E (<LOD - 0.46)	1.3 (1.1 - 1.5)	5.4Table 5 footnote E (1.9 - 9.0)	9.9Table 5 footnote E (5.5 - 14)
Total	3-5	3 (2012-2013)	521	5.76	1.2 (0.87 - 1.6)	0.29Table 5 footnote E (<LOD - 0.47)	1.2 (0.95 - 1.5)	4.0 (2.6 - 5.4)	6.0 (4.3 - 7.7)
Total	6-11	1 (2007-2009)	1031	6.79	1.3 (1.2 - 1.4)	0.28 (<LOD - 0.37)	1.3 (1.1 - 1.6)	4.5 (3.8 - 5.1)	7.1 (5.5 - 8.7)
Total	6-11	2 (2009-2011)	516	5.81	1.4 (1.1 - 1.7)	0.25Table 5 footnote E (<LOD - 0.41)	1.3 (0.94 - 1.7)	4.6Table 5 footnote E (2.6 - 6.6)	Table 5 footnote F
Total	6-11	3 (2012-2013)	1004	5.58	1.2 (1.1 - 1.4)	0.39 (0.30 - 0.49)	1.2 (1.0 - 1.3)	3.8 (2.8 - 4.8)	5.3Table 5 footnote E (3.0 - 7.6)
Total	12-19	1 (2007-2009)	980	6.22	1.5 (1.3 - 1.8)	0.29 (0.22 - 0.36)	1.6 (1.3 - 1.9)	5.9 (4.8 - 7.0)	8.3 (6.2 - 10)
Total	12-19	2 (2009-2011)	512	4.69	1.3 (1.1 - 1.6)	0.35 (0.23 - 0.47)	1.3 (0.99 - 1.6)	4.4 (2.9 - 5.9)	7.6Table 5 footnote E (4.3 - 11)
Total	12-19	3 (2012-2013)	992	6.15	1.3 (1.1 - 1.6)	0.30Table 5 footnote E (<LOD - 0.46)	1.4 (1.3 - 1.6)	4.8 (3.4 - 6.2)	8.0Table 5 footnote E (4.1 - 12)
Total	20-39	1 (2007-2009)	1165	8.84	1.3 (1.2 - 1.5)	Table 5 footnote F	1.4 (1.2 - 1.6)	4.8 (4.1 - 5.4)	7.3 (5.2 - 9.5)
Total	20-39	2 (2009-2011)	357	2.80	1.3 (1.1 - 1.5)	0.32 (0.21 - 0.42)	1.3 (0.92 - 1.6)	4.6 (3.7 - 5.5)	Table 5 footnote F
Total	20-39	3 (2012-2013)	1040	7.88	1.1 (0.92 - 1.4)	0.29 (<LOD - 0.39)	1.1 (0.81 - 1.3)	5.5 (3.9 - 7.0)	6.7 (5.1 - 8.3)
Total	40-59	1 (2007-2009)	1219	12.06	1.0 (0.96 - 1.1)	<LOD	1.2 (1.1 - 1.4)	4.4 (3.5 - 5.3)	6.6 (4.8 - 8.4)
Total	40-59	2 (2009-2011)	360	6.11	1.2 (0.97 - 1.5)	0.25Table 5 footnote E (<LOD - 0.37)	1.2 (0.98 - 1.4)	4.3Table 5 footnote E (2.7 - 6.0)	6.7Table 5 footnote E (2.6 - 11)
Total	40-59	3 (2012-2013)	1075	9.86	1.1 (1.0 - 1.3)	0.30 (<LOD - 0.36)	1.1 (0.94 - 1.2)	4.2 (3.1 - 5.3)	7.5Table 5 footnote E (4.3 - 11)
Total	60-79	1 (2007-2009)	1081	11.66	0.90 (0.81 - 0.99)	<LOD	0.99 (0.87 - 1.1)	3.7 (3.3 - 4.2)	5.2 (3.8 - 6.6)
Total	60-79	2 (2009-2011)	291	7.22	1.0 (0.84 - 1.3)	0.21Table 5 footnote E (<LOD - 0.31)	0.99 (0.76 - 1.2)	4.4Table 5 footnote E (2.5 - 6.2)	6.3 (4.4 - 8.1)
Total	60-79	3 (2012-2013)	1038	10.31	0.88 (0.77 - 1.0)	<LOD	0.88 (0.76 - 1.0)	3.3 (2.8 - 3.7)	5.5 (4.2 - 6.7)
Table 5 footnotes Table 5 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 5 footnote a referrer Table 5 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 5 footnote b referrer Table 5 footnote E Use data with caution. Return to table 5 footnote E referrer Table 5 footnote F Data is too unreliable to be published. Return to table 5 footnote F referrer

Bisphenol A (BPA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 6 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 6 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	2550	5.04	1.2 (1.1 - 1.3)	0.39 (0.35 - 0.44)	1.0 (0.92 - 1.1)	4.1 (3.6 - 4.6)	6.9 (5.1 - 8.7)
Total	3-79	3 (2012-2013)	5667	7.80	1.1 (1.0 - 1.2)	0.40 (0.36 - 0.45)	0.99 (0.94 - 1.0)	3.6 (3.0 - 4.2)	5.9 (4.4 - 7.5)
Males	3-79Table 6 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	1277	4.84	1.1 (0.96 - 1.2)	0.36 (0.24 - 0.48)	0.99 (0.93 - 1.1)	3.7 (2.7 - 4.8)	6.2Table 6 footnote E (3.5 - 8.8)
Males	3-79	3 (2012-2013)	2826	6.97	1.1 (0.96 - 1.2)	0.38 (0.32 - 0.45)	0.98 (0.90 - 1.1)	3.1 (2.8 - 3.4)	5.1 (3.9 - 6.4)
Females	3-79Table 6 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	1273	5.24	1.3 (1.2 - 1.5)	0.48 (0.40 - 0.57)	1.1 (0.95 - 1.3)	4.5 (3.5 - 5.5)	6.9 (4.5 - 9.4)
Females	3-79	3 (2012-2013)	2841	8.61	1.2 (1.1 - 1.4)	0.42 (0.37 - 0.46)	1.0 (0.91 - 1.1)	4.0 (3.1 - 5.0)	7.1Table 6 footnote E (4.4 - 9.9)
Total	3-5Table 6 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	523	4.20	2.4 (1.9 - 3.1)	0.88Table 6 footnote E (0.54 - 1.2)	2.0 (1.8 - 2.3)	10Table 6 footnote E (4.6 - 15)	13 (8.6 - 17)
Total	3-5	3 (2012-2013)	520	5.76	2.3 (1.8 - 2.9)	0.86Table 6 footnote E (0.48 - 1.2)	2.1 (1.4 - 2.7)	5.9 (4.1 - 7.8)	8.4 (6.7 - 10)
Total	6-11	1 (2007-2009)	1028	6.79	2.0 (1.8 - 2.2)	0.68 (0.53 - 0.82)	2.0 (1.8 - 2.1)	5.8 (4.8 - 6.9)	9.8 (7.4 - 12)
Total	6-11	2 (2009-2011)	514	5.81	1.5 (1.2 - 1.9)	0.44Table 6 footnote E (0.20 - 0.68)	1.4 (1.1 - 1.7)	Table 6 footnote F	10Table 6 footnote E (3.0 - 18)
Total	6-11	3 (2012-2013)	1004	5.58	1.5 (1.3 - 1.7)	0.58 (0.46 - 0.69)	1.4 (1.1 - 1.6)	3.9 (2.6 - 5.2)	5.3Table 6 footnote E (2.0 - 8.6)
Total	12-19	1 (2007-2009)	978	6.22	1.3 (1.2 - 1.4)	0.40 (0.30 - 0.50)	1.2 (0.99 - 1.4)	4.2 (3.3 - 5.0)	6.4Table 6 footnote E (4.0 - 8.8)
Total	12-19	2 (2009-2011)	510	4.69	1.0 (0.83 - 1.2)	0.30Table 6 footnote E (<LOD - 0.43)	0.94 (0.79 - 1.1)	3.4Table 6 footnote E (1.5 - 5.2)	5.0 (3.8 - 6.3)
Total	12-19	3 (2012-2013)	991	6.15	1.0 (0.85 - 1.2)	0.35 (0.25 - 0.44)	0.95 (0.82 - 1.1)	3.0 (2.3 - 3.8)	5.4Table 6 footnote E (2.6 - 8.2)
Total	20-39	1 (2007-2009)	1161	8.84	1.5 (1.4 - 1.6)	0.44 (0.33 - 0.55)	1.4 (1.2 - 1.6)	4.4 (3.4 - 5.4)	6.8 (5.9 - 7.7)
Total	20-39	2 (2009-2011)	355	2.80	1.1 (0.89 - 1.3)	0.39 (0.27 - 0.50)	0.99 (0.85 - 1.1)	2.8 (1.8 - 3.7)	Table 6 footnote F
Total	20-39	3 (2012-2013)	1040	7.88	1.0 (0.90 - 1.2)	0.36 (0.29 - 0.43)	0.93 (0.80 - 1.1)	3.3 (2.6 - 3.9)	5.4Table 6 footnote E (2.7 - 8.1)
Total	40-59	1 (2007-2009)	1214	12.06	1.3 (1.2 - 1.5)	0.36Table 6 footnote E (0.22 - 0.51)	1.2 (1.0 - 1.4)	4.7 (3.8 - 5.7)	7.5 (6.1 - 8.8)
Total	40-59	2 (2009-2011)	358	6.11	1.2 (0.99 - 1.4)	0.39 (0.27 - 0.50)	1.1 (0.86 - 1.3)	4.2Table 6 footnote E (2.3 - 6.2)	6.9Table 6 footnote E (3.4 - 10)
Total	40-59	3 (2012-2013)	1074	9.86	1.2 (1.1 - 1.3)	0.47 (0.42 - 0.52)	0.99 (0.90 - 1.1)	3.8 (2.9 - 4.6)	6.1Table 6 footnote E (3.7 - 8.5)
Total	60-79	1 (2007-2009)	1081	11.66	1.2 (1.1 - 1.4)	0.30 (0.21 - 0.39)	1.1 (0.94 - 1.3)	4.3 (3.0 - 5.6)	7.6 (5.4 - 9.8)
Total	60-79	2 (2009-2011)	290	7.22	1.2 (0.99 - 1.4)	0.29Table 6 footnote E (<LOD - 0.45)	1.0 (0.89 - 1.1)	4.7 (3.3 - 6.0)	6.8Table 6 footnote E (2.9 - 11)
Total	60-79	3 (2012-2013)	1038	10.31	1.0 (0.97 - 1.1)	0.35 (0.30 - 0.41)	0.99 (0.94 - 1.0)	3.0 (2.7 - 3.4)	4.7Table 6 footnote E (2.7 - 6.7)
Table 6 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 6 footnote a referrer Table 6 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 6 footnote b referrer Table 6 footnote E Use data with caution. Return to table 6 footnote E referrer Table 6 footnote F Data is too unreliable to be published. Return to table 6 footnote F referrer

Triclosan

Triclosan (CASRN 3380-34-5) is a synthetic chemical with wide application since 1972 as an antimicrobial agent and as a preservative (Jones et al., 2000). It is used as a medicinal ingredient in non-prescription drug products and as a non-medicinal ingredient in cosmetics, natural health products, and drug products. Cosmetic products containing triclosan have been notified to Health Canada, including skin moisturizers (body, face, and hands), face and eye makeup, deodorant sticks/sprays, fragrances, tanning products, skin cleansers, shaving preparations, and shampoos (Environment Canada & Health Canada, 2012a). In addition, a number of products containing triclosan as an active medicinal ingredient are regulated as non-prescription drug products in Canada, including toothpastes, skin cleansers, and moisturizers (Health Canada, 2013d). Triclosan is also used to control the spread of bacteria in household items such as cleaners, textiles, carpets, and cutting boards, and in medical devices (Jones et al., 2000). As a material preservative, triclosan is registered under the Pest Control Products Act (Canada, 2006); no domestic class pest-control products containing triclosan are currently registered for use in Canada (Environment Canada & Health Canada, 2012b; Health Canada, 2014c). The registrants of triclosan pesticide products have indicated their intention to discontinue the registration of their products. Since December 31, 2014, triclosan is no longer registered for use as a pesticide in Canada (Health Canada, 2014c).

Triclosan does not occur naturally in the environment (Environment Canada & Health Canada, 2012a). The use of triclosan-containing products results in its release to waste-water systems and subsequently surface water (Environment Canada & Health Canada, 2012a). The potential routes of exposure for the general public are oral and dermal contact with products such as toothpastes and cosmetics that contain triclosan, ingestion of triclosan-contaminated drinking water, breast milk, or ingestion of household dust (Environment Canada & Health Canada, 2012b).

Following oral exposures, triclosan is rapidly absorbed and distributed in humans, with plasma levels increasing rapidly within 1 to 4 hours (Environment Canada & Health Canada, 2012b). Absorption following dermal exposure to triclosan-containing products ranges from 11% to 17% in humans (Maibach, 1969; Queckenberg et al., 2010; Stierlin, 1972). Only limited absorption (approximately 5% to 10%) occurs under normal conditions of toothpaste use (SCCP, 2009). Following all routes of administration, absorbed triclosan is nearly totally converted to glucuronic and sulfuric acid conjugates (Fang et al., 2010). Triclosan is rapidly eliminated after metabolism with an observed half-life in humans ranging from 13 to 29 hours following oral administration (SCCP, 2009). About 24% to 83% of absorbed triclosan is excreted in urine, mostly as the glucuronide conjugate (Fang et al., 2010; Sandborgh-Englund et al., 2006). Excretion of triclosan in feces is as the free unchanged compound and represents a smaller portion of the administered dose (10% to 30%) (Environment Canada & Health Canada, 2012b). Currently, there is no evidence of bioaccumulation potential in humans (SCCP, 2009). The concentration of total triclosan in urine (conjugated and free) can be used as a biomarker of exposure to triclosan (Calafat et al., 2007).

Triclosan is not acutely toxic to mammals, but it can interact with cellular enzymes and receptors (Calafat et al., 2007). The potential effects of these interactions remain unknown. In rodents, there have been observations of adverse effects of triclosan on thyroid hormone homeostasis resulting from liver toxicity; however, the overall weight of evidence does not currently support effects of triclosan on thyroid function as a critical effect for risk characterization in humans (Environment Canada & Health Canada, 2012b). To date, triclosan has not been assessed for carcinogenic potential by the International Agency for Research on Cancer; the United States Environmental Protection Agency has classified triclosan as not likely to be carcinogenic to humans (EPA, 2008a).

Health Canada and Environment Canada have jointly reviewed triclosan in a preliminary risk assessment and have proposed to conclude that it is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health (Environment Canada & Health Canada, 2012b). In the same preliminary assessment, Health Canada's Pest Management Regulatory Agency has proposed to conclude that the use of pest control products containing triclosan in Canada does not pose an unacceptable risk to human health (Environment Canada & Health Canada, 2012b). However, at current environmental levels, it is proposed to conclude that triclosan is an ecological concern and therefore it meets the definition of toxic under the Canadian Environmental Protection Act, 1999(Canada, 1999).

Triclosan is included as a restricted ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Health Canada, 2014b). The Hotlist indicates concentration limits of triclosan in mouthwash and other cosmetic products (Health Canada, 2014b). In addition, the Hotlist indicates that oral cosmetics containing triclosan shall include a label statement indicating that the product is not to be used by children under 12 years of age (Health Canada, 2014b). The Hotlist also indicates that mouthwashes include a label statement to the effect of "avoid swallowing" (Health Canada, 2014b).

Total triclosan (including both free and conjugated forms) was analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and is presented as both µg/L and µg/g creatinine. Finding a measurable amount of triclosan in urine is an indicator of exposure to triclosan and does not necessarily mean that an adverse health effect will occur.

Triclosan - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 7 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2550	28.20	16 (13 - 20)	<LOD	9.5Table 7 footnote E (5.8 - 13)	400 (280 - 520)	710 (540 - 880)
Total	3-79	3 (2012-2013)	5645	34.47	17 (15 - 19)	<LOD	9.9 (8.4 - 11)	350 (270 - 430)	720 (460 - 980)
Males	3-79	2 (2009-2011)	1274	26.77	18 (13 - 26)	<LOD	12Table 7 footnote E (5.3 - 18)	510 (330 - 690)	790Table 7 footnote E (350 - 1200)
Males	3-79	3 (2012-2013)	2815	34.03	17 (14 - 21)	<LOD	10 (7.4 - 13)	330Table 7 footnote E (180 - 480)	760Table 7 footnote E (380 - 1100)
Females	3-79	2 (2009-2011)	1276	29.62	14 (11 - 18)	<LOD	7.5Table 7 footnote E (3.1 - 12)	310Table 7 footnote E (140 - 470)	680Table 7 footnote E (410 - 960)
Females	3-79	3 (2012-2013)	2830	34.91	17 (13 - 22)	<LOD	9.6 (7.8 - 12)	390Table 7 footnote E (220 - 550)	700Table 7 footnote E (280 - 1100)
Total	3-5	2 (2009-2011)	523	29.45	8.9 (7.3 - 11)	<LOD	7.3 (4.9 - 9.6)	50 (40 - 61)	120Table 7 footnote E (68 - 160)
Total	3-5	3 (2012-2013)	518	36.29	9.5 (7.4 - 12)	<LOD	7.7Table 7 footnote E (<LOD - 11)	78Table 7 footnote E (43 - 110)	110Table 7 footnote E (47 - 170)
Total	6-11	2 (2009-2011)	515	33.98	8.5 (6.7 - 11)	<LOD	3.8Table 7 footnote E (<LOD - 5.9)	130Table 7 footnote E (54 - 210)	250Table 7 footnote E (82 - 410)
Total	6-11	3 (2012-2013)	1001	36.26	11 (8.4 - 16)	<LOD	7.2Table 7 footnote E (<LOD - 10)	Table 7 footnote F	340Table 7 footnote E (190 - 500)
Total	12-19	2 (2009-2011)	510	19.02	20 (14 - 27)	<LOD	13Table 7 footnote E (7.7 - 18)	350Table 7 footnote E (230 - 480)	640Table 7 footnote E (400 - 870)
Total	12-19	3 (2012-2013)	984	28.35	19 (14 - 26)	<LOD	10 (7.2 - 13)	510Table 7 footnote E (220 - 800)	840 (580 - 1100)
Total	20-39	2 (2009-2011)	353	19.26	21Table 7 footnote E (13 - 32)	<LOD	17Table 7 footnote E (9.1 - 25)	470Table 7 footnote E (180 - 760)	910Table 7 footnote E (430 - 1400)
Total	20-39	3 (2012-2013)	1035	27.44	24 (18 - 30)	<LOD	15 (11 - 19)	420Table 7 footnote E (250 - 580)	Table 7 footnote F
Total	40-59	2 (2009-2011)	359	28.97	19Table 7 footnote E (12 - 29)	<LOD	12Table 7 footnote E (4.3 - 20)	470Table 7 footnote E (200 - 740)	740Table 7 footnote E (290 - 1200)
Total	40-59	3 (2012-2013)	1072	37.22	16 (12 - 22)	<LOD	8.9 (6.6 - 11)	380Table 7 footnote E (140 - 620)	910Table 7 footnote E (250 - 1600)
Total	60-79	2 (2009-2011)	290	41.72	--	<LOD	4.8Table 7 footnote E (<LOD - 6.8)	360Table 7 footnote E (160 - 560)	590 (430 - 750)
Total	60-79	3 (2012-2013)	1035	41.84	--	<LOD	6.9 (6.0 - 7.7)	260Table 7 footnote E (140 - 380)	580Table 7 footnote E (270 - 890)
Table 7 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 7 footnote a referrer Table 7 footnote E Use data with caution. Return to table 7 footnote E referrer Table 7 footnote F Data is too unreliable to be published. Return to table 7 footnote F referrer

Triclosan (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 8 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2540	28.20	15 (11 - 19)	<LOD	9.1 (7.2 - 11)	370 (260 - 480)	610 (400 - 830)
Total	3-79	3 (2012-2013)	5642	34.47	17 (15 - 20)	<LOD	9.9 (9.2 - 11)	350 (310 - 390)	640 (510 - 770)
Males	3-79	2 (2009-2011)	1270	26.77	15 (10 - 21)	<LOD	8.8 (6.1 - 11)	390 (280 - 490)	700Table 8 footnote E (360 - 1000)
Males	3-79	3 (2012-2013)	2815	34.03	15 (12 - 18)	<LOD	8.7 (7.1 - 10)	310Table 8 footnote E (190 - 440)	470 (340 - 610)
Females	3-79	2 (2009-2011)	1270	29.62	15 (11 - 19)	<LOD	9.9 (7.9 - 12)	320Table 8 footnote E (150 - 480)	570Table 8 footnote E (340 - 800)
Females	3-79	3 (2012-2013)	2827	34.91	21 (16 - 27)	<LOD	11 (8.0 - 13)	390 (260 - 520)	810 (560 - 1100)
Total	3-5	2 (2009-2011)	522	29.45	14 (12 - 17)	<LOD	12 (8.8 - 16)	84 (58 - 110)	180 (140 - 230)
Total	3-5	3 (2012-2013)	517	36.29	18 (15 - 23)	<LOD	13 (8.8 - 17)	110Table 8 footnote E (47 - 180)	260 (170 - 350)
Total	6-11	2 (2009-2011)	513	33.98	8.5 (6.2 - 12)	<LOD	5.0Table 8 footnote E (<LOD - 7.3)	150Table 8 footnote E (57 - 250)	270Table 8 footnote E (82 - 470)
Total	6-11	3 (2012-2013)	1001	36.26	14 (11 - 17)	<LOD	8.8 (7.0 - 11)	Table 8 footnote F	340Table 8 footnote E (160 - 530)
Total	12-19	2 (2009-2011)	508	19.02	14 (10 - 19)	<LOD	9.4Table 8 footnote E (5.5 - 13)	280Table 8 footnote E (150 - 420)	490Table 8 footnote E (280 - 710)
Total	12-19	3 (2012-2013)	983	28.35	14 (11 - 19)	<LOD	8.7 (7.0 - 11)	350Table 8 footnote E (160 - 540)	530 (380 - 680)
Total	20-39	2 (2009-2011)	351	19.26	17Table 8 footnote E (11 - 27)	<LOD	11Table 8 footnote E (6.9 - 15)	410Table 8 footnote E (220 - 600)	680Table 8 footnote E (290 - 1100)
Total	20-39	3 (2012-2013)	1035	27.44	22 (16 - 29)	<LOD	11 (7.6 - 15)	350 (270 - 430)	560Table 8 footnote E (320 - 810)
Total	40-59	2 (2009-2011)	357	28.97	17Table 8 footnote E (11 - 28)	<LOD	9.9Table 8 footnote E (<LOD - 17)	410Table 8 footnote E (230 - 590)	820Table 8 footnote E (440 - 1200)
Total	40-59	3 (2012-2013)	1071	37.22	17 (13 - 22)	<LOD	9.4 (7.1 - 12)	400Table 8 footnote E (240 - 560)	900Table 8 footnote E (410 - 1400)
Total	60-79	2 (2009-2011)	289	41.72	--	<LOD	7.1 (5.0 - 9.2)	370Table 8 footnote E (200 - 550)	600Table 8 footnote E (280 - 910)
Total	60-79	3 (2012-2013)	1035	41.84	--	<LOD	9.5 (8.2 - 11)	340Table 8 footnote E (200 - 480)	720Table 8 footnote E (430 - 1000)
Table 8 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 8 footnote a referrer Table 8 footnote E Use data with caution. Return to table 8 footnote E referrer Table 8 footnote F Data is too unreliable to be published. Return to table 8 footnote F referrer

Summaries and Results for Metals and Trace Elements

Arsenic

Arsenic (CASRN 7440-38-2) is a naturally occurring element making up a small fraction (0.00015%) of the Earth's crust (ATSDR, 2007a; Emsley, 2001). It is classified as a metalloid, exhibiting properties of both a metal and a non-metal. Arsenic is commonly found as an inorganic sulphide complexed with other metals (CCME, 1997). Arsenic also forms stable organic compounds in its trivalent (+3) and pentavalent (+5) states. Common organic arsenic compounds include monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), arsenobetaine, and arsenocholine (WHO, 2001).

Arsenic may enter lakes, rivers, or groundwater naturally through erosion and weathering of soils, minerals, and ores (Health Canada, 2006a). The primary anthropogenic sources of arsenic are the smelting of metal ores, the use of arsenical pesticides, and the burning of fossil fuels (WHO, 2001).

Arsenic is used in the manufacture of transistors, lasers, and semi-conductors, and in the processing of glass, pigments, textiles, paper, metal adhesives, ceramics, wood preservatives, ammunition, and explosives. Historical uses of arsenic include application of lead arsenate as a pesticide in apple orchards and vineyards and arsenic trioxide as a herbicide (ATSDR, 2007a; Health Canada, 2006a). Chromated copper arsenate was formerly used as a wood preservative in residential construction projects, such as playground structures and decks; however, it is now used only for industrial purposes and for domestic wood foundations (Health Canada, 2005a). Organic arsenical herbicides, such as MMA and DMA, are no longer registered for use in Canada (Environment Canada, 2008; Health Canada, 2014c).

The public can be exposed to arsenic through food, drinking water, soil, and ambient air (Environment Canada & Health Canada, 1993a). Food is the major source of exposure with total arsenic concentrations being highest in seafood (IARC, 2012a). Organic forms of arsenic, including arsenobetaine and arsenocholine, make up the majority of arsenic in seafood (Ackley et al., 1999; Leufroy et al., 2011; Ruttens et al., 2012). In other foods, there is growing evidence to suggest that inorganic arsenic may represent the predominant form of arsenic (Batista et al., 2011; CFIA, 2013; Conklin & Chen, 2012; Huang et al., 2012). Exposure to arsenic may also arise from indoor house dust; levels in dust can exceed levels in soil (Rasmussen et al., 2001). Further, exposure to arsenic may be elevated in populations residing in areas where industrial or natural sources occur.

Inorganic arsenic and organic arsenic are readily absorbed via the oral and inhalation routes of exposure; arsenic in all its forms is not readily absorbed via the dermal route. Absorption of arsenic is much lower for highly insoluble forms of arsenic such as arsenic sulfide, arsenic triselenide, and lead arsenate (ATSDR, 2007a). Following absorption, arsenic appears rapidly in blood circulation where it binds primarily to haemoglobin. Within 24 hours, it is found in the liver, kidney, lung, spleen, and skin. Skin, bone, and muscle represent the major storage organs. In cases of chronic exposure, arsenic will preferentially accumulate in tissues rich in keratin or sulfhydryl functional groups, such as hair, nails, skin, and other protein-containing tissues (HBM Commission, 2003). Metabolism of inorganic arsenic involves an initial reduction of pentavalent to trivalent arsenic followed by oxidative methylation to monomethylated, dimethylated, and trimethylated products, including MMA and DMA (WHO, 2011b). Methylation facilitates the excretion of inorganic arsenic from the body because the end-products MMA and DMA are water soluble and readily excreted in urine (WHO, 2001). Organic arsenic species do not undergo significant metabolism and are predominantly and rapidly eliminated in urine (WHO, 2001).

Biomarkers of arsenic exposure include the levels of arsenic or its metabolites in blood, hair, nails, and urine (WHO, 2001). Measurements of speciated metabolites in urine expressed either as inorganic arsenic or as the sum of metabolites (inorganic arsenic + MMA + DMA) are generally accepted as the most reliable indicator of recent arsenic exposure (ATSDR, 2007a; WHO, 2001). Measurements of arsenic in urine have been used to identify recent arsenic ingestion or above-average exposures in populations living near industrial point sources of arsenic (ATSDR, 2007a).

Acute oral arsenic exposure may cause gastrointestinal effects in humans as well as pain to the extremities and muscles (Health Canada, 2006a). These symptoms are often followed by numbness and tingling of the extremities and muscular cramping and may progress into burning paraesthesias of the extremities, palmoplantar hyperkeratosis, and deterioration in motor and sensory responses (Health Canada, 2006a).

Chronic exposure to inorganic arsenic has been associated with decreased lung function, non-cancer skin effects, and cardiovascular effects including increased incidence of high blood pressure and circulatory problems (ATSDR, 2007a; Environment Canada & Health Canada, 1993a). In addition, increased incidences of skin cancer and various cancers of the internal organs have been associated with chronic ingestion of inorganic arsenic-contaminated drinking water (Health Canada, 2006a). Much of the evidence comes from an epidemiological study conducted in southwestern Taiwan (Chen et al., 1985; Health Canada, 2006a; Tseng, 1977; Wu et al., 1989). Arsenic and inorganic arsenic compounds are classified as carcinogenic to humans by Health Canada and other international agencies (EPA, 1998; Health Canada, 2006a; IARC, 2012a).

Although the majority of assessments on the toxicity of arsenic have concentrated on the inorganic forms, recent studies have highlighted the potential for organic arsenic compounds, in particular the pentavalent DMA, to exert carcinogenic effects (Cohen et al., 2006; IARC, 2012a; Schwerdtle et al., 2003). The International Agency for Research on Cancer (IARC) has classified the methylated arsenic metabolites MMA and DMA as Group 2B, possibly carcinogenic to humans, based on evidence from experimental animals (IARC, 2012a). IARC has also evaluated arsenobetaine and other organic arsenic compounds and found them to be not classifiable as to their carcinogenicity to humans (Group 3) (IARC, 2012a).

Health Canada and Environment Canada concluded that arsenic and its inorganic compounds in Canada may be harmful to the environment and may constitute a danger to human life or health (Environment Canada & Health Canada, 1993a). Inorganic arsenic compounds are listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999). The Act allows the federal government to control the importation, manufacture, distribution, and use of inorganic arsenic compounds in Canada (Canada, 1999; Canada, 2000). Risk management actions under CEPA 1999 have been developed to control releases of arsenic from thermal electric power generation, base-metal smelting, wood preservation, and steel manufacturing processes (Environment Canada, 2010a). Arsenic and its compounds are included as prohibited ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations(Canada, 1985; Health Canada, 2014b). The Food and Drug Regulations prohibit the sale in Canada of drugs for human use containing arsenic or any of its salts or derivatives (Canada, 2012c). Further, the leachable arsenic content in a variety of consumer products is regulated under the Canada Consumer Product Safety Act (Canada, 2010b). These regulated consumer products include paints and other surface coatings on cribs, toys, and other products for use by a child in learning or play situations (Canada, 2010c; Canada, 2011b).

The Federal-Provincial-Territorial Committee on Drinking Water has developed a guideline for Canadian drinking water quality that establishes a maximum acceptable concentration for arsenic in drinking water (Health Canada, 2006a). The guideline was developed based on the incidence of internal (lung, bladder, and liver) cancers in humans and the ability of currently available treatment technologies to remove arsenic from drinking water at or below the guideline level (Health Canada, 2006a). Arsenic is also included in the list of various chemicals analyzed as part of Health Canada's ongoing Total Diet Study surveys (Health Canada, 2013e). The food items analyzed represent those that are most typical of the Canadian diet, and the surveys are used to provide dietary exposure estimates for chemicals that Canadians in different age-sex groups are exposed to through the food supply. The concentration of arsenic in some foods is regulated by Health Canada under the Food and Drug Regulations; current food tolerances, specifically those for arsenic in a variety of beverages including apple juice and bottled water, are in the process of being updated (Canada, 2012c; Health Canada, 2014d).

In a study carried out in British Columbia to assess the levels of trace elements in 61 non-smoking adults aged 30 to 65 years, the geometric mean concentration and 95th percentile of total arsenic in urine were 27.8 µg/g creatinine and 175.5 µg/g creatinine, respectively (Clark et al., 2007). In a biomonitoring study carried out in the region of the city of Quebec with 500 participants aged 18 to 65 years, the geometric mean of total arsenic in urine was 12.73 µg/L and in whole blood was 0.95 µg/L (INSPQ, 2004).

Arsenite (+3), arsenate (+5), and methylated metabolites of arsenic (MMA and DMA) were analyzed individually in the urine of Canadian Health Measures Survey (CHMS) cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years. The data from these cycles are presented as both µg As/L and µg As/g creatinine. The organoarsenic compounds, arsenobetaine and arsenocholine, were analyzed together in the urine of CHMS cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and arsenocholine was also analyzed alone in cycle 3. The data are presented as both µg As/L and µg As/g creatinine. Finding a measurable amount of arsenic in urine is an indicator of exposure to arsenic and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for the urinary arsenocholine in the Canadian population.

Arsenate - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 9 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 9 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2538	99.49	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2536	99.25	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1271	99.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1251	99.04	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1267	99.61	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1285	99.46	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	516	98.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	500	98.60	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	511	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	507	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	510	99.41	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	510	98.82	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	355	99.44	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	355	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	357	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	312	99.04	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	289	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	352	100	--	<LOD	<LOD	<LOD	<LOD
Table 9 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 9 footnote a referrer Table 9 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 9 footnote b referrer

Arsenate (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 10 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 10 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2528	99.49	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2535	99.25	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1267	99.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1251	99.04	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1261	99.61	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1284	99.46	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	515	98.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	499	98.60	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	509	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	507	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	508	99.41	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	510	98.82	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	353	99.44	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	355	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	355	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	312	99.04	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	288	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	352	100	--	<LOD	<LOD	<LOD	<LOD
Table 10 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 10 footnote a referrer Table 10 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 10 footnote b referrer

Arsenite - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 11 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 11 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2537	75.60	--	<LOD	<LOD	1.7 (1.1 - 2.3)	2.7Table 11 footnote E (1.3 - 4.0)
Total	3-79	3 (2012-2013)	2535	73.96	--	<LOD	<LOD	1.7Table 11 footnote E (0.92 - 2.5)	Table 11 footnote F
Males	3-79	2 (2009-2011)	1271	72.54	--	<LOD	<LOD	1.7 (1.1 - 2.3)	2.8Table 11 footnote E (0.88 - 4.7)
Males	3-79	3 (2012-2013)	1250	71.20	--	<LOD	<LOD	1.4 (1.0 - 1.8)	Table 11 footnote F
Females	3-79	2 (2009-2011)	1266	78.67	--	<LOD	<LOD	1.5Table 11 footnote E (0.72 - 2.3)	2.4Table 11 footnote E (1.1 - 3.7)
Females	3-79	3 (2012-2013)	1285	76.65	--	<LOD	<LOD	Table 11 footnote F	Table 11 footnote F
Total	3-5	2 (2009-2011)	516	84.50	--	<LOD	<LOD	0.79Table 11 footnote E (<LOD - 1.2)	1.3Table 11 footnote E (0.74 - 1.9)
Total	3-5	3 (2012-2013)	500	81.80	--	<LOD	<LOD	0.94 (<LOD - 1.2)	1.9Table 11 footnote E (0.75 - 3.0)
Total	6-11	2 (2009-2011)	511	78.86	--	<LOD	<LOD	1.0Table 11 footnote E (<LOD - 1.4)	1.8Table 11 footnote E (1.1 - 2.4)
Total	6-11	3 (2012-2013)	506	76.09	--	<LOD	<LOD	1.1 (0.81 - 1.4)	1.6Table 11 footnote E (0.82 - 2.5)
Total	12-19	2 (2009-2011)	510	72.35	--	<LOD	<LOD	1.9Table 11 footnote E (1.2 - 2.7)	Table 11 footnote F
Total	12-19	3 (2012-2013)	510	68.43	--	<LOD	<LOD	1.5Table 11 footnote E (<LOD - 2.3)	2.6Table 11 footnote E (1.1 - 4.0)
Total	20-39	2 (2009-2011)	355	69.86	--	<LOD	<LOD	1.9Table 11 footnote E (<LOD - 3.1)	Table 11 footnote F
Total	20-39	3 (2012-2013)	355	70.70	--	<LOD	<LOD	Table 11 footnote F	Table 11 footnote F
Total	40-59	2 (2009-2011)	356	70.51	--	<LOD	<LOD	1.3Table 11 footnote E (0.75 - 1.8)	2.0Table 11 footnote E (1.0 - 2.9)
Total	40-59	3 (2012-2013)	312	70.19	--	<LOD	<LOD	Table 11 footnote F	Table 11 footnote F
Total	60-79	2 (2009-2011)	289	73.01	--	<LOD	<LOD	1.9Table 11 footnote E (1.1 - 2.7)	Table 11 footnote F
Total	60-79	3 (2012-2013)	352	74.43	--	<LOD	<LOD	1.8 (1.1 - 2.4)	3.2Table 11 footnote E (1.3 - 5.2)
Table 11 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 11 footnote a referrer Table 11 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 11 footnote b referrer Table 11 footnote E Use data with caution. Return to table 11 footnote E referrer Table 11 footnote F Data is too unreliable to be published. Return to table 11 footnote F referrer

Arsenite (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 12 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 12 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2527	75.60	--	<LOD	<LOD	2.0 (1.6 - 2.3)	2.9 (1.9 - 3.9)
Total	3-79	3 (2012-2013)	2534	73.96	--	<LOD	<LOD	1.9Table 12 footnote E (1.2 - 2.7)	Table 12 footnote F
Males	3-79	2 (2009-2011)	1267	72.54	--	<LOD	<LOD	1.4Table 12 footnote E (0.85 - 1.9)	Table 12 footnote F
Males	3-79	3 (2012-2013)	1250	71.20	--	<LOD	<LOD	1.2 (0.94 - 1.5)	Table 12 footnote F
Females	3-79	2 (2009-2011)	1260	78.67	--	<LOD	<LOD	2.2 (1.6 - 2.8)	3.0 (2.1 - 3.9)
Females	3-79	3 (2012-2013)	1284	76.65	--	<LOD	<LOD	2.4Table 12 footnote E (0.86 - 3.9)	Table 12 footnote F
Total	3-5	2 (2009-2011)	515	84.50	--	<LOD	<LOD	1.9 (1.7 - 2.2)	2.9 (1.9 - 3.9)
Total	3-5	3 (2012-2013)	499	81.80	--	<LOD	<LOD	2.5Table 12 footnote E (1.3 - 3.7)	4.3Table 12 footnote E (2.6 - 6.1)
Total	6-11	2 (2009-2011)	509	78.86	--	<LOD	<LOD	1.6Table 12 footnote E (1.0 - 2.2)	2.2Table 12 footnote E (1.2 - 3.1)
Total	6-11	3 (2012-2013)	506	76.09	--	<LOD	<LOD	1.7 (1.1 - 2.2)	2.5Table 12 footnote E (1.3 - 3.6)
Total	12-19	2 (2009-2011)	508	72.35	--	<LOD	<LOD	1.4Table 12 footnote E (0.85 - 2.0)	2.9Table 12 footnote E (1.4 - 4.5)
Total	12-19	3 (2012-2013)	510	68.43	--	<LOD	<LOD	1.4Table 12 footnote E (<LOD - 2.0)	1.9Table 12 footnote E (1.0 - 2.8)
Total	20-39	2 (2009-2011)	353	69.86	--	<LOD	<LOD	1.9Table 12 footnote E (0.89 - 3.0)	2.6Table 12 footnote E (0.86 - 4.3)
Total	20-39	3 (2012-2013)	355	70.70	--	<LOD	<LOD	Table 12 footnote F	Table 12 footnote F
Total	40-59	2 (2009-2011)	354	70.51	--	<LOD	<LOD	1.9 (1.3 - 2.6)	2.0Table 12 footnote E (1.2 - 2.8)
Total	40-59	3 (2012-2013)	312	70.19	--	<LOD	<LOD	Table 12 footnote F	Table 12 footnote F
Total	60-79	2 (2009-2011)	288	73.01	--	<LOD	<LOD	2.3Table 12 footnote E (1.2 - 3.3)	Table 12 footnote F
Total	60-79	3 (2012-2013)	352	74.43	--	<LOD	<LOD	2.3Table 12 footnote E (0.79 - 3.8)	3.7Table 12 footnote E (1.7 - 5.6)
Table 12 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 12 footnote a referrer Table 12 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 12 footnote b referrer Table 12 footnote E Use data with caution. Return to table 12 footnote E referrer Table 12 footnote F Data is too unreliable to be published. Return to table 12 footnote F referrer

Arsenocholine - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 13 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	3 (2012-2013)	2536	100	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1251	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1285	100	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	500	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	507	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	510	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	355	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	312	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	352	100	--	<LOD	<LOD	<LOD	<LOD
Table 13 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 13 footnote a referrer

Arsenocholine (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 14 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	3 (2012-2013)	2535	100	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1251	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1284	100	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	499	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	507	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	510	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	355	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	312	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	352	100	--	<LOD	<LOD	<LOD	<LOD
Table 14 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 14 footnote a referrer

Arsenocholine and arsenobetaine - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 15 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 15 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2538	48.50	--	<LOD	1.4Table 15 footnote E (<LOD - 2.2)	28Table 15 footnote E (18 - 39)	48Table 15 footnote E (30 - 67)
Total	3-79	3 (2012-2013)	2536	48.15	--	<LOD	1.4Table 15 footnote E (<LOD - 2.1)	24Table 15 footnote E (11 - 36)	56 (37 - 75)
Males	3-79	2 (2009-2011)	1271	46.34	--	<LOD	1.5Table 15 footnote E (<LOD - 2.5)	29Table 15 footnote E (14 - 43)	Table 15 footnote F
Males	3-79	3 (2012-2013)	1251	47.40	--	<LOD	1.4Table 15 footnote E (<LOD - 2.0)	21Table 15 footnote E (13 - 29)	38 (25 - 51)
Females	3-79	2 (2009-2011)	1267	50.67	--	<LOD	Table 15 footnote F	28Table 15 footnote E (15 - 41)	49Table 15 footnote E (29 - 69)
Females	3-79	3 (2012-2013)	1285	48.87	--	<LOD	1.5Table 15 footnote E (<LOD - 2.6)	Table 15 footnote F	58Table 15 footnote E (33 - 83)
Total	3-5	2 (2009-2011)	516	59.69	--	<LOD	<LOD	Table 15 footnote F	34Table 15 footnote E (19 - 49)
Total	3-5	3 (2012-2013)	500	57.40	--	<LOD	<LOD	12Table 15 footnote E (6.3 - 17)	Table 15 footnote F
Total	6-11	2 (2009-2011)	511	58.12	--	<LOD	<LOD	Table 15 footnote F	Table 15 footnote F
Total	6-11	3 (2012-2013)	507	59.57	--	<LOD	<LOD	Table 15 footnote F	27Table 15 footnote E (14 - 39)
Total	12-19	2 (2009-2011)	510	57.65	--	<LOD	<LOD	12Table 15 footnote E (4.5 - 19)	38Table 15 footnote E (16 - 59)
Total	12-19	3 (2012-2013)	510	51.18	--	<LOD	<LOD	16Table 15 footnote E (7.2 - 24)	37Table 15 footnote E (17 - 56)
Total	20-39	2 (2009-2011)	355	38.59	2.3Table 15 footnote E (1.5 - 3.6)	<LOD	Table 15 footnote F	33Table 15 footnote E (15 - 52)	68Table 15 footnote E (20 - 110)
Total	20-39	3 (2012-2013)	355	44.51	--	<LOD	Table 15 footnote F	19Table 15 footnote E (11 - 28)	35Table 15 footnote E (12 - 58)
Total	40-59	2 (2009-2011)	357	30.81	1.8 (1.4 - 2.4)	<LOD	1.4Table 15 footnote E (<LOD - 2.5)	Table 15 footnote F	35Table 15 footnote E (19 - 52)
Total	40-59	3 (2012-2013)	312	34.29	2.2Table 15 footnote E (1.3 - 3.8)	<LOD	Table 15 footnote F	Table 15 footnote F	57Table 15 footnote E (30 - 84)
Total	60-79	2 (2009-2011)	289	29.41	3.6Table 15 footnote E (2.2 - 5.9)	<LOD	3.6Table 15 footnote E (1.4 - 5.8)	40Table 15 footnote E (21 - 59)	74Table 15 footnote E (33 - 120)
Total	60-79	3 (2012-2013)	352	30.11	2.6Table 15 footnote E (1.8 - 3.8)	<LOD	2.1Table 15 footnote E (0.86 - 3.4)	Table 15 footnote F	67Table 15 footnote E (29 - 100)
Table 15 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 15 footnote a referrer Table 15 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 15 footnote b referrer Table 15 footnote E Use data with caution. Return to table 15 footnote E referrer Table 15 footnote F Data is too unreliable to be published. Return to table 15 footnote F referrer

Arsenocholine and arsenobetaine (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 16 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 16 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2528	48.50	--	<LOD	1.5Table 16 footnote E (<LOD - 2.5)	22 (16 - 28)	44Table 16 footnote E (18 - 71)
Total	3-79	3 (2012-2013)	2535	48.15	--	<LOD	1.6 (1.1 - 2.1)	25Table 16 footnote E (12 - 39)	44Table 16 footnote E (24 - 63)
Males	3-79	2 (2009-2011)	1267	46.34	--	<LOD	Table 16 footnote F	18Table 16 footnote E (9.4 - 27)	Table 16 footnote F
Males	3-79	3 (2012-2013)	1251	47.40	--	<LOD	1.2 (0.77 - 1.6)	16Table 16 footnote E (7.3 - 24)	34 (25 - 43)
Females	3-79	2 (2009-2011)	1261	50.67	--	<LOD	<LOD	25 (19 - 32)	61Table 16 footnote E (20 - 100)
Females	3-79	3 (2012-2013)	1284	48.87	--	<LOD	2.1Table 16 footnote E (0.84 - 3.3)	33Table 16 footnote E (9.5 - 56)	Table 16 footnote F
Total	3-5	2 (2009-2011)	515	59.69	--	<LOD	<LOD	Table 16 footnote F	Table 16 footnote F
Total	3-5	3 (2012-2013)	499	57.40	--	<LOD	<LOD	21Table 16 footnote E (11 - 31)	Table 16 footnote F
Total	6-11	2 (2009-2011)	509	58.12	--	<LOD	<LOD	Table 16 footnote F	Table 16 footnote F
Total	6-11	3 (2012-2013)	507	59.57	--	<LOD	<LOD	Table 16 footnote F	40Table 16 footnote E (12 - 69)
Total	12-19	2 (2009-2011)	508	57.65	--	<LOD	<LOD	9.3Table 16 footnote E (4.0 - 15)	24Table 16 footnote E (10 - 38)
Total	12-19	3 (2012-2013)	510	51.18	--	<LOD	<LOD	10Table 16 footnote E (3.8 - 17)	Table 16 footnote F
Total	20-39	2 (2009-2011)	353	38.59	1.9Table 16 footnote E (1.2 - 2.8)	<LOD	Table 16 footnote F	22Table 16 footnote E (7.8 - 37)	Table 16 footnote F
Total	20-39	3 (2012-2013)	355	44.51	--	<LOD	1.4Table 16 footnote E (0.88 - 1.9)	12Table 16 footnote E (5.5 - 19)	21Table 16 footnote E (9.8 - 32)
Total	40-59	2 (2009-2011)	355	30.81	1.8 (1.3 - 2.5)	<LOD	1.9Table 16 footnote E (<LOD - 3.1)	17Table 16 footnote E (10 - 24)	24Table 16 footnote E (9.8 - 39)
Total	40-59	3 (2012-2013)	312	34.29	2.6Table 16 footnote E (1.6 - 4.4)	<LOD	Table 16 footnote F	33Table 16 footnote E (14 - 52)	Table 16 footnote F
Total	60-79	2 (2009-2011)	288	29.41	4.2Table 16 footnote E (2.6 - 6.8)	<LOD	4.6Table 16 footnote E (1.7 - 7.5)	47Table 16 footnote E (13 - 80)	84Table 16 footnote E (43 - 120)
Total	60-79	3 (2012-2013)	352	30.11	2.9Table 16 footnote E (1.9 - 4.4)	<LOD	Table 16 footnote F	35Table 16 footnote E (13 - 57)	Table 16 footnote F
Table 16 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 16 footnote a referrer Table 16 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 16 footnote b referrer Table 16 footnote E Use data with caution. Return to table 16 footnote E referrer Table 16 footnote F Data is too unreliable to be published. Return to table 16 footnote F referrer

Dimethylarsinic acid (DMA) - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 17 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 17 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2538	3.78	3.5 (3.0 - 4.0)	0.93 (0.89 - 0.97)	3.6 (3.1 - 4.1)	11 (8.3 - 13)	16Table 17 footnote E (6.6 - 25)
Total	3-79	3 (2012-2013)	2536	3.86	3.6 (3.2 - 4.0)	1.1 (0.89 - 1.4)	3.4 (3.0 - 3.8)	11 (7.8 - 13)	16Table 17 footnote E (7.4 - 25)
Males	3-79	2 (2009-2011)	1271	3.15	3.6 (3.1 - 4.3)	0.95 (<LOD - 1.3)	3.7 (2.8 - 4.5)	11 (7.9 - 14)	16Table 17 footnote E (7.7 - 24)
Males	3-79	3 (2012-2013)	1251	2.96	3.8 (3.3 - 4.4)	1.3Table 17 footnote E (0.75 - 1.8)	3.8 (3.3 - 4.3)	9.8 (7.8 - 12)	14Table 17 footnote E (4.8 - 23)
Females	3-79	2 (2009-2011)	1267	4.42	3.3 (2.8 - 3.9)	0.92 (0.75 - 1.1)	3.5 (3.0 - 3.9)	11 (7.5 - 14)	18Table 17 footnote E (7.3 - 29)
Females	3-79	3 (2012-2013)	1285	4.75	3.4 (2.9 - 4.1)	1.0 (0.85 - 1.2)	3.1 (2.7 - 3.5)	12 (8.4 - 16)	Table 17 footnote F
Total	3-5	2 (2009-2011)	516	3.68	3.6 (3.1 - 4.3)	1.4Table 17 footnote E (0.89 - 1.9)	3.5 (3.0 - 4.0)	9.4 (6.9 - 12)	13Table 17 footnote E (8.5 - 18)
Total	3-5	3 (2012-2013)	500	3.00	3.3 (3.0 - 3.8)	1.1 (0.83 - 1.4)	3.4 (2.8 - 3.9)	10 (7.9 - 12)	16Table 17 footnote E (9.9 - 21)
Total	6-11	2 (2009-2011)	511	2.74	3.9 (3.5 - 4.4)	1.5 (1.0 - 1.9)	4.1 (3.5 - 4.7)	9.8 (8.4 - 11)	14Table 17 footnote E (7.7 - 20)
Total	6-11	3 (2012-2013)	507	2.76	3.6 (3.1 - 4.1)	1.1Table 17 footnote E (<LOD - 1.6)	3.7 (3.0 - 4.4)	9.1 (6.6 - 12)	14Table 17 footnote E (6.9 - 22)
Total	12-19	2 (2009-2011)	510	2.75	3.6 (2.9 - 4.6)	0.94Table 17 footnote E (<LOD - 1.5)	3.5 (2.5 - 4.4)	11 (7.5 - 14)	17Table 17 footnote E (9.3 - 25)
Total	12-19	3 (2012-2013)	510	3.53	3.6 (3.0 - 4.3)	1.3 (0.88 - 1.7)	3.4 (2.6 - 4.2)	9.9 (6.6 - 13)	Table 17 footnote F
Total	20-39	2 (2009-2011)	355	5.63	3.6 (2.9 - 4.5)	0.92 (0.72 - 1.1)	3.9 (3.0 - 4.8)	Table 17 footnote F	22Table 17 footnote E (11 - 33)
Total	20-39	3 (2012-2013)	355	4.79	3.8 (3.3 - 4.5)	1.2Table 17 footnote E (<LOD - 1.9)	3.5 (2.9 - 4.1)	12Table 17 footnote E (4.4 - 20)	24Table 17 footnote E (8.5 - 40)
Total	40-59	2 (2009-2011)	357	5.32	3.2 (2.6 - 3.8)	0.91Table 17 footnote E (<LOD - 1.2)	3.1 (2.5 - 3.8)	9.0 (7.4 - 11)	12 (8.8 - 15)
Total	40-59	3 (2012-2013)	312	6.09	3.5 (2.8 - 4.4)	1.1 (0.77 - 1.5)	3.4 (2.7 - 4.1)	12Table 17 footnote E (6.0 - 17)	Table 17 footnote F
Total	60-79	2 (2009-2011)	289	3.46	3.6 (2.8 - 4.5)	0.92 (0.82 - 1.0)	3.6 (2.9 - 4.3)	13Table 17 footnote E (5.8 - 20)	21Table 17 footnote E (6.5 - 35)
Total	60-79	3 (2012-2013)	352	4.26	3.5 (3.0 - 4.2)	1.0 (0.86 - 1.2)	3.4 (2.6 - 4.2)	10 (7.4 - 13)	18Table 17 footnote E (10 - 26)
Table 17 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 17 footnote a referrer Table 17 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 17 footnote b referrer Table 17 footnote E Use data with caution. Return to table 17 footnote E referrer Table 17 footnote F Data is too unreliable to be published. Return to table 17 footnote F referrer

Dimethylarsinic acid (DMA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 18 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 18 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2528	3.78	3.5 (3.0 - 4.0)	1.4 (1.2 - 1.6)	3.0 (2.6 - 3.4)	9.5 (7.1 - 12)	15Table 18 footnote E (9.1 - 21)
Total	3-79	3 (2012-2013)	2535	3.86	3.7 (3.2 - 4.3)	1.4 (1.3 - 1.5)	3.4 (3.0 - 3.8)	11Table 18 footnote E (5.6 - 16)	20Table 18 footnote E (11 - 30)
Males	3-79	2 (2009-2011)	1267	3.15	3.1 (2.7 - 3.6)	1.3 (1.0 - 1.5)	2.9 (2.5 - 3.3)	7.7 (5.3 - 10)	10Table 18 footnote E (4.4 - 16)
Males	3-79	3 (2012-2013)	1251	2.96	3.1 (2.8 - 3.6)	1.3 (1.1 - 1.4)	3.0 (2.4 - 3.5)	7.2 (5.4 - 9.1)	13Table 18 footnote E (7.1 - 19)
Females	3-79	2 (2009-2011)	1261	4.42	3.9 (3.3 - 4.5)	1.6 (1.3 - 1.8)	3.3 (2.8 - 3.9)	11Table 18 footnote E (5.9 - 16)	18Table 18 footnote E (11 - 24)
Females	3-79	3 (2012-2013)	1284	4.75	4.3 (3.6 - 5.3)	1.5 (1.3 - 1.7)	3.8 (3.1 - 4.4)	15Table 18 footnote E (5.2 - 25)	24Table 18 footnote E (15 - 33)
Total	3-5	2 (2009-2011)	515	3.68	6.4 (5.6 - 7.3)	3.0 (2.7 - 3.3)	5.6 (4.7 - 6.5)	16 (11 - 20)	23Table 18 footnote E (10 - 36)
Total	3-5	3 (2012-2013)	499	3.00	6.5 (5.9 - 7.1)	2.8 (2.1 - 3.4)	6.1 (5.5 - 6.8)	14 (11 - 17)	24Table 18 footnote E (13 - 36)
Total	6-11	2 (2009-2011)	509	2.74	4.5 (4.1 - 5.0)	2.1 (1.9 - 2.3)	4.2 (3.8 - 4.7)	11 (7.9 - 13)	17Table 18 footnote E (10 - 24)
Total	6-11	3 (2012-2013)	507	2.76	4.5 (3.9 - 5.2)	2.2 (1.9 - 2.4)	4.1 (3.7 - 4.4)	9.9 (6.7 - 13)	14Table 18 footnote E (7.2 - 21)
Total	12-19	2 (2009-2011)	508	2.75	2.8 (2.3 - 3.5)	1.1 (0.76 - 1.4)	2.4 (1.9 - 3.0)	8.5Table 18 footnote E (4.5 - 13)	13Table 18 footnote E (7.6 - 19)
Total	12-19	3 (2012-2013)	510	3.53	2.7 (2.2 - 3.4)	1.2 (1.1 - 1.4)	2.3 (1.7 - 2.9)	7.4Table 18 footnote E (2.9 - 12)	12Table 18 footnote E (5.9 - 17)
Total	20-39	2 (2009-2011)	353	5.63	3.1 (2.5 - 3.9)	1.3 (0.97 - 1.6)	2.6 (1.9 - 3.3)	9.1Table 18 footnote E (5.8 - 12)	14Table 18 footnote E (7.2 - 21)
Total	20-39	3 (2012-2013)	355	4.79	2.9 (2.6 - 3.3)	1.1Table 18 footnote E (<LOD - 1.6)	2.7 (2.3 - 3.0)	Table 18 footnote F	17Table 18 footnote E (4.7 - 29)
Total	40-59	2 (2009-2011)	355	5.32	3.3 (2.9 - 3.7)	1.6 (1.3 - 1.8)	3.0 (2.7 - 3.2)	7.7 (5.5 - 9.9)	11Table 18 footnote E (6.1 - 15)
Total	40-59	3 (2012-2013)	312	6.09	4.1 (3.3 - 5.2)	1.5 (1.2 - 1.7)	3.8 (3.1 - 4.5)	Table 18 footnote F	24Table 18 footnote E (7.1 - 40)
Total	60-79	2 (2009-2011)	288	3.46	4.2 (3.4 - 5.3)	1.5Table 18 footnote E (0.88 - 2.1)	4.1 (3.1 - 5.0)	Table 18 footnote F	Table 18 footnote F
Total	60-79	3 (2012-2013)	352	4.26	4.0 (3.2 - 4.9)	1.5 (1.2 - 1.9)	3.6 (2.9 - 4.3)	11Table 18 footnote E (4.6 - 18)	20Table 18 footnote E (10 - 30)
Table 18 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 18 footnote a referrer Table 18 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 18 footnote b referrer Table 18 footnote E Use data with caution. Return to table 18 footnote E referrer Table 18 footnote F Data is too unreliable to be published. Return to table 18 footnote F referrer

Monomethylarsonic acid (MMA) - Geometric means and selected percentiles of urine concentrations (μg As/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 19 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 19 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2538	73.01	--	<LOD	<LOD	0.97 (0.94 - 0.99)	1.1Table 19 footnote E (<LOD - 1.5)
Total	3-79	3 (2012-2013)	2536	71.53	--	<LOD	<LOD	1.2 (1.1 - 1.4)	1.5 (1.3 - 1.7)
Males	3-79	2 (2009-2011)	1271	69.63	--	<LOD	<LOD	0.98 (0.81 - 1.2)	1.5Table 19 footnote E (0.88 - 2.1)
Males	3-79	3 (2012-2013)	1251	68.35	--	<LOD	<LOD	1.2 (1.0 - 1.4)	1.5 (1.3 - 1.7)
Females	3-79	2 (2009-2011)	1267	76.40	--	<LOD	<LOD	0.95 (0.90 - 1.0)	0.99 (0.88 - 1.1)
Females	3-79	3 (2012-2013)	1285	74.63	--	<LOD	<LOD	1.2 (0.88 - 1.5)	1.5 (1.3 - 1.8)
Total	3-5	2 (2009-2011)	516	77.91	--	<LOD	<LOD	0.92 (0.84 - 1.0)	0.98 (0.96 - 1.0)
Total	3-5	3 (2012-2013)	500	79.20	--	<LOD	<LOD	0.91 (<LOD - 1.2)	1.5 (1.1 - 1.9)
Total	6-11	2 (2009-2011)	511	76.52	--	<LOD	<LOD	0.93 (0.83 - 1.0)	1.2 (0.77 - 1.6)
Total	6-11	3 (2012-2013)	507	72.58	--	<LOD	<LOD	1.0 (0.84 - 1.2)	1.3 (1.1 - 1.4)
Total	12-19	2 (2009-2011)	510	62.94	--	<LOD	<LOD	0.99 (0.80 - 1.2)	1.5Table 19 footnote E (0.93 - 2.1)
Total	12-19	3 (2012-2013)	510	62.16	--	<LOD	<LOD	1.3 (1.1 - 1.6)	1.6 (1.3 - 1.8)
Total	20-39	2 (2009-2011)	355	70.14	--	<LOD	<LOD	0.98 (0.86 - 1.1)	1.3Table 19 footnote E (<LOD - 2.0)
Total	20-39	3 (2012-2013)	355	66.48	--	<LOD	<LOD	1.3 (1.0 - 1.5)	1.5 (1.3 - 1.7)
Total	40-59	2 (2009-2011)	357	71.43	--	<LOD	<LOD	0.96 (0.92 - 1.0)	1.0Table 19 footnote E (<LOD - 1.6)
Total	40-59	3 (2012-2013)	312	72.76	--	<LOD	<LOD	1.1 (0.84 - 1.4)	1.6 (1.1 - 2.2)
Total	60-79	2 (2009-2011)	289	81.31	--	<LOD	<LOD	0.93 (0.81 - 1.0)	0.99Table 19 footnote E (<LOD - 1.4)
Total	60-79	3 (2012-2013)	352	76.70	--	<LOD	<LOD	1.1 (0.79 - 1.5)	1.4 (1.2 - 1.6)
Table 19 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 19 footnote a referrer Table 19 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 19 footnote b referrer Table 19 footnote E Use data with caution. Return to table 19 footnote E referrer

Monomethylarsonic acid (MMA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg As/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) ^{Table 20 footnote a} and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 20 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2528	73.01	--	<LOD	<LOD	1.0 (0.79 - 1.2)	1.6 (1.3 - 1.9)
Total	3-79	3 (2012-2013)	2535	71.53	--	<LOD	<LOD	1.2 (1.1 - 1.4)	1.7 (1.5 - 1.9)
Males	3-79	2 (2009-2011)	1267	69.63	--	<LOD	<LOD	0.96 (0.92 - 0.99)	1.2Table 20 footnote E (0.70 - 1.7)
Males	3-79	3 (2012-2013)	1251	68.35	--	<LOD	<LOD	1.0 (0.87 - 1.1)	1.3 (1.0 - 1.6)
Females	3-79	2 (2009-2011)	1261	76.40	--	<LOD	<LOD	1.3 (0.95 - 1.7)	1.8 (1.3 - 2.3)
Females	3-79	3 (2012-2013)	1284	74.63	--	<LOD	<LOD	1.6 (1.3 - 1.9)	2.1 (1.8 - 2.5)
Total	3-5	2 (2009-2011)	515	77.91	--	<LOD	<LOD	1.5 (1.2 - 1.8)	2.2 (1.6 - 2.8)
Total	3-5	3 (2012-2013)	499	79.20	--	<LOD	<LOD	2.0 (1.5 - 2.5)	3.0 (2.0 - 4.0)
Total	6-11	2 (2009-2011)	509	76.52	--	<LOD	<LOD	0.99 (0.87 - 1.1)	1.5 (1.2 - 1.9)
Total	6-11	3 (2012-2013)	507	72.58	--	<LOD	<LOD	1.3 (1.1 - 1.5)	1.8 (1.5 - 2.0)
Total	12-19	2 (2009-2011)	508	62.94	--	<LOD	<LOD	0.93 (0.83 - 1.0)	0.99Table 20 footnote E (<LOD - 1.5)
Total	12-19	3 (2012-2013)	510	62.16	--	<LOD	<LOD	0.99 (0.75 - 1.2)	1.5 (1.0 - 2.0)
Total	20-39	2 (2009-2011)	353	70.14	--	<LOD	<LOD	0.98Table 20 footnote E (<LOD - 1.5)	1.6Table 20 footnote E (<LOD - 2.5)
Total	20-39	3 (2012-2013)	355	66.48	--	<LOD	<LOD	0.97 (<LOD - 1.2)	1.3 (0.87 - 1.8)
Total	40-59	2 (2009-2011)	355	71.43	--	<LOD	<LOD	0.99 (0.76 - 1.2)	1.5 (1.0 - 2.0)
Total	40-59	3 (2012-2013)	312	72.76	--	<LOD	<LOD	1.3 (0.92 - 1.6)	1.7 (1.3 - 2.0)
Total	60-79	2 (2009-2011)	288	81.31	--	<LOD	<LOD	1.4 (0.95 - 1.9)	1.8 (1.5 - 2.1)
Total	60-79	3 (2012-2013)	352	76.70	--	<LOD	<LOD	1.4Table 20 footnote E (0.87 - 1.9)	2.1Table 20 footnote E (1.3 - 2.9)
Table 20 footnote a In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as μg of arsenic species per litre (e.g., μg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to table 20 footnote a referrer Table 20 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 20 footnote b referrer Table 20 footnote E Use data with caution. Return to table 20 footnote E referrer

Cadmium

Cadmium (CASRN 7440-43-9) is among the least abundant metals in the Earth's crust at an average concentration of approximately 0.00001% (Emsley, 2001). It is a naturally occurring soft, silvery white, blue-tinged metal. Cadmium often occurs in zinc ores (Health Canada, 1986a). Common forms include soluble and insoluble species that may also be found as particulate matter in the atmosphere (ATSDR, 2012b; CCME, 1999a).

Cadmium is released to the environment as a result of natural processes, including forest fires, volcanic emissions, and weathering of soil and bedrock (Morrow, 2000). The main anthropogenic sources of atmospheric cadmium are industrial base-metal smelting and refining processes, and combustion processes such as coal-fired electrical plants and waste incineration where cadmium is released as a by-product (CCME, 1999a).

Cadmium is primarily used in the manufacture of nickel-cadmium batteries (USGS, 2012). It is also used in industrial coatings and electroplating, in pigments, and as a stabilizer in polyvinyl chloride plastics. Cadmium is present in metal alloy sheets, wires, rods, solders, and shields for various industrial applications (Environment Canada & Health Canada, 1994a). It is also sometimes used in costume jewellery and as a pigment in ceramic glazes. Cadmium may also be present in fertilizers as the result of recycling of by-products and waste materials for land application. It is frequently an impurity in galvanized pipes and can leach into drinking water (Health Canada, 1986a).

In smokers, inhalation of cigarette smoke is a major source of cadmium exposure (Environment Canada & Health Canada, 1994a; IARC, 2012a). For non-smoking adults and children, the largest source of cadmium exposure is through the ingestion of food (Environment Canada & Health Canada, 1994a; IARC, 2012a). Ambient air is a minor source of exposure with intakes estimated to be two to three orders of magnitude lower than food, although cadmium compounds are more readily absorbed following inhalation than ingestion (Friberg, 1985). Other potential sources of exposure include ingestion of drinking water, soil, or dust (ATSDR, 2012b; Environment Canada & Health Canada, 1994a; Rasmussen et al., 2013).

Absorption of dietary cadmium into the bloodstream depends on one's nutritional status and the levels of other components of the diet such as iron, calcium, and protein. The average gastrointestinal absorption of dietary cadmium is estimated at 5% in adult men and 10% or higher in women (CDC, 2009). About 25% to 60% of inhaled cadmium is absorbed through the lungs (ATSDR, 2012b). Absorbed cadmium accumulates mainly in the kidney and liver, with approximately one-third to one-half of the total body burden accumulating in the kidney (CDC, 2009). The biological half-life of cadmium in the kidney has been estimated to be approximately 10 to 12 years (Amzal et al., 2009; Lauwerys et al., 1994). Only a small proportion of absorbed cadmium is eliminated, mainly in the urine and feces with small amounts also eliminated through hair, nails, and sweat.

Cadmium can be measured in blood, urine, feces, liver, kidney, and hair among other tissues. Cadmium concentrations in urine best reflect cumulative exposure and the concentration of cadmium in the kidney, although slight fluctuations occur with recent exposures (Adams & Newcomb, 2014). Concentrations in blood reflect more recent exposures (Adams & Newcomb, 2014). Blood cadmium concentrations are about twice as high in smokers compared with non-smokers; concentrations can also be elevated following occupational exposures (ATSDR, 2012b).

Oral exposure to high doses of cadmium may cause severe gastrointestinal irritation and kidney effects (ATSDR, 2012b). Chronic exposure via inhalation has been associated with effects in the lungs, including emphysema, and in the kidneys (ATSDR, 2012b). The kidney is the critical organ that exhibits the first adverse effects following both oral and inhalation exposure (Lauwerys et al., 1994).

Cadmium and its compounds have been classified as probably carcinogenic to humans by inhalation by Environment Canada and Health Canada (Environment Canada & Health Canada, 1994a). More recently, the International Agency for Research on Cancer has classified cadmium and its compounds as carcinogenic to humans (Group 1) based on various data, including associations between occupational inhalation exposure and lung cancer (IARC, 2012a). There is insufficient evidence to determine whether or not cadmium is carcinogenic following oral exposure (ATSDR, 2012b).

Health Canada and Environment Canada concluded that inorganic cadmium compounds are a concern for human health based on a potential for carcinogenesis and effects on the kidneys (Environment Canada & Health Canada, 1994a). Inorganic cadmium compounds are listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999). The Act allows the federal government to control the importation, manufacture, distribution, and use of inorganic cadmium compounds in Canada (Canada, 1999; Canada, 2000). Risk management actions under CEPA 1999 have been developed to control releases of cadmium from thermal electric power generation, base-metal smelting, and steel manufacturing processes (Environment Canada, 2013a).

In Canada, the leachable cadmium content in a variety of consumer products is regulated under the Canada Consumer Product Safety Act (Canada, 2010b). Consumer products regulated for leachable cadmium content include glazed ceramics and glassware, as well as paints and other surface coatings on cribs, toys, and other products for use by a child in learning or play situations (Canada, 1998; Canada, 2010c; Canada, 2011b; Health Canada, 2009c). In addition, since children's jewellery items containing high levels of cadmium have been found on the Canadian marketplace, a guideline limit for total cadmium in children's jewellery was proposed by Health Canada in 2011 (Health Canada, 2011a). Cadmium and its compounds are included as prohibited ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist) (Health Canada, 2014b). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations. On the basis of health considerations, Health Canada, in collaboration with the Federal-Provincial-Territorial Committee on Drinking Water, has developed a guideline for Canadian drinking water quality that sets out the maximum acceptable concentration for cadmium in drinking water (Health Canada, 1986a; Health Canada, 2012e). Cadmium is also included in the list of various chemicals analyzed as part of Health Canada's ongoing Total Diet Study surveys (Health Canada, 2013e). The food items analyzed represent those that are most typical of the Canadian diet, and the surveys are used to provide dietary exposure estimates for chemicals that Canadians in different age-sex groups are exposed to through the food supply.

In a biomonitoring study carried out in the region of the city of Quebec with 500 participants aged 18 to 65 years, the geometric means for cadmium in whole blood was 0.69 µg/L (INSPQ, 2004). The First Nations Biomonitoring Initiative (FNBI) is a nationally representative biomonitoring study of adult First Nations peoples living on reserves south of the 60° parallel (AFN, 2013). It comprises 13 randomly selected First Nation communities in Canada with 503 First Nations participants aged 20 years and older. In 2011, the geometric mean and 95th percentile for cadmium in blood were 0.96 µg/L and 4.65 µg/L, respectively. In northern Canada, the contaminant component of the Inuit Health Survey (2007-2008) has measured the body burden of cadmium for 2,172 Inuit participants from 36 communities in Nunavut, Nunatsiavut, and the Inuvialuit Settlement Region (Laird et al., 2013). The geometric mean blood concentration of cadmium for all participants (18 years and older) was 1.6 µg/L.

Cadmium was analyzed in the whole blood of all Canadian Health Measures Survey participants aged 6 to 79 years in cycle 1 (2007-2009), and 3 to 79 years in cycle 2 (2009-2011) and cycle 3 (2012-2013). Data from these cycles are presented in blood as µg/L. Finding a measurable amount of cadmium in blood is an indicator of exposure to cadmium and does not necessarily mean that an adverse health effect will occur.

Cadmium - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 6-79 years ^{Table 21 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 21 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5319	2.91	0.34 (0.31 - 0.37)	0.091 (0.087 - 0.094)	0.27 (0.25 - 0.29)	2.4 (2.0 - 2.8)	3.6 (3.1 - 4.1)
Total	6-79	2 (2009-2011)	5575	4.27	0.30 (0.27 - 0.33)	0.089 (0.080 - 0.097)	0.27 (0.25 - 0.30)	1.7 (1.4 - 2.1)	2.6 (2.2 - 3.1)
Total	6-79	3 (2012-2013)	5067	8.51	0.34 (0.31 - 0.37)	0.10 (0.098 - 0.10)	0.28 (0.26 - 0.30)	2.1 (1.5 - 2.7)	3.4 (2.5 - 4.3)
Males	6-79	1 (2007-2009)	2576	3.34	0.30 (0.27 - 0.34)	0.084 (0.073 - 0.095)	0.22 (0.20 - 0.25)	2.3 (1.8 - 2.8)	3.4 (2.8 - 4.0)
Males	6-79	2 (2009-2011)	2687	4.84	0.27 (0.25 - 0.30)	0.084 (0.074 - 0.093)	0.24 (0.21 - 0.27)	1.7 (1.5 - 2.0)	2.5 (2.0 - 3.0)
Males	6-79	3 (2012-2013)	2540	9.53	0.31 (0.28 - 0.34)	0.099 (0.085 - 0.11)	0.23 (0.20 - 0.26)	2.1 (1.5 - 2.7)	3.5 (2.6 - 4.3)
Females	6-79	1 (2007-2009)	2743	2.52	0.38 (0.35 - 0.41)	0.093 (0.091 - 0.095)	0.32 (0.29 - 0.36)	2.5 (2.0 - 2.9)	3.7 (3.1 - 4.3)
Females	6-79	2 (2009-2011)	2888	3.74	0.33 (0.29 - 0.38)	0.091 (0.086 - 0.095)	0.31 (0.27 - 0.34)	1.6Table 21 footnote E (0.94 - 2.2)	2.7 (2.1 - 3.4)
Females	6-79	3 (2012-2013)	2527	7.48	0.39 (0.34 - 0.44)	0.10 (0.10 - 0.11)	0.33 (0.29 - 0.38)	1.8Table 21 footnote E (0.71 - 2.9)	3.4Table 21 footnote E (1.7 - 5.1)
Table 21 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 21 footnote a referrer Table 21 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 21 footnote b referrer Table 21 footnote E Use data with caution. Return to table 21 footnote E referrer

Cadmium - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 22 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 22 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	6070	5.16	0.29 (0.26 - 0.32)	0.083 (0.074 - 0.093)	0.26 (0.24 - 0.29)	1.7 (1.3 - 2.0)	2.6 (2.1 - 3.0)
Total	3-79	3 (2012-2013)	5538	11.48	0.33 (0.30 - 0.36)	0.099 (0.092 - 0.11)	0.27 (0.25 - 0.29)	2.0 (1.4 - 2.6)	3.4 (2.5 - 4.3)
Males	3-79Table 22 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	2940	5.78	0.26 (0.24 - 0.29)	0.079 (0.070 - 0.089)	0.23 (0.20 - 0.26)	1.7 (1.5 - 2.0)	2.4 (2.0 - 2.9)
Males	3-79	3 (2012-2013)	2769	12.35	0.29 (0.27 - 0.32)	0.089 (<LOD - 0.10)	0.22 (0.19 - 0.25)	2.1 (1.5 - 2.7)	3.3 (2.5 - 4.2)
Females	3-79Table 22 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	3130	4.57	0.32 (0.28 - 0.36)	0.089 (0.080 - 0.098)	0.30 (0.27 - 0.33)	1.5Table 22 footnote E (0.92 - 2.1)	2.7 (2.1 - 3.4)
Females	3-79	3 (2012-2013)	2769	10.62	0.37 (0.33 - 0.41)	0.10 (0.099 - 0.10)	0.32 (0.28 - 0.37)	1.7Table 22 footnote E (0.62 - 2.8)	3.4Table 22 footnote E (1.8 - 5.0)
Total	3-5Table 22 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	495	15.15	0.073 (0.065 - 0.081)	<LOD	0.078 (0.069 - 0.087)	0.099 (0.098 - 0.10)	Table 22 footnote F
Total	3-5	3 (2012-2013)	471	43.52	--	<LOD	0.091 (<LOD - 0.11)	0.16 (0.11 - 0.20)	0.18Table 22 footnote E (<LOD - 0.29)
Total	6-11	1 (2007-2009)	910	9.12	0.091 (0.082 - 0.10)	<LODTable 22 footnote E (<LOD - 0.053)	0.092 (0.090 - 0.094)	0.20 (0.18 - 0.21)	0.22 (0.19 - 0.26)
Total	6-11	2 (2009-2011)	961	14.05	0.083 (0.076 - 0.090)	<LOD	0.090 (0.087 - 0.094)	0.17Table 22 footnote E (0.088 - 0.25)	0.20 (0.18 - 0.23)
Total	6-11	3 (2012-2013)	944	27.44	0.095 (0.085 - 0.11)	<LOD	0.10 (0.099 - 0.10)	0.18 (0.16 - 0.20)	0.21 (0.18 - 0.24)
Total	12-19	1 (2007-2009)	945	3.92	0.16 (0.13 - 0.20)	0.066 (0.045 - 0.086)	Table 22 footnote F	Table 22 footnote F	Table 22 footnote F
Total	12-19	2 (2009-2011)	997	5.72	0.13 (0.12 - 0.15)	0.062 (0.040 - 0.084)	0.096 (0.095 - 0.097)	0.48Table 22 footnote E (0.27 - 0.70)	0.82Table 22 footnote E (0.45 - 1.2)
Total	12-19	3 (2012-2013)	977	12.49	0.17 (0.15 - 0.20)	<LOD	0.12Table 22 footnote E (<LOD - 0.17)	0.82Table 22 footnote E (0.31 - 1.3)	1.7Table 22 footnote E (0.91 - 2.4)
Total	20-39	1 (2007-2009)	1165	1.55	0.34 (0.30 - 0.38)	0.091 (0.084 - 0.098)	0.24 (0.21 - 0.27)	2.6 (2.0 - 3.1)	3.4 (3.1 - 3.7)
Total	20-39	2 (2009-2011)	1313	2.21	0.28 (0.24 - 0.34)	0.090 (0.066 - 0.11)	0.24 (0.20 - 0.29)	1.7Table 22 footnote E (1.0 - 2.3)	2.7 (2.1 - 3.2)
Total	20-39	3 (2012-2013)	1032	3.68	0.31 (0.24 - 0.41)	0.10 (0.084 - 0.12)	0.25 (0.20 - 0.29)	2.0Table 22 footnote E (0.71 - 3.3)	Table 22 footnote F
Total	40-59	1 (2007-2009)	1220	0.90	0.48 (0.43 - 0.54)	0.098Table 22 footnote E (0.054 - 0.14)	0.36 (0.32 - 0.41)	3.1 (2.3 - 3.9)	4.2 (3.7 - 4.7)
Total	40-59	2 (2009-2011)	1222	0.98	0.41 (0.37 - 0.46)	0.095 (0.090 - 0.10)	0.34 (0.31 - 0.37)	2.2 (1.5 - 2.8)	3.1 (2.3 - 3.8)
Total	40-59	3 (2012-2013)	1071	1.12	0.50 (0.43 - 0.57)	0.11 (0.084 - 0.13)	0.39 (0.30 - 0.48)	3.0 (2.3 - 3.7)	4.6 (3.7 - 5.5)
Total	60-79	1 (2007-2009)	1079	0.56	0.45 (0.42 - 0.49)	0.19 (0.18 - 0.20)	0.39 (0.37 - 0.41)	1.7 (1.2 - 2.2)	2.7 (2.2 - 3.2)
Total	60-79	2 (2009-2011)	1082	0.46	0.45 (0.41 - 0.50)	0.18 (0.13 - 0.23)	0.40 (0.35 - 0.44)	1.6 (1.3 - 2.0)	2.4 (1.9 - 2.8)
Total	60-79	3 (2012-2013)	1043	0	0.48 (0.43 - 0.54)	0.19 (0.17 - 0.20)	0.41 (0.35 - 0.46)	1.5 (1.3 - 1.8)	2.6 (1.9 - 3.3)
Table 22 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 22 footnote a referrer Table 22 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 22 footnote b referrer Table 22 footnote E Use data with caution. Return to table 22 footnote E referrer Table 22 footnote F Data is too unreliable to be published. Return to table 22 footnote F referrer

Fluoride

Fluorine (CASRN 16984-48-8) is the 13th most abundant element, occurring naturally in the Earth's crust at an average concentration of about 0.09% (ATSDR, 2003). It is widely distributed and naturally occurring, but it is rarely found in nature because it reacts readily with most organic and inorganic substances. Fluorides are formed when fluorine reacts with metals. Four inorganic fluorides of environmental importance are calcium fluoride (fluorspar and fluorite), sodium fluoride, sulphur hexafluoride, and hydrogen fluoride (Cotton & Wilkinson, 1988; Mackay & Mackay, 1989).

Fluorides are found in rocks, coal, clay, and soil. Gases and particles produced from volcanic eruptions and minerals leached from bedrock release inorganic fluorides into the environment (ATSDR, 2003; CCME, 2002). In addition to these natural sources, inorganic fluorides are released through human activities such as phosphate fertilizer production, chemical production, and aluminum smelting (Environment Canada & Health Canada, 1993b).

Hydrogen fluoride is one of the most commonly used fluoride compounds; it is a component in the production of refrigerants, herbicides, pharmaceuticals, aluminum, plastics, high-octane gasoline, electrical components, and fluorescent light bulbs (ATSDR, 2003). In water, hydrogen fluoride becomes hydrofluoric acid, which is used in the metal and glass manufacturing industries (ATSDR, 2003). Calcium fluoride is used in the production of steel, aluminum, glass, and enamel, and as the raw material for the production of hydrofluoric acid and hydrogen fluoride (CCME, 2002). Fluoride-containing compounds are often added to drinking water and dental products to prevent dental cavities. Toothpastes are the most commonly used dental product that contain fluoride (Health Canada, 2010c). Other fluoride-containing dental products available to consumers include fluoride supplements, fluoride mouth rinses, and dental floss. Fluoride is also used by professionals in some dental filling material, sealants, and fluoride varnishes. Sodium fluoride is also used as a preservative in wood and glues and in the production of glass, enamel, steel, and aluminum (CCME, 2002). Sulphur hexafluoride is used extensively in electrical switch gear such as power circuit breakers, compressed gas transmission lines, and various components in electrical substations.

Fluoride compounds are ubiquitous in the environment; however, the major sources of exposure to the general population are water, food, beverages, and dental products (Health Canada, 2010c). Following ingestion of soluble fluoride salts and inhalation of gaseous hydrogen fluoride, fluoride is rapidly and efficiently absorbed (ATSDR, 2003). Once absorbed, fluoride is rapidly distributed throughout the body via the bloodstream (ATSDR, 2003). In infants, about 80% to 90% of the total absorbed fluoride is retained in bones and teeth with the level dropping to about 60% in adults (Fawell et al., 2006). The remaining fluoride in adults and infants is excreted through urine (ATSDR, 2003). The biological half-life of fluoride is on the order of several hours (ATSDR, 2003; NRC, 2006). Urine and blood analyses are the most common tests for fluoride exposure (ATSDR, 2003).

The primary adverse effects associated with chronic excess fluoride intake are dental and skeletal fluorosis (IOM, 1997). Exposure to excessive levels of fluoride over a very long period of time can lead to skeletal fluorosis characterized by dense bones, joint pain, and limited range of joint movement (ATSDR, 2003). Dense bones are often more brittle or fragile than normal bones and there is an increased risk of bone fractures in older adults. Dental fluorosis is a dose-response effect caused by fluoride ingestion during tooth formation that becomes apparent upon eruption of the teeth. The effects of dental fluorosis can range from mild discolouration of the tooth surface to severe staining, enamel loss, and pitting (NRC, 2006).

Health Canada found that the weight of evidence from existing scientific data does not support an association between fluoride and increased risks of cancer, and has classified fluoride in Group VI, unclassifiable with respect to carcinogenicity in humans (Health Canada, 2010c). Similarly, the International Agency for Research on Cancer has classified fluorides (inorganic, used in drinking water) as Group 3, not classifiable as to its carcinogenicity to humans (IARC, 1987).

Health Canada and Environment Canada have reviewed and assessed inorganic fluorides under the Canadian Environmental Protection Act, 1999 (CEPA 1999) (Canada, 1999). The screening assessment concluded that levels of inorganic fluorides normally found in the Canadian environment are not considered harmful to human health but are a concern for the environment (Environment Canada & Health Canada, 1993b). Inorganic fluorides are listed on Schedule 1, List of Toxic Substances, under CEPA 1999. The Act allows the federal government to control the importation, manufacture, distribution, and use of inorganic fluorides in Canada (Canada, 1999; Canada, 2000).

Health Canada recommends that fluoride requirements be based on the beneficial effect on dental caries (Health Canada, 2010c). Young children tend to swallow toothpaste during brushing, so guidelines have been established that strive to balance the health risks with the health benefits of fluoride use. In general, toothpaste use is not recommended for children under the age of 3, unless recommended by a health professional. For children 3 to 6 years old, Health Canada recommends supervision during brushing and use of only a small amount of fluoridated toothpaste (Health Canada, 2010d). Fluoride-containing substances are included as restricted ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist) and are not permitted in oral products (Health Canada, 2014b). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations.

Health Canada completed a review of the health risks associated with fluoride in drinking water in which moderate dental fluorosis was chosen as the endpoint of concern for fluoride (Health Canada, 2010c). Although moderate dental fluorosis is not a health concern and is not considered to be a toxicological endpoint, Health Canada considers it to be an adverse effect based on its potential aesthetic concern. The current guideline for Canadian drinking water quality established by the Federal-Provincial-Territorial Committee on Drinking Water sets out the maximum acceptable concentration for fluoride in drinking water (Health Canada, 2010c). This guideline is considered to be protective against all potential adverse health effects, including those related to cancer, immunotoxicity, reproductive/developmental toxicity, genotoxicity, and/or neurotoxicity (Health Canada, 2010c). For communities wishing to fluoridate their water supply, Health Canada has determined an optimal concentration of fluoride in drinking water to promote dental health while protecting against adverse effects (Health Canada, 2010d). Tolerable upper intake levels for fluoride that account for its potential toxicity have been developed by the Institute of Medicine and adopted by Health Canada (Health Canada, 2010e; IOM, 1997).

The concentration of fluoride in some foods and prepackaged water and ice is regulated by Health Canada under the Food and Drug Regulations (Canada, 2012c). Food tolerances, or maximum levels, for fluoride currently exist for edible bone meal and fish protein as well as prepackaged ice or water, including those represented as mineral or spring water (Canada, 2012c).

The first cycle (2007-2009) of the Canadian Health Measures Survey (CHMS) included a National Oral Health Component supported by Health Canada (Health Canada, 2010f). In addition to many other dental considerations, dental fluorosis was measured in children ranging from 6 to 12 years old. The results from cycle 1 of the CHMS found that 60% of children had teeth considered normal, 24% had enamel with white flecks or spots where the cause was questionable, 12% had one or more teeth with fluorosis classified as very mild, and 4% had fluorosis classified as mild. The prevalence of moderate or severe fluorosis was too low to allow reporting (less than 0.3%).

Fluoride was analyzed in the urine of CHMS cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and is presented as both mg/L and mg/g creatinine. Finding a measurable amount of fluoride in urine is an indicator of exposure to fluoride and does not necessarily mean that an adverse health effect will occur.

Fluoride - Geometric means and selected percentiles of urine concentrations (mg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 23 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2530	0	0.50 (0.46 - 0.55)	0.19 (0.17 - 0.22)	0.48 (0.44 - 0.53)	1.2 (1.0 - 1.3)	1.5 (1.2 - 1.7)
Total	3-79	3 (2012-2013)	2671	0	0.43 (0.39 - 0.48)	0.15 (0.14 - 0.17)	0.44 (0.39 - 0.49)	1.1 (0.97 - 1.3)	1.4 (0.99 - 1.7)
Males	3-79	2 (2009-2011)	1267	0	0.53 (0.47 - 0.60)	0.23 (0.20 - 0.25)	0.51 (0.42 - 0.60)	1.3 (1.0 - 1.5)	1.6 (1.4 - 1.9)
Males	3-79	3 (2012-2013)	1320	0	0.44 (0.39 - 0.49)	0.16 (0.13 - 0.19)	0.44 (0.39 - 0.49)	1.1 (0.92 - 1.3)	1.3Table 23 footnote E (0.81 - 1.8)
Females	3-79	2 (2009-2011)	1263	0	0.47 (0.43 - 0.52)	0.17 (0.15 - 0.20)	0.47 (0.41 - 0.53)	1.1 (0.92 - 1.3)	1.3 (1.0 - 1.6)
Females	3-79	3 (2012-2013)	1351	0	0.43 (0.38 - 0.48)	0.14 (0.11 - 0.16)	0.45 (0.37 - 0.53)	1.1 (0.92 - 1.4)	1.4 (1.0 - 1.8)
Total	3-5	2 (2009-2011)	510	0	0.47 (0.42 - 0.52)	0.18 (0.13 - 0.23)	0.51 (0.44 - 0.58)	0.99 (0.88 - 1.1)	1.3 (0.92 - 1.7)
Total	3-5	3 (2012-2013)	493	0	0.39 (0.32 - 0.48)	0.13 (0.098 - 0.17)	0.37 (0.25 - 0.50)	0.99 (0.77 - 1.2)	1.2 (0.97 - 1.5)
Total	6-11	2 (2009-2011)	514	0	0.50 (0.44 - 0.57)	0.20 (0.17 - 0.24)	0.49 (0.42 - 0.55)	1.1 (0.90 - 1.3)	1.5 (1.1 - 1.8)
Total	6-11	3 (2012-2013)	549	0	0.40 (0.36 - 0.45)	0.18 (0.15 - 0.20)	0.38 (0.35 - 0.41)	0.85 (0.61 - 1.1)	1.1 (0.88 - 1.4)
Total	12-19	2 (2009-2011)	507	0	0.41 (0.37 - 0.46)	0.17 (0.15 - 0.19)	0.44 (0.36 - 0.52)	0.94 (0.82 - 1.1)	1.2 (0.98 - 1.3)
Total	12-19	3 (2012-2013)	549	0	0.39 (0.35 - 0.44)	0.16 (0.13 - 0.20)	0.37 (0.33 - 0.41)	0.93 (0.71 - 1.2)	1.1 (0.85 - 1.3)
Total	20-39	2 (2009-2011)	354	0	0.53 (0.47 - 0.59)	0.23 (0.19 - 0.27)	0.50 (0.38 - 0.62)	1.2 (0.96 - 1.5)	1.4 (1.1 - 1.8)
Total	20-39	3 (2012-2013)	371	0	0.43 (0.35 - 0.53)	0.15 (0.11 - 0.19)	0.47 (0.37 - 0.57)	1.1 (0.77 - 1.4)	1.3Table 23 footnote E (0.58 - 2.1)
Total	40-59	2 (2009-2011)	357	0	0.51 (0.44 - 0.61)	0.19 (0.13 - 0.25)	0.51 (0.40 - 0.61)	1.2 (0.93 - 1.6)	1.7 (1.3 - 2.2)
Total	40-59	3 (2012-2013)	359	0	0.46 (0.42 - 0.50)	0.16 (0.13 - 0.20)	0.46 (0.41 - 0.50)	1.2 (1.0 - 1.3)	1.4 (0.88 - 1.9)
Total	60-79	2 (2009-2011)	288	0	0.50 (0.44 - 0.56)	0.19Table 23 footnote E (0.11 - 0.27)	0.48 (0.42 - 0.54)	1.2 (0.99 - 1.5)	1.6 (1.3 - 2.0)
Total	60-79	3 (2012-2013)	350	0	0.43 (0.36 - 0.51)	0.13 (0.086 - 0.18)	0.45 (0.34 - 0.56)	1.3 (0.85 - 1.7)	1.7 (1.3 - 2.0)
Table 23 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 23 footnote a referrer Table 23 footnote E Use data with caution. Return to table 23 footnote E referrer

Fluoride (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (mg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 24 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2520	0	0.50 (0.45 - 0.55)	0.20 (0.18 - 0.22)	0.48 (0.41 - 0.54)	1.2 (0.99 - 1.4)	1.6 (1.3 - 2.0)
Total	3-79	3 (2012-2013)	2669	0	0.46 (0.41 - 0.51)	0.18 (0.16 - 0.21)	0.45 (0.37 - 0.53)	1.0 (0.88 - 1.1)	1.4 (1.1 - 1.7)
Males	3-79	2 (2009-2011)	1263	0	0.46 (0.40 - 0.52)	0.20 (0.16 - 0.24)	0.43 (0.36 - 0.50)	1.0 (0.85 - 1.2)	1.2 (0.86 - 1.6)
Males	3-79	3 (2012-2013)	1320	0	0.40 (0.35 - 0.45)	0.16 (0.12 - 0.20)	0.41 (0.33 - 0.48)	0.87 (0.75 - 0.98)	1.1 (0.90 - 1.2)
Females	3-79	2 (2009-2011)	1257	0	0.54 (0.49 - 0.60)	0.21 (0.18 - 0.24)	0.52 (0.45 - 0.60)	1.4 (1.2 - 1.6)	1.9 (1.5 - 2.3)
Females	3-79	3 (2012-2013)	1349	0	0.53 (0.47 - 0.59)	0.22 (0.19 - 0.25)	0.53 (0.43 - 0.63)	1.2 (0.93 - 1.4)	1.6 (1.3 - 2.0)
Total	3-5	2 (2009-2011)	509	0	0.81 (0.73 - 0.90)	0.40 (0.34 - 0.46)	0.78 (0.72 - 0.85)	1.7 (1.3 - 2.0)	2.8Table 24 footnote E (1.7 - 4.0)
Total	3-5	3 (2012-2013)	492	0	0.76 (0.68 - 0.86)	0.37 (0.30 - 0.44)	0.73 (0.55 - 0.90)	1.5 (1.3 - 1.6)	1.7 (1.4 - 1.9)
Total	6-11	2 (2009-2011)	512	0	0.58 (0.53 - 0.63)	0.30 (0.28 - 0.32)	0.57 (0.50 - 0.63)	1.2 (0.96 - 1.4)	1.5 (1.0 - 2.0)
Total	6-11	3 (2012-2013)	549	0	0.50 (0.43 - 0.57)	0.24 (0.19 - 0.28)	0.45 (0.39 - 0.50)	1.0 (0.91 - 1.1)	1.2 (0.86 - 1.5)
Total	12-19	2 (2009-2011)	505	0	0.32 (0.28 - 0.35)	0.15 (0.13 - 0.16)	0.32 (0.28 - 0.37)	0.62 (0.52 - 0.72)	0.75 (0.54 - 0.97)
Total	12-19	3 (2012-2013)	548	0	0.29 (0.25 - 0.33)	0.14 (0.12 - 0.16)	0.27 (0.23 - 0.31)	0.61 (0.45 - 0.76)	0.76 (0.63 - 0.89)
Total	20-39	2 (2009-2011)	352	0	0.46 (0.39 - 0.55)	0.20 (0.17 - 0.24)	0.42 (0.33 - 0.51)	1.1 (0.74 - 1.4)	Table 24 footnote F
Total	20-39	3 (2012-2013)	371	0	0.40 (0.35 - 0.46)	0.16 (0.12 - 0.19)	0.39 (0.30 - 0.49)	0.87 (0.71 - 1.0)	1.0 (0.76 - 1.2)
Total	40-59	2 (2009-2011)	355	0	0.53 (0.46 - 0.60)	0.22 (0.18 - 0.26)	0.54 (0.43 - 0.66)	1.2 (0.94 - 1.4)	1.6 (1.2 - 2.0)
Total	40-59	3 (2012-2013)	359	0	0.52 (0.46 - 0.59)	0.22 (0.20 - 0.24)	0.55 (0.44 - 0.66)	1.0 (0.87 - 1.2)	1.2 (0.77 - 1.7)
Total	60-79	2 (2009-2011)	287	0	0.58 (0.50 - 0.68)	0.22 (0.16 - 0.27)	0.55 (0.44 - 0.67)	1.6 (1.3 - 1.9)	1.9 (1.4 - 2.5)
Total	60-79	3 (2012-2013)	350	0	0.52 (0.43 - 0.62)	0.20 (0.16 - 0.24)	0.52 (0.45 - 0.59)	1.4Table 24 footnote E (0.86 - 1.9)	2.1Table 24 footnote E (1.1 - 3.0)
Table 24 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 24 footnote a referrer Table 24 footnote E Use data with caution. Return to table 24 footnote E referrer Table 24 footnote F Data is too unreliable to be published. Return to table 24 footnote F referrer

Lead

Lead (CASRN 7439-92-1) is a naturally occurring element present at a median background concentration of 0.008% in Canada (Rencz et al., 2006). It is a base metal and can exist in various oxidation states and in both inorganic and organic forms (ATSDR, 2007b). Inorganic forms include substances such as elemental lead, lead sulphate, lead carbonate and hydroxyl carbonate, lead oxides, lead chromate, and lead citrate (Rasmussen et al., 2014). Organic lead compounds include tetra-alkyl, trialkyl, and dialkyl lead compounds.

Lead is found in bedrock, soils, sediments, surface water, groundwater, and sea water (Health Canada, 2013f). It enters the environment from a variety of natural and anthropogenic sources. Natural processes include soil weathering, erosion, and volcanic activity (ATSDR, 2007b; IARC, 2006). Lead released from industrial emissions can be a major source of environmental contamination, especially near point sources such as smelters or refineries (ATSDR, 2007b). Historical use of leaded motor fuels has contributed to the ubiquitous distribution of lead throughout the globe (WHO, 2000).

In North America, tetraethyl and tetramethyl lead were added to motor vehicle fuels as an anti-knock agent up until the 1990s. Presently in Canada, the addition of lead to gasoline is prohibited, with the exception of fuels for piston engine aircraft and racing fuels for competition vehicles (Health Canada, 2013f). Lead is currently used in the refining and manufacturing of products such as lead acid automotive batteries, lead shot and fishing weights, sheet lead, lead solder, some brass and bronze products, and some ceramic glazes (ATSDR, 2007b; WHO, 2000). Other uses of lead include dyes in paints and pigments. It is also used in scientific equipment, as a stabilizer in plastics, in military equipment and ammunition, and in radiation detection and medical equipment for radiation shielding (ATSDR, 2007b; WHO, 2000). Lead is also used in the manufacturing of cable sheathing, circuit boards, chemical baths and storage vessel linings, chemical transmission pipes, electrical components, and polyvinyl chloride (Health Canada, 2013f).

Everyone is exposed to trace amounts of lead through food, drinking water, soil, household dust, air, and some consumer products. Over the past 30 years, lead exposure has declined by approximately 75% in Canadians (Statistics Canada, 2013b). The substantial decrease in exposure to lead is attributed mainly to the phase out of leaded gasoline, reduction of lead content in paint and surface coatings, and the elimination of lead solder in food cans (Health Canada, 2013g). Today, the main route of exposure for the general adult population is from ingestion of food and drinking water (ATSDR, 2007b; Health Canada, 2013f). For infants and children, the primary sources of exposure are food, drinking water, and the ingestion of non-food items containing lead such as house dust, paint, soil, and products (Health Canada, 2013f). Lead can enter the water supply from lead service lines in older homes, brass plumbing fittings that contain lead, or lead solder in the plumbing in homes. Other potential sources of exposure include costume jewellery, art supplies, leaded crystal, and glazes on ceramics and pottery; having a hobby, or living with someone who has, that uses lead or lead solder, such as making stained glass, ceramic glazing, lead shot or lead fishing weights, and furniture refinishing; living near airports with piston aircraft activity; and behaviours such as smoking (Health Canada, 2013g). The Canadian House Dust Study reported that lead is enriched in house dust compared with the natural geochemical background, as a result of the use of lead in consumer products, paints and building materials, and infiltration from outdoor sources (Rasmussen et al., 2011; Rasmussen et al., 2013).

Approximately 3% to 10% of ingested lead is absorbed into blood in adults; the amount absorbed can increase to up to 40% to 50% in children (Health Canada, 2013f). Nutritional calcium and iron deficiencies in children appear to increase lead absorption and decrease lead excretion (Health Canada, 2013f). Once absorbed by the human body, lead circulates in the bloodstream where it accumulates in tissues, particularly bone, and is excreted from the body. Some lead may also be absorbed into soft tissues such as the liver, kidneys, pancreas, and lungs. Bones account for approximately 70% of the total body burden of lead in children and more than 90% of the total body burden in adults (EPA, 2006). Lead stored in bone can be remobilized and released back into circulating blood. Pregnancy, lactation, menopause, andropause, post-menopause, extended bed rest, hyperparathyroidism, and osteoporosis are all conditions that can increase remobilization of lead from bone, increasing blood lead levels (Health Canada, 2013f).

During pregnancy, lead stored in maternal bone becomes a source of exposure to both fetus and mother (Rothenberg et al., 2000). Lead can also be present in breast milk and is transferred from lactating mothers to infants (ATSDR, 2007b; EPA, 2006). The half-life for lead in blood is approximately 30 days whereas the half-life for lead accumulated in the body, such as in bone, is around 10 to 30 years (ATSDR, 2007b; Health Canada, 2009d; Health Canada, 2013f). Excretion of absorbed lead, independent of the route of exposure, occurs primarily in urine and feces (ATSDR, 2007b). Blood lead is the preferred indicator of human exposure to lead, although other matrices such as urine, bone, and teeth have also been used (ATSDR, 2007b; CDC, 2009).

Lead is considered a cumulative general poison, with developing fetuses, infants, toddlers, and children being most susceptible to adverse health effects (WHO, 2011c). Following acute exposure, a variety of metabolic processes may be affected. Very high exposure may result in vomiting, diarrhea, convulsions, coma, and death. Cases of lead poisoning are rare in Canada (Health Canada, 2009d). Symptoms of chronic exposure to relatively low levels of lead are often not apparent (ATSDR, 2007b). Chronic low-level exposure may affect both the central and peripheral nervous systems (Health Canada, 2013f). Chronic low-level exposure to lead has also been associated with developmental neurotoxicity, increases in blood pressure, decreases in renal functioning, and reproductive problems as well as other health endpoints (ATSDR, 2007b; Bushnik et al., 2014; Health Canada, 2013f). Cognitive and neurobehavioural effects have been recognized as major concerns for children exposed to lead. In infants and children, neurodevelopmental effects are most strongly associated with lead exposure, specifically the reduction of intelligence quotient (Lanphear et al., 2005) and an increased risk of attention-related behaviours (Health Canada, 2013f). Based on available data, no threshold has yet been identified for the effects of lead exposure on cognitive function and neurobehavioural development. Developmental neurotoxicity has been associated with the lowest levels of lead exposure measured to date (Health Canada, 2013f). The International Agency for Research on Cancer classifies inorganic lead compounds as Group 2A, probably carcinogenic to humans (IARC, 2006).

Lead is listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999). The Act allows the federal government to control the importation, manufacture, distribution, and use of lead and lead compounds in Canada (Canada, 1999; Health Canada, 2009d). CEPA 1999 prohibits the addition of lead in gasoline and controls its release from secondary lead smelters, steel manufacturing, and mining effluents (Environment Canada, 2010b). The use of lead in toys, children's jewellery and other products intended for children, glazed ceramics and glass foodware, and other consumer products representing a potential risk of lead exposure is limited under the Canada Consumer Product Safety Act and its associated regulations (Canada, 2010b; Canada, 2010d; Health Canada, 2013f). Lead and its compounds are included as prohibited ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist) (Health Canada, 2014b). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations.

On the basis of health considerations, Health Canada developed a guideline for Canadian drinking water quality that established the maximum acceptable concentration for lead (Health Canada, 1992). This guideline is currently under review by Health Canada in collaboration with the Federal-Provincial-Territorial Committee on Drinking Water (Health Canada, 2013h). Health Canada has also published guidance on controlling corrosion in drinking water distribution systems to help control the leaching of metals, including lead, from the corrosion of distribution system materials and components (Health Canada, 2009e). The concentration of lead in some foods is managed by Health Canada under the Food and Drug Regulations; the existing food tolerances are in the process of being updated, with focus first being placed on a variety of beverages, including bottled water and fruit juices (Canada, 2012c; Health Canada, 2011b; Health Canada, 2014d). These regulatory updates are one of several Health Canada activities that are under way to ensure that dietary exposure to lead is as low as reasonably achievable (Health Canada, 2011b). Lead is also included in the list of various chemicals analyzed as part of Health Canada's ongoing Total Diet Study surveys (Health Canada, 2013e). The food items analyzed represent those that are most typical of the Canadian diet, and the surveys are used to provide dietary exposure estimates for chemicals that Canadians in different age-sex groups are exposed to through the food supply. From 1981 to 2000, the average dietary exposure to lead in Canadians decreased by approximately eight-fold (Health Canada, 2011b).

In 1994, the Federal-Provincial-Territorial Committee on Environmental and Occupational Health recommended a blood lead intervention level of 10 µg/dL as guidance for low-level exposure to lead (CEOH, 1994). Recent scientific assessments indicate that chronic health effects are occurring in children at blood lead levels below 10 µg/dL and that there is sufficient evidence that blood lead levels below 5 µg/dL are associated with adverse health effects (Health Canada, 2013f). The current guidance for lead in blood (CEOH, 1994) is under review by the federal, provincial, and territorial Council of Chief Medical Officers of Health.

A number of biomonitoring studies measuring blood lead levels have been conducted in various locations in Canada over the years. The reported geometric mean blood lead levels ranged from 0.7 to 5.6 µg/dL for various age groups within the Canadian population (Health Canada, 2013f). The highest concentrations were reported for communities with point sources of environmental lead such as smelting (Trail Health and Environment Committee, 2011). In northern Canada, the contaminant component of the Inuit Health Survey (2007-2008) has measured the body burden of lead for 2,172 Inuit participants from 36 communities in Nunavut, Nunatsiavut, and the Inuvialuit Settlement Region (Laird et al., 2013). The geometric mean blood lead level for all participants (18 years and older) was 3.52 µg/dL. In 2008, a study conducted in Hamilton on 643 children aged 0 to 6 years reported a geometric mean blood lead level of 2.21 µg/dL (Richardson et al., 2011). The First Nations Biomonitoring Initiative (FNBI) is a nationally representative biomonitoring study of adult First Nations peoples living on reserves south of the 60° parallel (AFN, 2013). It comprises 13 randomly selected First Nation communities in Canada with 503 First Nations participants aged 20 years and older. In 2011, the geometric mean and 95th percentile for lead in blood were 1.17 µg/dL and 3.27 µg/dL, respectively.

Lead was analyzed in the whole blood of all Canadian Health Measures Survey participants aged 6 to 79 years in cycle 1 (2007-2009), and 3 to 79 years in cycle 2 (2009-2011) and cycle 3 (2012-2013). Data from these cycles are presented in blood as µg/dL.

Lead - Geometric means and selected percentiles of whole blood concentrations (μg/dL) for the Canadian population aged 6-79 years ^{Table 25 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 25 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5319	0.02	1.3 (1.2 - 1.4)	0.60 (0.56 - 0.64)	1.2 (1.2 - 1.3)	3.0 (2.7 - 3.3)	3.8 (3.3 - 4.2)
Total	6-79	2 (2009-2011)	5575	0	1.2 (1.1 - 1.3)	0.54 (0.50 - 0.59)	1.1 (1.1 - 1.2)	2.5 (2.3 - 2.8)	3.2 (3.0 - 3.5)
Total	6-79	3 (2012-2013)	5067	0.10	1.1 (1.0 - 1.2)	0.49 (0.46 - 0.52)	1.0 (0.96 - 1.1)	2.4 (2.3 - 2.5)	3.2 (2.9 - 3.4)
Males	6-79	1 (2007-2009)	2576	0	1.5 (1.4 - 1.6)	0.71 (0.65 - 0.76)	1.4 (1.3 - 1.5)	3.2 (2.8 - 3.6)	4.2 (3.6 - 4.7)
Males	6-79	2 (2009-2011)	2687	0	1.3 (1.3 - 1.4)	0.62 (0.56 - 0.68)	1.2 (1.2 - 1.3)	2.8 (2.5 - 3.2)	3.4 (3.1 - 3.7)
Males	6-79	3 (2012-2013)	2540	0.08	1.2 (1.2 - 1.3)	0.57 (0.55 - 0.59)	1.2 (1.1 - 1.2)	2.7 (2.4 - 2.9)	3.6 (3.1 - 4.1)
Females	6-79	1 (2007-2009)	2743	0.04	1.2 (1.1 - 1.3)	0.55 (0.50 - 0.59)	1.1 (0.99 - 1.2)	2.7 (2.3 - 3.1)	3.5 (3.0 - 3.9)
Females	6-79	2 (2009-2011)	2888	0	1.1 (1.0 - 1.1)	0.50 (0.46 - 0.54)	1.0 (0.96 - 1.1)	2.3 (2.1 - 2.5)	2.8 (2.6 - 3.0)
Females	6-79	3 (2012-2013)	2527	0.12	0.97 (0.91 - 1.0)	0.42 (0.37 - 0.47)	0.94 (0.88 - 1.0)	2.2 (2.1 - 2.3)	2.7 (2.2 - 3.1)
Table 25 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 25 footnote a referrer Table 25 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 25 footnote b referrer

Lead - Geometric means and selected percentiles of whole blood concentrations (μg/dL) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 26 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 26 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	6070	0	1.2 (1.1 - 1.2)	0.54 (0.50 - 0.59)	1.1 (1.1 - 1.2)	2.5 (2.3 - 2.7)	3.2 (2.9 - 3.4)
Total	3-79	3 (2012-2013)	5538	0.09	1.1 (1.0 - 1.1)	0.49 (0.46 - 0.52)	1.0 (0.95 - 1.1)	2.4 (2.3 - 2.5)	3.2 (2.9 - 3.4)
Males	3-79Table 26 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	2940	0	1.3 (1.3 - 1.4)	0.62 (0.56 - 0.67)	1.2 (1.2 - 1.3)	2.8 (2.5 - 3.1)	3.4 (3.1 - 3.7)
Males	3-79	3 (2012-2013)	2769	0.07	1.2 (1.2 - 1.3)	0.56 (0.55 - 0.58)	1.1 (1.0 - 1.2)	2.6 (2.4 - 2.9)	3.6 (3.1 - 4.0)
Females	3-79Table 26 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	3130	0	1.1 (1.0 - 1.1)	0.50 (0.46 - 0.54)	1.0 (0.96 - 1.1)	2.3 (2.1 - 2.5)	2.8 (2.6 - 3.0)
Females	3-79	3 (2012-2013)	2769	0.11	0.96 (0.90 - 1.0)	0.42 (0.37 - 0.47)	0.93 (0.87 - 1.0)	2.2 (2.1 - 2.3)	2.6 (2.2 - 3.1)
Total	3-5Table 26 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	495	0	0.93 (0.87 - 1.0)	0.51 (0.44 - 0.58)	0.93 (0.86 - 1.0)	1.6 (1.5 - 1.8)	2.1 (1.8 - 2.4)
Total	3-5	3 (2012-2013)	471	0	0.77 (0.73 - 0.82)	0.40 (0.33 - 0.47)	0.72 (0.68 - 0.77)	1.4 (1.0 - 1.8)	2.2 (1.4 - 2.9)
Total	6-11	1 (2007-2009)	910	0	0.90 (0.81 - 0.99)	0.53 (0.49 - 0.56)	0.87 (0.77 - 0.97)	1.6 (1.4 - 1.7)	1.9 (1.6 - 2.2)
Total	6-11	2 (2009-2011)	961	0	0.79 (0.74 - 0.84)	0.44 (0.38 - 0.50)	0.74 (0.68 - 0.81)	1.4 (1.2 - 1.6)	1.7 (1.5 - 1.9)
Total	6-11	3 (2012-2013)	944	0	0.71 (0.67 - 0.76)	0.39 (0.36 - 0.42)	0.67 (0.64 - 0.71)	1.3 (1.1 - 1.5)	1.6 (1.3 - 1.9)
Total	12-19	1 (2007-2009)	945	0	0.80 (0.74 - 0.85)	0.47 (0.44 - 0.50)	0.76 (0.70 - 0.82)	1.3 (1.1 - 1.5)	1.6 (1.4 - 1.8)
Total	12-19	2 (2009-2011)	997	0	0.71 (0.68 - 0.75)	0.39 (0.35 - 0.43)	0.68 (0.63 - 0.72)	1.2 (1.1 - 1.2)	1.6 (1.3 - 1.8)
Total	12-19	3 (2012-2013)	977	0.10	0.64 (0.60 - 0.69)	0.34 (0.32 - 0.36)	0.60 (0.56 - 0.64)	1.2 (1.1 - 1.4)	1.5 (1.3 - 1.6)
Total	20-39	1 (2007-2009)	1165	0.09	1.1 (1.0 - 1.2)	0.57 (0.52 - 0.61)	1.0 (0.95 - 1.1)	2.3 (2.0 - 2.6)	3.1 (2.7 - 3.4)
Total	20-39	2 (2009-2011)	1313	0	0.98 (0.88 - 1.1)	0.50 (0.43 - 0.57)	0.94 (0.87 - 1.0)	1.8 (1.5 - 2.1)	2.2 (1.6 - 2.9)
Total	20-39	3 (2012-2013)	1032	0.19	0.90 (0.79 - 1.0)	0.44 (0.36 - 0.53)	0.88 (0.79 - 0.97)	1.7 (1.5 - 2.0)	2.1 (1.8 - 2.4)
Total	40-59	1 (2007-2009)	1220	0	1.6 (1.5 - 1.8)	0.82 (0.69 - 0.94)	1.5 (1.4 - 1.6)	3.1 (2.6 - 3.6)	3.8 (3.1 - 4.5)
Total	40-59	2 (2009-2011)	1222	0	1.4 (1.3 - 1.5)	0.70 (0.61 - 0.79)	1.4 (1.3 - 1.4)	2.7 (2.4 - 3.0)	3.2 (2.9 - 3.5)
Total	40-59	3 (2012-2013)	1071	0.09	1.3 (1.3 - 1.4)	0.61 (0.55 - 0.68)	1.3 (1.2 - 1.4)	2.6 (2.2 - 2.9)	3.5 (2.9 - 4.2)
Total	60-79	1 (2007-2009)	1079	0	2.1 (1.9 - 2.3)	1.0 (0.92 - 1.1)	2.0 (1.8 - 2.2)	4.1 (3.5 - 4.8)	5.2 (4.2 - 6.2)
Total	60-79	2 (2009-2011)	1082	0	1.9 (1.8 - 1.9)	1.0 (0.94 - 1.1)	1.7 (1.7 - 1.8)	3.5 (3.2 - 3.8)	4.2 (3.8 - 4.6)
Total	60-79	3 (2012-2013)	1043	0.10	1.6 (1.6 - 1.7)	0.81 (0.78 - 0.85)	1.6 (1.4 - 1.7)	3.3 (3.0 - 3.5)	4.0 (3.6 - 4.4)
Table 26 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 26 footnote a referrer Table 26 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 26 footnote b referrer

Mercury

Mercury (CASRN 7439-97-6) is a naturally occurring soft, silvery white metal present in the Earth's crust at an average concentration of approximately 0.000005% (Emsley, 2001). It is the only metal that is a liquid at room temperature. Mercury exists in elemental, inorganic, and organic forms (CCME, 1999b). Elemental and certain organic forms of mercury have sufficiently high vapour pressures to be present as vapour in air (ATSDR, 1999a). The most common organic mercury compounds in nature are methylmercury (monomethylmercury) and dimethylmercury. Mercury can be converted among its elemental, inorganic, and organic forms by a variety of processes, including biological transformation (Environment Canada, 2010c).

Mercury is found throughout the environment, including remote Arctic regions because of its persistence, mobility, and tendency to accumulate in colder climates. Natural sources include volcanic activity and natural erosion of mercury-containing deposits (Environment Canada & Health Canada, 2010). Metabolism of inorganic mercury by micro-organisms in the environment creates organic mercury (methylmercury) that often bioaccumulates in terrestrial and aquatic food chains (ATSDR, 1999a). Anthropogenic sources of inorganic mercury include metal mining and smelting; combustion of fossil fuels, particularly coal; incineration of municipal wastes; cement production; and sewage sludge and waste water (UNEP, 2002). Inorganic mercury may also be released to the environment following disposal of products containing mercury.

Mercury has unique properties that have made it useful in certain products such as wiring devices, switches, and scientific measuring devices, including vacuum gauges and thermometers (ATSDR, 1999a). Today it has been phased out of most products manufactured in Canada; however, many products that contain mercury are still imported into the Canadian marketplace (Canada, 2011c). Inorganic mercury is still found in some medical devices, such as thermostats and X-ray tubes, and in button-cell batteries used in small electronics and hearing aids. Mercury vapour is also present in many lamps and lights, including all fluorescent lamps, mercury vapour lamps, metal halide lamps, and sodium vapour lamps (Environment Canada, 2010c). Use of mercury-containing light bulbs is increasing because of widespread replacement of incandescent bulbs with compact fluorescent bulbs. Mercury is also used as an industrial catalyst and in laboratory reagents, disinfectants, embalming solutions, and some pharmaceuticals. A significant use of inorganic mercury is in dental amalgam, which is composed of approximately 50% mercury (IMERC, 2010). Of the total Canadian population in 2007-2009, 63.95% had one or more amalgam-restored tooth surfaces (Richardson, 2014).

Mercury exposure in the general population is primarily through the consumption of fish and seafood in which methylmercury is the predominant form (Health Canada, 2007a). To a much lesser extent, the general population is exposed to inorganic mercury from such sources as dental amalgams (Health Canada, 2007a). The general population may also be exposed to elemental mercury via inhalation of vapours in ambient air, ingestion, or through dental and medical treatments (ATSDR, 1999a).

Approximately 95% of organic mercury is absorbed from the gastrointestinal tract following oral ingestion (ATSDR, 1999a). Following absorption, organic mercury is distributed to all tissues, including hair, with highest accumulation in the kidneys (ATSDR, 1999a). It readily passes the blood-brain barrier and enters the brain, and in pregnant women can easily cross the placental barrier into the fetus (Health Canada, 2004). Absorbed organic mercury is demethylated in the body to inorganic mercury that accumulates primarily in the liver and kidneys. The biological half-life of methylmercury is approximately 50 days. The majority of mercury in the body is excreted via feces, with a small amount excreted as inorganic mercury in urine (ATSDR, 1999a).

Generally less than 10% of inorganic mercury is absorbed through the intestinal tract (Health Canada, 2004). Absorbed inorganic mercury accumulates readily in the kidneys (IPCS, 2003). It also accumulates in placental tissues but does not cross placental or blood-brain barriers as easily as elemental or methylmercury (Health Canada, 2004). Excretion of elemental and inorganic mercury compounds occurs mainly in urine and feces with an absorbed dose half-life of approximately 1 to 2 months (IPCS, 2003).

Elemental mercury is absorbed across the lungs and gastrointestinal tract with absorption rates of about 80% and 0.01%, respectively (Health Canada, 2004). Once absorbed, elemental mercury enters the bloodstream and is rapidly transported to other parts of the body, including the brain and kidneys. As with organic mercury, it readily crosses the blood-brain and placental barriers (Health Canada, 2004). Once in the body, elemental mercury is oxidized in the tissues to inorganic forms and can remain for weeks or months with an estimated half-life of approximately 60 days (Sandborgh-Englund et al., 1998).

Long-term exposure to elemental and inorganic mercury is commonly evaluated using mercury concentrations in urine (IPCS, 2003). Hair also may be used as a biomarker of chronic exposure, although inorganic forms of mercury are not excreted to any significant amount in scalp hair, making it an inappropriate biomarker of inorganic mercury exposure (ATSDR, 1999a; IPCS, 2003). Total blood mercury concentrations primarily reflect recent dietary exposure to organic forms of mercury, particularly methylmercury (ATSDR, 1999a; IPCS, 2003). The concentration of total mercury in blood is accepted as a reasonable measure of methylmercury exposure, however methylmercury itself may also be measured directly in blood. Based on a review of existing data from other countries, the World Health Organization has estimated that the average total blood mercury concentration for the general population is approximately 8 µg/L (WHO, 1990). In individuals who consume fish daily, methylmercury concentrations in blood can be as high as 200 µg/L (WHO, 1990).

Mercury is known to be toxic to humans, with the effects depending on the mercury form, the route of exposure, the timing of exposure, and the absorbed concentration. Chronic oral exposure to low levels of methylmercury may not result in any observable symptoms (Health Canada, 2007a). The primary effects associated with oral exposure to organic mercury compounds are neurological effects and developmental neurotoxicity (UNEP, 2002). Symptoms of organic mercury toxicity include a tingling sensation in the extremities; impaired peripheral vision, hearing, taste, and smell; slurred speech; muscle weakness and an unsteady gait; irritability; memory loss; depression; and sleeping difficulties (UNEP, 2002). Exposure of a fetus or young child to organic mercury can result in effects on the development of the nervous system, affecting fine-motor function, attention, verbal learning, and memory (ATSDR, 1999a; Health Canada, 2007a). Exposure to elemental mercury may be hazardous, depending upon the levels of exposure, because the vapour that can be released from this form is readily absorbed into the body through inhalation. Inhalation of mercury vapour may cause respiratory, cardiovascular, kidney, and neurological effects. Exposure to inorganic mercury from dental amalgams has not been associated with neurologic effects in children or adults (Bates et al., 2004; Bellinger et al., 2007; DeRouen et al., 2006; Factor-Litvak et al., 2003). Health Canada concluded that mercury exposure from dental amalgams does not pose a health impact for the general population (Health Canada, 1996a).

The International Agency for Research on Cancer (IARC) determined that methylmercury compounds are possibly carcinogenic to humans (Group 2B), based on animal data showing a link to certain cancers, particularly renal cancer (IARC, 1993). Elemental mercury and inorganic mercury compounds were classified by IARC as Group 3, not classifiable as to their carcinogenicity to humans (IARC, 1993).

The United Nations Environment Programme (UNEP) Global Risk Assessment for Mercury concluded that there was sufficient evidence of adverse impacts from mercury to warrant further international action to reduce the risks to human health and the environment (UNEP, 2002). International negotiations under UNEP resulted in the signing of the Minamata Convention on Mercury, a global legally binding agreement to prevent mercury emissions and releases (UNEP, 2013). The Minamata Convention is intended to reduce global atmospheric emissions, supply, trade, and demand for mercury, and to find environmentally sound solutions for storage of mercury and mercury-containing wastes.

In Canada, mercury and its compounds are listed as toxic substances on Schedule 1 of the Canadian Environmental Protection Act, 1999 (CEPA 1999) (Canada, 1999; Canada, 2012d). Existing and planned actions to manage the risks from mercury are summarized in the Government of Canada's Risk Management Strategy for Mercury (Environment Canada & Health Canada, 2010). These risk management actions include several Canada-wide standards that have been established to reduce the releases of mercury to the environment (CCME, 2000a; CCME, 2005; CCME, 2006; CCME, 2007). The Surface Coating Materials Regulations, in effect under the Canada Consumer Product Safety Act, restrict the level of mercury in all surface coating materials advertised, sold, or imported into Canada (Canada, 2005). In addition, the Toys Regulations prohibit any compound of mercury in the surface coating material that is applied to a product that is used by a child in learning or play situations (Canada, 2011b). In 2011, a regulation was proposed under CEPA 1999 with prohibitions on the import, manufacture, sale, and offer for sale of mercury-containing products that are not currently regulated under other legislation (Canada, 2011c). Mercury and its compounds are also included as prohibited ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Canada, 1985; Health Canada, 2014b). The Food and Drug Regulations prohibit sale in Canada of drugs for human use containing mercury or any of its salts or derivatives except in some specific instances, including those where it is present as a preservative (Canada, 2012c).

Health Canada has established a total mercury blood guidance value of 20 µg/L for the general adult population (Health Canada, 2004). For children (less than 18 years of age), pregnant women, and women of childbearing age (less than 50 years of age), a provisional methylmercury blood guidance value of 8 µg/L has been proposed for the protection of the developing nervous system (Legrand et al., 2010). On the basis of health considerations, Health Canada, in collaboration with the Federal-Provincial-Territorial Committee on Drinking Water, has developed a guideline for Canadian drinking water quality that establishes the maximum acceptable concentration for mercury in drinking water (Health Canada, 1986b; Health Canada, 2012e). Health Canada has also established maximum levels for mercury in retail fish (Health Canada, 2012f), and provides consumption advice for consumers of certain types of fish (Health Canada, 2008c). Eating Well with Canada's Food Guide recommends eating at least two food guide servings each week of fish that are low in mercury and high in omega-3 fatty acids (Health Canada, 2011c). Mercury is also included in the list of various chemicals analyzed as part of Health Canada's ongoing Total Diet Study surveys (Health Canada, 2013e). The food items analyzed represent those that are most typical of the Canadian diet, and the surveys are used to provide dietary exposure estimates for chemicals that Canadians in different age-sex groups are exposed to through the food supply.

During cycle 1 (2007-2009) of the CHMS, the geometric mean blood total mercury level of the Canadian population aged 6 to 79 years was 0.69 µg/L (Lye et al., 2013). The majority (97.8%) of Canadian women aged 16 to 49 years, including pregnant women, had blood mercury values below the provisional Health Canada blood guidance value of 8 µg/L (Lye et al., 2013). The mean urinary inorganic mercury concentration in dental amalgam-free participants from cycle 1 of the CHMS was 0.10 µg/L compared with the overall population mean concentration of 0.22 µg/L (Nicolae et al., 2013). In general, mean urinary inorganic mercury concentrations tended to increase with the number of amalgam surfaces and appeared to be influenced by age and sex (Nicolae et al., 2013). The population coverage of the CHMS excludes persons living on reserves and other Aboriginal settlements in the provinces of Canada. However, this subpopulation has been surveyed as part of the First Nations Biomonitoring Initiative (FNBI), a nationally representative biomonitoring study of adult First Nations peoples living on reserves south of the 60° parallel (AFN, 2013). It comprises 13 randomly selected First Nation communities in Canada with 503 First Nations participants aged 20 years and older. In 2011, the geometric mean and 95th percentile for total mercury in blood were 0.95 µg/L and 9.28 µg/L, respectively. For inorganic mercury in urine, the geometric mean and 95th percentile were 0.26 µg/L and 1.98 µg/L, respectively.

Total mercury was analyzed in the whole blood of all Canadian Health Measures Survey (CHMS) participants aged 6 to 79 years in cycle 1 (2007-2009), and 3 to 79 years in cycle 2 (2009-2011) and cycle 3 (2012-2013). Methylmercury was analyzed in the whole blood of CHMS participants aged 20 to 79 years in cycle 3 (2012-2013). Inorganic mercury was analyzed in the urine of all CHMS participants aged 6 to 79 years in cycle 1 (2007-2009) and 3 to 79 years in cycle 3 (2012-2013). Data from these cycles are presented in blood as µg/L (µg Hg/L for methylmercury) and in urine as both µg/L and µg/g creatinine. Finding a measurable amount of mercury in blood or urine is an indicator of exposure to mercury and does not necessarily mean that an adverse health effect will occur.

Mercury (inorganic) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 6-79 years ^{Table 27 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 27 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5444	49.63	--	<LOD	0.24 (0.19 - 0.29)	1.8 (1.6 - 2.0)	2.9 (2.5 - 3.3)
Total	6-79	3 (2012-2013)	5176	47.97	--	<LOD	0.20 (<LOD - 0.25)	1.3 (1.1 - 1.5)	2.0 (1.7 - 2.3)
Males	6-79	1 (2007-2009)	2636	48.33	--	<LOD	0.24 (0.19 - 0.29)	1.7 (1.6 - 1.9)	2.7 (2.3 - 3.0)
Males	6-79	3 (2012-2013)	2582	46.90	--	<LOD	0.20Table 27 footnote E (<LOD - 0.28)	1.2 (0.93 - 1.5)	1.9 (1.3 - 2.4)
Females	6-79	1 (2007-2009)	2808	50.85	--	<LOD	0.23 (0.18 - 0.29)	2.0 (1.7 - 2.3)	3.1 (2.7 - 3.6)
Females	6-79	3 (2012-2013)	2594	49.04	--	<LOD	0.20 (<LOD - 0.26)	1.4 (0.99 - 1.8)	2.2 (1.5 - 2.8)
Table 27 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 27 footnote a referrer Table 27 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 27 footnote b referrer Table 27 footnote E Use data with caution. Return to table 27 footnote E referrer

Mercury (inorganic) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 6-79 years ^{Table 28 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 28 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5432	49.63	--	<LOD	0.26 (0.19 - 0.32)	1.6 (1.5 - 1.8)	2.5 (2.1 - 2.9)
Total	6-79	3 (2012-2013)	5175	47.97	--	<LOD	0.24 (0.20 - 0.27)	1.0 (0.94 - 1.1)	1.6 (1.3 - 1.9)
Males	6-79	1 (2007-2009)	2628	48.33	--	<LOD	0.21 (0.16 - 0.26)	1.2 (1.1 - 1.3)	1.8 (1.5 - 2.1)
Males	6-79	3 (2012-2013)	2582	46.90	--	<LOD	0.21 (0.17 - 0.24)	0.87 (0.63 - 1.1)	1.2 (1.0 - 1.4)
Females	6-79	1 (2007-2009)	2804	50.85	--	<LOD	<LOD	2.1 (1.7 - 2.4)	2.8 (2.2 - 3.5)
Females	6-79	3 (2012-2013)	2593	49.04	--	<LOD	0.29 (0.23 - 0.35)	1.3 (0.88 - 1.6)	1.9 (1.5 - 2.4)
Table 28 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 28 footnote a referrer Table 28 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 28 footnote b referrer

Mercury (inorganic) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 29 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 29 footnote b	1 (2007-2009)
Total	3-79	3 (2012-2013)	5696	50.42	--	<LOD	0.19 (<LOD - 0.24)	1.3 (1.1 - 1.5)	2.0 (1.7 - 2.3)
Males	3-79Table 29 footnote b	1 (2007-2009)
Males	3-79	3 (2012-2013)	2842	49.37	--	<LOD	0.20Table 29 footnote E (<LOD - 0.27)	1.2 (0.92 - 1.5)	1.9 (1.3 - 2.4)
Females	3-79Table 29 footnote b	1 (2007-2009)
Females	3-79	3 (2012-2013)	2854	51.47	--	<LOD	0.19 (<LOD - 0.25)	1.4 (0.97 - 1.8)	2.1 (1.5 - 2.8)
Total	3-5Table 29 footnote b	1 (2007-2009)
Total	3-5	3 (2012-2013)	520	74.81	--	<LOD	<LOD	0.28Table 29 footnote E (<LOD - 0.48)	0.59Table 29 footnote E (0.35 - 0.84)
Total	6-11	1 (2007-2009)	1028	66.05	--	<LOD	<LOD	0.99Table 29 footnote E (0.56 - 1.4)	1.8Table 29 footnote E (0.99 - 2.7)
Total	6-11	3 (2012-2013)	1010	61.29	--	<LOD	<LOD	0.93Table 29 footnote E (0.50 - 1.4)	Table 29 footnote F
Total	12-19	1 (2007-2009)	975	57.54	--	<LOD	<LOD	1.2 (0.76 - 1.6)	2.2 (1.5 - 3.0)
Total	12-19	3 (2012-2013)	997	59.58	--	<LOD	<LOD	0.55Table 29 footnote E (0.33 - 0.78)	1.1Table 29 footnote E (0.53 - 1.6)
Total	20-39	1 (2007-2009)	1166	46.23	--	<LOD	0.22 (0.16 - 0.28)	1.4 (1.0 - 1.7)	2.3 (1.8 - 2.7)
Total	20-39	3 (2012-2013)	1048	45.13	--	<LOD	0.20Table 29 footnote E (<LOD - 0.28)	1.1 (0.87 - 1.3)	1.9Table 29 footnote E (0.89 - 3.0)
Total	40-59	1 (2007-2009)	1207	36.04	0.31 (0.25 - 0.37)	<LOD	0.37 (0.28 - 0.47)	2.5 (1.8 - 3.2)	3.5 (2.3 - 4.7)
Total	40-59	3 (2012-2013)	1080	36.20	0.31 (0.26 - 0.39)	<LOD	0.30 (0.20 - 0.40)	1.7 (1.2 - 2.2)	2.2 (1.7 - 2.6)
Total	60-79	1 (2007-2009)	1068	45.69	--	<LOD	0.25Table 29 footnote E (0.15 - 0.35)	2.0 (1.4 - 2.5)	3.0 (2.5 - 3.5)
Total	60-79	3 (2012-2013)	1041	39.00	0.26 (0.23 - 0.30)	<LOD	0.24 (0.18 - 0.30)	1.4 (0.98 - 1.8)	2.3 (1.6 - 2.9)
Table 29 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 29 footnote a referrer Table 29 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 29 footnote b referrer Table 29 footnote E Use data with caution. Return to table 29 footnote E referrer Table 29 footnote F Data is too unreliable to be published. Return to table 29 footnote F referrer

Mercury (inorganic) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 30 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 30 footnote b	1 (2007-2009)
Total	3-79	3 (2012-2013)	5694	50.42	--	<LOD	<LOD	1.0 (0.94 - 1.1)	1.6 (1.3 - 1.9)
Males	3-79Table 30 footnote b	1 (2007-2009)
Males	3-79	3 (2012-2013)	2842	49.37	--	<LOD	0.21 (0.17 - 0.24)	0.86 (0.63 - 1.1)	1.2 (1.1 - 1.4)
Females	3-79Table 30 footnote b	1 (2007-2009)
Females	3-79	3 (2012-2013)	2852	51.47	--	<LOD	<LOD	1.2 (0.87 - 1.5)	1.9 (1.5 - 2.3)
Total	3-5Table 30 footnote b	1 (2007-2009)
Total	3-5	3 (2012-2013)	519	74.81	--	<LOD	<LOD	0.73Table 30 footnote E (0.45 - 1.0)	1.0 (0.72 - 1.3)
Total	6-11	1 (2007-2009)	1025	66.05	--	<LOD	<LOD	1.3Table 30 footnote E (0.62 - 1.9)	2.0 (1.3 - 2.7)
Total	6-11	3 (2012-2013)	1010	61.29	--	<LOD	<LOD	0.99Table 30 footnote E (0.55 - 1.4)	1.9Table 30 footnote E (0.84 - 3.0)
Total	12-19	1 (2007-2009)	975	57.54	--	<LOD	<LOD	0.79 (0.55 - 1.0)	1.3Table 30 footnote E (0.79 - 1.8)
Total	12-19	3 (2012-2013)	997	59.58	--	<LOD	<LOD	0.42Table 30 footnote E (0.27 - 0.58)	0.73Table 30 footnote E (0.42 - 1.0)
Total	20-39	1 (2007-2009)	1162	46.23	--	<LOD	0.21 (0.18 - 0.24)	1.1 (0.89 - 1.4)	1.9 (1.5 - 2.2)
Total	20-39	3 (2012-2013)	1048	45.13	--	<LOD	0.22 (0.18 - 0.26)	0.85 (0.56 - 1.2)	1.2 (0.97 - 1.3)
Total	40-59	1 (2007-2009)	1202	36.04	0.39 (0.33 - 0.48)	<LOD	0.43 (0.33 - 0.52)	2.1 (1.5 - 2.7)	3.0 (2.3 - 3.7)
Total	40-59	3 (2012-2013)	1079	36.20	0.33 (0.29 - 0.38)	<LOD	0.33 (0.27 - 0.40)	1.3 (0.91 - 1.7)	1.7 (1.5 - 2.0)
Total	60-79	1 (2007-2009)	1068	45.69	--	<LOD	0.29Table 30 footnote E (0.17 - 0.42)	2.0 (1.7 - 2.3)	2.7 (2.1 - 3.4)
Total	60-79	3 (2012-2013)	1041	39.00	0.32 (0.28 - 0.36)	<LOD	0.32 (0.27 - 0.37)	1.3 (0.95 - 1.6)	2.2 (1.6 - 2.8)
Table 30 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 30 footnote a referrer Table 30 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 30 footnote b referrer Table 30 footnote E Use data with caution. Return to table 30 footnote E referrer

Mercury (total) - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 6-79 years ^{Table 31 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 31 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5319	11.64	0.69 (0.55 - 0.86)	<LOD	0.81 (0.64 - 0.97)	3.0 (2.2 - 3.9)	4.6Table 31 footnote E (2.5 - 6.7)
Total	6-79	2 (2009-2011)	5575	14.28	0.71 (0.57 - 0.89)	<LOD	0.76 (0.57 - 0.96)	3.5 (2.4 - 4.6)	5.6Table 31 footnote E (3.3 - 7.8)
Total	6-79	3 (2012-2013)	5067	34.93	0.81 (0.65 - 1.0)	<LOD	0.81 (0.63 - 0.99)	3.2Table 31 footnote E (1.5 - 5.0)	5.4Table 31 footnote E (3.1 - 7.6)
Males	6-79	1 (2007-2009)	2576	12.11	0.68 (0.55 - 0.84)	<LOD	0.79 (0.64 - 0.94)	3.1 (2.1 - 4.1)	5.1Table 31 footnote E (2.7 - 7.5)
Males	6-79	2 (2009-2011)	2687	14.77	0.74 (0.58 - 0.94)	<LOD	0.80 (0.56 - 1.0)	3.9 (2.7 - 5.2)	6.3Table 31 footnote E (2.9 - 9.7)
Males	6-79	3 (2012-2013)	2540	35.67	0.78 (0.61 - 1.0)	<LOD	0.77 (0.56 - 0.98)	3.3Table 31 footnote E (1.4 - 5.1)	5.7Table 31 footnote E (3.4 - 7.9)
Females	6-79	1 (2007-2009)	2743	11.19	0.70 (0.56 - 0.88)	<LODTable 31 footnote E (<LOD - 0.11)	0.82 (0.63 - 1.0)	3.0 (2.1 - 3.8)	4.5Table 31 footnote E (2.6 - 6.4)
Females	6-79	2 (2009-2011)	2888	13.82	0.69 (0.55 - 0.86)	<LOD	0.74 (0.56 - 0.92)	3.0 (2.0 - 4.0)	5.1Table 31 footnote E (3.0 - 7.2)
Females	6-79	3 (2012-2013)	2527	34.19	0.83 (0.68 - 1.0)	<LOD	0.84 (0.68 - 0.99)	3.2Table 31 footnote E (1.4 - 5.0)	5.1Table 31 footnote E (2.4 - 7.9)
Table 31 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 31 footnote a referrer Table 31 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 31 footnote b referrer Table 31 footnote E Use data with caution. Return to table 31 footnote E referrer

Mercury (total) - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 32 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 32 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	6070	15.55	0.69 (0.56 - 0.87)	<LOD	0.74 (0.55 - 0.93)	3.4 (2.4 - 4.5)	5.5Table 32 footnote E (3.3 - 7.6)
Total	3-79	3 (2012-2013)	5538	37.02	0.79 (0.64 - 0.97)	<LOD	0.79 (0.62 - 0.96)	3.2Table 32 footnote E (1.5 - 4.9)	5.2Table 32 footnote E (3.0 - 7.5)
Males	3-79Table 32 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	2940	16.16	0.72 (0.56 - 0.91)	<LOD	0.76 (0.53 - 0.99)	3.9 (2.7 - 5.1)	6.1Table 32 footnote E (2.7 - 9.5)
Males	3-79	3 (2012-2013)	2769	37.63	0.76 (0.60 - 0.97)	<LOD	0.74 (0.54 - 0.94)	3.2Table 32 footnote E (1.3 - 5.0)	5.6Table 32 footnote E (3.4 - 7.8)
Females	3-79Table 32 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	3130	14.98	0.67 (0.54 - 0.83)	<LOD	0.71 (0.53 - 0.88)	3.0 (2.0 - 4.0)	5.1Table 32 footnote E (3.0 - 7.1)
Females	3-79	3 (2012-2013)	2769	36.40	0.81 (0.67 - 0.99)	<LOD	0.82 (0.67 - 0.97)	3.2Table 32 footnote E (1.4 - 4.9)	5.1Table 32 footnote E (2.4 - 7.8)
Total	3-5Table 32 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	495	29.90	0.27 (0.20 - 0.36)	<LOD	0.19Table 32 footnote E (<LOD - 0.29)	1.4Table 32 footnote E (0.44 - 2.3)	3.0Table 32 footnote E (1.7 - 4.3)
Total	3-5	3 (2012-2013)	471	59.45	--	<LOD	<LOD	1.3 (1.0 - 1.7)	1.7Table 32 footnote E (0.88 - 2.5)
Total	6-11	1 (2007-2009)	910	24.84	0.26 (0.22 - 0.32)	<LOD	0.24 (0.18 - 0.29)	1.3 (1.0 - 1.6)	2.1Table 32 footnote E (1.3 - 2.9)
Total	6-11	2 (2009-2011)	961	29.03	0.28 (0.22 - 0.34)	<LOD	0.21Table 32 footnote E (0.11 - 0.30)	1.2 (0.84 - 1.5)	2.0 (1.3 - 2.6)
Total	6-11	3 (2012-2013)	944	54.77	--	<LOD	<LOD	1.2 (0.78 - 1.7)	1.9Table 32 footnote E (0.91 - 2.9)
Total	12-19	1 (2007-2009)	945	20.85	0.30 (0.23 - 0.40)	<LOD	0.28 (0.20 - 0.37)	1.3Table 32 footnote E (0.47 - 2.2)	2.2Table 32 footnote E (0.88 - 3.5)
Total	12-19	2 (2009-2011)	997	26.58	0.27 (0.21 - 0.35)	<LOD	0.19Table 32 footnote E (<LOD - 0.30)	1.3 (0.84 - 1.7)	2.4Table 32 footnote E (1.3 - 3.5)
Total	12-19	3 (2012-2013)	977	52.61	--	<LOD	<LOD	1.6Table 32 footnote E (0.62 - 2.6)	2.8Table 32 footnote E (1.3 - 4.4)
Total	20-39	1 (2007-2009)	1165	8.76	0.65 (0.52 - 0.81)	<LOD	0.76 (0.61 - 0.91)	3.0Table 32 footnote E (1.9 - 4.1)	4.9Table 32 footnote E (2.4 - 7.4)
Total	20-39	2 (2009-2011)	1313	10.05	0.64 (0.47 - 0.85)	<LOD	0.65 (0.43 - 0.86)	2.9 (2.0 - 3.9)	5.2Table 32 footnote E (2.6 - 7.8)
Total	20-39	3 (2012-2013)	1032	30.91	0.82 (0.65 - 1.0)	<LOD	0.77 (0.57 - 0.96)	4.1Table 32 footnote E (1.5 - 6.6)	6.0Table 32 footnote E (3.6 - 8.3)
Total	40-59	1 (2007-2009)	1220	3.52	1.0 (0.80 - 1.3)	0.21Table 32 footnote E (0.12 - 0.30)	1.1 (0.83 - 1.3)	3.6 (2.3 - 4.9)	6.4Table 32 footnote E (3.0 - 9.8)
Total	40-59	2 (2009-2011)	1222	5.16	1.0 (0.79 - 1.3)	0.15 (0.11 - 0.20)	1.0 (0.84 - 1.2)	4.1Table 32 footnote E (2.4 - 5.8)	7.3Table 32 footnote E (2.5 - 12)
Total	40-59	3 (2012-2013)	1071	20.54	0.96 (0.74 - 1.2)	<LOD	0.99 (0.78 - 1.2)	3.4Table 32 footnote E (1.5 - 5.4)	5.2Table 32 footnote E (2.8 - 7.6)
Total	60-79	1 (2007-2009)	1079	4.73	0.87 (0.64 - 1.2)	Table 32 footnote F	0.96 (0.75 - 1.2)	3.4 (2.4 - 4.4)	4.8Table 32 footnote E (2.7 - 6.9)
Total	60-79	2 (2009-2011)	1082	5.27	1.1 (0.86 - 1.5)	0.17Table 32 footnote E (<LOD - 0.28)	1.2 (0.89 - 1.5)	4.3 (3.1 - 5.5)	6.5Table 32 footnote E (3.9 - 9.1)
Total	60-79	3 (2012-2013)	1043	19.18	1.0 (0.82 - 1.3)	<LOD	0.99 (0.71 - 1.3)	3.8Table 32 footnote E (2.2 - 5.3)	6.7Table 32 footnote E (1.9 - 11)
Table 32 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 32 footnote a referrer Table 32 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 32 footnote b referrer Table 32 footnote E Use data with caution. Return to table 32 footnote E referrer Table 32 footnote F Data is too unreliable to be published. Return to table 32 footnote F referrer

Methylmercury - Geometric means and selected percentiles of whole blood concentrations (μg Hg/L) for the Canadian population aged 20-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 33 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	20-79	3 (2012-2013)	1032	18.70	0.64 (0.48 - 0.84)	<LOD	0.72 (0.50 - 0.95)	3.1Table 33 footnote E (1.2 - 5.0)	5.2Table 33 footnote E (2.7 - 7.6)
Males	20-79	3 (2012-2013)	502	18.33	0.63Table 33 footnote E (0.38 - 1.0)	<LOD	0.63Table 33 footnote E (0.23 - 1.0)	4.3Table 33 footnote E (1.2 - 7.3)	7.5Table 33 footnote E (3.9 - 11)
Females	20-79	3 (2012-2013)	530	19.06	0.65 (0.53 - 0.79)	<LOD	0.83 (0.68 - 0.97)	2.6Table 33 footnote E (1.3 - 3.9)	4.4Table 33 footnote E (2.8 - 6.1)
Total	20-39	3 (2012-2013)	359	24.51	0.56 (0.42 - 0.76)	<LOD	0.60 (0.38 - 0.81)	Table 33 footnote F	4.6Table 33 footnote E (1.7 - 7.4)
Total	40-59	3 (2012-2013)	313	19.17	0.60Table 33 footnote E (0.41 - 0.89)	<LOD	0.66Table 33 footnote E (0.24 - 1.1)	3.0Table 33 footnote E (0.85 - 5.1)	5.4Table 33 footnote E (2.1 - 8.7)
Total	60-79	3 (2012-2013)	360	12.50	0.87 (0.62 - 1.2)	<LOD	0.99 (0.65 - 1.3)	3.1Table 33 footnote E (1.8 - 4.5)	Table 33 footnote F
Table 33 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 33 footnote a referrer Table 33 footnote E Use data with caution. Return to table 33 footnote E referrer Table 33 footnote F Data is too unreliable to be published. Return to table 33 footnote F referrer

Summary and Results for Nicotine Metabolite

Cotinine

Cotinine (CASRN 486-56-6) is the major primary metabolite of nicotine, a chemical found naturally in the tobacco plant and present in tobacco products such as cigarettes, cigars, and smokeless tobacco products (e.g. chewing tobacco and snuff) (Benowitz & Jacob, 1994). Nicotine is also incorporated into nicotine replacement therapies such as the nicotine gum, patch, lozenge, inhaler, e-cigarettes, and buccal spray.

Human exposure to nicotine occurs primarily through the use of tobacco products, exposure to environmental tobacco smoke, and the use of nicotine replacement therapies (HSDB, 2009). In addition, infants breast fed by women who smoke may be exposed to nicotine in breast milk (HSDB, 2009).

Inhalation is the most effective intake route with on average 60% to 80% of nicotine absorbed through the lungs (Iwase et al., 1991). Nicotine can also be absorbed through the skin and gastrointestinal tract, but at a much lower efficiency (Karaconji, 2005). Once inside the body, approximately 70% to 80% of nicotine is metabolized into cotinine. It has a half-life of 10 to 20 hours and can remain in the body at detectable levels for up to 4 days (Benowitz & Jacob, 1994; Curvall et al., 1990). Cotinine is considered to be the most relevant biomarker for exposure to tobacco products and tobacco smoke (Brown et al., 2005; CDC, 2009; Seaton & Vesell, 1993).

Tobacco smoke is a combination of gases, liquids, and breathable particles, some of which are harmful to human health. It contains over 4,000 chemicals, including at least 70 that cause, initiate, or promote cancer, and has been classified by the International Agency for Research on Cancer (IARC) as Group 1, carcinogenic to humans (Health Canada, 2011d; IARC, 2004). Exposure to these chemicals also contributes directly to other diseases, such as emphysema and heart disease, and an increased risk of asthma (CDC, 2004). During pregnancy, smoking may lead to miscarriages, low-birth-weight infants and less breast milk (WHO, 2010a). Most of these chemicals are formed during the combustion of tobacco; others are found naturally in tobacco and are released as the tobacco burns (CDC, 2004). Smokeless tobaccos, including chewing tobacco and snuff, contain 28 known cancer-causing chemicals and, similar to the tobaccos used in cigarettes, pipes, and cigars, can lead to nicotine dependence and addiction (Health Canada, 2010g; IARC, 2007). Smokeless tobacco use causes oral and pancreatic cancer and has been classified by IARC as Group 1, carcinogenic to humans (IARC, 2007). It can also cause serious dental health problems, including recession of the gums, tooth loss, and discolouration of the teeth and gums (Walsh & Epstein, 2000). Levels of cotinine in the blood and urine of non-smokers have been correlated with some adverse health effects related to tobacco smoke exposure, and cotinine itself may contribute to the neuropharmacological effects of tobacco smoking (Benowitz, 1996; Crooks & Dwoskin, 1997).

As a result of the adverse health effects associated with tobacco use, the Government of Canada, along with provincial and territorial governments and various municipalities, has taken several steps to reduce the prevalence of tobacco use as well as exposure to tobacco smoke. These steps include prohibitions on the sale of tobacco to youth, requirements to apply health warnings on tobacco packaging, and restrictions on the promotion of tobacco products, including the display of tobacco products at retail outlets (Health Canada, 2006b). Additional steps include the offer of cessation help along with initiatives to eliminate smoking in workplaces and enclosed public locations (Health Canada, 2006b).

The First Nations Biomonitoring Initiative (FNBI) is a nationally representative biomonitoring study of adult First Nations peoples living on reserves south of the 60° parallel (AFN, 2013). It comprises 13 randomly selected First Nation communities in Canada with 503 First Nations participants aged 20 years and older. In 2011, the 50th percentile concentrations of cotinine in urine from smokers and non-smokers were 315.79 µg/L and <1.1 µg/L, respectively. Data from cycle 1 (2007-2009) of the Canadian Health Measures Survey (CHMS) demonstrated that a substantial proportion of the Canadian population is exposed to secondhand smoke. The study found that certain non-smoking subpopulations, including children, adolescents, and those exposed to secondhand smoke in the home, had higher percentages with detectable cotinine concentrations (≥1.1 µg/L), indicating secondhand smoke exposure (Wong et al., 2013). A study of occupationally exposed non-smoking bar workers in the Toronto area examined the effects of a 2004 smoke-free workplace bylaw; the study showed a 1-month post-ban decline in the geometric mean of urinary cotinine from 10.3 µg/L to 3.10 µg/L (Repace et al., 2013). A concentration of 50 µg/L urine for cotinine is recommended for determining smoking status; levels greater than this concentration are attributed to smokers (SRNT Subcommittee on Biochemical Verification, 2002). Using this concentration, a study assessed the validity of self-reported cigarette smoking status among Canadians using urinary cotinine data from cycle 1 (2007-2009) of the CHMS (Wong et al., 2012). Compared with estimates based on urinary cotinine concentration, smoking prevalence based on self-reporting was only 0.3 percentage points lower, indicating that accurate estimates of the prevalence of cigarette smoking among Canadians can be derived from self-reported smoking status data.

Cotinine was analyzed in the urine of all CHMS participants aged 6 to 79 years in cycle 1 (2007-2009), and 3 to 79 years in cycle 2 (2009-2011) and cycle 3 (2012-2013). Data from these cycles are presented as both µg/L and µg/g creatinine for non-smokers and smokers. Survey participants aged 3 to 11 years were assumed to be non-smokers. In this survey, a smoker is defined as someone who is a current daily or occasional smoker and a non-smoker is defined as someone who does not currently smoke and has either never smoked or who was previously a daily or occasional smoker. Finding a measurable amount of cotinine in urine is an indicator of exposure to nicotine and does not necessarily mean that an adverse health effect will occur.

In addition to free cotinine, nicotine and several other metabolites (cotinine-N-glucuronide, nicotine-N-glucuronide, trans-3-hydroxycotinine, trans-3-hydroxycotinine-O-glucuronide, and anabasine) were analyzed in cycle 3 (2012-2013) of the CHMS. Free and total 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of a tobacco-specific N-nitrosamine found only in tobacco and products derived from tobacco, were also analyzed in cycle 3 (2012-2013) of the CHMS. Data on these tobacco chemicals and their metabolites are available from Statistics Canada through the Research Data Centres Program.

Cotinine (non-smokers) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 6-79 years ^{Table 34 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 34 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	4704	85.84	--	<LOD	<LOD	3.3Table 34 footnote E (1.6 - 4.9)	Table 34 footnote F
Total	6-79	2 (2009-2011)	4895	86.88	--	<LOD	<LOD	2.6Table 34 footnote E (<LOD - 4.2)	Table 34 footnote F
Total	6-79	3 (2012-2013)	4456	88.64	--	<LOD	<LOD	<LOD	Table 34 footnote F
Males	6-79	1 (2007-2009)	2252	82.95	--	<LOD	<LOD	4.4Table 34 footnote E (1.7 - 7.0)	Table 34 footnote F
Males	6-79	2 (2009-2011)	2304	84.55	--	<LOD	<LOD	Table 34 footnote F	Table 34 footnote F
Males	6-79	3 (2012-2013)	2183	87.27	--	<LOD	<LOD	Table 34 footnote F	Table 34 footnote F
Females	6-79	1 (2007-2009)	2452	88.50	--	<LOD	<LOD	Table 34 footnote F	9.9Table 34 footnote E (3.4 - 16)
Females	6-79	2 (2009-2011)	2591	88.96	--	<LOD	<LOD	1.4Table 34 footnote E (<LOD - 2.3)	Table 34 footnote F
Females	6-79	3 (2012-2013)	2273	89.97	--	<LOD	<LOD	<LOD	Table 34 footnote F
Table 34 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 34 footnote a referrer Table 34 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 34 footnote b referrer Table 34 footnote E Use data with caution. Return to table 34 footnote E referrer Table 34 footnote F Data is too unreliable to be published. Return to table 34 footnote F referrer

Cotinine (non-smokers) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 6-79 years ^{Table 35 footnote a}, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 35 footnote b	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	4694	85.84	--	<LOD	<LOD	4.6 (3.3 - 5.8)	Table 35 footnote F
Total	6-79	2 (2009-2011)	4883	86.88	--	<LOD	<LOD	3.1 (2.1 - 4.1)	Table 35 footnote F
Total	6-79	3 (2012-2013)	4455	88.64	--	<LOD	<LOD	2.5 (2.0 - 3.1)	Table 35 footnote F
Males	6-79	1 (2007-2009)	2246	82.95	--	<LOD	<LOD	4.8Table 35 footnote E (2.7 - 6.9)	Table 35 footnote F
Males	6-79	2 (2009-2011)	2299	84.55	--	<LOD	<LOD	3.8Table 35 footnote E (1.7 - 5.9)	Table 35 footnote F
Males	6-79	3 (2012-2013)	2183	87.27	--	<LOD	<LOD	2.3Table 35 footnote E (1.4 - 3.3)	Table 35 footnote F
Females	6-79	1 (2007-2009)	2448	88.50	--	<LOD	<LOD	4.0 (2.7 - 5.3)	Table 35 footnote F
Females	6-79	2 (2009-2011)	2584	88.96	--	<LOD	<LOD	3.0 (2.2 - 3.7)	Table 35 footnote F
Females	6-79	3 (2012-2013)	2272	89.97	--	<LOD	<LOD	2.7 (2.1 - 3.2)	4.4Table 35 footnote E (1.7 - 7.0)
Table 35 footnote a For the purpose of total population comparisons, only values from participants aged 6-79 years were included as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 35 footnote a referrer Table 35 footnote b If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 35 footnote b referrer Table 35 footnote E Use data with caution. Return to table 35 footnote E referrer Table 35 footnote F Data is too unreliable to be published. Return to table 35 footnote F referrer

Cotinine (non-smokers) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 36 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 36 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	5468	86.85	--	<LOD	<LOD	2.6Table 36 footnote E (<LOD - 4.4)	Table 36 footnote F
Total	3-79	3 (2012-2013)	4978	88.59	--	<LOD	<LOD	<LOD	Table 36 footnote F
Males	3-79Table 36 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	2594	84.93	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Males	3-79	3 (2012-2013)	2444	87.11	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Females	3-79Table 36 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	2874	88.59	--	<LOD	<LOD	1.5Table 36 footnote E (<LOD - 2.5)	Table 36 footnote F
Females	3-79	3 (2012-2013)	2534	90.02	--	<LOD	<LOD	<LOD	Table 36 footnote F
Total	3-5Table 36 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	573	86.56	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	3-5	3 (2012-2013)	522	88.12	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	6-11	1 (2007-2009)	1045	83.83	--	<LOD	<LOD	3.9Table 36 footnote E (1.9 - 5.8)	10Table 36 footnote E (5.7 - 14)
Total	6-11	2 (2009-2011)	1061	83.79	--	<LOD	<LOD	4.9Table 36 footnote E (1.9 - 7.9)	12Table 36 footnote E (6.3 - 18)
Total	6-11	3 (2012-2013)	1007	86.79	--	<LOD	<LOD	Table 36 footnote F	7.1Table 36 footnote E (2.7 - 11)
Total	12-19	1 (2007-2009)	882	80.27	--	<LOD	<LOD	8.3Table 36 footnote E (3.8 - 13)	19Table 36 footnote E (8.3 - 30)
Total	12-19	2 (2009-2011)	928	80.06	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	12-19	3 (2012-2013)	889	82.56	--	<LOD	<LOD	Table 36 footnote F	13Table 36 footnote E (7.6 - 19)
Total	20-39	1 (2007-2009)	874	85.35	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	20-39	2 (2009-2011)	1009	86.22	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	20-39	3 (2012-2013)	792	90.53	--	<LOD	<LOD	<LOD	Table 36 footnote F
Total	40-59	1 (2007-2009)	947	88.81	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	40-59	2 (2009-2011)	972	91.56	--	<LOD	<LOD	<LOD	Table 36 footnote F
Total	40-59	3 (2012-2013)	851	91.19	--	<LOD	<LOD	Table 36 footnote F	Table 36 footnote F
Total	60-79	1 (2007-2009)	956	90.69	--	<LOD	<LOD	<LOD	Table 36 footnote F
Total	60-79	2 (2009-2011)	925	93.08	--	<LOD	<LOD	<LOD	Table 36 footnote F
Total	60-79	3 (2012-2013)	917	92.58	--	<LOD	<LOD	<LOD	Table 36 footnote F
Table 36 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 36 footnote a referrer Table 36 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 36 footnote b referrer Table 36 footnote E Use data with caution. Return to table 36 footnote E referrer Table 36 footnote F Data is too unreliable to be published. Return to table 36 footnote F referrer

Cotinine (non-smokers) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 37 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79Table 37 footnote b	1 (2007-2009)
Total	3-79	2 (2009-2011)	5455	86.85	--	<LOD	<LOD	3.3 (2.2 - 4.4)	Table 37 footnote F
Total	3-79	3 (2012-2013)	4976	88.59	--	<LOD	<LOD	2.6 (2.0 - 3.2)	6.1Table 37 footnote E (1.9 - 10)
Males	3-79Table 37 footnote b	1 (2007-2009)
Males	3-79	2 (2009-2011)	2588	84.93	--	<LOD	<LOD	3.9Table 37 footnote E (2.0 - 5.9)	Table 37 footnote F
Males	3-79	3 (2012-2013)	2444	87.11	--	<LOD	<LOD	2.4Table 37 footnote E (1.4 - 3.3)	Table 37 footnote F
Females	3-79Table 37 footnote b	1 (2007-2009)
Females	3-79	2 (2009-2011)	2867	88.59	--	<LOD	<LOD	3.0 (2.0 - 3.9)	Table 37 footnote F
Females	3-79	3 (2012-2013)	2532	90.02	--	<LOD	<LOD	2.9 (2.3 - 3.5)	5.2Table 37 footnote E (2.6 - 7.8)
Total	3-5Table 37 footnote b	1 (2007-2009)
Total	3-5	2 (2009-2011)	572	86.56	--	<LOD	<LOD	Table 37 footnote F	Table 37 footnote F
Total	3-5	3 (2012-2013)	521	88.12	--	<LOD	<LOD	5.6Table 37 footnote E (3.5 - 7.7)	Table 37 footnote F
Total	6-11	1 (2007-2009)	1042	83.83	--	<LOD	<LOD	6.2Table 37 footnote E (1.9 - 10)	Table 37 footnote F
Total	6-11	2 (2009-2011)	1059	83.79	--	<LOD	<LOD	5.2Table 37 footnote E (1.9 - 8.5)	12Table 37 footnote E (5.4 - 18)
Total	6-11	3 (2012-2013)	1007	86.79	--	<LOD	<LOD	3.5Table 37 footnote E (1.1 - 5.8)	7.7Table 37 footnote E (2.6 - 13)
Total	12-19	1 (2007-2009)	881	80.27	--	<LOD	<LOD	7.9Table 37 footnote E (4.6 - 11)	Table 37 footnote F
Total	12-19	2 (2009-2011)	926	80.06	--	<LOD	<LOD	Table 37 footnote F	Table 37 footnote F
Total	12-19	3 (2012-2013)	889	82.56	--	<LOD	<LOD	3.2Table 37 footnote E (<LOD - 5.5)	Table 37 footnote F
Total	20-39	1 (2007-2009)	871	85.35	--	<LOD	<LOD	4.5Table 37 footnote E (1.7 - 7.4)	Table 37 footnote F
Total	20-39	2 (2009-2011)	1007	86.22	--	<LOD	<LOD	Table 37 footnote F	Table 37 footnote F
Total	20-39	3 (2012-2013)	792	90.53	--	<LOD	<LOD	2.2 (1.5 - 2.9)	3.3Table 37 footnote E (1.3 - 5.2)
Total	40-59	1 (2007-2009)	944	88.81	--	<LOD	<LOD	4.6Table 37 footnote E (2.9 - 6.4)	Table 37 footnote F
Total	40-59	2 (2009-2011)	970	91.56	--	<LOD	<LOD	2.8Table 37 footnote E (1.7 - 3.9)	4.7Table 37 footnote E (1.6 - 7.8)
Total	40-59	3 (2012-2013)	850	91.19	--	<LOD	<LOD	3.0Table 37 footnote E (1.5 - 4.4)	Table 37 footnote F
Total	60-79	1 (2007-2009)	956	90.69	--	<LOD	<LOD	3.0 (1.9 - 4.0)	Table 37 footnote F
Total	60-79	2 (2009-2011)	921	93.08	--	<LOD	<LOD	2.7 (1.9 - 3.6)	Table 37 footnote F
Total	60-79	3 (2012-2013)	917	92.58	--	<LOD	<LOD	2.6 (1.9 - 3.2)	4.1Table 37 footnote E (1.4 - 6.8)
Table 37 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 37 footnote a referrer Table 37 footnote b Data not available as participants under the age of 6 years were not included in cycle 1 (2007-2009). Return to table 37 footnote b referrer Table 37 footnote E Use data with caution. Return to table 37 footnote E referrer Table 37 footnote F Data is too unreliable to be published. Return to table 37 footnote F referrer

Cotinine (smokers) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 38 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	1 (2007-2009)	805	4.22	590 (420 - 820)	Table 38 footnote F	1000 (810 - 1200)	2200 (2000 - 2400)	2600 (2300 - 2900)
Total	12-79	2 (2009-2011)	819	5.74	490 (340 - 700)	Table 38 footnote F	1000 (810 - 1200)	2200 (1900 - 2500)	2600 (2100 - 3100)
Total	12-79	3 (2012-2013)	701	5.14	490 (410 - 590)	Table 38 footnote F	990 (900 - 1100)	2000 (1600 - 2300)	2300 (2000 - 2600)
Males	12-79	1 (2007-2009)	406	4.43	660Table 38 footnote E (400 - 1100)	Table 38 footnote F	1200 (920 - 1500)	2300 (2000 - 2600)	2800 (2400 - 3300)
Males	12-79	2 (2009-2011)	425	4.47	470Table 38 footnote E (280 - 770)	Table 38 footnote F	1000 (780 - 1200)	2300 (1900 - 2700)	2900 (2300 - 3500)
Males	12-79	3 (2012-2013)	387	5.17	460 (340 - 630)	Table 38 footnote F	990 (820 - 1100)	2100 (1700 - 2500)	2400 (2100 - 2600)
Females	12-79	1 (2007-2009)	399	4.01	520 (390 - 700)	Table 38 footnote F	860 (640 - 1100)	2100 (1900 - 2300)	2500 (2300 - 2700)
Females	12-79	2 (2009-2011)	394	7.11	510Table 38 footnote E (320 - 810)	Table 38 footnote F	1000 (720 - 1300)	2100 (1800 - 2400)	2400 (1900 - 2900)
Females	12-79	3 (2012-2013)	314	5.10	550 (380 - 790)	Table 38 footnote F	990 (760 - 1200)	1700 (1200 - 2300)	2100 (1700 - 2500)
Total	12-19	1 (2007-2009)	102	10.78	160Table 38 footnote E (78 - 330)	Table 38 footnote F	Table 38 footnote F	1600 (1400 - 1900)	Table 38 footnote X
Total	12-19	2 (2009-2011)	102	11.76	Table 38 footnote F	<LOD	Table 38 footnote F	1700 (1200 - 2300)	Table 38 footnote X
Total	12-19	3 (2012-2013)	98	14.29	Table 38 footnote F	Table 38 footnote X	Table 38 footnote F	2100Table 38 footnote E (1200 - 3000)	Table 38 footnote X
Total	20-39	1 (2007-2009)	300	3.00	500Table 38 footnote E (300 - 850)	Table 38 footnote F	930 (620 - 1200)	2000 (1800 - 2200)	2500 (2100 - 2900)
Total	20-39	2 (2009-2011)	311	9.00	400Table 38 footnote E (260 - 630)	Table 38 footnote F	850 (570 - 1100)	2200 (1600 - 2900)	2900 (2200 - 3600)
Total	20-39	3 (2012-2013)	254	5.12	310Table 38 footnote E (190 - 520)	Table 38 footnote F	700Table 38 footnote E (350 - 1100)	1600 (1300 - 1900)	2000 (1600 - 2400)
Total	40-59	1 (2007-2009)	275	3.27	830 (610 - 1100)	Table 38 footnote F	1200 (910 - 1500)	2500 (2200 - 2800)	2800 (2400 - 3100)
Total	40-59	2 (2009-2011)	253	1.58	800Table 38 footnote E (480 - 1300)	Table 38 footnote F	1400 (1000 - 1700)	2200 (1900 - 2600)	2600 (2000 - 3300)
Total	40-59	3 (2012-2013)	228	2.63	770 (550 - 1100)	340Table 38 footnote E (150 - 530)	1000 (890 - 1200)	2100 (1700 - 2600)	2300 (2000 - 2700)
Total	60-79	1 (2007-2009)	128	3.91	650Table 38 footnote E (430 - 980)	Table 38 footnote F	860 (600 - 1100)	2200 (1900 - 2400)	Table 38 footnote X
Total	60-79	2 (2009-2011)	153	1.96	Table 38 footnote F	Table 38 footnote F	980 (720 - 1200)	1800 (1500 - 2000)	Table 38 footnote X
Total	60-79	3 (2012-2013)	121	2.48	940 (800 - 1100)	390Table 38 footnote E (240 - 540)	990 (830 - 1200)	2100 (1400 - 2700)	Table 38 footnote X
Table 38 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 38 footnote a referrer Table 38 footnote E Use data with caution. Return to table 38 footnote E referrer Table 38 footnote F Data is too unreliable to be published. Return to table 38 footnote F referrer Table 38 footnote X Suppressed to meet the confidentiality requirements of the Statistics Act. Return to table 38 footnote X referrer

Cotinine (smokers) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009), cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 39 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	1 (2007-2009)	803	4.22	650 (480 - 890)	Table 39 footnote F	1000 (830 - 1200)	3000 (2500 - 3500)	4400 (3500 - 5300)
Total	12-79	2 (2009-2011)	816	5.74	430Table 39 footnote E (290 - 630)	Table 39 footnote F	840 (620 - 1100)	2700 (1800 - 3700)	3800Table 39 footnote E (2300 - 5300)
Total	12-79	3 (2012-2013)	701	5.14	440 (340 - 570)	Table 39 footnote F	750 (590 - 900)	2600Table 39 footnote E (1600 - 3700)	3900Table 39 footnote E (2100 - 5800)
Males	12-79	1 (2007-2009)	405	4.43	560Table 39 footnote E (360 - 880)	Table 39 footnote F	930 (680 - 1200)	2300 (1900 - 2700)	3200 (2300 - 4200)
Males	12-79	2 (2009-2011)	425	4.47	370Table 39 footnote E (210 - 620)	Table 39 footnote F	730 (480 - 980)	2700Table 39 footnote E (1600 - 3700)	3700Table 39 footnote E (2300 - 5100)
Males	12-79	3 (2012-2013)	387	5.17	360Table 39 footnote E (250 - 520)	Table 39 footnote F	710 (500 - 920)	2300 (1500 - 3100)	3000Table 39 footnote E (1900 - 4100)
Females	12-79	1 (2007-2009)	398	4.01	780 (590 - 1000)	Table 39 footnote F	1100 (900 - 1400)	3700 (2900 - 4500)	5500 (4300 - 6600)
Females	12-79	2 (2009-2011)	391	7.11	520Table 39 footnote E (300 - 890)	Table 39 footnote F	1000 (650 - 1400)	Table 39 footnote F	4800Table 39 footnote E (2300 - 7400)
Females	12-79	3 (2012-2013)	314	5.10	600 (420 - 850)	Table 39 footnote F	860Table 39 footnote E (510 - 1200)	3200Table 39 footnote E (1000 - 5300)	4900 (3300 - 6400)
Total	12-19	1 (2007-2009)	102	10.78	120Table 39 footnote E (58 - 250)	<LOD	290Table 39 footnote E (<LOD - 470)	1400Table 39 footnote E (600 - 2200)	Table 39 footnote X
Total	12-19	2 (2009-2011)	102	11.76	Table 39 footnote F	<LOD	Table 39 footnote F	1300 (990 - 1500)	Table 39 footnote X
Total	12-19	3 (2012-2013)	98	14.29	Table 39 footnote F	Table 39 footnote X	Table 39 footnote F	940 (610 - 1300)	Table 39 footnote X
Total	20-39	1 (2007-2009)	299	3.00	510Table 39 footnote E (310 - 840)	Table 39 footnote F	850 (560 - 1100)	2200 (1900 - 2600)	2500 (1900 - 3000)
Total	20-39	2 (2009-2011)	311	9.00	330Table 39 footnote E (200 - 530)	Table 39 footnote F	710 (470 - 940)	2300 (1500 - 3000)	3200Table 39 footnote E (1700 - 4700)
Total	20-39	3 (2012-2013)	254	5.12	230Table 39 footnote E (120 - 410)	Table 39 footnote F	520Table 39 footnote E (310 - 720)	1500Table 39 footnote E (830 - 2200)	2100Table 39 footnote E (1300 - 2900)
Total	40-59	1 (2007-2009)	275	3.27	1000 (810 - 1300)	Table 39 footnote F	1300 (920 - 1600)	4100 (2900 - 5400)	5500 (4400 - 6600)
Total	40-59	2 (2009-2011)	251	1.58	710Table 39 footnote E (400 - 1200)	Table 39 footnote F	990Table 39 footnote E (560 - 1400)	3400Table 39 footnote E (1400 - 5400)	4900Table 39 footnote E (2800 - 7000)
Total	40-59	3 (2012-2013)	228	2.63	840Table 39 footnote E (520 - 1300)	390Table 39 footnote E (190 - 580)	940Table 39 footnote E (570 - 1300)	3500Table 39 footnote E (1500 - 5500)	5200Table 39 footnote E (2500 - 7800)
Total	60-79	1 (2007-2009)	127	3.91	840Table 39 footnote E (530 - 1300)	Table 39 footnote F	1300 (1000 - 1500)	3200 (2100 - 4300)	Table 39 footnote X
Total	60-79	2 (2009-2011)	152	1.96	Table 39 footnote F	Table 39 footnote F	1000 (700 - 1400)	3000Table 39 footnote E (1700 - 4300)	Table 39 footnote X
Total	60-79	3 (2012-2013)	121	2.48	960 (730 - 1200)	390 (270 - 500)	960Table 39 footnote E (530 - 1400)	3100Table 39 footnote E (1600 - 4700)	Table 39 footnote X
Table 39 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 39 footnote a referrer Table 39 footnote E Use data with caution. Return to table 39 footnote E referrer Table 39 footnote F Data is too unreliable to be published. Return to table 39 footnote F referrer Table 39 footnote X Suppressed to meet the confidentiality requirements of the Statistics Act. Return to table 39 footnote X referrer

Summaries and Results for Polycyclic Aromatic Hydrocarbon Metabolites

Overview

Polycyclic aromatic hydrocarbons (PAHs) are a group of organic compounds characterized by the presence of two or more fused aromatic rings. The United States Environmental Protection Agency has prioritized 16 PAHs because of their potential human health and/or ecological toxicity (EPA, 2013). The table below lists seven of these priority PAHs and their metabolites measured in cycle 3 of the Canadian Health Measures Survey (CHMS).

Hydroxylated polycyclic aromatic hydrocarbon (PAH) metabolites measured in the Canadian Health Measures Survey cycle 3 (2012-2013) and their parent PAH compounds

PAH	CASRN	Hydroxylated PAH metabolites	CASRN
Benzo[a]pyrene	50-32-8	3-Hydroxybenzo[a]pyrene	13345-21-6
Chrysene	218-01-9	2-Hydroxychrysene	65945-06-4
		3-Hydroxychrysene	63019-39-6
		4-Hydroxychrysene	63019-40-9
		6-Hydroxychrysene	37515-51-8
Fluoranthene	206-44-0	3-Hydroxyfluoranthene	17798-09-3
Fluorene	86-73-7	2-Hydroxyfluorene	2443-58-5
		3-Hydroxyfluorene	6344-67-8
		9-Hydroxyfluorene	1689-64-1
Naphthalene	91-20-3	1-Hydroxynaphthalene	90-15-3
		2-Hydroxynaphthalene	135-19-3
Phenanthrene	85-01-8	1-Hydroxyphenanthrene	2433-56-9
		2-Hydroxyphenanthrene	605-55-0
		3-Hydroxyphenanthrene	605-87-8
		4-Hydroxyphenanthrene	7651-86-7
		9-Hydroxyphenanthrene	484-17-3
Pyrene	129-00-0	1-Hydroxypyrene	5315-79-7

PAHs are released to the environment from both natural and anthropogenic sources; the contribution from anthropogenic sources is substantially higher than from natural sources (ATSDR, 1995). In Canada, forest fires are the largest natural source of PAHs in the environment (Environment Canada, 2010d). Other natural sources include crude oil, coal, and volcanic eruptions. Anthropogenic PAH emissions are predominantly due to the incomplete combustion of organic substances from waste incineration, tobacco smoke, cooking, vehicle exhaust, mining and refining operations, oil spills, and the use of creosote-treated products (ATSDR, 1995; ATSDR, 2005a; Environment Canada & Health Canada, 1994b).

For the general population, the major routes of exposure to PAHs are ingestion and inhalation from sources including diet, smoking, and ambient and indoor air (IARC, 2010; WHO, 2011b). Levels in food depend on the source of the food and the method of cooking (ATSDR, 1995). PAHs can be formed when food is charbroiled, grilled, roasted, fried, or baked. Drinking water is considered to be a negligible source of exposure in Canada (Environment Canada & Health Canada, 1994b). Vehicle exhaust, tobacco smoke, emissions from wood and charcoal-fired stoves, house dust, and ambient air all contribute to inhalation exposure. Human exposure to PAHs may also occur through skin contact with soot and tars (ATSDR, 1995).

PAHs can be absorbed following inhalation, oral, and dermal exposure. They undergo multi-step metabolism leading to several types of metabolites, including hydroxylated PAHs (Strickland et al., 1996). Elimination occurs through urine and feces, with urinary hydroxylated PAH metabolites observed within a few days of exposure (Viau et al., 1995). These metabolites are excreted both in the free form and as glucuronic acid and sulphate conjugates (Castaño-Vinyals et al., 2004).

Several approaches exist to assess human exposure to PAHs. The analysis of urinary hydroxylated PAH metabolites is the most common approach and has been used in several biomonitoring studies (Becker et al., 2003; CDC, 2009).

Evaluating health effects of exposure to individual PAH species in humans is difficult because exposure is generally to PAH mixtures. Studies in laboratory animals have shown that several PAHs are carcinogenic, mutagenic, and/or teratogenic (IARC, 2010; IARC, 2012a). The carcinogenic potency of PAHs differs among PAH species, and can differ across routes of exposure (ATSDR, 1995). For some PAHs, formation of epoxides through metabolic activation is considered a key step in eliciting carcinogenic effects (Guillén & Sopelana, 2003). Benzo[a]pyrene, PAH-containing mixtures such as soot and coal tar, as well as occupational PAH exposures during selected industrial activities (i.e. coal-tar distillation, coal gasification, coke production, aluminium production) have recently been classified as carcinogenic to humans (Group 1) by the International Agency for Research on Cancer (IARC) (IARC, 2012a). However, IARC has also classified some PAHs, such as chrysene and naphthalene, as possibly carcinogenic to humans (Group 2B) and others, such as fluoranthene, fluorene, phenanthrene, and pyrene, as not classifiable as to their carcinogenicity to humans (Group 3) (IARC, 2010). PAHs also elicit adverse immunologic effects, developmental and reproductive effects, as well as hepatic and renal effects in laboratory animals, but generally at doses higher than those that elicit a carcinogenic response (ATSDR, 1995).

In Canada, PAHs are listed as toxic substances on Schedule 1 of the Canadian Environmental Protection Act, 1999, based on an evaluation of the environmental and health effects of several PAHs, including benzo[a]pyrene (Canada, 1999; Canada, 2000; Environment Canada & Health Canada, 1994b). Several environmental performance agreements, codes of practice, and recommendations have been established to reduce releases of PAHs to the environment from the aluminum production, metal refining and founding, and wood preservation sectors (Environment Canada, 2010d). Health Canada has established a maximum level for PAHs in a specific food product called olive-pomace oil (Health Canada, 2012f).

In the following sections, some priority PAHs are discussed, and data on the levels of urinary hydroxylated PAH metabolites in the Canadian population are presented.

Benzo[a]pyrene

Benzo[a]pyrene is a polycyclic aromatic hydrocarbon (PAH) composed of five fused benzene rings. It is not manufactured in Canada and no industrial uses are known (Health Canada, 1986c).

In laboratory rats, 40% to 60% of benzo[a]pyrene was shown to be absorbed following exposure through gavage or diet (Faust, 1994). Based on laboratory studies, approximately 3% of benzo[a]pyrene is expected to be absorbed through skin after 24 hours (Kao et al., 1985), although an optimized absorption study using rats showed 46% absorption over 5 days (Yang et al., 1986). Benzo[a]pyrene absorption through skin may be facilitated by metabolism in the cellular epidermis and the formation of stable adducts of benzo[a]pyrene metabolites and cellular structures. Evidence for absorption of benzo[a]pyrene following inhalation comes from the presence of urinary metabolites in workers exposed to PAHs in air (ATSDR, 1995). Inhalation absorption of benzo[a]pyrene is highly dependent on the type of particles onto which it is adsorbed. After absorption, benzo[a]pyrene distributes to several organs, including lungs, liver, and intestines (Faust, 1994). Like other PAHs, benzo[a]pyrene can be metabolized by many tissues forming various arene epoxides that after rearrangement produce hydroxylated PAHs and dihydrodiols (Bouchard & Viau, 1996). The metabolite 3-hydroxybenzo[a]pyrene has been used as a human urine biomarker for exposure to benzo[a]pyrene (Chien & Yeh, 2012).

Adverse health effects have been observed in laboratory animals following benzo[a]pyrene exposure via inhalation, oral, and dermal routes. Non-carcinogenic effects have been observed, but generally at dose levels at least an order of magnitude higher than that of carcinogenic effects (ATSDR, 1995; Health Canada, 1986c; Jules et al., 2012). The diolepoxides formed during metabolism of benzo[a]pyrene are considered to be the primary carcinogenic agents (IARC, 2012b). Occupational exposures to benzo[a]pyrene-containing mixtures have been associated with a series of cancers (IARC, 2012b). Based on the strong evidence for the carcinogenicity of benzo[a]pyrene in many animal species, and supported by evidence from laboratory and human studies, the International Agency for Research on Cancer has classified benzo[a]pyrene as Group 1, a known human carcinogen (IARC, 2012b). Prior to this, Environment Canada and Health Canada had classified benzo[a]pyrene as probably carcinogenic to humans (Group II) based primarily on results from studies with laboratory animals (Environment Canada & Health Canada, 1994b).

The Federal-Provincial-Territorial Committee on Drinking Water has developed a guideline for Canadian drinking water quality that establishes a maximum acceptable concentration for benzo[a]pyrene in drinking water (Health Canada, 1986c). This guideline, which was reaffirmed in 2005 (Health Canada, 2012e), is currently under review and is expected to be published for public consultation in early 2015.

The benzo[a]pyrene metabolite, 3-hydroxybenzo[a]pyrene, was analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and is presented as both µg/L and µg/g creatinine. Finding a measurable amount of 3-hydroxybenzo[a]pyrene in urine is an indicator of exposure to benzo[a]pyrene and does not necessarily mean that an adverse health effect will occur.

3-Hydroxybenzo[ a]pyrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 48 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2294	99.91	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2378	99.96	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1163	100	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1188	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1131	99.82	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1190	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	420	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	453	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	466	99.79	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	468	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	473	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	486	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	328	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	340	99.71	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	340	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	300	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	267	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	331	100	--	<LOD	<LOD	<LOD	<LOD
Table 48 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 48 footnote a referrer

3-Hydroxybenzo[ a]pyrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 49 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2284	99.91	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2377	99.96	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1159	100	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1188	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1125	99.82	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1189	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	419	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	452	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	464	99.79	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	468	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	471	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	486	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	326	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	340	99.71	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	338	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	300	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	266	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	331	100	--	<LOD	<LOD	<LOD	<LOD
Table 49 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 49 footnote a referrer

Chrysene

Chrysene is a polycyclic aromatic hydrocarbon (PAH) composed of four fused benzene rings. There are no known uses of chrysene other than its use as a research chemical (ATSDR, 1995).

Chrysene is highly lipophilic. In animal pharmacokinetic studies, approximately 75% of chrysene was absorbed when administered through oral, inhalation, and dermal routes of exposure; after absorption, it preferentially distributed to adipose tissues (Borges, 1994). Chrysene is metabolized into several mono- and dihydroxychrysene metabolites (CDC, 2009). Chrysene metabolites are excreted predominantly in the feces. However, PAH biomonitoring studies in humans have attempted to measure urinary levels of 1-, 2-, 3-, 4, and 6-hydroxychrysene, and have been able to detect urinary 3- and 6-hydroxychrysene in a small proportion of samples (Nethery et al., 2012).

Data on the systemic toxicity of chrysene in animals and humans are limited (Borges, 1994). In mice, chrysene exposure resulted in an increased incidence of skin papillomas and hepatic and lung tumours (Chang et al., 1983; Wislocki et al., 1986). Based on a limited amount of available carcinogenicity data, the International Agency for Research on Cancer has classified chrysene as Group 2B, possibly carcinogenic to humans (IARC, 2010).

The urinary chrysene metabolites 3- and 6-hydroxychrysene were measured for 73 non-smoking, non-occupationally exposed individuals (aged 16 to 64 years) living approximately 1 km from an aluminum plant in Baie-Comeau, Quebec. These chrysene metabolites were measured as part of a spectrum of PAH metabolites. Although the levels of some other urinary PAH metabolites were higher compared with a control group of 71 individuals living at least 11 km from the plant, the urinary concentrations of these chrysene metabolites were below the limit of detection (0.032 µg/L for 3-hydroxychrysene and 0.019 µg/L for 6-hydroxychrysene) for most samples (Bouchard et al., 2009). Similarly, 2-, 3-, 4-, and 6-hydroxychrysene concentrations were below the limit of detection when measured in urine of pregnant women living in Hamilton, Ontario (Nethery et al., 2012).

The chrysene metabolites, 2-, 3-, 4-, and 6-hydroxychrysene, were analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and are presented as both µg/L and µg/g creatinine. Given that chrysene metabolites are predominantly excreted in the feces, their urinary absence alone does not indicate that exposure to chrysene did not occur. Finding a measurable amount of chrysene metabolites in urine is an indicator of exposure to chrysene and does not necessarily mean that an adverse health effect will occur.

2-Hydroxychrysene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 50 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2497	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2496	99.96	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1254	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1243	99.76	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1259	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	499	99.60	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	492	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	508	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	498	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	504	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	352	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	345	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	357	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	283	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	99.71	--	<LOD	<LOD	<LOD	<LOD
Table 50 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 50 footnote a referrer

2-Hydroxychrysene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 51 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2487	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2495	99.96	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1250	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	100	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1237	99.76	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1258	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	498	99.60	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	491	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	506	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	496	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	504	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	350	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	345	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	355	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	282	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	99.71	--	<LOD	<LOD	<LOD	<LOD
Table 51 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 51 footnote a referrer

3-Hydroxychrysene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 52 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2495	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2498	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1255	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	99.92	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1240	99.60	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1261	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	499	99.60	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	492	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	506	99.41	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	498	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	505	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	351	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	358	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	283	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	100	--	<LOD	<LOD	<LOD	<LOD
Table 52 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 52 footnote a referrer

3-Hydroxychrysene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 53 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2485	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2497	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1251	99.92	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	99.92	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1234	99.60	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1260	99.92	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	498	99.60	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	491	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	504	99.41	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	496	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	505	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	349	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	356	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	282	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	100	--	<LOD	<LOD	<LOD	<LOD
Table 53 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 53 footnote a referrer

4-Hydroxychrysene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 54 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2498	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2498	99.84	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1257	99.76	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	99.84	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1241	99.76	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1261	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	498	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	492	99.39	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	508	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	499	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	505	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	352	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	358	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	99.68	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	283	99.65	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	100	--	<LOD	<LOD	<LOD	<LOD
Table 54 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 54 footnote a referrer

4-Hydroxychrysene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 55 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2488	99.76	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2497	99.84	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1253	99.76	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1237	99.84	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1235	99.76	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1260	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	497	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	491	99.39	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	506	99.61	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	496	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	497	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	505	100	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	350	99.72	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	356	100	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	311	99.68	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	282	99.65	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	100	--	<LOD	<LOD	<LOD	<LOD
Table 55 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 55 footnote a referrer

6-Hydroxychrysene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 56 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2459	96.87	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2494	99.84	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1239	96.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1234	99.84	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1220	97.38	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1260	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	494	97.37	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	492	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	499	95.79	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	494	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	489	97.55	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	504	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	344	96.80	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	99.42	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	354	96.33	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	310	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	279	97.49	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	99.71	--	<LOD	<LOD	<LOD	<LOD
Table 56 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 56 footnote a referrer

6-Hydroxychrysene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 57 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2449	96.87	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2493	99.84	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1235	96.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1234	99.84	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1214	97.38	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1259	99.84	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	493	97.37	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	491	100	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	497	95.79	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	494	100	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	487	97.55	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	504	99.80	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	342	96.80	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	346	99.42	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	352	96.33	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	310	100	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	278	97.49	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	348	99.71	--	<LOD	<LOD	<LOD	<LOD
Table 57 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 57 footnote a referrer

Fluoranthene

Fluoranthene, also known as benzo[j,k]fluorene, is a polycyclic aromatic hydrocarbon (PAH) with five fused aromatic rings. It is found naturally in the environment in some bacteria, algae, and plants, and as a result of anthropogenic releases from incomplete combustion of organic substances (EPA, 1980). Fluoranthene is used in the synthesis of dyes and in biomedical research (Wu et al., 2010).

Limited pharmacokinetic data for fluoranthene are available. Similar to other structurallyrelated PAHs, fluoranthene may be absorbed following oral, inhalation, or dermal exposure (Faust, 1993a; Storer et al., 1984). Because of its high lipophilicity, fluoranthene distributes to adipose tissue (EPA, 1980). Metabolism of fluoranthene produces hydroxylated metabolites, and urinary 3-hydroxyfluoranthene is considered an indicator of recent exposures.

Kidney and liver effects were observed in rats orally administered fluoranthene (Faust, 1993a). Fluoranthene exposure in mice has resulted in lung tumours (Busby Jr. et al., 1989; IARC, 2010). Dermal exposure in mice to a combination of benzo[a]pyrene and fluoranthene significantly increased the incidence of skin tumours (IARC, 2010). Based on the limited data on fluoranthene carcinogenicity, the International Agency for Research on Cancer has classified fluoranthene as Group 3, not classifiable as to its carcinogenicity to humans (IARC, 2010).

The urinary fluoranthene metabolite, 3-hydroxyfluoranthene, was measured for 73 non-smoking, non-occupationally exposed individuals (aged 16 to 64 years) living approximately 1 km from an aluminum plant in Baie-Comeau, Quebec. The fluoranthene metabolite was measured as part of a spectrum of PAH metabolites. Although the levels of some other urinary PAH metabolites were higher compared with a control group of 71 individuals living at least 11 km from the plant, the concentration of 3-hydroxyfluoranthene was below the limit of detection (0.030 µg/L) for most samples (Bouchard et al., 2009).

The fluoranthene metabolite, 3-hydroxyfluoranthene, was analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and is presented as both µg/L and µg/g creatinine. Finding a measurable amount of 3-hydroxyfluoranthene in urine is an indicator of exposure to fluoranthene and does not necessarily mean that an adverse health effect will occur.

3-Hydroxyfluoranthene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 58 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2265	98.23	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2263	98.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1145	98.25	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1133	98.41	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1120	98.21	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1130	98.32	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	428	97.20	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	435	97.93	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	463	97.41	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	450	98.67	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	460	99.57	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	469	98.08	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	319	99.69	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	312	98.72	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	329	97.87	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	288	98.26	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	266	97.74	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	309	98.71	--	<LOD	<LOD	<LOD	<LOD
Table 58 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 58 footnote a referrer

3-Hydroxyfluoranthene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 59 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2257	98.23	--	<LOD	<LOD	<LOD	<LOD
Total	3-79	3 (2012-2013)	2262	98.37	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	2 (2009-2011)	1142	98.25	--	<LOD	<LOD	<LOD	<LOD
Males	3-79	3 (2012-2013)	1133	98.41	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	2 (2009-2011)	1115	98.21	--	<LOD	<LOD	<LOD	<LOD
Females	3-79	3 (2012-2013)	1129	98.32	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	2 (2009-2011)	428	97.20	--	<LOD	<LOD	<LOD	<LOD
Total	3-5	3 (2012-2013)	434	97.93	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	2 (2009-2011)	462	97.41	--	<LOD	<LOD	<LOD	<LOD
Total	6-11	3 (2012-2013)	450	98.67	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	2 (2009-2011)	458	99.57	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	469	98.08	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	2 (2009-2011)	317	99.69	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	312	98.72	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	2 (2009-2011)	327	97.87	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	288	98.26	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	2 (2009-2011)	265	97.74	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	309	98.71	--	<LOD	<LOD	<LOD	<LOD
Table 59 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 59 footnote a referrer

Fluorene

Fluorene is a polycyclic aromatic hydrocarbon (PAH) with three fused aromatic rings. Fluorene and its derivatives are used in the manufacture of dyes, pharmaceuticals, polymer materials, photonics, and basic research (Belfield et al., 1999; Bernius et al., 2000; Mondal et al., 2009).

Animal studies indicate that fluorene is absorbed following oral, inhalation, and dermal exposure (ATSDR, 1995). Metabolism of fluorene produces several hydroxylated metabolites that are further conjugated with glucuronic or sulphonic acids and rapidly eliminated in the urine (ATSDR, 1995). Several urinary monohydroxy fluorene metabolites, including 2-, 3-, and 9-hydroxyfluorene, have been identified in humans and are considered indicators of recent PAH exposure (Becker et al., 2003; CDC, 2009; Nethery et al., 2012). Urinary 3-hydroxyfluorene may be a good predictive biomarker for specifically assessing inhalation exposure to fluorene (Nethery et al., 2012).

Hematological and liver effects were observed in laboratory animals exposed orally to fluorene (ATSDR, 1995). Data on the carcinogenicity of fluorene in humans have not been identified and the International Agency for Research on Cancer has classified fluorene as Group 3, not classifiable as to its carcinogenicity in humans (IARC, 2010).

In a pilot biomonitoring study carried out in Hamilton, Ontario, with 19 pregnant women aged 19 to 42 years, the geometric means for 2-, 3-, and 9-hydroxyfluorene in urine were 0.2157 µg/g creatinine, 0.04827 µg/g creatinine, and 0.3908 µg/g creatinine, respectively (Nethery et al., 2012).

The fluorene metabolites, 2-, 3-, and 9-hydroxyfluorene, were analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and are presented as both µg/L and µg/g creatinine. Finding a measurable amount of fluorene metabolites in urine is an indicator of exposure to fluorene and does not necessarily mean that an adverse health effect will occur.

2-Hydroxyfluorene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 60 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2524	0	0.27 (0.24 - 0.29)	0.069 (0.058 - 0.080)	0.24 (0.21 - 0.27)	1.2 (0.95 - 1.5)	2.3 (1.7 - 2.8)
Total	3-79	3 (2012-2013)	2514	0	0.26 (0.24 - 0.29)	0.063 (0.051 - 0.075)	0.22 (0.20 - 0.24)	1.6 (1.4 - 1.8)	2.2 (1.6 - 2.7)
Males	3-79	2 (2009-2011)	1268	0	0.32 (0.27 - 0.38)	0.087 (0.071 - 0.10)	0.27 (0.23 - 0.32)	1.6Table 60 footnote E (0.95 - 2.3)	3.0 (2.1 - 4.0)
Males	3-79	3 (2012-2013)	1243	0	0.32 (0.29 - 0.35)	0.079 (0.058 - 0.10)	0.26 (0.23 - 0.29)	1.8 (1.5 - 2.0)	2.5 (1.7 - 3.2)
Females	3-79	2 (2009-2011)	1256	0	0.22 (0.21 - 0.25)	0.064 (0.051 - 0.076)	0.21 (0.17 - 0.26)	0.88Table 60 footnote E (0.54 - 1.2)	1.8 (1.3 - 2.3)
Females	3-79	3 (2012-2013)	1271	0	0.21 (0.17 - 0.27)	0.050 (0.035 - 0.065)	0.18 (0.14 - 0.21)	1.4Table 60 footnote E (0.84 - 2.0)	2.0 (1.4 - 2.6)
Total	3-5	2 (2009-2011)	506	0	0.17 (0.16 - 0.19)	0.069 (0.061 - 0.077)	0.18 (0.16 - 0.20)	0.37 (0.29 - 0.45)	0.47 (0.32 - 0.62)
Total	3-5	3 (2012-2013)	496	0	0.16 (0.13 - 0.18)	0.045 (0.029 - 0.060)	0.17 (0.13 - 0.21)	0.41 (0.32 - 0.51)	0.61 (0.41 - 0.81)
Total	6-11	2 (2009-2011)	511	0	0.22 (0.18 - 0.25)	0.088 (0.077 - 0.10)	0.24 (0.19 - 0.29)	0.48 (0.40 - 0.56)	0.57 (0.38 - 0.76)
Total	6-11	3 (2012-2013)	502	0	0.19 (0.17 - 0.21)	0.062 (0.045 - 0.078)	0.18 (0.16 - 0.21)	0.49 (0.38 - 0.60)	0.66 (0.53 - 0.78)
Total	12-19	2 (2009-2011)	506	0	0.26 (0.24 - 0.29)	0.098 (0.073 - 0.12)	0.26 (0.22 - 0.30)	0.73 (0.55 - 0.90)	1.1 (0.87 - 1.3)
Total	12-19	3 (2012-2013)	506	0	0.28 (0.23 - 0.33)	0.079 (0.063 - 0.095)	0.25 (0.19 - 0.31)	1.0Table 60 footnote E (0.52 - 1.5)	Table 60 footnote F
Total	20-39	2 (2009-2011)	355	0	0.30 (0.25 - 0.35)	0.085 (0.061 - 0.11)	0.28 (0.22 - 0.33)	1.3 (0.88 - 1.7)	2.2 (1.5 - 3.0)
Total	20-39	3 (2012-2013)	351	0	0.36 (0.29 - 0.46)	0.087 (0.066 - 0.11)	0.33 (0.27 - 0.39)	1.8 (1.3 - 2.4)	Table 60 footnote F
Total	40-59	2 (2009-2011)	359	0	0.30 (0.25 - 0.37)	0.066Table 60 footnote E (0.037 - 0.095)	0.25 (0.18 - 0.31)	1.9 (1.2 - 2.6)	3.3 (2.4 - 4.2)
Total	40-59	3 (2012-2013)	312	0	0.27 (0.21 - 0.34)	0.062 (0.044 - 0.081)	0.21 (0.16 - 0.27)	1.6 (1.2 - 2.0)	2.0Table 60 footnote E (1.3 - 2.8)
Total	60-79	2 (2009-2011)	287	0	0.21 (0.18 - 0.25)	0.054 (0.043 - 0.064)	0.18 (0.15 - 0.20)	1.1Table 60 footnote E (0.63 - 1.5)	2.3Table 60 footnote E (1.2 - 3.3)
Total	60-79	3 (2012-2013)	347	0	0.21 (0.16 - 0.27)	0.041Table 60 footnote E (0.020 - 0.062)	0.17 (0.14 - 0.20)	1.7Table 60 footnote E (0.82 - 2.7)	3.0Table 60 footnote E (1.3 - 4.8)
Table 60 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 60 footnote a referrer Table 60 footnote E Use data with caution. Return to table 60 footnote E referrer Table 60 footnote F Data is too unreliable to be published. Return to table 60 footnote F referrer

2-Hydroxyfluorene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 61 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2514	0	0.27 (0.24 - 0.29)	0.10 (0.091 - 0.11)	0.21 (0.19 - 0.22)	1.1 (0.82 - 1.4)	1.9 (1.4 - 2.4)
Total	3-79	3 (2012-2013)	2513	0	0.27 (0.25 - 0.29)	0.095 (0.089 - 0.10)	0.20 (0.18 - 0.23)	1.4 (1.1 - 1.7)	2.0 (1.6 - 2.3)
Males	3-79	2 (2009-2011)	1264	0	0.27 (0.23 - 0.32)	0.096 (0.089 - 0.10)	0.21 (0.18 - 0.23)	1.4Table 61 footnote E (0.81 - 1.9)	2.4Table 61 footnote E (1.3 - 3.5)
Males	3-79	3 (2012-2013)	1243	0	0.27 (0.23 - 0.31)	0.083 (0.071 - 0.096)	0.20 (0.16 - 0.23)	1.5 (1.0 - 2.0)	1.9 (1.4 - 2.3)
Females	3-79	2 (2009-2011)	1250	0	0.26 (0.24 - 0.28)	0.12 (0.10 - 0.13)	0.21 (0.19 - 0.22)	0.87Table 61 footnote E (0.46 - 1.3)	1.7 (1.3 - 2.1)
Females	3-79	3 (2012-2013)	1270	0	0.27 (0.23 - 0.32)	0.10 (0.097 - 0.11)	0.21 (0.18 - 0.24)	1.4 (0.87 - 1.9)	2.0 (1.5 - 2.5)
Total	3-5	2 (2009-2011)	505	0	0.31 (0.28 - 0.34)	0.16 (0.14 - 0.18)	0.30 (0.26 - 0.33)	0.62 (0.46 - 0.78)	0.75 (0.63 - 0.88)
Total	3-5	3 (2012-2013)	495	0	0.30 (0.28 - 0.33)	0.16 (0.15 - 0.18)	0.28 (0.26 - 0.31)	0.57 (0.50 - 0.65)	0.77 (0.58 - 0.95)
Total	6-11	2 (2009-2011)	509	0	0.25 (0.22 - 0.28)	0.14 (0.12 - 0.16)	0.23 (0.19 - 0.26)	0.46 (0.37 - 0.55)	0.59 (0.41 - 0.78)
Total	6-11	3 (2012-2013)	502	0	0.24 (0.21 - 0.27)	0.12 (0.11 - 0.13)	0.22 (0.18 - 0.26)	0.55 (0.44 - 0.66)	0.67 (0.58 - 0.75)
Total	12-19	2 (2009-2011)	504	0	0.20 (0.18 - 0.22)	0.099 (0.092 - 0.11)	0.17 (0.16 - 0.18)	0.44 (0.33 - 0.55)	Table 61 footnote F
Total	12-19	3 (2012-2013)	506	0	0.21 (0.18 - 0.24)	0.099 (0.091 - 0.11)	0.17 (0.15 - 0.20)	0.58Table 61 footnote E (0.33 - 0.83)	1.1Table 61 footnote E (0.37 - 1.8)
Total	20-39	2 (2009-2011)	353	0	0.27 (0.22 - 0.33)	0.10 (0.080 - 0.12)	0.20 (0.17 - 0.24)	1.1Table 61 footnote E (0.56 - 1.6)	2.2Table 61 footnote E (1.0 - 3.3)
Total	20-39	3 (2012-2013)	351	0	0.28 (0.23 - 0.35)	0.096 (0.080 - 0.11)	0.22 (0.16 - 0.29)	1.3Table 61 footnote E (0.50 - 2.1)	1.7 (1.1 - 2.2)
Total	40-59	2 (2009-2011)	357	0	0.30 (0.26 - 0.36)	0.10 (0.081 - 0.12)	0.22 (0.18 - 0.25)	1.6 (1.1 - 2.1)	2.5 (1.6 - 3.3)
Total	40-59	3 (2012-2013)	312	0	0.31 (0.25 - 0.38)	0.090 (0.074 - 0.11)	0.23 (0.17 - 0.29)	1.7 (1.1 - 2.2)	2.2 (1.6 - 2.9)
Total	60-79	2 (2009-2011)	286	0	0.25 (0.22 - 0.28)	0.098 (0.092 - 0.10)	0.18 (0.16 - 0.20)	1.3Table 61 footnote E (0.78 - 1.8)	1.8 (1.3 - 2.2)
Total	60-79	3 (2012-2013)	347	0	0.24 (0.19 - 0.30)	0.084 (0.069 - 0.099)	0.16 (0.12 - 0.20)	1.6Table 61 footnote E (0.92 - 2.2)	2.2Table 61 footnote E (1.2 - 3.1)
Table 61 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 61 footnote a referrer Table 61 footnote E Use data with caution. Return to table 61 footnote E referrer Table 61 footnote F Data is too unreliable to be published. Return to table 61 footnote F referrer

3-Hydroxyfluorene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 62 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2523	0.04	0.096 (0.087 - 0.11)	0.022 (0.020 - 0.025)	0.081 (0.072 - 0.089)	0.64 (0.46 - 0.81)	1.3 (0.96 - 1.7)
Total	3-79	3 (2012-2013)	2513	0	0.10 (0.090 - 0.11)	0.019 (0.016 - 0.022)	0.082 (0.072 - 0.091)	0.95 (0.70 - 1.2)	1.3 (1.0 - 1.7)
Males	3-79	2 (2009-2011)	1266	0	0.12 (0.099 - 0.14)	0.028 (0.024 - 0.032)	0.096 (0.080 - 0.11)	0.79Table 62 footnote E (0.34 - 1.2)	1.7Table 62 footnote E (1.1 - 2.3)
Males	3-79	3 (2012-2013)	1242	0	0.13 (0.11 - 0.15)	0.024 (0.016 - 0.031)	0.099 (0.093 - 0.11)	1.1 (0.75 - 1.4)	1.5 (1.1 - 1.9)
Females	3-79	2 (2009-2011)	1257	0.08	0.078 (0.070 - 0.086)	0.019 (0.015 - 0.023)	0.071 (0.058 - 0.083)	0.38Table 62 footnote E (0.15 - 0.60)	0.99Table 62 footnote E (0.59 - 1.4)
Females	3-79	3 (2012-2013)	1271	0	0.078 (0.061 - 0.10)	0.016 (0.012 - 0.020)	0.063 (0.043 - 0.083)	0.68Table 62 footnote E (0.39 - 0.98)	1.2 (0.84 - 1.6)
Total	3-5	2 (2009-2011)	507	0	0.069 (0.063 - 0.077)	0.025 (0.020 - 0.030)	0.071 (0.061 - 0.080)	0.16 (0.10 - 0.22)	0.23Table 62 footnote E (0.099 - 0.37)
Total	3-5	3 (2012-2013)	496	0	0.064 (0.054 - 0.075)	0.016Table 62 footnote E (0.0076 - 0.024)	0.068 (0.052 - 0.083)	0.18 (0.13 - 0.23)	0.26 (0.18 - 0.34)
Total	6-11	2 (2009-2011)	511	0	0.084 (0.069 - 0.10)	0.033 (0.028 - 0.038)	0.087 (0.066 - 0.11)	0.22 (0.17 - 0.27)	0.26 (0.19 - 0.32)
Total	6-11	3 (2012-2013)	501	0	0.077 (0.067 - 0.089)	0.023 (0.016 - 0.031)	0.080 (0.073 - 0.087)	0.25Table 62 footnote E (0.16 - 0.35)	0.36Table 62 footnote E (0.21 - 0.52)
Total	12-19	2 (2009-2011)	506	0.20	0.093 (0.082 - 0.11)	0.029 (0.022 - 0.036)	0.093 (0.081 - 0.11)	0.31Table 62 footnote E (0.19 - 0.42)	0.53Table 62 footnote E (0.33 - 0.73)
Total	12-19	3 (2012-2013)	506	0	0.10 (0.088 - 0.12)	0.028 (0.019 - 0.037)	0.088 (0.074 - 0.10)	0.59Table 62 footnote E (0.24 - 0.93)	0.94Table 62 footnote E (0.31 - 1.6)
Total	20-39	2 (2009-2011)	354	0	0.11 (0.092 - 0.13)	0.025 (0.018 - 0.032)	0.10 (0.079 - 0.12)	0.75Table 62 footnote E (0.39 - 1.1)	1.1Table 62 footnote E (0.70 - 1.5)
Total	20-39	3 (2012-2013)	351	0	0.14 (0.11 - 0.18)	0.026Table 62 footnote E (0.014 - 0.038)	0.10 (0.089 - 0.11)	1.1 (0.77 - 1.4)	1.4Table 62 footnote E (0.72 - 2.0)
Total	40-59	2 (2009-2011)	358	0	0.11 (0.090 - 0.14)	0.020Table 62 footnote E (0.011 - 0.030)	0.080 (0.062 - 0.099)	1.2Table 62 footnote E (0.66 - 1.8)	2.2 (1.5 - 3.0)
Total	40-59	3 (2012-2013)	311	0	0.11 (0.079 - 0.14)	0.018Table 62 footnote E (0.011 - 0.025)	0.078 (0.052 - 0.10)	0.99Table 62 footnote E (0.54 - 1.4)	1.3Table 62 footnote E (0.76 - 1.8)
Total	60-79	2 (2009-2011)	287	0	0.067 (0.056 - 0.079)	0.018 (0.014 - 0.022)	0.050 (0.043 - 0.057)	0.44Table 62 footnote E (0.24 - 0.64)	1.1Table 62 footnote E (0.58 - 1.7)
Total	60-79	3 (2012-2013)	348	0	0.074 (0.057 - 0.095)	0.012Table 62 footnote E (0.0050 - 0.018)	0.052 (0.037 - 0.068)	0.95Table 62 footnote E (0.28 - 1.6)	1.8Table 62 footnote E (0.83 - 2.8)
Table 62 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 62 footnote a referrer Table 62 footnote E Use data with caution. Return to table 62 footnote E referrer

3-Hydroxyfluorene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 63 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2513	0.04	0.096 (0.087 - 0.11)	0.032 (0.031 - 0.034)	0.070 (0.063 - 0.077)	0.68Table 63 footnote E (0.41 - 0.95)	1.1 (0.84 - 1.3)
Total	3-79	3 (2012-2013)	2512	0	0.10 (0.095 - 0.11)	0.029 (0.025 - 0.032)	0.072 (0.063 - 0.081)	0.83 (0.64 - 1.0)	1.2 (0.94 - 1.4)
Males	3-79	2 (2009-2011)	1262	0	0.10 (0.086 - 0.12)	0.031 (0.029 - 0.033)	0.074 (0.060 - 0.088)	0.81Table 63 footnote E (0.47 - 1.1)	1.4Table 63 footnote E (0.88 - 1.9)
Males	3-79	3 (2012-2013)	1242	0	0.11 (0.090 - 0.13)	0.026 (0.021 - 0.030)	0.077 (0.062 - 0.091)	0.84 (0.64 - 1.0)	1.0 (0.82 - 1.3)
Females	3-79	2 (2009-2011)	1251	0.08	0.089 (0.081 - 0.098)	0.035 (0.031 - 0.038)	0.069 (0.063 - 0.074)	Table 63 footnote F	0.99 (0.73 - 1.3)
Females	3-79	3 (2012-2013)	1270	0	0.10 (0.084 - 0.12)	0.032 (0.028 - 0.036)	0.071 (0.061 - 0.082)	0.79Table 63 footnote E (0.38 - 1.2)	1.2 (0.92 - 1.6)
Total	3-5	2 (2009-2011)	506	0	0.12 (0.11 - 0.14)	0.061 (0.057 - 0.066)	0.11 (0.089 - 0.13)	0.25 (0.19 - 0.30)	0.32Table 63 footnote E (0.16 - 0.49)
Total	3-5	3 (2012-2013)	495	0	0.12 (0.11 - 0.14)	0.062 (0.053 - 0.072)	0.11 (0.10 - 0.13)	0.27 (0.23 - 0.30)	0.40 (0.27 - 0.53)
Total	6-11	2 (2009-2011)	509	0	0.098 (0.085 - 0.11)	0.050 (0.042 - 0.057)	0.094 (0.080 - 0.11)	0.20 (0.15 - 0.25)	0.26 (0.20 - 0.33)
Total	6-11	3 (2012-2013)	501	0	0.099 (0.083 - 0.12)	0.044 (0.038 - 0.050)	0.085 (0.070 - 0.10)	0.25Table 63 footnote E (0.11 - 0.38)	0.43Table 63 footnote E (0.23 - 0.62)
Total	12-19	2 (2009-2011)	504	0.20	0.071 (0.062 - 0.082)	0.031 (0.027 - 0.035)	0.063 (0.055 - 0.070)	0.22Table 63 footnote E (0.11 - 0.33)	Table 63 footnote F
Total	12-19	3 (2012-2013)	506	0	0.079 (0.069 - 0.090)	0.033 (0.028 - 0.038)	0.065 (0.056 - 0.074)	Table 63 footnote F	0.61Table 63 footnote E (0.25 - 0.96)
Total	20-39	2 (2009-2011)	352	0	0.099 (0.081 - 0.12)	0.033 (0.027 - 0.038)	0.070 (0.056 - 0.083)	0.66Table 63 footnote E (0.28 - 1.0)	1.1Table 63 footnote E (0.47 - 1.7)
Total	20-39	3 (2012-2013)	351	0	0.11 (0.083 - 0.14)	0.032 (0.026 - 0.037)	0.079 (0.060 - 0.098)	0.78Table 63 footnote E (0.36 - 1.2)	0.99 (0.69 - 1.3)
Total	40-59	2 (2009-2011)	356	0	0.11 (0.092 - 0.14)	0.033 (0.028 - 0.038)	0.072 (0.052 - 0.093)	1.0 (0.72 - 1.4)	1.6 (1.2 - 2.0)
Total	40-59	3 (2012-2013)	311	0	0.12 (0.095 - 0.16)	0.027 (0.019 - 0.035)	0.078 (0.058 - 0.099)	1.1 (0.80 - 1.4)	1.5 (1.0 - 1.9)
Total	60-79	2 (2009-2011)	286	0	0.078 (0.067 - 0.090)	0.028 (0.025 - 0.031)	0.055 (0.047 - 0.063)	0.58Table 63 footnote E (0.23 - 0.92)	0.96 (0.81 - 1.1)
Total	60-79	3 (2012-2013)	348	0	0.085 (0.067 - 0.11)	0.025 (0.022 - 0.028)	0.053 (0.041 - 0.064)	0.82Table 63 footnote E (0.48 - 1.2)	1.4 (1.0 - 1.8)
Table 63 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 63 footnote a referrer Table 63 footnote E Use data with caution. Return to table 63 footnote E referrer Table 63 footnote F Data is too unreliable to be published. Return to table 63 footnote F referrer

9-Hydroxyfluorene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 64 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2514	0	0.16 (0.15 - 0.17)	0.051 (0.045 - 0.058)	0.16 (0.14 - 0.17)	0.46 (0.37 - 0.55)	0.66 (0.57 - 0.76)
Total	3-79	3 (2012-2013)	2499	0	0.15 (0.13 - 0.17)	0.045 (0.037 - 0.053)	0.14 (0.13 - 0.16)	0.53 (0.44 - 0.61)	0.71 (0.60 - 0.82)
Males	3-79	2 (2009-2011)	1260	0	0.17 (0.15 - 0.20)	0.057 (0.048 - 0.066)	0.17 (0.13 - 0.20)	0.58 (0.46 - 0.70)	0.73 (0.61 - 0.85)
Males	3-79	3 (2012-2013)	1238	0	0.17 (0.15 - 0.18)	0.051 (0.037 - 0.065)	0.16 (0.15 - 0.17)	0.58 (0.46 - 0.71)	0.73 (0.62 - 0.85)
Females	3-79	2 (2009-2011)	1254	0	0.15 (0.13 - 0.16)	0.048 (0.040 - 0.055)	0.14 (0.13 - 0.16)	0.39 (0.33 - 0.46)	0.49 (0.32 - 0.66)
Females	3-79	3 (2012-2013)	1261	0	0.13 (0.11 - 0.16)	0.041 (0.031 - 0.050)	0.13 (0.10 - 0.16)	0.49 (0.36 - 0.63)	0.65 (0.43 - 0.86)
Total	3-5	2 (2009-2011)	505	0	0.098 (0.088 - 0.11)	0.040 (0.032 - 0.048)	0.098 (0.086 - 0.11)	0.24 (0.19 - 0.29)	0.30 (0.25 - 0.34)
Total	3-5	3 (2012-2013)	490	0	0.084 (0.070 - 0.099)	0.029 (0.022 - 0.036)	0.085 (0.065 - 0.10)	0.22 (0.15 - 0.28)	0.29 (0.21 - 0.37)
Total	6-11	2 (2009-2011)	509	0	0.11 (0.091 - 0.13)	0.042 (0.032 - 0.051)	0.11 (0.086 - 0.13)	0.29 (0.21 - 0.37)	0.38 (0.28 - 0.47)
Total	6-11	3 (2012-2013)	498	0	0.091 (0.082 - 0.10)	0.038 (0.030 - 0.045)	0.081 (0.072 - 0.090)	0.24 (0.19 - 0.30)	0.34 (0.26 - 0.42)
Total	12-19	2 (2009-2011)	501	0	0.15 (0.13 - 0.17)	0.060 (0.047 - 0.073)	0.14 (0.12 - 0.17)	0.38 (0.32 - 0.45)	0.49 (0.35 - 0.62)
Total	12-19	3 (2012-2013)	505	0	0.13 (0.12 - 0.15)	0.047 (0.039 - 0.055)	0.13 (0.11 - 0.15)	0.38Table 64 footnote E (0.23 - 0.54)	0.58 (0.40 - 0.77)
Total	20-39	2 (2009-2011)	355	0	0.17 (0.15 - 0.20)	0.058 (0.041 - 0.076)	0.18 (0.15 - 0.21)	0.52 (0.34 - 0.70)	0.66 (0.53 - 0.79)
Total	20-39	3 (2012-2013)	351	0	0.20 (0.17 - 0.22)	0.065Table 64 footnote E (0.041 - 0.089)	0.19 (0.13 - 0.25)	0.54Table 64 footnote E (0.34 - 0.74)	0.77 (0.60 - 0.93)
Total	40-59	2 (2009-2011)	358	0	0.17 (0.15 - 0.20)	0.048Table 64 footnote E (0.029 - 0.066)	0.17 (0.13 - 0.20)	0.51 (0.34 - 0.68)	0.80 (0.55 - 1.1)
Total	40-59	3 (2012-2013)	310	0	0.17 (0.13 - 0.20)	0.045 (0.035 - 0.056)	0.15 (0.11 - 0.19)	0.58 (0.49 - 0.68)	0.76 (0.56 - 0.95)
Total	60-79	2 (2009-2011)	286	0	0.16 (0.14 - 0.18)	0.052 (0.046 - 0.058)	0.15 (0.13 - 0.17)	0.48 (0.31 - 0.66)	0.73Table 64 footnote E (0.46 - 1.0)
Total	60-79	3 (2012-2013)	345	0	0.13 (0.11 - 0.16)	0.037Table 64 footnote E (0.018 - 0.056)	0.12 (0.10 - 0.15)	0.49Table 64 footnote E (0.28 - 0.71)	0.71 (0.48 - 0.94)
Table 64 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 64 footnote a referrer Table 64 footnote E Use data with caution. Return to table 64 footnote E referrer

9-Hydroxyfluorene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 65 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2504	0	0.16 (0.15 - 0.17)	0.059 (0.053 - 0.066)	0.14 (0.13 - 0.16)	0.43 (0.35 - 0.52)	0.62 (0.51 - 0.72)
Total	3-79	3 (2012-2013)	2498	0	0.16 (0.14 - 0.17)	0.055 (0.048 - 0.062)	0.14 (0.13 - 0.16)	0.48 (0.43 - 0.52)	0.72 (0.64 - 0.81)
Males	3-79	2 (2009-2011)	1256	0	0.15 (0.13 - 0.17)	0.055 (0.047 - 0.064)	0.13 (0.11 - 0.15)	0.50 (0.35 - 0.64)	0.62 (0.50 - 0.73)
Males	3-79	3 (2012-2013)	1238	0	0.14 (0.12 - 0.16)	0.049 (0.041 - 0.058)	0.13 (0.10 - 0.15)	0.46 (0.35 - 0.56)	0.62 (0.48 - 0.76)
Females	3-79	2 (2009-2011)	1248	0	0.17 (0.15 - 0.19)	0.065 (0.058 - 0.071)	0.15 (0.13 - 0.18)	0.42 (0.34 - 0.50)	0.62 (0.44 - 0.80)
Females	3-79	3 (2012-2013)	1260	0	0.17 (0.15 - 0.20)	0.061 (0.050 - 0.071)	0.15 (0.14 - 0.17)	0.57Table 65 footnote E (0.35 - 0.80)	0.83 (0.63 - 1.0)
Total	3-5	2 (2009-2011)	504	0	0.17 (0.15 - 0.19)	0.068 (0.053 - 0.083)	0.17 (0.15 - 0.20)	0.41 (0.31 - 0.50)	0.62 (0.42 - 0.81)
Total	3-5	3 (2012-2013)	489	0	0.16 (0.14 - 0.18)	0.065 (0.058 - 0.072)	0.15 (0.12 - 0.18)	0.44 (0.36 - 0.52)	0.54 (0.45 - 0.64)
Total	6-11	2 (2009-2011)	507	0	0.13 (0.11 - 0.15)	0.056 (0.049 - 0.064)	0.11 (0.090 - 0.13)	0.31 (0.22 - 0.40)	0.42Table 65 footnote E (0.20 - 0.64)
Total	6-11	3 (2012-2013)	498	0	0.12 (0.10 - 0.13)	0.046Table 65 footnote E (0.029 - 0.063)	0.11 (0.096 - 0.13)	0.27 (0.22 - 0.31)	0.43 (0.30 - 0.56)
Total	12-19	2 (2009-2011)	499	0	0.11 (0.097 - 0.13)	0.048 (0.039 - 0.056)	0.10 (0.083 - 0.12)	0.27 (0.19 - 0.35)	0.37Table 65 footnote E (0.16 - 0.57)
Total	12-19	3 (2012-2013)	505	0	0.10 (0.087 - 0.12)	0.042 (0.035 - 0.048)	0.088 (0.077 - 0.098)	0.25 (0.17 - 0.34)	0.37Table 65 footnote E (0.22 - 0.51)
Total	20-39	2 (2009-2011)	353	0	0.15 (0.13 - 0.18)	0.060 (0.049 - 0.070)	0.14 (0.11 - 0.16)	0.35Table 65 footnote E (0.15 - 0.54)	0.56 (0.39 - 0.73)
Total	20-39	3 (2012-2013)	351	0	0.15 (0.13 - 0.18)	0.055 (0.038 - 0.072)	0.13 (0.092 - 0.16)	0.51 (0.33 - 0.69)	0.68 (0.52 - 0.84)
Total	40-59	2 (2009-2011)	356	0	0.17 (0.16 - 0.19)	0.064 (0.055 - 0.073)	0.16 (0.14 - 0.18)	0.52 (0.40 - 0.63)	0.64Table 65 footnote E (0.40 - 0.88)
Total	40-59	3 (2012-2013)	310	0	0.19 (0.16 - 0.23)	0.063 (0.043 - 0.084)	0.20 (0.15 - 0.24)	0.62Table 65 footnote E (0.38 - 0.86)	0.81 (0.52 - 1.1)
Total	60-79	2 (2009-2011)	285	0	0.19 (0.16 - 0.22)	0.065 (0.044 - 0.086)	0.16 (0.13 - 0.19)	0.52 (0.34 - 0.70)	0.77 (0.56 - 0.98)
Total	60-79	3 (2012-2013)	345	0	0.15 (0.13 - 0.18)	0.056 (0.038 - 0.073)	0.15 (0.13 - 0.17)	0.45 (0.31 - 0.60)	0.64 (0.52 - 0.76)
Table 65 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 65 footnote a referrer Table 65 footnote E Use data with caution. Return to table 65 footnote E referrer

Naphthalene

Naphthalene is a polycyclic aromatic hydrocarbon (PAH) with two fused benzene rings. Naphthalene is manufactured and imported into Canada for a wide variety of industrial uses (Environment Canada & Health Canada, 2008c). The major consumer products made from naphthalene are moth repellents, in the form of mothballs or crystals. Other commercial use of naphthalene include components of polyvinyl chloride phthalate plasticizers, dyes, resins, and leather-tanning agents (EPA, 2008b; IARC, 2002).

Naphthalene evaporates easily and is often found in the gaseous phase in ambient air (WHO, 2010b). Although diet and smoking are the most important sources of intake for most PAHs, inhalation of ambient and indoor air is the main source of naphthalene exposure for the general population. In Canada, indoor air exposure accounts for more than 95% of the total daily exposure across age groups (Environment Canada & Health Canada, 2008c). A recent study identified mothballs and some building materials and furnishings (vinyl and wooden furniture, and painted walls and ceilings) as significant contributors to indoor naphthalene concentrations in Canadian homes (Kang et al., 2012). Other sources of naphthalene in indoor and ambient air include migration of volatile organic compounds from attached garages, during cooking, and from kerosene space heaters and wood stoves (Batterman et al., 2007; Environment Canada & Health Canada, 2008c). Food and drinking water are considered minor sources of exposure to naphthalene (NTP, 2002).

Naphthalene is rapidly absorbed and metabolized following oral and inhalation exposures in laboratory animals (Bagchi et al., 2002; NTP, 2002). Naphthalene is also absorbed following dermal application in humans and laboratory animals (Storer et al., 1984; Turkall et al., 1994). Like other PAHs, naphthalene undergoes multi-step metabolism, the result of which includes the production of the hydroxynaphthalene metabolites, 1- and 2-hydroxynaphthalene (WHO, 2010b). Urinary levels of hydroxynaphthalene metabolites are reflective of recent exposure and have been measured in several human studies (Bouchard et al., 2009; CDC, 2009; Nethery et al., 2012). Urinary 2-hydroxynaphthalene is a unique biomarker of naphthalene metabolism (CDC, 2009). 1-Hydroxynaphthalene is a metabolite of both naphthalene and the insecticide carbaryl, making it difficult to distinguish between these exposures in the general population (Meeker et al., 2007).

In humans, the most serious effects of acute exposure to naphthalene are reported in individuals with glucose 6-phosphate dehydrogenase deficiency, where hemolytic anemia is the primary adverse effect (Health Canada, 2013i; WHO, 2010b). Reports from occupational exposure and animal studies suggest chronic exposure to naphthalene may lead to the development of lens opacities such as cataracts (Health Canada, 2013i; WHO, 2010b). Respiratory tract lesions have also been observed in laboratory animals following acute and chronic exposures (WHO, 2010b). Naphthalene has been observed to induce airway tumours in laboratory animals (NTP, 2002). Increased cell proliferation due to cytotoxicity (cell damage) is considered a key element in the development of airway tumours (WHO, 2010b). The International Agency for Research on Cancer has classified naphthalene as Group 2B, possibly carcinogenic to humans (IARC, 2002). The carcinogenicity of naphthalene has been proposed to involve non-genotoxic mechanisms (IARC, 2002). Based upon an assessment of acute and chronic effects, Health Canada has established a long-term residential maximum exposure limit for naphthalene (Health Canada, 2013i). The guideline is considered to protect against the carcinogenic and non-carcinogenic effects to the respiratory tract resulting from naphthalene exposure.

On the basis of its potential cancer risk, and the margin between levels to which Canadians might be exposed and the critical effect level for non-cancer effects, Health Canada and Environment Canada have concluded that naphthalene is a concern for human health (Environment Canada & Health Canada, 2008c). As a result, naphthalene is listed as a toxic substance on Schedule 1 of the Canadian Environmental Protection Act, 1999 (Canada, 1999; Canada, 2010e). In an effort to reduce exposure to naphthalene, several risk management approaches have been taken (Canada, 2010f). In 2010, the Pest Management Regulatory Agency (PMRA) re-evaluated the insecticidal uses of naphthalene. PMRA concluded that pest control products containing naphthalene do not present unacceptable risks to human health when used according to label directions and has granted continued registration (Health Canada, 2010h). As a condition of the continued registration of naphthalene uses, Health Canada has introduced new packaging and labelling requirements for naphthalene-containing consumer products (mothballs and moth flakes) in order to minimize exposure (Health Canada, 2012g). Naphthalene and 2-hydroxynaphthalene are included as prohibited ingredients and 1-hydroxynaphthalene and its salts as restricted ingredients on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist) (Health Canada 2014b). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Canada, 1985; Health Canada, 2014b).

1-Hydroxynaphthalene and 2-hydroxynaphthalene have been measured in urine as biomarkers of exposure to naphthalene in several studies. For various adult populations in Quebec living near industrial facilities, the reported geometric means ranged from 0.80 to 3.17 µg/g creatinine for 1-hydroxynaphthalene and 1.38 to 3.26 µg/g creatinine for 2-hydroxynaphthalene (Bouchard et al., 2001; Bouchard et al., 2009). These naphthalene metabolites were also measured in a pilot biomonitoring study carried out in Hamilton, Ontario, with 19 pregnant women aged 19 to 42 years. The geometric mean urinary concentrations were 1.411 µg/g creatinine for 1-hydroxynaphthalene and 2.605 µg/g creatinine for 2-hydroxynaphthalene (Nethery et al., 2012). A study aiming to assess naphthalene exposure in pregnant Canadian women residing in Ottawa, Ontario, reported geometric mean concentrations in urine ranging from 1.04-1.32 µg/L and 2.72-2.92 µg/L for 1-hydroxynaphthalene and 2-hydroxynaphthalene, respectively (Wheeler et al., 2014).

Naphthalene metabolites, 1-hydroxynaphthalene and 2-hydroxynaphthalene, were analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and are presented as both µg/L and µg/g creatinine. Finding a measurable amount of naphthalene metabolites in urine can be an indicator of exposure to naphthalene or carbaryl (for 1-hydroxynaphthalene) and does not necessarily mean that an adverse health effect will occur.

Naphthalene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Zhu et al., 2013) and cycle 3 (2012-2013). Further details on the indoor air studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

1-Hydroxynaphthalene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 66 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2522	0.79	1.5 (1.3 - 1.7)	0.27 (0.18 - 0.37)	1.3 (1.1 - 1.5)	9.9 (7.7 - 12)	15 (12 - 19)
Total	3-79	3 (2012-2013)	2511	2.27	1.0 (0.89 - 1.2)	0.19 (0.16 - 0.23)	0.85 (0.68 - 1.0)	7.8 (6.6 - 9.0)	11 (8.2 - 14)
Males	3-79	2 (2009-2011)	1267	0.39	1.6 (1.3 - 2.0)	0.29Table 66 footnote E (0.16 - 0.42)	1.3 (1.0 - 1.7)	11 (9.5 - 14)	17 (13 - 21)
Males	3-79	3 (2012-2013)	1241	1.69	1.3 (1.1 - 1.6)	0.24 (0.18 - 0.30)	1.1 (0.75 - 1.4)	8.3 (6.4 - 10)	12Table 66 footnote E (7.2 - 16)
Females	3-79	2 (2009-2011)	1255	1.2	1.4 (1.2 - 1.6)	0.26Table 66 footnote E (0.14 - 0.37)	1.2 (1.1 - 1.4)	6.2Table 66 footnote E (2.4 - 10)	Table 66 footnote F
Females	3-79	3 (2012-2013)	1270	2.83	0.80 (0.57 - 1.1)	0.18 (0.12 - 0.23)	0.72 (0.48 - 0.97)	6.6Table 66 footnote E (3.7 - 9.4)	9.9 (6.8 - 13)
Total	3-5	2 (2009-2011)	506	0.4	1.4 (1.2 - 1.6)	0.43 (0.35 - 0.50)	1.2 (1.0 - 1.4)	5.4Table 66 footnote E (3.3 - 7.5)	Table 66 footnote F
Total	3-5	3 (2012-2013)	495	1.82	0.69 (0.54 - 0.88)	0.19Table 66 footnote E (0.12 - 0.26)	0.68 (0.53 - 0.82)	2.9 (2.1 - 3.8)	4.2 (2.7 - 5.7)
Total	6-11	2 (2009-2011)	511	0.39	0.95 (0.79 - 1.1)	0.25Table 66 footnote E (<LOD - 0.40)	0.92 (0.73 - 1.1)	2.8 (2.1 - 3.5)	4.0 (2.9 - 5.2)
Total	6-11	3 (2012-2013)	502	2.19	0.75 (0.63 - 0.90)	0.23 (0.16 - 0.30)	0.68 (0.55 - 0.82)	3.0Table 66 footnote E (1.8 - 4.2)	Table 66 footnote F
Total	12-19	2 (2009-2011)	505	1.39	1.2 (0.98 - 1.4)	0.28Table 66 footnote E (0.14 - 0.41)	1.0 (0.83 - 1.2)	4.1Table 66 footnote E (2.1 - 6.1)	Table 66 footnote F
Total	12-19	3 (2012-2013)	505	2.57	0.95 (0.70 - 1.3)	0.19Table 66 footnote E (0.12 - 0.26)	0.74 (0.50 - 0.98)	7.2 (4.8 - 9.6)	Table 66 footnote F
Total	20-39	2 (2009-2011)	354	1.13	1.4 (1.1 - 1.7)	0.29Table 66 footnote E (0.14 - 0.43)	1.4 (1.0 - 1.7)	7.1Table 66 footnote E (4.5 - 9.7)	13 (9.9 - 15)
Total	20-39	3 (2012-2013)	350	2.29	1.2 (0.84 - 1.6)	0.20Table 66 footnote E (0.12 - 0.28)	0.91Table 66 footnote E (0.56 - 1.3)	8.4Table 66 footnote E (5.2 - 12)	12Table 66 footnote E (5.4 - 18)
Total	40-59	2 (2009-2011)	359	1.11	1.7 (1.3 - 2.2)	0.28Table 66 footnote E (0.11 - 0.44)	1.3 (0.97 - 1.7)	13 (10 - 15)	19Table 66 footnote E (11 - 27)
Total	40-59	3 (2012-2013)	311	3.22	1.1Table 66 footnote E (0.74 - 1.6)	0.18Table 66 footnote E (0.10 - 0.25)	0.97Table 66 footnote E (0.27 - 1.7)	8.1 (5.2 - 11)	11 (7.1 - 15)
Total	60-79	2 (2009-2011)	287	0.35	1.7 (1.3 - 2.2)	0.25Table 66 footnote E (0.12 - 0.39)	1.6 (1.2 - 1.9)	Table 66 footnote F	Table 66 footnote F
Total	60-79	3 (2012-2013)	348	1.72	0.99 (0.77 - 1.3)	0.21Table 66 footnote E (0.13 - 0.28)	0.86 (0.68 - 1.0)	7.0 (4.6 - 9.4)	13Table 66 footnote E (7.5 - 19)
Table 66 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 66 footnote a referrer Table 66 footnote E Use data with caution. Return to table 66 footnote E referrer Table 66 footnote F Data is too unreliable to be published. Return to table 66 footnote F referrer

1-Hydroxynaphthalene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 67 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2512	0.79	1.5 (1.3 - 1.7)	0.32 (0.23 - 0.41)	1.2 (1.0 - 1.4)	9.5 (7.0 - 12)	15 (12 - 18)
Total	3-79	3 (2012-2013)	2510	2.27	1.1 (0.91 - 1.2)	0.20 (0.16 - 0.25)	0.99 (0.81 - 1.2)	6.9 (5.4 - 8.4)	10 (7.7 - 12)
Males	3-79	2 (2009-2011)	1263	0.39	1.4 (1.1 - 1.7)	0.27 (0.18 - 0.36)	1.1 (0.84 - 1.3)	9.8Table 67 footnote E (6.0 - 14)	16 (12 - 20)
Males	3-79	3 (2012-2013)	1241	1.69	1.1 (0.85 - 1.4)	0.20 (0.15 - 0.25)	1.0 (0.66 - 1.3)	7.6 (5.0 - 10)	9.2 (6.8 - 12)
Females	3-79	2 (2009-2011)	1249	1.2	1.6 (1.4 - 1.8)	0.41 (0.31 - 0.50)	1.4 (1.2 - 1.5)	8.7 (5.6 - 12)	Table 67 footnote F
Females	3-79	3 (2012-2013)	1269	2.83	1.0 (0.77 - 1.4)	0.23Table 67 footnote E (0.14 - 0.31)	0.97 (0.66 - 1.3)	6.5Table 67 footnote E (3.1 - 9.9)	12 (8.3 - 15)
Total	3-5	2 (2009-2011)	505	0.4	2.5 (2.2 - 2.9)	0.74 (0.53 - 0.94)	2.2 (1.9 - 2.6)	8.4Table 67 footnote E (3.5 - 13)	16Table 67 footnote E (5.7 - 25)
Total	3-5	3 (2012-2013)	494	1.82	1.3 (1.1 - 1.6)	0.46 (0.34 - 0.57)	1.2 (1.1 - 1.4)	4.9 (3.6 - 6.2)	6.7 (4.8 - 8.6)
Total	6-11	2 (2009-2011)	509	0.39	1.1 (0.92 - 1.3)	0.35Table 67 footnote E (0.22 - 0.48)	1.0 (0.85 - 1.1)	3.4 (2.5 - 4.2)	4.9 (3.4 - 6.5)
Total	6-11	3 (2012-2013)	502	2.19	0.96 (0.76 - 1.2)	0.30 (0.26 - 0.34)	0.79 (0.61 - 0.98)	4.1Table 67 footnote E (2.5 - 5.8)	5.8Table 67 footnote E (3.2 - 8.5)
Total	12-19	2 (2009-2011)	503	1.39	0.90 (0.75 - 1.1)	0.26 (0.18 - 0.35)	0.83 (0.72 - 0.94)	3.5Table 67 footnote E (1.9 - 5.0)	Table 67 footnote F
Total	12-19	3 (2012-2013)	505	2.57	0.72 (0.56 - 0.92)	0.15Table 67 footnote E (0.089 - 0.22)	0.67 (0.46 - 0.88)	4.7Table 67 footnote E (1.3 - 8.2)	Table 67 footnote F
Total	20-39	2 (2009-2011)	352	1.13	1.3 (0.97 - 1.7)	0.24Table 67 footnote E (0.15 - 0.33)	1.2 (0.79 - 1.7)	8.2Table 67 footnote E (3.8 - 13)	13Table 67 footnote E (7.2 - 18)
Total	20-39	3 (2012-2013)	350	2.29	0.89 (0.62 - 1.3)	0.17Table 67 footnote E (0.074 - 0.26)	0.78Table 67 footnote E (0.40 - 1.2)	5.9Table 67 footnote E (2.1 - 9.6)	9.1Table 67 footnote E (5.7 - 13)
Total	40-59	2 (2009-2011)	357	1.11	1.7 (1.3 - 2.1)	0.37Table 67 footnote E (0.19 - 0.54)	1.3Table 67 footnote E (0.74 - 1.9)	13Table 67 footnote E (8.3 - 18)	18Table 67 footnote E (10 - 27)
Total	40-59	3 (2012-2013)	311	3.22	1.3 (0.88 - 1.8)	0.23Table 67 footnote E (0.11 - 0.36)	1.3Table 67 footnote E (0.80 - 1.8)	9.8 (6.3 - 13)	13 (8.6 - 17)
Total	60-79	2 (2009-2011)	286	0.35	2.0 (1.6 - 2.5)	0.50 (0.36 - 0.65)	1.5 (1.2 - 1.8)	Table 67 footnote F	Table 67 footnote F
Total	60-79	3 (2012-2013)	348	1.72	1.1 (0.93 - 1.4)	0.24Table 67 footnote E (0.13 - 0.36)	1.0 (0.70 - 1.3)	6.5Table 67 footnote E (4.1 - 8.9)	11 (8.0 - 14)
Table 67 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 67 footnote a referrer Table 67 footnote E Use data with caution. Return to table 67 footnote E referrer Table 67 footnote F Data is too unreliable to be published. Return to table 67 footnote F referrer

2-Hydroxynaphthalene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 68 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2503	0	3.8 (3.4 - 4.4)	0.84 (0.68 - 1.0)	3.8 (3.2 - 4.4)	17 (14 - 20)	24 (18 - 30)
Total	3-79	3 (2012-2013)	2506	0	4.1 (3.6 - 4.6)	0.93 (0.79 - 1.1)	4.0 (3.4 - 4.6)	18 (14 - 22)	26 (22 - 30)
Males	3-79	2 (2009-2011)	1251	0	4.0 (3.3 - 4.9)	0.99 (0.81 - 1.2)	3.9 (3.1 - 4.8)	19 (13 - 26)	26 (19 - 32)
Males	3-79	3 (2012-2013)	1239	0	4.6 (4.0 - 5.3)	0.96 (0.80 - 1.1)	4.4 (3.7 - 5.2)	20 (13 - 27)	30 (22 - 38)
Females	3-79	2 (2009-2011)	1252	0	3.7 (3.2 - 4.2)	0.63Table 68 footnote E (0.40 - 0.87)	3.5 (3.0 - 4.1)	17 (13 - 20)	23Table 68 footnote E (13 - 32)
Females	3-79	3 (2012-2013)	1267	0	3.7 (2.9 - 4.7)	0.88 (0.65 - 1.1)	3.7 (2.8 - 4.6)	16 (12 - 20)	23 (18 - 28)
Total	3-5	2 (2009-2011)	499	0	3.3 (2.8 - 3.8)	1.1 (0.91 - 1.2)	3.0 (2.4 - 3.6)	11Table 68 footnote E (5.8 - 15)	17Table 68 footnote E (8.9 - 24)
Total	3-5	3 (2012-2013)	494	0	3.2 (2.6 - 4.0)	0.72 (0.50 - 0.93)	3.4 (2.7 - 4.1)	12Table 68 footnote E (6.7 - 16)	19Table 68 footnote E (12 - 26)
Total	6-11	2 (2009-2011)	509	0	3.2 (2.6 - 4.0)	1.1 (0.82 - 1.3)	3.0 (2.3 - 3.8)	8.8Table 68 footnote E (4.7 - 13)	Table 68 footnote F
Total	6-11	3 (2012-2013)	498	0	3.2 (2.8 - 3.7)	0.84 (0.60 - 1.1)	3.2 (2.6 - 3.8)	10Table 68 footnote E (6.3 - 14)	14 (9.6 - 18)
Total	12-19	2 (2009-2011)	503	0	4.4 (3.8 - 5.0)	1.1 (0.93 - 1.3)	4.4 (3.5 - 5.3)	15 (9.6 - 20)	24 (19 - 29)
Total	12-19	3 (2012-2013)	505	0	5.3 (4.6 - 6.2)	1.2 (0.77 - 1.7)	5.0 (3.8 - 6.2)	23 (15 - 32)	36 (30 - 43)
Total	20-39	2 (2009-2011)	352	0	4.4 (3.5 - 5.5)	0.88Table 68 footnote E (0.53 - 1.2)	4.8 (3.8 - 5.9)	17 (13 - 21)	22 (18 - 27)
Total	20-39	3 (2012-2013)	350	0	5.2 (4.3 - 6.3)	1.2 (0.91 - 1.6)	5.6 (3.6 - 7.6)	18Table 68 footnote E (9.7 - 26)	26Table 68 footnote E (15 - 37)
Total	40-59	2 (2009-2011)	354	0	4.1 (3.1 - 5.4)	0.75Table 68 footnote E (0.27 - 1.2)	3.7Table 68 footnote E (2.1 - 5.2)	21Table 68 footnote E (13 - 30)	31 (20 - 42)
Total	40-59	3 (2012-2013)	311	0	4.2 (3.5 - 5.2)	0.97 (0.77 - 1.2)	4.1 (2.7 - 5.5)	18Table 68 footnote E (9.6 - 26)	28 (21 - 35)
Total	60-79	2 (2009-2011)	286	0	2.8 (2.4 - 3.3)	0.58Table 68 footnote E (0.31 - 0.86)	2.5 (1.9 - 3.2)	12Table 68 footnote E (7.5 - 16)	22 (19 - 26)
Total	60-79	3 (2012-2013)	348	0	3.0 (2.5 - 3.5)	0.73 (0.48 - 0.97)	2.9 (2.4 - 3.4)	14Table 68 footnote E (6.4 - 22)	24 (15 - 33)
Table 68 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 68 footnote a referrer Table 68 footnote E Use data with caution. Return to table 68 footnote E referrer Table 68 footnote F Data is too unreliable to be published. Return to table 68 footnote F referrer

2-Hydroxynaphthalene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 69 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2493	0	3.8 (3.4 - 4.3)	1.2 (1.0 - 1.3)	3.4 (2.9 - 4.0)	15 (13 - 17)	20 (17 - 22)
Total	3-79	3 (2012-2013)	2505	0	4.3 (3.9 - 4.7)	1.3 (1.1 - 1.5)	4.1 (3.4 - 4.7)	14 (12 - 17)	19 (16 - 21)
Males	3-79	2 (2009-2011)	1247	0	3.5 (2.9 - 4.1)	1.0 (0.94 - 1.2)	2.9 (2.3 - 3.5)	14 (10 - 19)	20 (14 - 25)
Males	3-79	3 (2012-2013)	1239	0	3.9 (3.3 - 4.5)	1.1 (0.91 - 1.4)	3.5 (2.6 - 4.4)	13 (9.7 - 17)	18 (15 - 21)
Females	3-79	2 (2009-2011)	1246	0	4.3 (3.9 - 4.6)	1.4 (1.1 - 1.7)	3.8 (3.3 - 4.2)	15 (12 - 18)	20 (16 - 23)
Females	3-79	3 (2012-2013)	1266	0	4.7 (4.0 - 5.5)	1.6 (1.3 - 1.8)	4.4 (3.4 - 5.3)	15 (13 - 17)	19 (16 - 23)
Total	3-5	2 (2009-2011)	498	0	5.9 (5.1 - 6.8)	2.1 (1.9 - 2.2)	5.0 (4.2 - 5.9)	16 (11 - 21)	23Table 69 footnote E (13 - 33)
Total	3-5	3 (2012-2013)	493	0	6.3 (5.4 - 7.3)	2.2 (1.7 - 2.7)	5.8 (4.8 - 6.8)	19 (13 - 25)	27Table 69 footnote E (17 - 37)
Total	6-11	2 (2009-2011)	507	0	3.8 (3.2 - 4.5)	1.5 (1.3 - 1.8)	3.6 (2.6 - 4.6)	9.4 (6.8 - 12)	12Table 69 footnote E (5.1 - 19)
Total	6-11	3 (2012-2013)	498	0	4.1 (3.4 - 5.0)	1.5 (1.1 - 1.9)	3.9 (3.3 - 4.5)	11 (8.3 - 14)	13Table 69 footnote E (4.5 - 22)
Total	12-19	2 (2009-2011)	501	0	3.4 (3.0 - 3.9)	1.1 (1.0 - 1.3)	3.1 (2.6 - 3.6)	9.9 (7.6 - 12)	13 (10 - 16)
Total	12-19	3 (2012-2013)	505	0	4.1 (3.7 - 4.4)	1.4 (1.1 - 1.7)	3.6 (3.2 - 4.0)	12 (9.6 - 15)	15 (11 - 20)
Total	20-39	2 (2009-2011)	350	0	3.9 (3.3 - 4.7)	1.2 (0.93 - 1.4)	3.4 (2.5 - 4.4)	15 (10 - 19)	19 (15 - 23)
Total	20-39	3 (2012-2013)	350	0	4.0 (3.4 - 4.8)	1.3Table 69 footnote E (0.80 - 1.8)	4.0 (3.1 - 4.9)	11 (8.7 - 13)	14 (11 - 18)
Total	40-59	2 (2009-2011)	352	0	4.1 (3.3 - 5.2)	1.0Table 69 footnote E (0.64 - 1.4)	3.7 (2.8 - 4.7)	19 (14 - 25)	25 (20 - 30)
Total	40-59	3 (2012-2013)	311	0	5.0 (4.1 - 6.0)	1.4 (1.1 - 1.8)	5.1 (3.4 - 6.7)	18 (14 - 21)	21 (17 - 25)
Total	60-79	2 (2009-2011)	285	0	3.3 (2.9 - 3.7)	1.1 (1.0 - 1.3)	2.6 (2.1 - 3.1)	14 (9.7 - 18)	18 (15 - 20)
Total	60-79	3 (2012-2013)	348	0	3.4 (3.0 - 3.9)	1.0 (0.77 - 1.2)	3.2 (2.7 - 3.6)	12 (8.1 - 16)	17 (13 - 21)
Table 69 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 69 footnote a referrer Table 69 footnote E Use data with caution. Return to table 69 footnote E referrer

Phenanthrene

Phenanthrene is a polycyclic aromatic hydrocarbon (PAH) with three fused benzene rings. It is used in the manufacture of dyes, polymer materials, and biomedical research (Mondal et al., 2009).

After oral administration in rats, phenanthrene was found to be absorbed from the gastrointestinal tract (Faust, 1993b). It is also absorbed through the skin in humans following dermal exposure (Storer et al., 1984). Metabolism of phenanthrene proceeds through the formation of epoxides that rearrange to form hydroxy and dihydrodiol metabolites (Jacob & Seidel, 2002). Phenanthrene metabolites are primarily excreted in the urine (Faust, 1993b).

Urinary hydroxylated phenanthrene metabolites (1-, 2-, 3-, 4-, and 9-hydroxyphenanthrene) have been assessed in several biomonitoring studies and are indicators of recent PAH exposure (Becker et al., 2003; CDC, 2009; Jacob & Seidel, 2002; Nethery et al., 2012). Their relatively high abundance in the urine and the availability of validated analytical methods for their detection and quantification make them good biomarkers for assessing exposure. Additionally, urinary concentrations of monohydroxyphenanthrene metabolites are less sensitive to smoking status than other PAH metabolites; they are therefore better suited for assessing exposures where the study population comprises both smokers and non-smokers (Jacob et al., 1999; Rihs et al., 2005) . Urinary 3-hydroxyphenanthrene may be a predictive biomarker for specifically assessing inhalation exposure to phenanthrene (Nethery et al., 2012).

In animal studies, phenanthrene did not elicit systemic or carcinogenic effects (ATSDR, 1995). The International Agency for Research on Cancer has classified phenanthrene as Group 3, not classifiable as to its carcinogenicity in humans (IARC, 2010).

In a pilot biomonitoring study carried out in Hamilton, Ontario, with 19 pregnant women aged 19 to 42 years, the geometric means for 1-, 2-, 3-, and 4-hydroxyphenanthrene in urine were 0.2439 µg/g creatinine, 0.0824 µg/g creatinine, 0.06989 µg/g creatinine, and 0.040 µg/g creatinine, respectively (Nethery et al., 2012).

Phenanthrene metabolites, 1-, 2-, 3-, 4-, and 9-hydroxyphenanthrene, were analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and are presented as both µg/L and µg/g creatinine. Finding a measurable amount of phenanthrene metabolites in urine is an indicator of exposure to phenanthrene and does not necessarily mean that an adverse health effect will occur.

1-Hydroxyphenanthrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 70 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2522	0.04	0.15 (0.14 - 0.17)	0.049 (0.042 - 0.056)	0.15 (0.14 - 0.17)	0.47 (0.38 - 0.57)	0.69 (0.53 - 0.84)
Total	3-79	3 (2012-2013)	2505	0.04	0.15 (0.13 - 0.16)	0.040 (0.028 - 0.051)	0.13 (0.12 - 0.15)	0.50 (0.38 - 0.62)	0.73 (0.58 - 0.88)
Males	3-79	2 (2009-2011)	1268	0	0.16 (0.14 - 0.19)	0.054 (0.046 - 0.062)	0.16 (0.14 - 0.19)	0.50 (0.38 - 0.62)	0.73 (0.57 - 0.90)
Males	3-79	3 (2012-2013)	1241	0.08	0.16 (0.14 - 0.18)	0.051 (0.038 - 0.064)	0.15 (0.13 - 0.17)	0.48 (0.37 - 0.59)	0.78 (0.54 - 1.0)
Females	3-79	2 (2009-2011)	1254	0.08	0.14 (0.13 - 0.16)	0.041 (0.032 - 0.049)	0.14 (0.12 - 0.16)	0.42 (0.30 - 0.54)	0.66Table 70 footnote E (0.40 - 0.92)
Females	3-79	3 (2012-2013)	1264	0	0.13 (0.11 - 0.16)	0.035 (0.026 - 0.044)	0.13 (0.096 - 0.15)	0.51 (0.35 - 0.66)	0.67 (0.56 - 0.79)
Total	3-5	2 (2009-2011)	505	0	0.11 (0.097 - 0.13)	0.044 (0.037 - 0.051)	0.10 (0.094 - 0.12)	0.29 (0.23 - 0.36)	0.34 (0.26 - 0.42)
Total	3-5	3 (2012-2013)	490	0	0.092 (0.079 - 0.11)	0.031 (0.021 - 0.042)	0.097 (0.086 - 0.11)	0.27 (0.22 - 0.31)	0.36 (0.30 - 0.42)
Total	6-11	2 (2009-2011)	510	0	0.12 (0.11 - 0.14)	0.046 (0.039 - 0.054)	0.12 (0.097 - 0.14)	0.30 (0.21 - 0.39)	0.42 (0.32 - 0.51)
Total	6-11	3 (2012-2013)	501	0.20	0.11 (0.094 - 0.12)	0.031Table 70 footnote E (0.015 - 0.047)	0.11 (0.092 - 0.12)	0.26 (0.21 - 0.30)	0.36 (0.30 - 0.42)
Total	12-19	2 (2009-2011)	506	0	0.15 (0.14 - 0.17)	0.058 (0.044 - 0.073)	0.15 (0.13 - 0.18)	0.44 (0.29 - 0.59)	0.55 (0.43 - 0.67)
Total	12-19	3 (2012-2013)	505	0	0.15 (0.13 - 0.18)	0.050 (0.035 - 0.066)	0.14 (0.11 - 0.17)	0.53 (0.40 - 0.65)	0.76Table 70 footnote E (0.41 - 1.1)
Total	20-39	2 (2009-2011)	355	0	0.16 (0.14 - 0.18)	0.049 (0.033 - 0.066)	0.17 (0.15 - 0.19)	0.49 (0.35 - 0.63)	0.64Table 70 footnote E (0.41 - 0.87)
Total	20-39	3 (2012-2013)	350	0	0.18 (0.16 - 0.21)	0.052 (0.036 - 0.068)	0.20 (0.14 - 0.26)	0.46Table 70 footnote E (0.27 - 0.65)	0.70Table 70 footnote E (0.28 - 1.1)
Total	40-59	2 (2009-2011)	359	0	0.16 (0.14 - 0.19)	0.052Table 70 footnote E (0.031 - 0.073)	0.16 (0.12 - 0.19)	0.51Table 70 footnote E (0.32 - 0.71)	0.77 (0.58 - 0.97)
Total	40-59	3 (2012-2013)	311	0	0.14 (0.12 - 0.17)	0.036Table 70 footnote E (0.018 - 0.055)	0.13 (0.095 - 0.16)	0.51Table 70 footnote E (0.30 - 0.73)	0.69Table 70 footnote E (0.43 - 0.94)
Total	60-79	2 (2009-2011)	287	0.35	0.15 (0.13 - 0.17)	0.038 (0.026 - 0.050)	0.16 (0.13 - 0.18)	0.50 (0.37 - 0.64)	0.81 (0.53 - 1.1)
Total	60-79	3 (2012-2013)	348	0	0.14 (0.11 - 0.17)	0.032Table 70 footnote E (0.0094 - 0.054)	0.12 (0.085 - 0.15)	0.68 (0.53 - 0.82)	0.85Table 70 footnote E (0.37 - 1.3)
Table 70 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 70 footnote a referrer Table 70 footnote E Use data with caution. Return to table 70 footnote E referrer

1-Hydroxyphenanthrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 71 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2512	0.04	0.15 (0.14 - 0.16)	0.069 (0.064 - 0.075)	0.14 (0.12 - 0.15)	0.37 (0.31 - 0.44)	0.52 (0.41 - 0.63)
Total	3-79	3 (2012-2013)	2504	0.04	0.15 (0.14 - 0.16)	0.059 (0.050 - 0.068)	0.14 (0.13 - 0.15)	0.39 (0.31 - 0.46)	0.59 (0.47 - 0.72)
Males	3-79	2 (2009-2011)	1264	0	0.14 (0.13 - 0.16)	0.060 (0.051 - 0.069)	0.13 (0.11 - 0.15)	0.35 (0.27 - 0.43)	0.51 (0.39 - 0.64)
Males	3-79	3 (2012-2013)	1241	0.08	0.13 (0.12 - 0.15)	0.052 (0.042 - 0.061)	0.13 (0.11 - 0.14)	0.34 (0.29 - 0.39)	0.53Table 71 footnote E (0.32 - 0.75)
Females	3-79	2 (2009-2011)	1248	0.08	0.17 (0.15 - 0.18)	0.078 (0.066 - 0.090)	0.15 (0.13 - 0.16)	0.39 (0.31 - 0.46)	0.55 (0.40 - 0.71)
Females	3-79	3 (2012-2013)	1263	0	0.17 (0.15 - 0.19)	0.070 (0.058 - 0.081)	0.15 (0.13 - 0.17)	0.47 (0.36 - 0.57)	0.63 (0.52 - 0.74)
Total	3-5	2 (2009-2011)	504	0	0.20 (0.17 - 0.22)	0.094 (0.077 - 0.11)	0.18 (0.16 - 0.21)	0.40 (0.32 - 0.47)	0.57 (0.39 - 0.75)
Total	3-5	3 (2012-2013)	489	0	0.18 (0.17 - 0.19)	0.088 (0.073 - 0.10)	0.16 (0.14 - 0.18)	0.38 (0.33 - 0.43)	0.53 (0.42 - 0.64)
Total	6-11	2 (2009-2011)	508	0	0.14 (0.13 - 0.16)	0.079 (0.071 - 0.087)	0.12 (0.11 - 0.14)	0.31 (0.26 - 0.37)	0.44Table 71 footnote E (0.26 - 0.63)
Total	6-11	3 (2012-2013)	501	0.20	0.13 (0.12 - 0.15)	0.068 (0.060 - 0.077)	0.12 (0.10 - 0.14)	0.29 (0.20 - 0.38)	0.37 (0.28 - 0.45)
Total	12-19	2 (2009-2011)	504	0	0.12 (0.11 - 0.13)	0.059 (0.055 - 0.063)	0.11 (0.095 - 0.12)	0.25 (0.18 - 0.32)	0.32 (0.25 - 0.40)
Total	12-19	3 (2012-2013)	505	0	0.11 (0.097 - 0.13)	0.052 (0.040 - 0.064)	0.099 (0.090 - 0.11)	0.29 (0.22 - 0.35)	0.37Table 71 footnote E (0.10 - 0.64)
Total	20-39	2 (2009-2011)	353	0	0.14 (0.12 - 0.16)	0.057 (0.043 - 0.071)	0.12 (0.090 - 0.16)	0.35 (0.23 - 0.47)	0.49 (0.36 - 0.62)
Total	20-39	3 (2012-2013)	350	0	0.14 (0.12 - 0.16)	0.060 (0.041 - 0.079)	0.13 (0.12 - 0.14)	0.34 (0.27 - 0.41)	0.50 (0.39 - 0.61)
Total	40-59	2 (2009-2011)	357	0	0.17 (0.15 - 0.18)	0.078 (0.067 - 0.088)	0.15 (0.12 - 0.17)	0.42 (0.36 - 0.47)	0.58 (0.45 - 0.70)
Total	40-59	3 (2012-2013)	311	0	0.17 (0.15 - 0.19)	0.062Table 71 footnote E (0.038 - 0.085)	0.16 (0.13 - 0.19)	0.48Table 71 footnote E (0.30 - 0.67)	0.63 (0.44 - 0.82)
Total	60-79	2 (2009-2011)	286	0.35	0.18 (0.16 - 0.19)	0.075 (0.060 - 0.089)	0.16 (0.14 - 0.18)	0.38Table 71 footnote E (0.24 - 0.53)	0.62 (0.47 - 0.78)
Total	60-79	3 (2012-2013)	348	0	0.16 (0.13 - 0.19)	0.059 (0.048 - 0.069)	0.13 (0.11 - 0.15)	0.46 (0.36 - 0.57)	0.81Table 71 footnote E (0.24 - 1.4)
Table 71 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 71 footnote a referrer Table 71 footnote E Use data with caution. Return to table 71 footnote E referrer

2-Hydroxyphenanthrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 72 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2520	0	0.067 (0.062 - 0.071)	0.027 (0.024 - 0.031)	0.065 (0.060 - 0.069)	0.17 (0.14 - 0.20)	0.23 (0.18 - 0.29)
Total	3-79	3 (2012-2013)	2503	0	0.061 (0.054 - 0.068)	0.021 (0.016 - 0.025)	0.056 (0.048 - 0.064)	0.18 (0.16 - 0.20)	0.28 (0.24 - 0.33)
Males	3-79	2 (2009-2011)	1265	0	0.074 (0.066 - 0.083)	0.029 (0.025 - 0.033)	0.070 (0.062 - 0.078)	0.18 (0.13 - 0.23)	0.26 (0.19 - 0.33)
Males	3-79	3 (2012-2013)	1238	0	0.071 (0.065 - 0.078)	0.027 (0.023 - 0.031)	0.065 (0.058 - 0.071)	0.19 (0.15 - 0.23)	0.31 (0.21 - 0.41)
Females	3-79	2 (2009-2011)	1255	0	0.060 (0.056 - 0.065)	0.024 (0.020 - 0.029)	0.058 (0.052 - 0.064)	0.14 (0.11 - 0.16)	0.19Table 72 footnote E (0.12 - 0.26)
Females	3-79	3 (2012-2013)	1265	0	0.052 (0.044 - 0.063)	0.017 (0.013 - 0.021)	0.047 (0.035 - 0.059)	0.15 (0.11 - 0.18)	0.22Table 72 footnote E (0.10 - 0.33)
Total	3-5	2 (2009-2011)	506	0	0.043 (0.038 - 0.049)	0.023 (0.019 - 0.027)	0.040 (0.033 - 0.046)	0.086 (0.060 - 0.11)	0.11 (0.077 - 0.15)
Total	3-5	3 (2012-2013)	490	0	0.033 (0.028 - 0.038)	0.014 (0.010 - 0.018)	0.031 (0.028 - 0.035)	0.074 (0.067 - 0.081)	0.090 (0.076 - 0.10)
Total	6-11	2 (2009-2011)	510	0	0.052 (0.046 - 0.059)	0.025 (0.021 - 0.030)	0.050 (0.045 - 0.056)	0.10 (0.076 - 0.13)	0.14 (0.11 - 0.17)
Total	6-11	3 (2012-2013)	500	0	0.041 (0.036 - 0.045)	0.018 (0.014 - 0.022)	0.040 (0.034 - 0.047)	0.090 (0.073 - 0.11)	0.12 (0.085 - 0.17)
Total	12-19	2 (2009-2011)	506	0	0.067 (0.061 - 0.074)	0.033 (0.024 - 0.042)	0.064 (0.058 - 0.069)	0.16 (0.11 - 0.20)	0.19 (0.15 - 0.24)
Total	12-19	3 (2012-2013)	505	0	0.064 (0.054 - 0.075)	0.024 (0.017 - 0.032)	0.061 (0.051 - 0.071)	0.16 (0.12 - 0.20)	0.26Table 72 footnote E (0.13 - 0.38)
Total	20-39	2 (2009-2011)	354	0	0.069 (0.060 - 0.078)	0.028 (0.023 - 0.033)	0.067 (0.059 - 0.074)	0.17 (0.13 - 0.21)	0.23Table 72 footnote E (0.13 - 0.32)
Total	20-39	3 (2012-2013)	350	0	0.083 (0.072 - 0.095)	0.031 (0.026 - 0.036)	0.087 (0.068 - 0.11)	0.19Table 72 footnote E (0.12 - 0.26)	0.33Table 72 footnote E (0.17 - 0.49)
Total	40-59	2 (2009-2011)	359	0	0.073 (0.064 - 0.083)	0.027 (0.018 - 0.036)	0.071 (0.062 - 0.081)	0.20 (0.14 - 0.26)	0.27 (0.20 - 0.35)
Total	40-59	3 (2012-2013)	311	0	0.057 (0.048 - 0.068)	0.019Table 72 footnote E (0.011 - 0.028)	0.050 (0.037 - 0.062)	0.16Table 72 footnote E (0.098 - 0.23)	0.27Table 72 footnote E (0.17 - 0.37)
Total	60-79	2 (2009-2011)	285	0	0.064 (0.058 - 0.071)	0.026 (0.018 - 0.034)	0.062 (0.055 - 0.070)	0.15 (0.11 - 0.19)	Table 72 footnote F
Total	60-79	3 (2012-2013)	347	0	0.059 (0.049 - 0.073)	0.019Table 72 footnote E (0.012 - 0.027)	0.054 (0.043 - 0.064)	0.24Table 72 footnote E (0.12 - 0.36)	Table 72 footnote F
Table 72 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 72 footnote a referrer Table 72 footnote E Use data with caution. Return to table 72 footnote E referrer Table 72 footnote F Data is too unreliable to be published. Return to table 72 footnote F referrer

2-Hydroxyphenanthrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 73 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2510	0	0.067 (0.062 - 0.072)	0.030 (0.027 - 0.034)	0.062 (0.057 - 0.067)	0.14 (0.12 - 0.16)	0.18 (0.16 - 0.20)
Total	3-79	3 (2012-2013)	2502	0	0.063 (0.058 - 0.068)	0.028 (0.025 - 0.031)	0.056 (0.052 - 0.060)	0.16 (0.14 - 0.18)	0.21 (0.17 - 0.26)
Males	3-79	2 (2009-2011)	1261	0	0.063 (0.058 - 0.070)	0.029 (0.027 - 0.031)	0.059 (0.052 - 0.066)	0.15 (0.12 - 0.18)	0.19 (0.15 - 0.23)
Males	3-79	3 (2012-2013)	1238	0	0.059 (0.053 - 0.066)	0.028 (0.024 - 0.031)	0.054 (0.049 - 0.059)	0.17 (0.14 - 0.19)	0.20 (0.16 - 0.24)
Females	3-79	2 (2009-2011)	1249	0	0.070 (0.062 - 0.078)	0.033 (0.028 - 0.039)	0.066 (0.060 - 0.072)	0.14 (0.11 - 0.17)	0.18 (0.12 - 0.23)
Females	3-79	3 (2012-2013)	1264	0	0.067 (0.060 - 0.075)	0.031 (0.025 - 0.036)	0.061 (0.050 - 0.073)	0.16 (0.12 - 0.19)	0.22 (0.17 - 0.28)
Total	3-5	2 (2009-2011)	505	0	0.077 (0.066 - 0.089)	0.040 (0.032 - 0.047)	0.076 (0.064 - 0.088)	0.15 (0.12 - 0.19)	0.18Table 73 footnote E (0.089 - 0.27)
Total	3-5	3 (2012-2013)	489	0	0.063 (0.056 - 0.071)	0.034 (0.027 - 0.040)	0.058 (0.051 - 0.064)	0.13 (0.11 - 0.15)	0.17 (0.14 - 0.19)
Total	6-11	2 (2009-2011)	508	0	0.061 (0.055 - 0.067)	0.034 (0.029 - 0.039)	0.057 (0.052 - 0.061)	0.11 (0.080 - 0.15)	0.17 (0.12 - 0.22)
Total	6-11	3 (2012-2013)	500	0	0.052 (0.045 - 0.060)	0.027 (0.020 - 0.034)	0.048 (0.039 - 0.058)	0.10 (0.085 - 0.12)	0.13 (0.10 - 0.16)
Total	12-19	2 (2009-2011)	504	0	0.051 (0.046 - 0.057)	0.027 (0.025 - 0.029)	0.047 (0.042 - 0.052)	0.10 (0.073 - 0.13)	0.13Table 73 footnote E (0.078 - 0.18)
Total	12-19	3 (2012-2013)	505	0	0.048 (0.040 - 0.058)	0.024 (0.020 - 0.028)	0.045 (0.036 - 0.053)	0.099 (0.072 - 0.13)	0.13Table 73 footnote E (0.060 - 0.21)
Total	20-39	2 (2009-2011)	352	0	0.061 (0.053 - 0.071)	0.029 (0.026 - 0.032)	0.057 (0.048 - 0.066)	0.15 (0.10 - 0.19)	0.18 (0.14 - 0.22)
Total	20-39	3 (2012-2013)	350	0	0.064 (0.055 - 0.073)	0.029 (0.024 - 0.033)	0.055 (0.049 - 0.062)	0.17 (0.14 - 0.20)	0.20 (0.14 - 0.26)
Total	40-59	2 (2009-2011)	357	0	0.074 (0.067 - 0.081)	0.033 (0.028 - 0.038)	0.071 (0.063 - 0.078)	0.17 (0.13 - 0.20)	0.18 (0.14 - 0.22)
Total	40-59	3 (2012-2013)	311	0	0.067 (0.059 - 0.077)	0.029 (0.024 - 0.035)	0.066 (0.057 - 0.075)	0.17 (0.12 - 0.21)	0.22 (0.16 - 0.29)
Total	60-79	2 (2009-2011)	284	0	0.075 (0.067 - 0.084)	0.036 (0.029 - 0.043)	0.066 (0.061 - 0.072)	0.14Table 73 footnote E (0.085 - 0.19)	Table 73 footnote F
Total	60-79	3 (2012-2013)	347	0	0.068 (0.057 - 0.082)	0.029 (0.022 - 0.037)	0.057 (0.048 - 0.066)	0.19 (0.13 - 0.24)	Table 73 footnote F
Table 73 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 73 footnote a referrer Table 73 footnote E Use data with caution. Return to table 73 footnote E referrer Table 73 footnote F Data is too unreliable to be published. Return to table 73 footnote F referrer

3-Hydroxyphenanthrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 74 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2515	0	0.087 (0.080 - 0.095)	0.026 (0.023 - 0.029)	0.089 (0.080 - 0.098)	0.28 (0.22 - 0.35)	0.39 (0.31 - 0.46)
Total	3-79	3 (2012-2013)	2505	0	0.083 (0.077 - 0.090)	0.021 (0.016 - 0.026)	0.081 (0.075 - 0.087)	0.29 (0.24 - 0.34)	0.48 (0.40 - 0.57)
Males	3-79	2 (2009-2011)	1265	0	0.10 (0.087 - 0.12)	0.030 (0.026 - 0.035)	0.099 (0.085 - 0.11)	0.33 (0.25 - 0.42)	0.45 (0.30 - 0.60)
Males	3-79	3 (2012-2013)	1241	0	0.099 (0.092 - 0.11)	0.029 (0.020 - 0.039)	0.098 (0.084 - 0.11)	0.33 (0.25 - 0.40)	0.54 (0.44 - 0.64)
Females	3-79	2 (2009-2011)	1250	0	0.075 (0.069 - 0.082)	0.022 (0.018 - 0.026)	0.078 (0.066 - 0.090)	0.22 (0.14 - 0.29)	0.35 (0.26 - 0.44)
Females	3-79	3 (2012-2013)	1264	0	0.070 (0.060 - 0.082)	0.017 (0.013 - 0.021)	0.065 (0.051 - 0.079)	0.28 (0.22 - 0.34)	0.40 (0.27 - 0.52)
Total	3-5	2 (2009-2011)	501	0	0.077 (0.068 - 0.086)	0.030 (0.026 - 0.034)	0.076 (0.064 - 0.088)	0.18Table 74 footnote E (0.10 - 0.25)	0.28 (0.20 - 0.35)
Total	3-5	3 (2012-2013)	490	0	0.065 (0.058 - 0.074)	0.020 (0.015 - 0.024)	0.067 (0.059 - 0.075)	0.19 (0.16 - 0.22)	0.28 (0.22 - 0.34)
Total	6-11	2 (2009-2011)	509	0	0.084 (0.071 - 0.099)	0.029 (0.023 - 0.035)	0.092 (0.072 - 0.11)	0.21 (0.16 - 0.27)	0.28 (0.21 - 0.34)
Total	6-11	3 (2012-2013)	501	0	0.069 (0.059 - 0.081)	0.021 (0.014 - 0.029)	0.073 (0.059 - 0.087)	0.17 (0.13 - 0.21)	0.22 (0.16 - 0.28)
Total	12-19	2 (2009-2011)	506	0	0.094 (0.084 - 0.11)	0.033 (0.025 - 0.042)	0.091 (0.077 - 0.10)	0.26 (0.18 - 0.33)	0.35Table 74 footnote E (0.20 - 0.50)
Total	12-19	3 (2012-2013)	505	0	0.091 (0.081 - 0.10)	0.028Table 74 footnote E (0.015 - 0.040)	0.089 (0.075 - 0.10)	0.28 (0.19 - 0.38)	0.42 (0.30 - 0.55)
Total	20-39	2 (2009-2011)	355	0	0.091 (0.078 - 0.11)	0.027 (0.020 - 0.034)	0.099 (0.070 - 0.13)	0.30 (0.21 - 0.39)	0.38 (0.27 - 0.49)
Total	20-39	3 (2012-2013)	350	0	0.11 (0.093 - 0.13)	0.035 (0.026 - 0.044)	0.10 (0.077 - 0.13)	0.30Table 74 footnote E (0.19 - 0.40)	0.58Table 74 footnote E (0.25 - 0.91)
Total	40-59	2 (2009-2011)	358	0	0.091 (0.078 - 0.11)	0.023Table 74 footnote E (0.014 - 0.032)	0.093 (0.082 - 0.10)	0.34 (0.27 - 0.41)	0.44Table 74 footnote E (0.27 - 0.60)
Total	40-59	3 (2012-2013)	311	0	0.078 (0.066 - 0.092)	0.021 (0.015 - 0.027)	0.074 (0.060 - 0.088)	0.29 (0.22 - 0.35)	0.38 (0.26 - 0.50)
Total	60-79	2 (2009-2011)	286	0	0.073 (0.063 - 0.085)	0.020 (0.016 - 0.025)	0.073 (0.059 - 0.086)	0.24 (0.18 - 0.29)	0.33Table 74 footnote E (0.12 - 0.54)
Total	60-79	3 (2012-2013)	348	0	0.072 (0.058 - 0.089)	0.015Table 74 footnote E (0.0058 - 0.024)	0.066 (0.050 - 0.083)	0.48 (0.32 - 0.65)	0.58 (0.39 - 0.76)
Table 74 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 74 footnote a referrer Table 74 footnote E Use data with caution. Return to table 74 footnote E referrer

3-Hydroxyphenanthrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 75 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2505	0	0.087 (0.080 - 0.094)	0.038 (0.035 - 0.041)	0.079 (0.073 - 0.085)	0.23 (0.18 - 0.27)	0.37 (0.29 - 0.46)
Total	3-79	3 (2012-2013)	2504	0	0.086 (0.080 - 0.092)	0.032 (0.029 - 0.035)	0.082 (0.072 - 0.091)	0.26 (0.23 - 0.28)	0.35 (0.28 - 0.42)
Males	3-79	2 (2009-2011)	1261	0	0.086 (0.076 - 0.098)	0.035 (0.031 - 0.039)	0.079 (0.069 - 0.090)	0.26 (0.18 - 0.35)	0.42 (0.29 - 0.55)
Males	3-79	3 (2012-2013)	1241	0	0.083 (0.074 - 0.093)	0.031 (0.027 - 0.036)	0.078 (0.063 - 0.093)	0.26 (0.24 - 0.27)	0.35 (0.25 - 0.44)
Females	3-79	2 (2009-2011)	1244	0	0.087 (0.079 - 0.095)	0.042 (0.037 - 0.046)	0.079 (0.072 - 0.086)	0.19 (0.15 - 0.23)	0.31Table 75 footnote E (0.15 - 0.47)
Females	3-79	3 (2012-2013)	1263	0	0.090 (0.081 - 0.099)	0.036 (0.033 - 0.039)	0.084 (0.073 - 0.095)	0.26 (0.20 - 0.32)	0.35 (0.26 - 0.45)
Total	3-5	2 (2009-2011)	500	0	0.14 (0.12 - 0.15)	0.067 (0.059 - 0.076)	0.13 (0.11 - 0.15)	0.29 (0.25 - 0.33)	0.36 (0.27 - 0.44)
Total	3-5	3 (2012-2013)	489	0	0.13 (0.12 - 0.14)	0.065 (0.056 - 0.074)	0.11 (0.097 - 0.12)	0.28 (0.24 - 0.31)	0.41 (0.31 - 0.51)
Total	6-11	2 (2009-2011)	507	0	0.098 (0.087 - 0.11)	0.049 (0.039 - 0.058)	0.087 (0.075 - 0.10)	0.20 (0.14 - 0.25)	0.27Table 75 footnote E (0.098 - 0.44)
Total	6-11	3 (2012-2013)	501	0	0.088 (0.076 - 0.10)	0.043 (0.038 - 0.048)	0.082 (0.064 - 0.10)	0.18 (0.13 - 0.24)	0.24 (0.17 - 0.30)
Total	12-19	2 (2009-2011)	504	0	0.072 (0.064 - 0.081)	0.037 (0.034 - 0.039)	0.068 (0.061 - 0.074)	0.14Table 75 footnote E (0.060 - 0.22)	0.23Table 75 footnote E (0.13 - 0.32)
Total	12-19	3 (2012-2013)	505	0	0.069 (0.062 - 0.077)	0.034 (0.029 - 0.038)	0.060 (0.051 - 0.068)	0.15 (0.11 - 0.19)	0.24Table 75 footnote E (0.13 - 0.36)
Total	20-39	2 (2009-2011)	353	0	0.081 (0.071 - 0.093)	0.038 (0.033 - 0.042)	0.069 (0.055 - 0.082)	0.23Table 75 footnote E (0.12 - 0.33)	0.38Table 75 footnote E (0.23 - 0.52)
Total	20-39	3 (2012-2013)	350	0	0.084 (0.070 - 0.10)	0.031 (0.025 - 0.038)	0.081 (0.065 - 0.098)	0.25 (0.20 - 0.31)	0.34 (0.22 - 0.47)
Total	40-59	2 (2009-2011)	356	0	0.092 (0.083 - 0.10)	0.037 (0.032 - 0.043)	0.086 (0.073 - 0.099)	0.27 (0.18 - 0.35)	0.45 (0.32 - 0.58)
Total	40-59	3 (2012-2013)	311	0	0.092 (0.081 - 0.10)	0.033 (0.026 - 0.040)	0.097 (0.087 - 0.11)	0.28 (0.20 - 0.35)	0.34 (0.22 - 0.45)
Total	60-79	2 (2009-2011)	285	0	0.085 (0.075 - 0.096)	0.039 (0.032 - 0.045)	0.077 (0.071 - 0.083)	0.18Table 75 footnote E (0.11 - 0.24)	0.30Table 75 footnote E (0.13 - 0.47)
Total	60-79	3 (2012-2013)	348	0	0.083 (0.069 - 0.10)	0.030 (0.022 - 0.038)	0.069 (0.059 - 0.079)	0.33 (0.24 - 0.41)	0.43Table 75 footnote E (0.18 - 0.68)
Table 75 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 75 footnote a referrer Table 75 footnote E Use data with caution. Return to table 75 footnote E referrer

4-Hydroxyphenanthrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 76 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2519	0.08	0.024 (0.022 - 0.027)	0.0065 (0.0055 - 0.0075)	0.019 (0.016 - 0.022)	0.091 (0.074 - 0.11)	0.13 (0.11 - 0.15)
Total	3-79	3 (2012-2013)	2495	4.33	0.021 (0.019 - 0.023)	0.0055 (0.0044 - 0.0065)	0.020 (0.016 - 0.023)	0.086 (0.068 - 0.10)	0.14 (0.11 - 0.18)
Males	3-79	2 (2009-2011)	1266	0	0.027 (0.023 - 0.031)	0.0071 (0.0053 - 0.0088)	0.022 (0.017 - 0.027)	0.10 (0.074 - 0.13)	0.15 (0.10 - 0.20)
Males	3-79	3 (2012-2013)	1236	3.32	0.024 (0.021 - 0.027)	0.0067 (0.0047 - 0.0087)	0.023 (0.020 - 0.026)	0.097 (0.074 - 0.12)	0.15 (0.11 - 0.19)
Females	3-79	2 (2009-2011)	1253	0.16	0.022 (0.020 - 0.024)	0.0058 (0.0047 - 0.0070)	0.017 (0.014 - 0.020)	0.085 (0.065 - 0.10)	0.13 (0.095 - 0.16)
Females	3-79	3 (2012-2013)	1259	5.32	0.018 (0.015 - 0.023)	0.0044 (0.0031 - 0.0058)	0.017 (0.011 - 0.022)	0.076 (0.052 - 0.10)	0.13Table 76 footnote E (0.079 - 0.18)
Total	3-5	2 (2009-2011)	505	0	0.017 (0.015 - 0.020)	0.0056 (0.0045 - 0.0068)	0.014 (0.012 - 0.016)	0.051 (0.042 - 0.061)	0.063Table 76 footnote E (0.032 - 0.093)
Total	3-5	3 (2012-2013)	488	4.30	0.014 (0.012 - 0.016)	0.0045 (0.0031 - 0.0059)	0.013 (0.011 - 0.016)	0.047 (0.038 - 0.056)	0.062 (0.051 - 0.073)
Total	6-11	2 (2009-2011)	510	0	0.020 (0.016 - 0.023)	0.0063 (0.0054 - 0.0073)	0.016 (0.012 - 0.020)	0.057 (0.040 - 0.075)	0.074 (0.049 - 0.099)
Total	6-11	3 (2012-2013)	500	4.40	0.014 (0.013 - 0.017)	0.0046 (0.0033 - 0.0059)	0.015 (0.012 - 0.018)	0.041 (0.032 - 0.050)	0.062 (0.050 - 0.073)
Total	12-19	2 (2009-2011)	505	0.20	0.023 (0.020 - 0.025)	0.0075 (0.0055 - 0.0096)	0.018 (0.016 - 0.021)	0.067 (0.053 - 0.081)	0.094 (0.062 - 0.12)
Total	12-19	3 (2012-2013)	504	4.56	0.021 (0.018 - 0.024)	0.0068 (0.0053 - 0.0083)	0.018 (0.015 - 0.021)	0.077 (0.052 - 0.10)	0.11Table 76 footnote E (0.070 - 0.16)
Total	20-39	2 (2009-2011)	355	0	0.026 (0.022 - 0.031)	0.0064 (0.0045 - 0.0083)	0.025Table 76 footnote E (0.014 - 0.036)	0.088 (0.057 - 0.12)	0.13 (0.086 - 0.18)
Total	20-39	3 (2012-2013)	349	2.87	0.027 (0.022 - 0.034)	0.0072 (0.0054 - 0.0090)	0.028 (0.020 - 0.036)	0.095Table 76 footnote E (0.057 - 0.13)	0.16Table 76 footnote E (0.088 - 0.24)
Total	40-59	2 (2009-2011)	357	0	0.027 (0.023 - 0.032)	0.0075 (0.0053 - 0.0098)	0.020 (0.015 - 0.024)	0.11 (0.085 - 0.14)	0.15Table 76 footnote E (0.097 - 0.21)
Total	40-59	3 (2012-2013)	308	4.55	0.021 (0.017 - 0.025)	0.0045Table 76 footnote E (<LOD - 0.0067)	0.019 (0.014 - 0.025)	0.090Table 76 footnote E (0.050 - 0.13)	0.12Table 76 footnote E (0.075 - 0.17)
Total	60-79	2 (2009-2011)	287	0.35	0.022 (0.019 - 0.026)	0.0057 (0.0044 - 0.0070)	0.018 (0.013 - 0.022)	0.086Table 76 footnote E (0.054 - 0.12)	0.14Table 76 footnote E (0.075 - 0.21)
Total	60-79	3 (2012-2013)	346	5.20	0.020 (0.016 - 0.024)	0.0047Table 76 footnote E (<LOD - 0.0071)	0.018 (0.013 - 0.022)	Table 76 footnote F	0.25Table 76 footnote E (0.12 - 0.39)
Table 76 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 76 footnote a referrer Table 76 footnote E Use data with caution. Return to table 76 footnote E referrer Table 76 footnote F Data is too unreliable to be published. Return to table 76 footnote F referrer

4-Hydroxyphenanthrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 77 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2509	0.08	0.024 (0.022 - 0.026)	0.0089 (0.0084 - 0.0095)	0.020 (0.016 - 0.024)	0.077 (0.060 - 0.094)	0.11 (0.082 - 0.14)
Total	3-79	3 (2012-2013)	2494	4.33	0.022 (0.020 - 0.024)	0.0077 (0.0066 - 0.0088)	0.019 (0.016 - 0.021)	0.076 (0.067 - 0.085)	0.10 (0.083 - 0.12)
Males	3-79	2 (2009-2011)	1262	0	0.022 (0.019 - 0.026)	0.0078 (0.0070 - 0.0087)	0.020 (0.019 - 0.020)	0.088 (0.061 - 0.11)	0.13 (0.085 - 0.17)
Males	3-79	3 (2012-2013)	1236	3.32	0.020 (0.017 - 0.023)	0.0071 (0.0056 - 0.0087)	0.017 (0.014 - 0.019)	0.077 (0.063 - 0.091)	0.099 (0.081 - 0.12)
Females	3-79	2 (2009-2011)	1247	0.16	0.026 (0.023 - 0.029)	0.0092 (0.0089 - 0.0095)	0.027 (0.018 - 0.035)	0.068 (0.051 - 0.086)	0.10 (0.070 - 0.13)
Females	3-79	3 (2012-2013)	1258	5.32	0.023 (0.021 - 0.026)	0.0081 (0.0069 - 0.0094)	0.022 (0.019 - 0.025)	0.076 (0.061 - 0.090)	0.11 (0.079 - 0.14)
Total	3-5	2 (2009-2011)	504	0	0.030 (0.026 - 0.035)	0.0095 (0.0089 - 0.010)	0.024 (0.021 - 0.028)	0.085 (0.069 - 0.10)	0.097 (0.076 - 0.12)
Total	3-5	3 (2012-2013)	487	4.30	0.026 (0.024 - 0.029)	0.011 (0.010 - 0.012)	0.023 (0.019 - 0.027)	0.068 (0.062 - 0.074)	0.095 (0.075 - 0.12)
Total	6-11	2 (2009-2011)	508	0	0.022 (0.018 - 0.026)	0.0091 (0.0088 - 0.0094)	0.016 (0.012 - 0.020)	0.060 (0.042 - 0.078)	0.080 (0.060 - 0.10)
Total	6-11	3 (2012-2013)	500	4.40	0.018 (0.016 - 0.021)	0.0078 (0.0066 - 0.0089)	0.017 (0.014 - 0.020)	0.045 (0.040 - 0.050)	0.052 (0.043 - 0.061)
Total	12-19	2 (2009-2011)	503	0.20	0.017 (0.015 - 0.019)	0.0077 (0.0068 - 0.0086)	0.019Table 77 footnote E (0.011 - 0.027)	0.042 (0.030 - 0.054)	0.059 (0.039 - 0.078)
Total	12-19	3 (2012-2013)	504	4.56	0.016 (0.014 - 0.018)	0.0070 (0.0060 - 0.0080)	0.013 (0.011 - 0.016)	0.036 (0.025 - 0.047)	Table 77 footnote F
Total	20-39	2 (2009-2011)	353	0	0.023 (0.019 - 0.027)	0.0078 (0.0065 - 0.0091)	0.020 (0.018 - 0.021)	0.070Table 77 footnote E (0.041 - 0.098)	0.11Table 77 footnote E (0.067 - 0.16)
Total	20-39	3 (2012-2013)	349	2.87	0.021 (0.017 - 0.026)	0.0080 (0.0064 - 0.0096)	0.017 (0.012 - 0.022)	0.077 (0.059 - 0.095)	0.093 (0.071 - 0.11)
Total	40-59	2 (2009-2011)	355	0	0.027 (0.024 - 0.030)	0.0091 (0.0087 - 0.0095)	0.027 (0.018 - 0.036)	0.091 (0.074 - 0.11)	0.14Table 77 footnote E (0.088 - 0.19)
Total	40-59	3 (2012-2013)	308	4.55	0.024 (0.020 - 0.029)	0.0080 (0.0054 - 0.011)	0.024 (0.018 - 0.030)	0.083 (0.060 - 0.11)	0.11Table 77 footnote E (0.070 - 0.15)
Total	60-79	2 (2009-2011)	286	0.35	0.026 (0.023 - 0.031)	0.0090 (0.0082 - 0.0098)	0.029Table 77 footnote E (0.018 - 0.040)	0.081Table 77 footnote E (0.048 - 0.11)	0.13Table 77 footnote E (0.070 - 0.19)
Total	60-79	3 (2012-2013)	346	5.20	0.023 (0.019 - 0.027)	0.0074 (0.0058 - 0.0090)	0.020 (0.015 - 0.024)	0.096Table 77 footnote E (0.059 - 0.13)	0.14Table 77 footnote E (0.075 - 0.21)
Table 77 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 77 footnote a referrer Table 77 footnote E Use data with caution. Return to table 77 footnote E referrer Table 77 footnote F Data is too unreliable to be published. Return to table 77 footnote F referrer

9-Hydroxyphenanthrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 78 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2474	5.86	0.039 (0.034 - 0.044)	0.0075 (0.0066 - 0.0084)	0.036 (0.029 - 0.043)	0.24 (0.18 - 0.31)	0.41 (0.33 - 0.49)
Total	3-79	3 (2012-2013)	2295	3.66	0.036 (0.033 - 0.040)	0.0080 (0.0059 - 0.010)	0.034 (0.029 - 0.038)	0.19 (0.14 - 0.23)	0.32 (0.21 - 0.43)
Males	3-79	2 (2009-2011)	1249	5.44	0.043 (0.035 - 0.052)	0.0080 (0.0065 - 0.0094)	0.043 (0.033 - 0.053)	0.25Table 78 footnote E (0.15 - 0.35)	0.49 (0.32 - 0.65)
Males	3-79	3 (2012-2013)	1155	2.60	0.040 (0.036 - 0.045)	0.0099 (0.0086 - 0.011)	0.037 (0.032 - 0.041)	0.19 (0.15 - 0.22)	0.26Table 78 footnote E (0.12 - 0.40)
Females	3-79	2 (2009-2011)	1225	6.29	0.035 (0.031 - 0.040)	0.0070 (0.0053 - 0.0086)	0.032 (0.028 - 0.036)	0.23Table 78 footnote E (0.11 - 0.34)	0.38 (0.26 - 0.50)
Females	3-79	3 (2012-2013)	1140	4.74	0.032 (0.026 - 0.039)	0.0070 (0.0045 - 0.0095)	0.032 (0.026 - 0.037)	0.19Table 78 footnote E (0.083 - 0.29)	0.39 (0.25 - 0.53)
Total	3-5	2 (2009-2011)	490	11.43	0.018 (0.015 - 0.022)	<LOD	0.020 (0.017 - 0.023)	0.072 (0.054 - 0.089)	0.095Table 78 footnote E (0.041 - 0.15)
Total	3-5	3 (2012-2013)	426	4.46	0.019 (0.017 - 0.022)	0.0069Table 78 footnote E (<LOD - 0.0099)	0.019 (0.015 - 0.023)	0.057 (0.042 - 0.072)	0.072 (0.051 - 0.093)
Total	6-11	2 (2009-2011)	502	5.78	0.019 (0.015 - 0.023)	0.0044Table 78 footnote E (<LOD - 0.0075)	0.022 (0.017 - 0.026)	0.056 (0.043 - 0.069)	0.076 (0.055 - 0.097)
Total	6-11	3 (2012-2013)	447	4.92	0.019 (0.017 - 0.022)	0.0058Table 78 footnote E (<LOD - 0.0091)	0.021 (0.019 - 0.023)	0.048 (0.041 - 0.054)	Table 78 footnote F
Total	12-19	2 (2009-2011)	499	5.41	0.027 (0.023 - 0.032)	0.0073 (0.0058 - 0.0089)	0.029 (0.023 - 0.035)	0.099 (0.076 - 0.12)	0.15Table 78 footnote E (0.092 - 0.20)
Total	12-19	3 (2012-2013)	480	3.75	0.026 (0.021 - 0.031)	0.0070Table 78 footnote E (0.0040 - 0.0099)	0.022 (0.018 - 0.026)	0.10 (0.066 - 0.13)	Table 78 footnote F
Total	20-39	2 (2009-2011)	348	3.45	0.041 (0.034 - 0.050)	0.0088Table 78 footnote E (0.0055 - 0.012)	0.040 (0.030 - 0.050)	0.23Table 78 footnote E (0.088 - 0.38)	0.39Table 78 footnote E (0.20 - 0.58)
Total	20-39	3 (2012-2013)	331	2.11	0.040 (0.031 - 0.051)	0.0094 (0.0072 - 0.012)	0.036 (0.030 - 0.043)	0.19 (0.13 - 0.25)	0.23Table 78 footnote E (0.088 - 0.36)
Total	40-59	2 (2009-2011)	350	3.14	0.049 (0.040 - 0.059)	0.0089 (0.0071 - 0.011)	0.045 (0.034 - 0.056)	0.31 (0.23 - 0.38)	0.48 (0.40 - 0.56)
Total	40-59	3 (2012-2013)	287	4.18	0.041 (0.031 - 0.054)	0.0080 (0.0052 - 0.011)	0.043 (0.031 - 0.055)	0.22Table 78 footnote E (0.086 - 0.35)	0.38Table 78 footnote E (0.22 - 0.53)
Total	60-79	2 (2009-2011)	285	3.51	0.043 (0.033 - 0.056)	0.0065Table 78 footnote E (<LOD - 0.0092)	0.035 (0.024 - 0.045)	0.31Table 78 footnote E (0.19 - 0.42)	0.60Table 78 footnote E (0.34 - 0.85)
Total	60-79	3 (2012-2013)	324	1.85	0.041 (0.034 - 0.050)	Table 78 footnote F	0.040 (0.031 - 0.049)	0.28Table 78 footnote E (0.076 - 0.49)	Table 78 footnote F
Table 78 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 78 footnote a referrer Table 78 footnote E Use data with caution. Return to table 78 footnote E referrer Table 78 footnote F Data is too unreliable to be published. Return to table 78 footnote F referrer

9-Hydroxyphenanthrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 79 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2464	5.86	0.039 (0.034 - 0.044)	0.010 (0.0091 - 0.011)	0.032 (0.026 - 0.038)	0.22 (0.16 - 0.28)	0.34 (0.26 - 0.42)
Total	3-79	3 (2012-2013)	2294	3.66	0.037 (0.034 - 0.041)	0.011 (0.0095 - 0.012)	0.032 (0.028 - 0.037)	0.17 (0.13 - 0.21)	0.29 (0.20 - 0.38)
Males	3-79	2 (2009-2011)	1245	5.44	0.037 (0.030 - 0.045)	0.0099 (0.0077 - 0.012)	0.029 (0.022 - 0.035)	0.23Table 79 footnote E (0.14 - 0.33)	0.38 (0.27 - 0.48)
Males	3-79	3 (2012-2013)	1155	2.60	0.033 (0.028 - 0.040)	0.0097 (0.0079 - 0.012)	0.030 (0.023 - 0.037)	0.16 (0.11 - 0.21)	0.23 (0.16 - 0.30)
Females	3-79	2 (2009-2011)	1219	6.29	0.041 (0.035 - 0.048)	0.010Table 79 footnote E (0.0060 - 0.014)	0.035 (0.027 - 0.043)	0.21Table 79 footnote E (0.13 - 0.29)	0.29Table 79 footnote E (0.18 - 0.39)
Females	3-79	3 (2012-2013)	1139	4.74	0.041 (0.037 - 0.046)	0.012 (0.010 - 0.013)	0.035 (0.030 - 0.039)	0.21Table 79 footnote E (0.12 - 0.30)	0.39 (0.25 - 0.53)
Total	3-5	2 (2009-2011)	489	11.43	0.032 (0.027 - 0.037)	<LOD	0.037 (0.030 - 0.043)	0.11 (0.086 - 0.13)	0.14Table 79 footnote E (0.086 - 0.20)
Total	3-5	3 (2012-2013)	425	4.46	0.037 (0.035 - 0.040)	0.017 (0.013 - 0.020)	0.036 (0.032 - 0.040)	0.081 (0.066 - 0.095)	0.10 (0.086 - 0.12)
Total	6-11	2 (2009-2011)	500	5.78	0.022 (0.018 - 0.027)	0.0068Table 79 footnote E (<LOD - 0.010)	0.025 (0.021 - 0.029)	0.053 (0.044 - 0.063)	0.071 (0.050 - 0.093)
Total	6-11	3 (2012-2013)	447	4.92	0.025 (0.022 - 0.028)	0.012 (0.0086 - 0.015)	0.023 (0.020 - 0.025)	0.057 (0.046 - 0.069)	0.082Table 79 footnote E (0.037 - 0.13)
Total	12-19	2 (2009-2011)	497	5.41	0.021 (0.018 - 0.024)	0.0076 (0.0060 - 0.0092)	0.020 (0.017 - 0.022)	0.059Table 79 footnote E (0.037 - 0.082)	0.087Table 79 footnote E (0.043 - 0.13)
Total	12-19	3 (2012-2013)	480	3.75	0.019 (0.017 - 0.022)	0.0087 (0.0071 - 0.010)	0.016 (0.014 - 0.018)	0.056Table 79 footnote E (0.030 - 0.082)	0.097Table 79 footnote E (0.042 - 0.15)
Total	20-39	2 (2009-2011)	346	3.45	0.037 (0.029 - 0.047)	0.010Table 79 footnote E (0.0047 - 0.015)	0.028 (0.020 - 0.035)	0.26Table 79 footnote E (0.11 - 0.41)	0.36Table 79 footnote E (0.22 - 0.51)
Total	20-39	3 (2012-2013)	331	2.11	0.030 (0.023 - 0.040)	0.010 (0.0066 - 0.013)	0.025Table 79 footnote E (0.012 - 0.038)	0.12Table 79 footnote E (0.048 - 0.20)	0.17Table 79 footnote E (0.093 - 0.25)
Total	40-59	2 (2009-2011)	348	3.14	0.049 (0.040 - 0.060)	0.012Table 79 footnote E (0.0067 - 0.018)	0.043 (0.030 - 0.056)	0.25 (0.19 - 0.31)	0.40Table 79 footnote E (0.25 - 0.55)
Total	40-59	3 (2012-2013)	287	4.18	0.048 (0.038 - 0.060)	0.011 (0.0076 - 0.015)	0.042Table 79 footnote E (0.024 - 0.061)	0.24Table 79 footnote E (0.10 - 0.37)	0.39Table 79 footnote E (0.23 - 0.56)
Total	60-79	2 (2009-2011)	284	3.51	0.051 (0.040 - 0.064)	0.013Table 79 footnote E (0.0078 - 0.019)	0.039Table 79 footnote E (0.023 - 0.056)	0.29Table 79 footnote E (0.18 - 0.40)	Table 79 footnote F
Total	60-79	3 (2012-2013)	324	1.85	0.048 (0.040 - 0.058)	0.013 (0.0097 - 0.017)	0.041 (0.031 - 0.051)	0.25Table 79 footnote E (0.14 - 0.36)	0.37Table 79 footnote E (0.21 - 0.54)
Table 79 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 79 footnote a referrer Table 79 footnote E Use data with caution. Return to table 79 footnote E referrer Table 79 footnote F Data is too unreliable to be published. Return to table 79 footnote F referrer

Pyrene

Pyrene is a polycyclic aromatic hydrocarbon (PAH) with four fused benzene rings. Pyrene is used as an intermediate in the synthesis of dyes and fluorescent molecular probes for biomedical research (WHO, 1998).

Pyrene absorption occurs rapidly in the respiratory tract, but more slowly through the gastrointestinal tract and skin (Faust, 1993c). After oral administration in rats, pyrene has been found predominantly in the gastrointestinal tract (Mitchell & Tu, 1979). 1-Hydroxypyrene has been identified as the primary metabolite of pyrene (IARC, 2010). In humans, urinary elimination of 1-hydroxypyrene is triphasic with half-lives of 5, 22, and 408 hours (ACGIH, 2005). Monitoring studies of pyrene exposure can measure urinary levels of 1-hydroxypyrene to assess recent and chronic exposures (Becker et al., 2003; CDC, 2009; Hopf et al., 2009; Jongeneelen et al., 1985). Urinary 1-hydroxypyrene may also serve as a useful biomarker for total PAH exposure, given that pyrene is found in most PAH mixtures (Hopf et al., 2009; WHO, 1998).

Subchronic oral exposure to pyrene results in kidney and liver effects in laboratory animals, and the liver has been suggested as the main target organ for toxicity (Faust, 1993c; TRL, 1989). Because the carcinogenic evidence is limited, the International Agency for Research on Cancer has classified pyrene as Group 3, not classifiable as to its carcinogenicity to humans (IARC, 2010).

1-Hydroxypyrene was measured in the urine of 73 non-smoking, non-occupationally exposed residents (aged 16 to 64 years) living approximately 1 km from an aluminum plant in Baie-Comeau, Quebec. The geometric mean levels ranged from 0.090 to 0.111 µg/g creatinine, compared with 0.048 to 0.077 µg/g creatinine for 71 control individuals living at least 11 km from the plant (Bouchard et al., 2009). Firefighters from Toronto, Ontario, were assessed for their exposure to PAHs from firefighting operations while wearing protective equipment (Caux et al., 2002). Urine was collected from 43 individuals for 20 hours after exposure, and urinary 1-hydroxypyrene levels ranged from <0.043 to 7.00 µg/g creatinine (Caux et al., 2002). In a pilot biomonitoring study carried out in Hamilton, Ontario, with 19 pregnant women aged 19 to 42 years, the geometric means for 1-hydroxypyrene in urine was 0.1359 µg/g creatinine (Nethery et al., 2012).

1-Hydroxypyrene was analyzed in the urine of Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years and is presented as both µg/L and µg/g creatinine. Finding a measurable amount of 1-hydroxypyrene in urine is an indicator of exposure to pyrene and does not necessarily mean that an adverse health effect will occur.

1-Hydroxypyrene - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 80 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2422	0.04	0.11 (0.099 - 0.12)	0.031 (0.027 - 0.034)	0.10 (0.092 - 0.11)	0.35 (0.31 - 0.39)	0.57 (0.47 - 0.68)
Total	3-79	3 (2012-2013)	2410	0.04	0.088 (0.078 - 0.10)	0.027 (0.020 - 0.035)	0.087 (0.078 - 0.096)	0.31 (0.26 - 0.35)	0.46 (0.38 - 0.55)
Males	3-79	2 (2009-2011)	1206	0	0.12 (0.11 - 0.14)	0.040 (0.034 - 0.045)	0.12 (0.10 - 0.13)	0.38 (0.25 - 0.50)	0.59 (0.46 - 0.73)
Males	3-79	3 (2012-2013)	1178	0.08	0.10 (0.090 - 0.12)	0.033 (0.023 - 0.042)	0.094 (0.088 - 0.10)	0.36 (0.30 - 0.43)	0.52 (0.45 - 0.60)
Females	3-79	2 (2009-2011)	1216	0.08	0.095 (0.088 - 0.10)	0.026 (0.021 - 0.031)	0.095 (0.085 - 0.10)	0.33 (0.28 - 0.37)	0.48 (0.34 - 0.62)
Females	3-79	3 (2012-2013)	1232	0	0.077 (0.064 - 0.092)	0.022Table 80 footnote E (0.014 - 0.031)	0.077 (0.061 - 0.093)	0.26 (0.21 - 0.30)	0.36 (0.25 - 0.48)
Total	3-5	2 (2009-2011)	504	0	0.12 (0.11 - 0.13)	0.050 (0.041 - 0.059)	0.11 (0.10 - 0.12)	0.27 (0.20 - 0.34)	0.40 (0.30 - 0.51)
Total	3-5	3 (2012-2013)	493	0	0.093 (0.077 - 0.11)	0.029 (0.023 - 0.036)	0.098 (0.081 - 0.12)	0.26 (0.21 - 0.31)	0.31 (0.25 - 0.37)
Total	6-11	2 (2009-2011)	507	0	0.13 (0.11 - 0.15)	0.049 (0.039 - 0.058)	0.12 (0.096 - 0.14)	0.34 (0.25 - 0.42)	0.47 (0.34 - 0.60)
Total	6-11	3 (2012-2013)	501	0	0.092 (0.084 - 0.10)	0.032 (0.024 - 0.039)	0.097 (0.088 - 0.11)	0.21 (0.16 - 0.26)	0.28 (0.22 - 0.33)
Total	12-19	2 (2009-2011)	480	0	0.15 (0.14 - 0.17)	0.050Table 80 footnote E (0.031 - 0.069)	0.15 (0.13 - 0.17)	0.44 (0.36 - 0.52)	0.62 (0.45 - 0.79)
Total	12-19	3 (2012-2013)	473	0	0.12 (0.097 - 0.14)	0.040Table 80 footnote E (0.024 - 0.057)	0.11 (0.092 - 0.13)	0.34 (0.24 - 0.43)	0.47 (0.34 - 0.60)
Total	20-39	2 (2009-2011)	327	0	0.13 (0.11 - 0.15)	0.041 (0.027 - 0.054)	0.12 (0.10 - 0.14)	0.35 (0.29 - 0.42)	0.48Table 80 footnote E (0.27 - 0.69)
Total	20-39	3 (2012-2013)	308	0	0.12 (0.10 - 0.15)	0.037 (0.025 - 0.048)	0.11 (0.077 - 0.15)	0.36 (0.25 - 0.47)	Table 80 footnote F
Total	40-59	2 (2009-2011)	329	0.30	0.10 (0.084 - 0.12)	0.026Table 80 footnote E (0.012 - 0.039)	0.094 (0.076 - 0.11)	0.44Table 80 footnote E (0.22 - 0.65)	0.58 (0.47 - 0.69)
Total	40-59	3 (2012-2013)	296	0	0.080 (0.067 - 0.095)	0.027Table 80 footnote E (0.016 - 0.039)	0.079 (0.063 - 0.095)	0.26Table 80 footnote E (0.14 - 0.38)	0.43Table 80 footnote E (0.26 - 0.60)
Total	60-79	2 (2009-2011)	275	0	0.067 (0.057 - 0.079)	0.024 (0.018 - 0.030)	0.062 (0.048 - 0.076)	0.20 (0.16 - 0.24)	Table 80 footnote F
Total	60-79	3 (2012-2013)	339	0.29	0.064 (0.051 - 0.081)	0.015Table 80 footnote E (0.0086 - 0.022)	0.060 (0.041 - 0.079)	0.31 (0.20 - 0.41)	0.50Table 80 footnote E (0.29 - 0.71)
Table 80 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 80 footnote a referrer Table 80 footnote E Use data with caution. Return to table 80 footnote E referrer Table 80 footnote F Data is too unreliable to be published. Return to table 80 footnote F referrer

1-Hydroxypyrene (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 81 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2412	0.04	0.11 (0.10 - 0.12)	0.045 (0.042 - 0.048)	0.099 (0.096 - 0.10)	0.28 (0.24 - 0.33)	0.40 (0.31 - 0.50)
Total	3-79	3 (2012-2013)	2409	0.04	0.094 (0.084 - 0.10)	0.034 (0.028 - 0.040)	0.088 (0.079 - 0.096)	0.25 (0.20 - 0.29)	0.36 (0.24 - 0.47)
Males	3-79	2 (2009-2011)	1202	0	0.11 (0.093 - 0.12)	0.042 (0.036 - 0.047)	0.098 (0.091 - 0.10)	0.31 (0.24 - 0.39)	0.43Table 81 footnote E (0.28 - 0.59)
Males	3-79	3 (2012-2013)	1178	0.08	0.089 (0.076 - 0.10)	0.030 (0.020 - 0.039)	0.087 (0.075 - 0.099)	0.25 (0.18 - 0.31)	0.35 (0.26 - 0.44)
Females	3-79	2 (2009-2011)	1210	0.08	0.11 (0.10 - 0.12)	0.048 (0.044 - 0.052)	0.099 (0.094 - 0.11)	0.26 (0.21 - 0.31)	0.38 (0.28 - 0.49)
Females	3-79	3 (2012-2013)	1231	0	0.099 (0.087 - 0.11)	0.038 (0.027 - 0.049)	0.088 (0.071 - 0.11)	0.25 (0.19 - 0.30)	0.42Table 81 footnote E (0.23 - 0.60)
Total	3-5	2 (2009-2011)	503	0	0.21 (0.20 - 0.23)	0.11 (0.089 - 0.12)	0.20 (0.18 - 0.23)	0.41 (0.35 - 0.46)	0.51 (0.42 - 0.60)
Total	3-5	3 (2012-2013)	492	0	0.18 (0.16 - 0.20)	0.094 (0.078 - 0.11)	0.17 (0.15 - 0.20)	0.34 (0.28 - 0.41)	0.43 (0.38 - 0.49)
Total	6-11	2 (2009-2011)	505	0	0.15 (0.13 - 0.16)	0.074 (0.063 - 0.085)	0.14 (0.12 - 0.15)	0.28 (0.22 - 0.34)	0.37 (0.26 - 0.49)
Total	6-11	3 (2012-2013)	501	0	0.12 (0.11 - 0.13)	0.066 (0.057 - 0.074)	0.11 (0.091 - 0.12)	0.21 (0.17 - 0.25)	0.27 (0.23 - 0.31)
Total	12-19	2 (2009-2011)	478	0	0.12 (0.10 - 0.13)	0.056 (0.051 - 0.062)	0.10 (0.091 - 0.12)	0.28 (0.20 - 0.37)	0.39Table 81 footnote E (0.21 - 0.57)
Total	12-19	3 (2012-2013)	473	0	0.089 (0.073 - 0.11)	0.044 (0.031 - 0.057)	0.087 (0.074 - 0.10)	0.19Table 81 footnote E (0.12 - 0.26)	0.26Table 81 footnote E (0.15 - 0.37)
Total	20-39	2 (2009-2011)	325	0	0.12 (0.096 - 0.14)	0.050 (0.035 - 0.065)	0.10 (0.083 - 0.12)	0.28 (0.18 - 0.38)	0.41 (0.27 - 0.54)
Total	20-39	3 (2012-2013)	308	0	0.10 (0.087 - 0.12)	0.036 (0.026 - 0.047)	0.099 (0.087 - 0.11)	0.26Table 81 footnote E (0.083 - 0.44)	0.54Table 81 footnote E (0.20 - 0.88)
Total	40-59	2 (2009-2011)	327	0.30	0.10 (0.090 - 0.12)	0.043 (0.039 - 0.047)	0.094 (0.085 - 0.10)	0.33 (0.25 - 0.41)	0.59Table 81 footnote E (0.24 - 0.94)
Total	40-59	3 (2012-2013)	296	0	0.093 (0.080 - 0.11)	0.033Table 81 footnote E (0.020 - 0.046)	0.088 (0.074 - 0.10)	0.26Table 81 footnote E (0.15 - 0.37)	0.38Table 81 footnote E (0.20 - 0.56)
Total	60-79	2 (2009-2011)	274	0	0.079 (0.069 - 0.091)	0.035 (0.028 - 0.042)	0.078 (0.072 - 0.084)	0.16 (0.13 - 0.20)	0.23Table 81 footnote E (0.11 - 0.36)
Total	60-79	3 (2012-2013)	339	0.29	0.073 (0.060 - 0.090)	0.028 (0.023 - 0.034)	0.062 (0.050 - 0.075)	0.23 (0.16 - 0.30)	0.35 (0.23 - 0.48)
Table 81 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 81 footnote a referrer Table 81 footnote E Use data with caution. Return to table 81 footnote E referrer

Summaries and Results for Volatile Organic Compounds

Benzene and Benzene Metabolites

Benzene (CASRN 71-43-2) is a colorless liquid and volatile organic compound (VOC) that is naturally present in ambient air at low concentrations (Health Canada, 2009f). It was first isolated and synthesized in the early 1800s and presently is commercially recovered from both coal and petroleum sources for industrial applications (ATSDR, 2007c).

Benzene is used widely in industry as a solvent and as an intermediate in the production of a variety of chemicals, with typical end-products including plastics and elastomers, phenol and acetone, and nylon resins (ATSDR, 2007c; Environment Canada & Health Canada, 1993c). Benzene is also used at various stages in the manufacturing of synthetic fibres, rubbers, lubricants, dyes, detergents, drugs, and pesticides (ATSDR, 2007c).

Benzene is released to the environment from natural and anthropogenic sources. It is naturally present in crude oil, and is formed during the incomplete combustion of organic materials (Environment Canada & Health Canada, 1993c). Benzene enters the environment as a result of natural processes including petroleum seepage, weathering of rock and soil, volcanic activity, forest fires, and releases from plant life (Environment Canada & Health Canada, 1993c). Anthropogenic sources include the production, storage, use, and transport of isolated benzene, crude oil, and other petroleum products. Examples include evaporative releases from gasoline at service stations and combustion by-products in the form of motor vehicle exhaust (Health Canada, 2009f). Natural sources are generally considered to contribute less benzene to the environment than anthropogenic sources (Environment Canada & Health Canada, 1993c).

The general population is exposed to benzene mainly through inhalation of ambient air; higher exposures occur particularly in areas of heavy vehicle traffic and at gasoline service stations, and from tobacco smoke (ATSDR, 2007c). Exposure to benzene in ambient air accounts for an estimated 98% to 99% of total benzene intake for Canadian non-smokers (Health Canada, 2009f). Inside residences, benzene levels in air have been shown to be higher for homes with attached garages, or where smoking occurs (Héroux et al., 2008; Héroux et al., 2010; Wheeler et al., 2013). Various marketplace products containing benzene can also contribute to its presence in indoor air (Environment Canada & Health Canada, 1993c). Although benzene has been detected in tap water and in certain foods and beverages, these are not considered to constitute major sources of exposure for the general population (ATSDR, 2007c; Health Canada, 2009f).

Following inhalation, benzene is readily absorbed into the blood and is distributed throughout the body, concentrating in adipose tissue (EPA, 2002). In the lung and liver, benzene is metabolized into several reactive metabolites including benzene oxide (EPA, 2002; McHale et al., 2012). Benzene metabolism can branch into several alternative metabolic pathways: spontaneous rearrangement of benzene oxide produces phenol, a major product; reaction with glutathione ultimately forms S-phenylmercapturic acid (S-PMA); and an iron-catalyzed reaction leads to the formation of trans,trans-muconic acid (t,t-MA) (EPA, 2002). Excretion of benzene occurs via exhalation of benzene from the lungs and as conjugated metabolites in urine; all benzene metabolites may be conjugated with sulphate or glucuronic acid (EPA, 2002). Phenol, S-PMA, and t,t-MA are considered urinary biomarkers of recent benzene exposure (Boogaard & van Sittert, 1995; Qu et al., 2005; Weisel, 2010). Measurements of t,t-MA and S-PMA are more sensitive and reliable indicators of benzene exposure because urinary phenol may be a result of dietary or environmental exposure to phenol or other phenolic compounds (ATSDR, 2007c). Benzene levels in blood are a reliable biomarker of benzene exposure and reflect recent exposure (Arnold et al., 2013; Weisel, 2010).

Benzene is known to cause a number of health effects in humans with the specific adverse effects dependent upon the concentration and duration of benzene exposure. Exposure to benzene can be hematotoxic in humans and laboratory animals, with bone marrow the principal target organ (EPA, 2002). Available data indicate that benzene metabolites produced in the liver may be carried to bone marrow where hematotoxicity occurs (EPA, 2002). In rodents, chronic inhalation exposure to benzene has been shown to cause leukemia (EPA, 2002). Epidemiologic studies and case studies provide strong evidence of an association between exposure to high levels of benzene and leukemia risk in occupationally exposed humans (EPA, 2002).

Benzene has been classified as carcinogenic to humans by Environment Canada and Health Canada (Group I) and the International Agency for Research on Cancer (Group 1) (Environment Canada & Health Canada, 1993c; IARC, 2012b). A common mode of action has not been established for hematotoxic and carcinogenic effects; however, it is generally accepted that acute myelogenous leukemia and non-cancer effects are caused by one or more reactive metabolites of benzene (ATSDR, 2007c; McHale et al., 2012; Meek & Klaunig, 2010; Smith, 2010).

Globally, benzene has become one of the most intensively regulated substances (Capleton & Levy, 2005). In Canada, regulations have been put in place to limit the concentration of benzene in gasoline as well as emissions from vehicles (Canada, 1997; Environment Canada, 2014). Benzene is listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999) and is a candidate for full lifecycle management to prevent or minimize its release into the environment (Canada, 1999; Environment Canada & Health Canada, 1993c). In 2000-2001, the Canadian Council of Ministers of the Environment endorsed the Canada-wide standard for benzene requiring industry reduction of total benzene emissions and use of best management practices (CCME, 2000b; CCME, 2001). With the implementation of these standards, emissions of benzene from industry to ambient air fell by 71% between 1995 and 2008 (CCME, 2012).Benzene is also included as a prohibited ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Canada, 1985; Health Canada, 2014b).

The Government of Canada has also taken a number of actions to address VOCs, a large class of compounds that includes benzene. As a class, they are environmental and health concerns because of their contribution to the formation of smog. The Government of Canada has taken and proposed a number of actions to address VOC emissions resulting from the use of consumer and commercial products in Canada (Canada, 2009a; Canada, 2009b; Environment Canada, 2002; Environment Canada, 2013b).

Health Canada, in collaboration with the Federal-Provincial-Territorial Committee on Drinking Water, has developed a guideline for Canadian drinking water quality that establishes the maximum acceptable concentration for benzene in drinking water based on cancer endpoints, and that is considered protective of both cancer and non-cancer effects (Health Canada, 2009f). Health Canada has identified benzene as a priority indoor air contaminant and has developed a guidance document for benzene in residential indoor air (Health Canada, 2013j). On the basis of a low but non-negligible cancer risk at indoor exposure levels, the guidance recommends that individuals take actions to reduce exposure to benzene indoors as much as possible. In particular, exposure reduction strategies have been recommended targeting attached garages and indoor smoking as primary sources of benzene indoors.

Exposure to benzene was assessed in firefighters in Montréal, Quebec, by means of urinary measurements of t,t-MA. Urine samples were collected from 43 firefighters over a period of 20 hours following the end of a fire (Caux et al., 2002). Among the 43 firefighters in this study, six had t,t-MA concentrations exceeding 1700 µg/g creatinine. This value corresponds to a benzene air concentration approximately 1,000 times greater than the average concentration in ambient air (Boogaard & van Sittert, 1995; Environment Canada & Health Canada, 1993c).

Benzene was analyzed in the whole blood of Canadian Health Measures Survey (CHMS) cycle 3 (2012-2013) participants aged 12 to 79 years. Benzene metabolites, t,t-MA and S-PMA, were analyzed in the urine of CHMS cycle 2 (2009-2011) and cycle 3 (2012-2013) participants aged 3 to 79 years. Data are presented as µg/L blood for benzene and µg/L and µg/g creatinine for t,t-MA and S-PMA. Finding a measurable amount of benzene in blood or t,t-MA and S-PMA in urine can be an indicator of exposure to benzene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood benzene in the Canadian population.

Benzene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Statistics Canada, 2012; Wheeler et al., 2013; Zhu et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Benzene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 82 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2488	12.58	0.036 (0.025 - 0.050)	<LOD	0.039 (0.030 - 0.049)	0.15 (0.12 - 0.19)	0.24 (0.18 - 0.29)
Males	12-79	3 (2012-2013)	1245	11.57	0.037 (0.026 - 0.052)	<LOD	0.040 (0.030 - 0.049)	0.15 (0.13 - 0.18)	0.24 (0.18 - 0.30)
Females	12-79	3 (2012-2013)	1243	13.60	0.035Table 82 footnote E (0.024 - 0.051)	<LOD	0.038 (0.028 - 0.049)	0.17Table 82 footnote E (0.093 - 0.24)	0.23Table 82 footnote E (0.11 - 0.35)
Total	12-19	3 (2012-2013)	750	14.00	0.028 (0.019 - 0.040)	<LOD	0.034 (0.025 - 0.043)	0.084 (0.063 - 0.10)	0.12 (0.076 - 0.16)
Total	20-39	3 (2012-2013)	548	10.40	0.037Table 82 footnote E (0.023 - 0.059)	Table 82 footnote F	0.040 (0.027 - 0.054)	0.13 (0.080 - 0.17)	0.18 (0.14 - 0.22)
Total	40-59	3 (2012-2013)	598	8.70	0.040 (0.030 - 0.055)	<LOD	0.039 (0.028 - 0.050)	0.23 (0.16 - 0.31)	0.40Table 82 footnote E (0.24 - 0.56)
Total	60-79	3 (2012-2013)	592	16.72	0.031Table 82 footnote E (0.021 - 0.047)	<LOD	0.038 (0.026 - 0.051)	0.13 (0.085 - 0.17)	0.20 (0.16 - 0.24)
Table 82 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 82 footnote a referrer Table 82 footnote E Use data with caution. Return to table 82 footnote E referrer Table 82 footnote F Data is too unreliable to be published. Return to table 82 footnote F referrer

S-Phenylmercapturic acid ( S-PMA) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 83 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2525	22.10	0.20 (0.18 - 0.23)	<LOD	0.12 (0.095 - 0.15)	1.3 (0.85 - 1.7)	3.5 (2.5 - 4.5)
Total	3-79	3 (2012-2013)	2472	34.67	0.17 (0.14 - 0.21)	<LOD	0.10Table 83 footnote E (<LOD - 0.16)	Table 83 footnote F	3.4 (2.3 - 4.5)
Males	3-79	2 (2009-2011)	1267	20.21	0.23 (0.20 - 0.26)	<LOD	0.13 (0.10 - 0.16)	Table 83 footnote F	3.9Table 83 footnote E (2.5 - 5.4)
Males	3-79	3 (2012-2013)	1223	31.07	0.20 (0.16 - 0.25)	<LOD	0.19Table 83 footnote E (0.080 - 0.30)	1.9Table 83 footnote E (0.51 - 3.3)	4.0 (2.7 - 5.3)
Females	3-79	2 (2009-2011)	1258	24.01	0.18 (0.15 - 0.22)	<LOD	0.11 (<LOD - 0.14)	1.1Table 83 footnote E (0.66 - 1.6)	2.5Table 83 footnote E (0.89 - 4.1)
Females	3-79	3 (2012-2013)	1249	38.19	0.14 (0.10 - 0.19)	<LOD	0.099 (<LOD - 0.12)	Table 83 footnote F	3.3Table 83 footnote E (1.4 - 5.2)
Total	3-5	2 (2009-2011)	507	20.32	0.15 (0.13 - 0.17)	<LOD	0.12 (0.094 - 0.14)	0.40 (0.29 - 0.52)	0.64Table 83 footnote E (0.40 - 0.88)
Total	3-5	3 (2012-2013)	491	28.51	0.11 (0.10 - 0.12)	<LOD	0.099 (0.096 - 0.10)	0.32 (0.26 - 0.37)	0.51Table 83 footnote E (0.30 - 0.72)
Total	6-11	2 (2009-2011)	511	25.24	0.14 (0.11 - 0.17)	<LOD	0.099 (0.083 - 0.12)	0.38 (0.28 - 0.49)	0.58Table 83 footnote E (0.33 - 0.82)
Total	6-11	3 (2012-2013)	491	38.90	0.099 (0.084 - 0.12)	<LOD	0.099 (0.092 - 0.11)	0.31 (0.23 - 0.39)	0.41 (0.35 - 0.47)
Total	12-19	2 (2009-2011)	506	18.97	0.17 (0.15 - 0.20)	<LOD	0.13 (0.094 - 0.16)	0.62 (0.45 - 0.79)	1.1Table 83 footnote E (0.53 - 1.6)
Total	12-19	3 (2012-2013)	497	32.19	0.14 (0.11 - 0.19)	<LOD	0.10Table 83 footnote E (<LOD - 0.15)	Table 83 footnote F	2.3Table 83 footnote E (0.74 - 4.0)
Total	20-39	2 (2009-2011)	355	19.44	0.21 (0.17 - 0.27)	<LOD	0.12 (<LOD - 0.16)	1.4 (1.1 - 1.8)	3.0Table 83 footnote E (1.5 - 4.5)
Total	20-39	3 (2012-2013)	345	35.07	0.20Table 83 footnote E (0.14 - 0.30)	<LOD	0.17Table 83 footnote E (<LOD - 0.29)	Table 83 footnote F	3.3Table 83 footnote E (1.4 - 5.3)
Total	40-59	2 (2009-2011)	359	25.91	0.24 (0.18 - 0.30)	<LOD	0.13Table 83 footnote E (<LOD - 0.20)	2.9Table 83 footnote E (1.1 - 4.7)	5.2Table 83 footnote E (3.2 - 7.3)
Total	40-59	3 (2012-2013)	306	35.62	0.20Table 83 footnote E (0.14 - 0.30)	<LOD	0.17Table 83 footnote E (<LOD - 0.29)	Table 83 footnote F	3.4Table 83 footnote E (1.8 - 5.0)
Total	60-79	2 (2009-2011)	287	23.69	0.19 (0.15 - 0.23)	<LOD	0.12 (0.094 - 0.15)	1.1Table 83 footnote E (0.57 - 1.7)	3.4Table 83 footnote E (1.3 - 5.4)
Total	60-79	3 (2012-2013)	342	39.77	0.14 (0.11 - 0.18)	<LOD	0.093 (0.087 - 0.099)	Table 83 footnote F	5.1Table 83 footnote E (2.0 - 8.3)
Table 83 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 83 footnote a referrer Table 83 footnote E Use data with caution. Return to table 83 footnote E referrer Table 83 footnote F Data is too unreliable to be published. Return to table 83 footnote F referrer

S-Phenylmercapturic acid ( S-PMA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 84 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2515	22.10	0.20 (0.17 - 0.24)	<LOD	0.19 (0.12 - 0.26)	1.2Table 84 footnote E (0.62 - 1.8)	3.1 (2.0 - 4.2)
Total	3-79	3 (2012-2013)	2471	34.67	0.18 (0.15 - 0.22)	<LOD	0.14 (0.11 - 0.16)	1.4Table 84 footnote E (0.86 - 2.0)	2.9 (1.9 - 4.0)
Males	3-79	2 (2009-2011)	1263	20.21	0.19 (0.16 - 0.23)	<LOD	0.13Table 84 footnote E (<LOD - 0.20)	1.8Table 84 footnote E (0.84 - 2.8)	3.0Table 84 footnote E (1.0 - 5.0)
Males	3-79	3 (2012-2013)	1223	31.07	0.17 (0.14 - 0.21)	<LOD	0.12 (0.089 - 0.16)	1.4 (0.94 - 1.9)	2.2Table 84 footnote E (1.2 - 3.3)
Females	3-79	2 (2009-2011)	1252	24.01	0.20 (0.16 - 0.26)	<LOD	0.19 (0.14 - 0.24)	0.91Table 84 footnote E (0.57 - 1.2)	3.1Table 84 footnote E (1.1 - 5.2)
Females	3-79	3 (2012-2013)	1248	38.19	0.18 (0.14 - 0.24)	<LOD	0.14 (0.12 - 0.16)	Table 84 footnote F	3.4Table 84 footnote E (1.7 - 5.1)
Total	3-5	2 (2009-2011)	506	20.32	0.26 (0.23 - 0.29)	<LOD	0.29 (0.19 - 0.39)	0.69 (0.56 - 0.82)	0.91 (0.71 - 1.1)
Total	3-5	3 (2012-2013)	490	28.51	0.22 (0.20 - 0.24)	<LOD	0.20 (0.16 - 0.24)	0.52 (0.39 - 0.65)	0.79Table 84 footnote E (0.50 - 1.1)
Total	6-11	2 (2009-2011)	509	25.24	0.15 (0.13 - 0.19)	<LOD	0.17Table 84 footnote E (<LOD - 0.28)	0.46 (0.31 - 0.61)	0.60 (0.40 - 0.80)
Total	6-11	3 (2012-2013)	491	38.90	0.13 (0.11 - 0.15)	<LOD	0.13 (0.10 - 0.15)	0.32 (0.27 - 0.37)	0.41 (0.36 - 0.45)
Total	12-19	2 (2009-2011)	504	18.97	0.13 (0.11 - 0.15)	<LOD	0.10 (0.091 - 0.11)	0.50 (0.34 - 0.66)	0.78Table 84 footnote E (0.50 - 1.1)
Total	12-19	3 (2012-2013)	497	32.19	0.11 (0.087 - 0.14)	<LOD	0.092 (<LOD - 0.11)	Table 84 footnote F	1.3Table 84 footnote E (0.59 - 2.0)
Total	20-39	2 (2009-2011)	353	19.44	0.19 (0.14 - 0.25)	<LOD	Table 84 footnote F	1.6Table 84 footnote E (0.59 - 2.6)	2.9Table 84 footnote E (1.7 - 4.1)
Total	20-39	3 (2012-2013)	345	35.07	0.15 (0.11 - 0.21)	<LOD	0.12 (0.081 - 0.16)	1.1Table 84 footnote E (0.43 - 1.8)	1.7Table 84 footnote E (0.86 - 2.6)
Total	40-59	2 (2009-2011)	357	25.91	0.23 (0.17 - 0.31)	<LOD	0.19 (0.13 - 0.24)	Table 84 footnote F	4.2Table 84 footnote E (1.5 - 7.0)
Total	40-59	3 (2012-2013)	306	35.62	0.24 (0.17 - 0.34)	<LOD	0.17 (0.12 - 0.23)	2.0Table 84 footnote E (0.60 - 3.5)	3.5Table 84 footnote E (1.8 - 5.3)
Total	60-79	2 (2009-2011)	286	23.69	0.21 (0.17 - 0.27)	<LOD	0.19 (0.15 - 0.23)	1.2Table 84 footnote E (0.55 - 1.9)	2.9Table 84 footnote E (1.3 - 4.5)
Total	60-79	3 (2012-2013)	342	39.77	0.17 (0.13 - 0.23)	<LOD	0.12 (0.080 - 0.16)	2.1Table 84 footnote E (0.64 - 3.5)	3.5Table 84 footnote E (2.2 - 4.9)
Table 84 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 84 footnote a referrer Table 84 footnote E Use data with caution. Return to table 84 footnote E referrer Table 84 footnote F Data is too unreliable to be published. Return to table 84 footnote F referrer

trans,trans-Muconic acid ( t,t-MA) - Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 85 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2523	0.20	64 (57 - 71)	15 (12 - 19)	59 (52 - 66)	330 (260 - 390)	500 (330 - 680)
Total	3-79	3 (2012-2013)	2492	0	56 (47 - 67)	14 (11 - 16)	53 (41 - 65)	250 (160 - 340)	400 (290 - 510)
Males	3-79	2 (2009-2011)	1267	0.24	68 (58 - 81)	19 (13 - 25)	66 (54 - 78)	340 (260 - 420)	480 (330 - 630)
Males	3-79	3 (2012-2013)	1231	0	64 (53 - 78)	17 (14 - 20)	59 (45 - 73)	260Table 85 footnote E (140 - 380)	400Table 85 footnote E (140 - 650)
Females	3-79	2 (2009-2011)	1256	0.16	59 (51 - 70)	13 (9.2 - 17)	56 (47 - 64)	320 (220 - 420)	610Table 85 footnote E (330 - 890)
Females	3-79	3 (2012-2013)	1261	0	49 (41 - 60)	11 (7.2 - 14)	46 (34 - 59)	230Table 85 footnote E (120 - 340)	430 (290 - 580)
Total	3-5	2 (2009-2011)	506	0.40	75 (63 - 90)	20 (15 - 24)	68 (52 - 83)	380Table 85 footnote E (220 - 540)	670 (510 - 840)
Total	3-5	3 (2012-2013)	489	0	65 (57 - 75)	14 (12 - 17)	51 (41 - 61)	440 (390 - 490)	730Table 85 footnote E (440 - 1000)
Total	6-11	2 (2009-2011)	511	0.20	71 (57 - 87)	17 (13 - 21)	63 (41 - 85)	380Table 85 footnote E (240 - 510)	540 (360 - 720)
Total	6-11	3 (2012-2013)	496	0	61 (49 - 75)	12 (7.3 - 16)	55 (39 - 71)	330Table 85 footnote E (200 - 470)	740Table 85 footnote E (220 - 1300)
Total	12-19	2 (2009-2011)	506	0	75 (61 - 92)	15Table 85 footnote E (8.4 - 21)	66 (47 - 85)	380 (290 - 480)	560 (440 - 680)
Total	12-19	3 (2012-2013)	506	0	65 (48 - 88)	13 (8.3 - 18)	61 (45 - 77)	360Table 85 footnote E (220 - 510)	670Table 85 footnote E (350 - 1000)
Total	20-39	2 (2009-2011)	355	0.56	62 (48 - 81)	13Table 85 footnote E (6.3 - 19)	70 (54 - 86)	310Table 85 footnote E (120 - 510)	610Table 85 footnote E (300 - 910)
Total	20-39	3 (2012-2013)	347	0	66 (46 - 95)	15Table 85 footnote E (9.0 - 22)	66Table 85 footnote E (40 - 92)	270Table 85 footnote E (140 - 400)	380Table 85 footnote E (160 - 590)
Total	40-59	2 (2009-2011)	359	0	65 (54 - 80)	17 (14 - 20)	57 (41 - 73)	310Table 85 footnote E (170 - 460)	470Table 85 footnote E (200 - 750)
Total	40-59	3 (2012-2013)	307	0	50 (39 - 65)	15Table 85 footnote E (8.4 - 21)	47 (32 - 61)	160Table 85 footnote E (73 - 240)	360Table 85 footnote E (130 - 590)
Total	60-79	2 (2009-2011)	286	0	54 (43 - 67)	14Table 85 footnote E (7.6 - 21)	52 (37 - 67)	240Table 85 footnote E (120 - 370)	400 (300 - 500)
Total	60-79	3 (2012-2013)	347	0	50 (40 - 62)	10Table 85 footnote E (4.5 - 16)	44 (34 - 55)	260Table 85 footnote E (70 - 460)	550Table 85 footnote E (170 - 930)
Table 85 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 85 footnote a referrer Table 85 footnote E Use data with caution. Return to table 85 footnote E referrer

trans,trans-Muconic acid ( t,t-MA) (creatinine adjusted) - Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011) and cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 86 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	2513	0.20	63 (58 - 70)	19 (16 - 21)	54 (48 - 60)	280 (230 - 340)	450 (370 - 520)
Total	3-79	3 (2012-2013)	2491	0	58 (51 - 66)	19 (17 - 21)	51 (43 - 58)	220 (160 - 280)	390 (270 - 510)
Males	3-79	2 (2009-2011)	1263	0.24	59 (50 - 69)	17 (15 - 19)	52 (40 - 63)	230 (150 - 320)	380 (280 - 480)
Males	3-79	3 (2012-2013)	1231	0	54 (48 - 60)	19 (16 - 21)	51 (44 - 57)	160Table 86 footnote E (97 - 210)	290Table 86 footnote E (110 - 470)
Females	3-79	2 (2009-2011)	1250	0.16	69 (61 - 77)	20 (17 - 23)	55 (48 - 63)	320 (240 - 400)	490 (320 - 650)
Females	3-79	3 (2012-2013)	1260	0	63 (54 - 74)	19 (16 - 22)	51 (39 - 62)	270 (190 - 340)	460 (300 - 630)
Total	3-5	2 (2009-2011)	505	0.40	130 (110 - 160)	36 (31 - 41)	110 (87 - 130)	590 (420 - 750)	990Table 86 footnote E (580 - 1400)
Total	3-5	3 (2012-2013)	488	0	130 (110 - 150)	34 (31 - 37)	87 (70 - 100)	910 (650 - 1200)	1500Table 86 footnote E (810 - 2100)
Total	6-11	2 (2009-2011)	509	0.20	82 (68 - 99)	24 (20 - 28)	69 (52 - 87)	380 (290 - 470)	490 (360 - 620)
Total	6-11	3 (2012-2013)	496	0	78 (65 - 93)	21 (18 - 23)	65 (55 - 75)	380Table 86 footnote E (220 - 530)	720Table 86 footnote E (260 - 1200)
Total	12-19	2 (2009-2011)	504	0	57 (48 - 69)	18 (15 - 20)	43 (29 - 57)	320 (230 - 410)	410 (340 - 490)
Total	12-19	3 (2012-2013)	506	0	49 (40 - 61)	15 (13 - 17)	38 (27 - 49)	230Table 86 footnote E (140 - 310)	450 (290 - 600)
Total	20-39	2 (2009-2011)	353	0.56	55 (46 - 66)	16 (14 - 19)	48 (36 - 60)	270Table 86 footnote E (120 - 420)	430 (300 - 570)
Total	20-39	3 (2012-2013)	347	0	50 (38 - 66)	16 (10 - 21)	46Table 86 footnote E (22 - 70)	160 (120 - 200)	240Table 86 footnote E (90 - 390)
Total	40-59	2 (2009-2011)	357	0	66 (53 - 82)	19 (14 - 23)	54 (37 - 71)	270 (200 - 340)	Table 86 footnote F
Total	40-59	3 (2012-2013)	307	0	59 (47 - 75)	22 (19 - 24)	54 (41 - 66)	190Table 86 footnote E (95 - 280)	290Table 86 footnote E (120 - 450)
Total	60-79	2 (2009-2011)	285	0	63 (54 - 73)	20 (18 - 23)	55 (44 - 65)	220Table 86 footnote E (120 - 330)	400Table 86 footnote E (210 - 590)
Total	60-79	3 (2012-2013)	347	0	57 (48 - 70)	20 (18 - 23)	43 (32 - 53)	Table 86 footnote F	490Table 86 footnote E (220 - 760)
Table 86 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 86 footnote a referrer Table 86 footnote E Use data with caution. Return to table 86 footnote E referrer Table 86 footnote F Data is too unreliable to be published. Return to table 86 footnote F referrer

Ethylbenzene

Ethylbenzene (CASRN 100-41-4) is a colourless liquid and a volatile organic compound (VOC). It is a high-production volume industrial chemical produced commercially primarily by alkylating benzene with ethylene (ATSDR, 2010a; IARC, 2000). The quantity of ethylbenzene manufactured in Canada has remained relatively stable since 1999 (Environment Canada & Health Canada, 2014a).

Major uses of ethylbenzene include manufacturing of styrene and synthetic rubber (ATSDR, 2010a; Environment Canada & Health Canada, 2014a; IARC, 2000). It is also used in the production of diethylbenzene, acetophenone, and other chemicals, as a solvent in the semiconductor industry, and as a general solvent used in manufactured products (ATSDR, 2010a). Ethylbenzene is a constituent of asphalt, naphtha, and automotive and aviation fuels, including gasoline which typically contains about 2% ethylbenzene by weight (ATSDR, 2010a). Commercial mixed xylenes contain ethylbenzene at levels up to 25% and, as such, ethylbenzene may be present in significant amounts in some paints, including spray paints and primers, lacquers, printing inks, insecticides, and solvents comprising xylenes (ATSDR, 2010a; Environment Canada & Health Canada, 2014a; IARC, 2000).

Ethylbenzene is released to the environment, primarily to the atmosphere, from natural and anthropogenic sources. It has been measured in emissions from volcanoes, forest fires, crude petroleum, and coal deposits (ATSDR, 2010a; Environment Canada & Health Canada, 2014a; IARC, 2000). Anthropogenic sources include the manufacture, processing, storage, use, transportation and disposal of fuels, solvents, petrochemicals, and polymers. Releases of ethylbenzene to air, especially as a product of fuel combustion, may be increasing as well, with increasing population and demand for energy (Environment Canada & Health Canada, 2014a).

For the general population, most exposure to ethylbenzene originates from the inhalation of indoor air (Environment Canada & Health Canada, 2014a; Health Canada, 2007b). Inside residences, ethylbenzene levels in air have been shown to be higher for homes with a garage on the property, with a higher number of occupants, with recent renovations, and in which fragrances and paint remover have been recently used (Wheeler et al., 2013). Use of consumer products such as lacquers, stains, varnishes, and concrete floor sealers can also result in inhalation exposures of short duration but potentially high concentration. Although cigarette smoke may contribute to the concentration of ethylbenzene in the home, it is unlikely a significant source (Environment Canada & Health Canada, 2014a; Health Canada, 2010i). Various other marketplace products containing ethylbenzene can also contribute to its presence in indoor air (ATSDR, 2010a; Environment Canada & Health Canada, 2014a). Although ethylbenzene has been detected in outdoor air, drinking water, soil, and food, they are not considered to constitute major sources of exposure for the general population (Health Canada, 2007b).

Following inhalation, oral, and dermal exposures, ethylbenzene is readily absorbed and distributed throughout the body (ATSDR, 2010a; IARC, 2000). Absorption of ethylbenzene by inhalation is approximately 49% to 64%, in humans (ATSDR, 2010a). Once absorbed, ethylbenzene is eliminated from the blood and body mostly in the urine with minor amounts exhaled in the breath, and has an elimination half-life ranging from less than 1 to 25 hours (ATSDR, 2010a). Following oral exposure, absorption of ethylbenzene is approximately 72% to 92% in laboratory animals and elimination is rapid, occurring predominantly via urinary excretion (ATSDR, 2010a). In contrast, following uptake through the skin only a small proportion of absorbed ethylbenzene is eliminated in the urine and none in exhaled air (ATSDR, 2010a). Ethylbenzene levels in blood are the most accurate biomarker of ethylbenzene exposure and are reflective of recent exposures (ATSDR, 2010a).

In humans, ethylbenzene can be irritating to the eyes, nose, throat, lungs, and skin, and it has been associated with symptoms of headaches, dizziness, vertigo, and feelings of intoxication (ATSDR, 2010a; Environment Canada & Health Canada, 2014a). Acute inhalation exposure has been generally associated with reversible neurological symptoms and respiratory tract irritation whereas chronic exposure has been associated with impaired neurological function, including cognitive and neuromuscular performance (ATSDR, 2010a; Environment Canada & Health Canada, 2014a). Studies in laboratory animals exposed by inhalation to ethylbenzene provide supporting evidence for central nervous system effects, neuromuscular and behavioural changes, and hearing loss (ATSDR, 2010a; Environment Canada & Health Canada, 2014a). In laboratory animals, chronic exposure to high levels of ethylbenzene in air and via the oral route has been associated with kidney and liver damage, some minor developmental effects, and effects in blood, pituitary, thyroid, and respiratory tissues (ATSDR, 2010a; Environment Canada & Health Canada, 2014a). Ethylbenzene is classified as possibly carcinogenic to humans (Group 2B carcinogen) according to the International Agency for Research on Cancer (IARC, 2000). However, the more recent evaluation by Health Canada and Environment Canada concludes that ethylbenzene is likely to be a non-linear threshold carcinogen, indicating that there is a threshold below which tumour formation would not be expected (Environment Canada & Health Canada, 2014a).

Health Canada and Environment Canada have jointly reviewed ethylbenzene in a draft screening assessment and have proposed to conclude that it is entering or may enter the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health (Environment Canada & Health Canada, 2014a). Following from this, as part of the proposed risk management plan for ethylbenzene, the Government of Canada is considering risk management activities to minimize releases of ethylbenzene during the indoor use of lacquers, stains, varnishes, and concrete floor sealers (Environment Canada & Health Canada, 2014b).

The Government of Canada has also taken a number of actions to address VOCs, a large class of compounds that includes ethylbenzene. As a class, they are environmental and health concerns because of their contribution to the formation of smog. The Government of Canada has taken and proposed a number of actions to address VOC emissions resulting from the use of consumer and commercial products in Canada (Canada, 2009a; Canada, 2009b; Environment Canada, 2002; Environment Canada, 2013b).

The current guideline for Canadian drinking water quality for ethylbenzene establishes an aesthetic objective for ethylbenzene based on its odour threshold (Health Canada, 1986d; Health Canada, 2012e). This guideline was deemed protective for acute exposure, but a health-based value has not yet been established (Health Canada, 2012e). Recently, Health Canada released for public comment a revised guideline technical document by the Federal-Provincial-Territorial Committee on Drinking Water, based on the most current available scientific information on ethylbenzene (Health Canada, 2014e). A final guideline technical document is expected to be available in the summer of 2015.

Ethylbenzene was analyzed in the whole blood of Canadian Health Measures Survey (CHMS) participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood. Finding a measurable amount of ethylbenzene in blood can be an indicator of recent exposure to ethylbenzene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood ethylbenzene in the Canadian population.

Ethylbenzene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Statistics Canada, 2012; Wheeler et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Ethylbenzene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 87 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2441	17.90	0.026 (0.020 - 0.033)	<LOD	0.025 (0.017 - 0.033)	0.084 (0.070 - 0.098)	0.12 (0.095 - 0.15)
Males	12-79	3 (2012-2013)	1212	17.49	0.028 (0.022 - 0.034)	<LOD	0.026 (0.018 - 0.034)	0.088 (0.063 - 0.11)	0.14 (0.096 - 0.18)
Females	12-79	3 (2012-2013)	1229	18.31	0.025 (0.018 - 0.033)	<LOD	0.025 (0.016 - 0.033)	0.080 (0.057 - 0.10)	0.11 (0.076 - 0.14)
Total	12-19	3 (2012-2013)	731	19.84	0.020 (0.016 - 0.027)	<LOD	0.021 (0.015 - 0.027)	0.064 (0.044 - 0.084)	0.081 (0.056 - 0.11)
Total	20-39	3 (2012-2013)	532	17.29	0.026 (0.019 - 0.035)	<LOD	0.026Table 87 footnote E (0.012 - 0.041)	0.077Table 87 footnote E (0.040 - 0.11)	0.12Table 87 footnote E (0.058 - 0.17)
Total	40-59	3 (2012-2013)	591	14.89	0.029 (0.024 - 0.037)	<LOD	0.027 (0.020 - 0.034)	0.10 (0.082 - 0.12)	0.14 (0.10 - 0.18)
Total	60-79	3 (2012-2013)	587	19.08	0.025 (0.019 - 0.032)	<LOD	0.024 (0.016 - 0.032)	0.079 (0.064 - 0.094)	0.12Table 87 footnote E (0.062 - 0.17)
Table 87 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 87 footnote a referrer Table 87 footnote E Use data with caution. Return to table 87 footnote E referrer

Styrene

Styrene (CASRN 100-42-5) is a colourless liquid classified as a volatile organic compound (VOC) and a high-production volume industrial chemical. Styrene was first recovered by distillation of a natural resin (storax balsam), sapwood, and bark tissues of trees (ATSDR, 2010b; IARC, 2002).

Styrene has been synthetically produced since the early 19th century and is a well-known impurity of coal tar industrial processing and petroleum cracking (IARC, 2002). Styrene is available as a commercial product and is used worldwide in the manufacture of plastics, glass fiber-reinforced resins, protective coatings, ion-exchange resins, and synthetic rubber (ATSDR, 2010b; IARC, 2002). Commercial styrene contains several components, including benzene, ethylbenzene, xylene, and other VOCs (IARC, 2002). In Canada, industrial uses of styrene include the manufacture of polystyrene, styrene-butadiene latex and rubber, acrylonitrile-butadiene styrene resins, and unsaturated polyester resins (Environment Canada & Health Canada, 1993d). Styrene-based polymer materials are used in the manufacturing of a wide range of products, most of which also contain a small amount of unlinked styrene monomer (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). Examples of products made with or containing styrene include foam insulation, automobile tires, packaging materials, custom mouldings, waxes and surface coatings, adhesives, and metal cleaners (ATSDR, 2010b; Environment Canada & Health Canada, 1993d).

Styrene is released to the environment from natural and anthropogenic sources. Styrene releases to the environment are mainly atmospheric and occur as a result of the manufacture, use, and disposal of styrene-containing products, industrial releases, vehicle exhaust, incineration, and tobacco smoke (Environment Canada & Health Canada,1993d; ATSDR, 2010b). Production, use, and disposal of styrene and styrene-containing products can also result in releases to the aquatic environment via wastewater. Natural sources of styrene releases to the environment include biodegradation of vegetation and organic material (ATSDR, 2010b; Environment Canada & Health Canada, 1993d).

The most common route of exposure to styrene in the general population is inhalation, with levels of styrene often higher in indoor air than outdoor (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). Styrene is a minor and natural component of tobacco smoke, and tobacco smoke is the major contributor to the total styrene exposure in smokers (Environment Canada & Health Canada, 1993d; Zhu et al., 2013). In addition to tobacco smoke, common sources of styrene present in air are automobile exhaust, the use and manufacturing of styrene, and the use of photocopiers and laser printers (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). Further, it is not uncommon for short-term inhalation exposures to styrene to occur as a result of indoor air releases from new building materials made with polymer resins, synthetic rubbers, laminated materials, and from fresh adhesives and surface coatings. Additional exposures in the general population may occur through ingestion of food and beverages; however, most styrene associated with food is residue of styrene monomer leached from packaged food in polystyrene containers (ATSDR, 2010b; Genualdi et al, 2014). Intake of styrene from drinking water is generally negligible (Environment Canada & Health Canada, 1993d). Exposure through skin and eye contact can also occur when handling liquid styrene-containing products.

Styrene is readily absorbed and distributed throughout the body following inhalation, with the highest concentrations measured in adipose tissue (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). Following oral exposure in laboratory animals, styrene absorption was rapid and complete with distribution to the kidney, liver, pancreas, adipose tissue and, to a lesser extent, the stomach, and small and large intestines (ATSDR, 2010b). Styrene absorbed into the body was rapidly eliminated from all tissues within 1 to 3 days (ATSDR, 2010b). Half-lives are estimated to range between 1 and 13 hours depending on the phase of elimination; in adipose tissue, an elimination half-life of 2 to 5 days has been estimated (ATSDR, 2010b). In humans, approximately 97% of the styrene absorbed is excreted as urinary metabolites, with the remainder eliminated unchanged in expired air (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). The primary intermediate metabolite of styrene is styrene-7, 8-oxide, which is hydrolyzed to styrene glycol and further metabolized to mandelic and phenylglyoxylic acids, the principal urinary metabolites (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). The major site of styrene metabolism is the liver. At high exposures that saturate metabolic enzymes, increased amounts of unchanged styrene are excreted in expired air (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). In laboratory animals, following oral exposure styrene was rapidly excreted in urine with 90% eliminated within 24 hours, and less than 2% in the feces (ATSDR, 2010b). The most reliable biomarker of recent exposure to styrene is measurement of styrene in blood, urine, and breath (ATSDR, 2010b).

Acute exposure to styrene is irritating to the eyes, nose, and throat, and induces dermatitis (ATSDR, 2010b; IARC, 2002). In humans, acute exposure to high levels of styrene in air is associated with central nervous system effects, including nausea, headache, tiredness, and concentration problems, similar to the narcotic effects of other organic solvents; effects are generally reversible after the source of exposure is eliminated (ATSDR, 2010b; Environment Canada & Health Canada, 1993d). Chronic exposure to styrene is associated with central and peripheral nervous system effects, slower reaction times, decreased colour discrimination, hearing problems, altered hand-eye coordination, and impairment of verbal learning skills (ATSDR, 2010b; ATSDR, 2012c; IARC, 2002). Whether chronic styrene exposure results in permanent damage to the nervous system in humans has not been determined (ATSDR, 2010b). Data from studies in humans and laboratory animals exposed via inhalation and the oral route to high levels of styrene also suggest styrene can be immunosuppressive (ATSDR, 2010b; Environment Canada & Health Canada, 1993d; IARC, 2002). Chronic exposure to high levels of styrene in air in the presence of other chemicals, including carcinogens, has been weakly associated with lymphomas and other cancers and chromosomal alterations (ATSDR, 2010b; IARC, 2002). Styrene has been classified as possibly carcinogenic to humans, on the basis of limited evidence in animals and humans by Environment Canada and Health Canada (Group III) and the International Agency for Research on Cancer (IARC; Group 2B) (Environment Canada & Health Canada, 1993d; IARC, 2002). The styrene primary intermediate metabolite styrene-7, 8-oxide is classified by IARC as a Group 2A carcinogen, probably carcinogenic to humans (IARC, 2002). Recently, the U.S. National Toxicology Program listed styrene as reasonably anticipated to be a human carcinogen based on human cancer studies, laboratory animal studies, and supporting mechanistic data (ATSDR, 2011; NTP, 2011).

Health Canada and Environment Canada concluded that levels of styrene normally found in the Canadian environment are not a concern to human health (Environment Canada & Health Canada, 1993d). Styrene is also part of a larger class of compounds called VOCs that, as a group, are environmental and health concerns because of their contribution to the formation of smog. The Government of Canada has taken and proposed a number of actions to address VOC emissions resulting from the use of consumer and commercial products in Canada (Canada, 2009a; Canada, 2009b; Environment Canada, 2002; Environment Canada, 2013b). Because styrene has not been detected in Canadian drinking water supplies, no guideline for Canadian drinking water quality has been established by the Federal-Provincial-Territorial Committee on Drinking Water.

Styrene was analyzed in the whole blood of Canadian Health Measures Survey (CHMS) participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood. Finding a measurable amount of styrene in blood can be an indicator of exposure to styrene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood styrene in the Canadian population.

Styrene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Zhu et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Styrene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 88 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2063	7.61	0.043Table 88 footnote E (0.029 - 0.062)	Table 88 footnote F	0.043 (0.030 - 0.055)	0.12 (0.076 - 0.16)	0.17Table 88 footnote E (0.10 - 0.23)
Males	12-79	3 (2012-2013)	1036	6.95	0.043Table 88 footnote E (0.029 - 0.064)	Table 88 footnote F	0.045 (0.033 - 0.057)	0.12 (0.079 - 0.15)	0.17Table 88 footnote E (0.099 - 0.24)
Females	12-79	3 (2012-2013)	1027	8.28	0.042Table 88 footnote E (0.028 - 0.061)	Table 88 footnote F	0.041 (0.028 - 0.055)	0.11Table 88 footnote E (0.062 - 0.17)	0.16Table 88 footnote E (0.092 - 0.23)
Total	12-19	3 (2012-2013)	626	8.47	0.037Table 88 footnote E (0.024 - 0.057)	Table 88 footnote F	0.040 (0.029 - 0.052)	0.094Table 88 footnote E (0.029 - 0.16)	0.15Table 88 footnote E (0.063 - 0.24)
Total	20-39	3 (2012-2013)	435	7.36	0.043Table 88 footnote E (0.029 - 0.065)	<LOD	0.043Table 88 footnote E (0.024 - 0.061)	0.12Table 88 footnote E (0.055 - 0.18)	0.18Table 88 footnote E (0.10 - 0.26)
Total	40-59	3 (2012-2013)	493	5.68	0.045Table 88 footnote E (0.031 - 0.066)	0.016Table 88 footnote E (<LOD - 0.026)	0.044 (0.032 - 0.056)	0.13 (0.090 - 0.16)	0.18Table 88 footnote E (0.11 - 0.25)
Total	60-79	3 (2012-2013)	509	8.64	0.041Table 88 footnote E (0.027 - 0.063)	Table 88 footnote F	0.044 (0.029 - 0.058)	0.11 (0.069 - 0.15)	0.14Table 88 footnote E (0.049 - 0.24)
Table 88 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 88 footnote a referrer Table 88 footnote E Use data with caution. Return to table 88 footnote E referrer Table 88 footnote F Data is too unreliable to be published. Return to table 88 footnote F referrer

Tetrachloroethylene (Perchloroethylene)

Tetrachloroethylene (CASRN 127-18-4), commonly known as perchloroethylene, is a colourless liquid classified as a volatile organic compound (Canada, 2011d; Canada, 2011e; Environment Canada & Health Canada, 1993e; IARC, 2014). It is an industrial chemical produced commercially by chlorination of other hydrocarbons, including acetylene, via trichloroethylene (IARC, 2014). The use of tetrachloroethylene has changed over the years. In the mid-20th century, tetrachloroethylene was primarily used in the dry-cleaning industry and was the primary organic solvent used for vapour degreasing in metal-cleaning operations (IARC, 2014). In the 1980s, changes in use coincided with the introduction of environmental regulations and improved technology controls in Canada and internationally (Canada, 2011d; Canada, 2011e; IARC, 2014). Since the 1990s, the most common use of tetrachloroethylene was as a feedstock for producing fluorocarbons (IARC, 2014). However, under the Montreal Protocol on Substances that Deplete the Ozone layer, the production of chlorofluorocarbons is being phased out by 2030 (IARC, 2014; UNEP, 2007). In Canada, tetrachloroethylene production ceased in 1992 and, since then, importation has continued primarily for domestic use as a chemical feedstock and as a solvent in the dry-cleaning and metal-cleaning industries (Environment Canada & Health Canada, 1993e; Health Canada, 1996b).

Releases of tetrachloroethylene are mainly to the atmosphere by evaporative losses from anthropogenic sources (ATSDR, 1997a; Environment Canada & Health Canada, 1993e). Production, use, and disposal of tetrachloroethylene and tetrachloroethylene-containing products can also result in releases to the environment via wastewater. A small amount of tetrachloroethylene is produced naturally in the environment by marine algae (Abrahamsson et al., 1995).

The primary route of exposure to tetrachloroethylene for the general population is through inhalation of indoor air containing tetrachloroethylene emitted by freshly dry-cleaned clothes, automotive products, and other consumer products containing tetracholroethylene (Environment Canada & Health Canada, 1993e). Tetrachloroethylene has been detected in drinking water; the ingestion of drinking water is, generally, a minor contributor to overall tetrachloroethylene exposure (Environment Canada & Health Canada, 1993e). Exposure can also occur during the use of consumer products containing tetrachloroethylene, and from ambient air and food (ATSDR, 1997a; Environment Canada & Health Canada, 1993e). Living near a dry-cleaning facility may also increase the potential for exposure (ATSDR, 1997a; CDC, 2009; IARC, 2014).

Tetrachloroethylene is rapidly absorbed into the blood and is distributed throughout the body with some concentration in adipose tissue (ATSDR, 1997a; Environment Canada & Health Canada, 1993e; IARC, 2014). Tetrachloroethylene is metabolized in the kidney, liver, and lungs forming the major metabolite trichloroacetic acid (TCA) and other minor metabolites including trichloroethanol (IARC, 2014). Absorbed tetrachloroethylene is rapidly eliminated unchanged from the body within minutes and hours via exhalation, followed by a slower excretion of metabolites in urine (IARC, 2014). The half-lives of tetrachloroethylene in vessel-rich tissue, muscle tissue, and adipose tissue are estimated to be 12 to 16 hours, 30 to 40 hours, and 55 hours, respectively (ATSDR, 1997a). Tetrachloroethylene metabolites can be measured in urine whereas tetrachloroethylene can be measured in exhaled air and blood; the latter is considered the most reliable biomarker of recent exposure (ATSDR, 1997a; IARC, 2014).

Exposure to tetrachloroethylene is known to cause a number of health effects in humans. Acute exposure via inhalation, ingestion, and skin contact can result in irritation of membranes (ATSDR, 1997a). At very high concentrations, acute inhalation and oral exposure to tetrachloroethylene can induce atrophy of olfactory nerves, tremors, and central nervous system depression, as well as kidney and liver dysfunction in laboratory animals; these symptoms are similar to those observed in humans following accidental poisonings and solvent abuse (ATSDR, 1997a; Environment Canada & Health Canada, 1993e). Tetrachloroethylene exposure is also associated with narcotic and anesthetic effects increasing in severity with increasing exposure (ATSDR, 1997a; Environment Canada & Health Canada, 1993e; EPA, 2012). These neurological symptoms may be reversible following cessation of acute exposure; however, chronic exposures may result in more persistent neurological impairments (ATSDR, 1997a; Environment Canada & Health Canada, 1993e; IARC, 2014). Multiple cancer sites of interest have been evaluated by the International Agency for Research (IARC) on Cancer Expert Working Group and positive associations for cancer of the bladder in humans are consistently found (IARC, 2014). Tetrachloroethylene has been classified by IARC as probably carcinogenic to humans (Group 2A), on the basis of limited evidence in humans and sufficient evidence in laboratory animals, and as possibly carcinogenic to humans (Group III) by Environment Canada and Health Canada (Environment Canada & Health Canada, 1993e; IARC, 2014).

The Government of Canada conducted a scientific assessment on the impact of tetrachloroethylene exposure on humans and the environment and concluded that it is toxic to the environment, but not to human health, as per criteria set out under the Canadian Environmental Protection Act(Environment Canada & Health Canada, 1993e). Tetrachloroethylene is listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 and is a risk-managed substance involving a full life cycle management approach to prevent or minimize its release into the environment (Canada, 1999). In Canada, Regulations for Tetrachloroethylene Use in Dry Cleaning and Reporting Requirements have been introduced to reduce releases of tetrachloroethylene from dry-cleaning facilities (Canada, 2011d; Canada, 2011e). The Government of Canada has also introduced Solvent Degreasing Regulations to reduce total Canadian consumption of trichloroethylene and tetrachloroethylene used in solvent-degreasing operations (Canada, 2011e; Environment Canada, 2013c). Tetrachloroethylene is included as a prohibited ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist). The Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances, when present in a cosmetic, may contravene the general prohibition found in section 16 of the Food and Drugs Act or a provision of the Cosmetic Regulations (Canada, 1985; Health Canada, 2014b). In addition, Health Canada has developed a guideline for Canadian drinking water quality that establishes the maximum acceptable concentration for tetrachloroethylene in drinking water (Health Canada, 1996b). Recently, Health Canada published for public comment a revised guideline technical document by the Federal-Provincial-Territorial Committee on Drinking Water, based on the most current available scientific information on tetrachloroethylene (Health Canada, 2014f). A final guideline technical document is expected to be available in the Fall of 2015.

Tetrachloroethylene was analyzed in the whole blood of Canadian Health Measures Survey (CHMS) participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood. Finding a measurable amount of tetrachloroethylene in blood can be an indicator of exposure to tetrachloroethylene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood tetrachloroethylene in the Canadian population.

Tetrachloroethylene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Zhu et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Tetrachloroethylene (Perchloroethylene) - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 89 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2453	60.82	--	<LOD	<LOD	0.10 (0.067 - 0.14)	0.17Table 89 footnote E (0.10 - 0.23)
Males	12-79	3 (2012-2013)	1228	58.96	--	<LOD	<LOD	0.13 (0.086 - 0.17)	0.19 (0.13 - 0.25)
Females	12-79	3 (2012-2013)	1225	62.69	--	<LOD	<LOD	0.096Table 89 footnote E (0.060 - 0.13)	0.13Table 89 footnote E (0.039 - 0.22)
Total	12-19	3 (2012-2013)	739	60.76	--	<LOD	<LOD	Table 89 footnote F	Table 89 footnote F
Total	20-39	3 (2012-2013)	543	60.04	--	<LOD	<LOD	0.093Table 89 footnote E (0.052 - 0.13)	0.15Table 89 footnote E (0.080 - 0.23)
Total	40-59	3 (2012-2013)	587	65.08	--	<LOD	<LOD	0.10Table 89 footnote E (0.058 - 0.14)	0.13 (0.089 - 0.17)
Total	60-79	3 (2012-2013)	584	57.36	--	<LOD	<LOD	0.16Table 89 footnote E (0.062 - 0.25)	Table 89 footnote F
Table 89 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 89 footnote a referrer Table 89 footnote E Use data with caution. Return to table 89 footnote E referrer Table 89 footnote F Data is too unreliable to be published. Return to table 89 footnote F referrer

Toluene

Toluene (CASRN 108-88-3) is a colourless liquid and volatile organic compound (VOC). It is produced commercially, primarily through the conversion of petroleum to gasoline and other fuels or recovered as a by-product in the coke oven and styrene-manufacturing industries (ATSDR, 2000; Environment Canada & Health Canada, 1992).

Toluene is used widely as an industrial solvent and an intermediate in the production of a variety of chemicals. Major uses of toluene have included the manufacture of benzene, benzene derivatives, trinitrotoluene and toluene diisocyanate, and in the blending of gasoline fuels as octane boosters (ATSDR, 2000; CDC, 2009). It has also been widely used as a solvent in paints and finishes, adhesives, polymers and resins, dyes, automotive products, and some personal care products (ATSDR, 2000; Environment Canada & Health Canada, 1992; Health Canada, 2012c). The use of toluene in solvent-based products and processes has decreased as alternative formulations with lower VOC content, as well as alcohol-based and water-based products and processes, are now available.

Toluene is released to the environment from natural and anthropogenic sources. It has been measured in emissions from volcanoes, forest fires, natural gas deposits, and crude oil (ATSDR, 2000; Environment Canada & Health Canada, 1992). Anthropogenic sources of atmospheric toluene include primarily the volatilization of petroleum fuels, toluene-based solvents and thinners, motor vehicle exhaust, and the off-gassing of toluene from some building materials, consumer, and automotive products (ATSDR, 2000; Environment Canada & Health Canada, 1992). Toluene can also be released to the environment in waste from manufacturing and processing facilities, from spills and accidental releases, and from the disposal of toluene-containing products (ATSDR, 2000; CCME, 2004a; Environment Canada & Health Canada, 1992).

The general population is exposed to toluene mainly through the inhalation of indoor air (Health Canada, 2011e). Cigarette smoking may significantly increase exposure and, in smokers, inhalation of cigarette smoke is expected to be a major contributor to the total toluene exposure (ATSDR, 2000; Health Canada, 2011e; Health Canada, 2012h). Inside residences, toluene levels in air have been shown to be higher in newer homes and homes with a garage on the property and in homes where painting or paint remover has been used in the previous week (Wheeler et al., 2013). Toluene is also found in tobacco smoke, and regular smoking in the home is a significant predictor of toluene in indoor air (Health Canada, 2012h). Although toluene has been detected in drinking water and in certain foods, they are not considered to constitute major sources of exposure for the general population (Environment Canada & Health Canada, 1992).

Following inhalation, toluene is readily absorbed and distributed throughout the body (ATSDR, 2000; Environment Canada & Health Canada, 1992). The majority of absorbed toluene is rapidly eliminated from the body with a small amount in adipose tissues eliminated more slowly (ATSDR, 2000). Up to 20% of absorbed toluene is exhaled unchanged and less than 1% is excreted unchanged in the urine (ATSDR, 2000; Donald et al., 1991). The elimination of toluene following inhalation has half-lives ranging from less than 3 minutes to 12 hours in blood and from 0.5 to 3 days in subcutaneous adipose tissues of humans (ATSDR, 2000). Toluene levels in blood are the most accurate biomarker of toluene exposure and are reflective of recent exposure (ATSDR, 2000; CDC, 2009).

Toluene exposure can be irritating to the eye, nose, throat, lungs and skin, and has been associated with symptoms of headaches, dizziness, reduced coordination, and feelings of intoxication (ATSDR, 2000; CCOHS, 2013a; Health Canada, 2011e; Health Canada, 2012h; IARC, 1999b). Acute inhalation exposure has been generally associated with reversible neurological symptoms whereas chronic exposure is associated with impaired neurological function including cognitive and neuromuscular performance, as well as negative effects on colour vision and hearing (ATSDR, 2000; CCOHS, 2013a; CDC, 2009; Health Canada, 2011e; IARC, 1999b). Studies in laboratory animals exposed to toluene provide supporting evidence for behavioural changes, hearing loss and subtle changes in brain structure, brain electrophysiology and brain chemistry (ATSDR, 2000; Bowen & Hannigan, 2006; Gospe & Zhou, 2000). Exposure to high levels of toluene in humans during pregnancy has been associated with fetal toxicity and developmental effects in children, at levels associated with potential maternal toxicity such as in solvent abuse (ATSDR, 2000; Bowen & Hannigan, 2006; Donald et al., 1991; Yücel et al., 2008). Toluene carcinogenicity to humans is not classifiable according to the International Agency for Research on Cancer (Group 3) and the US Environmental Protection Agency (Group D) (EPA, 2005; IARC, 1999b).

Under the Canadian Environmental Protection Act, Health Canada and Environment Canada concluded that at current environmental concentrations, toluene is not a concern for human life or health (Environment Canada & Health Canada, 1992). Toluene is also part of a larger class of compounds called VOCs that, as a group, are environmental and health concerns because of their contribution to the formation of smog. The Government of Canada has taken and proposed a number of actions to address VOC emissions resulting from the use of consumer and commercial products in Canada (Canada, 2009a; Canada, 2009b; Environment Canada, 2002; Environment Canada, 2013b).

In 2011, Health Canada released a residential indoor air quality guideline for both short- and long-term exposure to toluene (Health Canada, 2011e). The current guideline for Canadian drinking water quality establishes aesthetic objectives for toluene based upon its odour threshold (Health Canada, 1986d; Health Canada, 2012e). This guideline was deemed protective of acute exposure, but a health-based value has not been established (Health Canada, 1986d; Health Canada, 2012e). Recently, Health Canada released for public comment a revised guideline technical document by the Federal-Provincial-Territorial Committee on Drinking Water, based on the most current available scientific information on toluene (Health Canada, 2014e). A final guideline technical document is expected to be available in the Summer of 2015.

Toluene was analyzed in the whole blood of Canadian Health Measures Survey participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood. Finding a measurable amount of toluene in blood can be an indicator of recent exposure to toluene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood toluene in the Canadian population.

Toluene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) ( Wheeler et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Toluene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 90 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2449	0.69	0.096 (0.083 - 0.11)	0.036 (0.030 - 0.042)	0.079 (0.067 - 0.090)	0.39 (0.32 - 0.46)	0.58 (0.46 - 0.71)
Males	12-79	3 (2012-2013)	1224	0.65	0.098 (0.081 - 0.12)	0.034 (0.025 - 0.043)	0.081 (0.066 - 0.095)	0.42 (0.33 - 0.51)	0.59 (0.42 - 0.77)
Females	12-79	3 (2012-2013)	1225	0.73	0.093 (0.081 - 0.11)	0.037 (0.034 - 0.041)	0.077 (0.064 - 0.089)	0.35 (0.24 - 0.46)	0.55Table 90 footnote E (0.34 - 0.76)
Total	12-19	3 (2012-2013)	732	0.55	0.074 (0.066 - 0.083)	0.034 (0.026 - 0.042)	0.070 (0.058 - 0.082)	0.19 (0.14 - 0.24)	0.26 (0.19 - 0.32)
Total	20-39	3 (2012-2013)	533	0.94	0.089 (0.069 - 0.11)	0.036 (0.028 - 0.045)	0.074 (0.050 - 0.098)	0.29Table 90 footnote E (0.16 - 0.43)	0.42Table 90 footnote E (0.23 - 0.61)
Total	40-59	3 (2012-2013)	594	0.51	0.12 (0.10 - 0.14)	0.041 (0.033 - 0.049)	0.085 (0.071 - 0.10)	0.58 (0.38 - 0.79)	0.86 (0.64 - 1.1)
Total	60-79	3 (2012-2013)	590	0.85	0.086 (0.070 - 0.11)	0.031 (0.024 - 0.039)	0.080 (0.065 - 0.096)	0.31 (0.22 - 0.40)	0.46 (0.39 - 0.53)
Table 90 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 90 footnote a referrer Table 90 footnote E Use data with caution. Return to table 90 footnote E referrer

Trichloroethylene

Trichloroethylene (CASRN 79-01-6) is a colourless liquid classified as a volatile organic compound. It has been produced commercially by chlorination of acetylene and ethylene since the 1920s (ATSDR, 1997b; IARC, 1995). There has been a general decline in demand for trichloroethylene over the years (Health Canada, 2005b; IARC, 2014). This decline may be due to several factors, including use of alternative solvents, an increase in solvent recovery/recycling by users, and the introduction of regulations and controls to address concerns about environmental, health, and safety implications of chlorinated solvents (Health Canada, 2005b; IARC, 2014). In Canada, production of trichloroethylene stopped in 1985 (Health Canada, 2005b). Since then, it continues to be imported for use primarily as a solvent in the vapour-degreasing and cold-cleaning of metal parts and, in smaller amounts, in dry-cleaning operations, specialty paints and paint removers, and various other household products (Environment Canada, 2013d; Environment Canada, 2013e; Health Canada, 2005b). Trichloroethylene is also used as a chemical intermediate in the production of other chemicals (IARC, 2014).

Trichloroethylene enters the environment primarily through evaporation from anthropogenic sources (ATSDR, 1997b; Environment Canada, 2013e). Although the majority of anthropogenic releases enter the atmosphere, production, use, and disposal of trichloroethylene and trichloroethylene-containing products can also result in releases to the environment via wastewater. A small amount of trichloroethylene is produced naturally in the environment by marine algae (Abrahamsson et al., 1995).

The most common exposure route to trichloroethylene for the general population is inhalation of indoor air containing trichloroethylene emitted from specialty paints, adhesives, and household products (CDC, 2009; Environment Canada & Health Canada, 1993f). Canadians may also be exposed to trichloroethylene through its presence in drinking water, air, and food (Health Canada, 2005b).

Following all routes of exposure, trichloroethylene is rapidly and nearly completely absorbed into the blood and distributed throughout the body (ATSDR, 1997b; Environment Canada & Health Canada, 1993f; EPA, 2011). Absorbed trichloroethylene is rapidly distributed mainly to the brain, kidney, liver, muscle, and adipose tissue (ATSDR, 1997b). Trichloroethylene is metabolized in the kidney, liver, and lungs forming the major metabolites trichloroacetic acid (TCA) and trichloroethanol (TCOH) (ATSDR, 1997b; EPA, 2011). Absorbed trichloroethylene is rapidly eliminated from the body, within minutes and hours, via exhalation of trichloroethylene and urinary excretion of the metabolites along with minimal amounts of unchanged trichloroethylene (ATSDR, 1997b; EPA, 2011). The most reliable biomarker of recent exposure to trichloroethylene is its measurement in blood and breath (ATSDR, 1997b; IARC, 1995). Measurement of the metabolites TCA and TCOH in blood and urine are less reliable because of intra-individual differences in urinary concentrations and a lack of specificity for trichloroethylene exposure (ATSDR, 1997b; IARC, 1995).

Exposure to trichloroethylene is known to cause a number of health effects in humans. Acute exposure via inhalation, ingestion, and skin contact can result in irritation of membranes (ATSDR, 1997b; Health Canada, 2005b; IARC, 1995). Trichloroethylene exposure is also associated with narcotic and anesthetic effects increasing in severity with increasing exposure (Environment Canada & Health Canada, 1993f; IARC, 1995). These neurological symptoms may be reversible following cessation of acute exposure; however, chronic exposures may result in more persistent neurological impairments (ATSDR, 1997b; Environment Canada & Health Canada, 1993f; EPA, 2011). Recently, the International Agency for Research on Cancer updated its classification for trichloroethylene to Group 1 carcinogenic to humans, on the basis of new and sufficient evidence for cancer of the kidney in humans, with strong support from studies in laboratory animals (IARC, 2014). A positive association has also been shown between trichloroethylene exposure and cancer of the liver and biliary tract, and non-Hodgkin lymphoma (EPA, 2011; IARC, 2014; WHO, 2000).

The Government of Canada conducted a scientific assessment on the impact of trichloroethylene exposure on humans and the environment and concluded that it may enter the environment in quantities or under conditions that may constitute a danger in Canada to human life or health as per criteria set out under the Canadian Environmental Protection Act (Environment Canada & Health Canada, 1993f). Trichloroethylene is listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (CEPA 1999) (Canada, 1999). Under CEPA 1999, the Government of Canada published Solvent Degreasing Regulations to reduce total Canadian consumption of trichloroethylene and tetrachloroethylene used in solvent-degreasing operations (Environment Canada, 2013c). Improvements have also been implemented in the commercial dry-cleaning industry to prevent and minimize releases of dry-cleaning solvents, particularly trichloroethylene and tetrachloroethylene (Canada, 2011d; Canada, 2011e; IARC, 2014). The current guideline for Canadian drinking water quality, established by the Federal-Provincial-Territorial Committee on Drinking Water, sets out the maximum acceptable concentration for trichloroethylene in drinking water (Health Canada, 2005b).

Trichloroethylene was analyzed in the whole blood of Canadian Health Measures Survey (CHMS) participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood. Finding a measurable amount of trichloroethylene in blood can be an indicator of exposure to trichloroethylene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood trichloroethylene in the Canadian population.

Trichloroethylene was also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Zhu et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

Trichloroethylene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 91 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2474	99.51	--	<LOD	<LOD	<LOD	<LOD
Males	12-79	3 (2012-2013)	1240	99.35	--	<LOD	<LOD	<LOD	<LOD
Females	12-79	3 (2012-2013)	1234	99.68	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	746	99.73	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	543	99.63	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	594	99.33	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	591	99.32	--	<LOD	<LOD	<LOD	<LOD
Table 91 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 91 footnote a referrer

Trihalomethanes

Disinfection by-products are a group of chemical compounds formed when water disinfection agents (e.g. chlorine, chloramines, ozone, chlorine dioxide) interact with organic precursors or bromide naturally present in water (CCME, 1999c; CDC, 2009; Health Canada, 2006c). Disinfection by-products include, among others, trihalomethanes (THMs), haloacetic acids, haloacetonitriles, haloketones, and chlorophenols. THM formation increases as a function of the concentration of chlorine and organic matter; in the presence of bromides, brominated THMs are formed (Health Canada, 2006c). In cycle 3 of the Canadian Health Measures Survey (CHMS), four THMs were measured: chloroform, bromoform, bromodichloromethane, and dibromochloromethane. Each of these compounds consists of three halogen groups attached to a single carbon atom and are classified as volatile organic compounds (CCME, 1999c). Chloroform is the most common THM and the most frequently measured disinfection by-product in chlorinated drinking water in Canada (ATSDR, 2005b; Health Canada, 2006c).

Trihalomethanes measured in the Canadian Health Measures Survey cycle 3 (2012-2013).

Trihalomethanes	CASRN
Bromodichloromethane	75-27-4
Dibromochloromethane	124-48-1
Tribromomethane (Bromoform)	75-25-2
Trichloromethane (Chloroform)	67-66-3

The four THMs are also commercially produced chemicals (ATSDR, 1999b; ATSDR, 2005b). Chloroform and bromodichloromethane are used as chemical intermediates in the manufacturing of organic chemicals and as solvents, although chloroform has not been manufactured in Canada since 1978 (ATSDR, 2005b; Health Canada, 2006c). In Canada, the use of chloroform as an anaesthetic has been discontinued and its use in dentifrices, liniments, and antitussives has been banned (CCME, 1999c; Environment Canada & Health Canada, 2000). Dibromochloromethane is used as an intermediate in the manufacture of refrigerants, pesticides, propellants, and other organic chemicals (Health Canada, 2006c). Bromoform is used as a solvent in the synthesis of pharmaceuticals and in fire-resistant chemicals, as well as gauge fluid used in the aircraft and shipbuilding industries (Health Canada, 2006c).

A small proportion of THMs present in the environment may be due to natural production by marine algae and natural degradation and transformation processes (ATSDR, 1999b; ATSDR, 2005b). Anthropogenic sources are generally considered to be larger contributors of THMs in the environment than natural ones. In Canada, the major anthropogenic sources of THMs are disinfected water from drinking water treatment plants, chlorinated effluents from municipal wastewater treatment plants and industrial plants, and cooling waters from power plants and industrial plants (Environment Canada & Health Canada, 1993g). Chlorine use in the treatment of drinking water has virtually eliminated waterborne diseases because of its ability to kill or inactivate most microorganisms commonly found in water (Health Canada, 2006c). It is used in the majority of drinking water treatment plants in Canada to treat the water directly in the treatment plant and/or to maintain a chlorine residual in the distribution system to prevent bacterial regrowth (Health Canada, 2006c). Effluent wastewaters are disinfected to protect downstream municipal water supplies, recreational waters, and shellfish-growing areas from bacterial contamination and other microorganisms causing water-borne disease (Environment Canada & Health Canada, 1993g). In addition to drinking water, disinfection effluents, and cooling waters, anthropogenic sources of THMs include chemical manufacturing plants and industrial sites, swimming pools, hot tubs, and water parks (ATSDR, 2005b; CCME, 1999c; Health Canada, 2006c).

The general population is exposed to THMs primarily by drinking chlorinated water (CDC, 2009; Environment Canada & Health Canada, 2000; Health Canada, 2006c). Exposure also occurs through inhalation during showering and bathing and by skin absorption during bathing and swimming (CDC, 2009; Health Canada, 2006c). Minor exposures may occur from the consumption of food and beverages (Health Canada, 2006c). Swimming pools and hot tubs are additional sources of THM exposure (Aggazzotti et al., 1998).

Following ingestion, all four THMs are rapidly absorbed into the blood and distributed throughout the body, primarily in the fat, blood, liver, kidney, lungs, and nervous system (ATSDR, 1989; Health Canada, 2006c; WHO, 2004). THMs are well absorbed following both oral and inhalation exposure, with dermal exposure as another potentially significant route of exposure (ATSDR, 1989; Health Canada, 2006c; IPCS, 2000; WHO, 2004). Estimated half-lives for THMs in the body generally range from 1.5 hours to 6 hours; about 95% of absorbed bromodichloromethane is eliminated from the body in 8 hours (ATSDR, 1989; Health Canada, 2006c; WHO, 2004). Absorbed THMs are mainly eliminated from the body by exhalation of unchanged compounds and volatile metabolites, with only minor amounts excreted in the urine, and less in the feces (Health Canada, 2006c; IPCS, 2000). Unchanged disinfection by-products measured in blood are the most accurate biomarkers of exposure to disinfection by-products and reflect recent exposures (CDC, 2009).

Each of the four THMs is irritating to the eye and respiratory tract, and acute inhalation exposure has been associated with reddening of the face (Health Canada, 2006c; IPCS, 2000; WHO, 2004). Acute high-level inhalation and oral exposures to these disinfection by-products in laboratory animals induce general narcotic and anesthetic effects increasing in severity with exposure level and are generally reversible following cessation of exposure (Health Canada, 2006c; IPCS, 2000; WHO, 2004). Some studies in laboratory animals indicate that THMs containing bromine, such as bromodichloromethane, may be more toxic than chloroform and other chlorine-containing disinfection by-products (Health Canada, 2006c). Chronic exposures to THMs in drinking water are weakly and inconsistently associated with cancer of liver, kidney, colon, rectal, brain, pancreas, and bladder (Health Canada, 2006c; IPCS, 2000; WHO, 2004). Results of studies in laboratory animals chronically exposed by the oral route to high levels of individual THMs provide supporting evidence of an association between cancers of the kidney, liver, and intestines with exposures to disinfection by-products (ATSDR, 1989; Health Canada, 2006c; WHO, 2004). Based upon available evidence in laboratory animals, chloroform and bromodichloromethane have been classified as possibly carcinogenic to humans (Group 2B) by the International Agency for Research on Cancer (IARC, 1999b; IARC, 1999c). There is insufficient evidence to determine whether or not bromoform, dibromochloromethane, and chlorinated drinking water are carcinogenic (IARC, 1991; IARC, 1999b).

Health Canada and Environment Canada have reviewed and assessed chlorinated wastewater effluents, defined as those effluents to which chlorine or chlorination agents are added for disinfection, under the Canadian Environmental Protection Act. The screening assessment concluded that chlorinated wastewater effluents discharged to the Canadian environment by municipal wastewater treatment plants are a concern for the environment (Environment Canada & Health Canada, 1993g). However, there is insufficient information to determine whether chlorinated wastewater effluents are harmful to human health. Chlorinated wastewater effluents are listed on Schedule 1, List of Toxic Substances, under the Canadian Environmental Protection Act, 1999 (Canada, 1999). Under Canada's Food and Drugs Act, manufacturers are not permitted to import or sell a drug for human use in Canada that contains chloroform (Canada, 2012c; Environment Canada & Health Canada, 2000).

The Federal-Provincial-Territorial Committee on Drinking Water has developed a guideline for Canadian drinking water quality that establishes a maximum acceptable concentration for total THMs (defined as the sum of chloroform, bromoform, dibromochloromethane, and bromodichloromethane) in drinking water (Health Canada, 2006c). The Canadian guideline states that utilities should make every effort to maintain concentrations as low as reasonably achievable without compromising the effectiveness of disinfection (Health Canada, 2006c). The approach to reducing THM exposure is generally focused on reducing the formation of chlorinated disinfection by-products. This can be achieved by removing organic matter from the water before chlorine is added, by optimizing the disinfection process or using alternative disinfection strategies, or by using a different water source.

Four THMs - chloroform, bromoform, dibromochloromethane, and bromodichloromethane - were analyzed in the whole blood of CHMS cycle 3 (2012-2013) participants aged 12 to 79 years. Data are presented as µg/L blood. Finding a measurable amount of THMs in blood can be an indicator of exposure to THMs and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood THMs in the Canadian population.

Bromodichloromethane - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 92 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2499	98.88	--	<LOD	<LOD	<LOD	<LOD
Males	12-79	3 (2012-2013)	1245	98.96	--	<LOD	<LOD	<LOD	<LOD
Females	12-79	3 (2012-2013)	1254	98.80	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	744	98.12	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	556	98.92	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	595	99.66	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	604	99.01	--	<LOD	<LOD	<LOD	<LOD
Table 92 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 92 footnote a referrer

Dibromochloromethane - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 93 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2527	97.07	--	<LOD	<LOD	<LOD	<LOD
Males	12-79	3 (2012-2013)	1263	96.52	--	<LOD	<LOD	<LOD	<LOD
Females	12-79	3 (2012-2013)	1264	97.63	--	<LOD	<LOD	<LOD	<LOD
Total	12-19	3 (2012-2013)	757	96.83	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	557	97.13	--	<LOD	<LOD	<LOD	0.015Table 93 footnote E (<LOD - 0.023)
Total	40-59	3 (2012-2013)	604	98.01	--	<LOD	<LOD	<LOD	<LOD
Total	60-79	3 (2012-2013)	609	96.39	--	<LOD	<LOD	<LOD	<LOD
Table 93 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 93 footnote a referrer Table 93 footnote E Use data with caution. Return to table 93 footnote E referrer

Tribromomethane (Bromoform) - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 94 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2496	94.79	--	<LOD	<LOD	<LOD	0.010Table 94 footnote E (<LOD - 0.015)
Males	12-79	3 (2012-2013)	1244	95.02	--	<LOD	<LOD	<LOD	0.012Table 94 footnote E (<LOD - 0.016)
Females	12-79	3 (2012-2013)	1252	94.57	--	<LOD	<LOD	<LOD	<LODTable 94 footnote E (<LOD - 0.013)
Total	12-19	3 (2012-2013)	744	94.49	--	<LOD	<LOD	<LOD	<LOD
Total	20-39	3 (2012-2013)	554	94.40	--	<LOD	<LOD	<LOD	<LOD
Total	40-59	3 (2012-2013)	595	96.47	--	<LOD	<LOD	<LOD	0.011Table 94 footnote E (<LOD - 0.016)
Total	60-79	3 (2012-2013)	603	93.86	--	<LOD	<LOD	<LOD	Table 94 footnote F
Table 94 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 94 footnote a referrer Table 94 footnote E Use data with caution. Return to table 94 footnote E referrer Table 94 footnote F Data is too unreliable to be published. Return to table 94 footnote F referrer

Trichloromethane (Chloroform) - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 95 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2527	77.44	--	<LOD	<LOD	0.021 (0.016 - 0.026)	0.029 (0.019 - 0.038)
Males	12-79	3 (2012-2013)	1263	77.51	--	<LOD	<LOD	0.021 (0.015 - 0.027)	0.035Table 95 footnote E (0.018 - 0.052)
Females	12-79	3 (2012-2013)	1264	77.37	--	<LOD	<LOD	0.021 (0.016 - 0.027)	0.028 (0.019 - 0.037)
Total	12-19	3 (2012-2013)	757	77.81	--	<LOD	<LOD	0.020Table 95 footnote E (<LOD - 0.028)	0.031Table 95 footnote E (<LOD - 0.049)
Total	20-39	3 (2012-2013)	557	76.48	--	<LOD	<LOD	0.023 (0.016 - 0.029)	0.036Table 95 footnote E (0.015 - 0.058)
Total	40-59	3 (2012-2013)	604	78.81	--	<LOD	<LOD	0.019 (<LOD - 0.025)	0.027 (0.019 - 0.036)
Total	60-79	3 (2012-2013)	609	76.52	--	<LOD	<LOD	0.020Table 95 footnote E (<LOD - 0.027)	0.028Table 95 footnote E (<LOD - 0.041)
Table 95 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 95 footnote a referrer Table 95 footnote E Use data with caution. Return to table 95 footnote E referrer

Xylenes

Xylenes (CASRN 1330-20-7) are classified as volatile organic compounds (VOCs) (ATSDR, 2007d; CCOHS, 2013b; Environment Canada & Health Canada, 1993h). The three isomers of xylene are ortho-xylene (o-xylene; CASRN 95-47-6), meta-xylene (m-xylene; CASRN 108-38-3) and para-xylene (p-xylene; CASRN 106-42-3); they differ from each other in the position of the two methyl group substitutions on the aromatic ring. The term "total xylenes" refers to all three isomers of xylene, whereas "mixed xylene" is a mixture of total xylenes and ethylbenzene (6% to 15%) (CCOHS, 2013b). Xylenes are primarily produced either directly or as by-products of petroleum and coal refiningand as by-products of olefin manufacturing (ATSDR, 2007d; Environment Canada & Health Canada, 1993h).

Xylene has been extensively and increasingly used in a wide range of applications as a solvent, as a replacement for benzene in the solvent components of various commercial products, and as a mixture in gasoline (ATSDR, 2007d). Xylene may be widely used as a solvent in paint thinners, varnishes, lacquers, stains, concrete sealers, cleaning products, adhesives, inks, cleaning and degreasing agents, and in the production of dyes, perfumes, plastics, pharmaceuticals, and pesticides (ATSDR, 2007d; Environment Canada & Health Canada, 1993h; IPCS, 1997).

Xylenes are released to the environment from natural and anthropogenic sources. Xylenes have been measured in emissions from volcanoes, forest fires, and in volatiles from plants and vegetation (ATSDR, 2007d; CCME, 2004b). Anthropogenic sources of atmospheric xylene include volatilization of petroleum fuels and xylene-based solvents and thinners, gasoline use and motor vehicle exhaust, and the off-gassing of xylene from some building materials, and consumer and automotive products containing xylenes (ATSDR, 2007d; Environment Canada & Health Canada, 1993h). Xylenes are also released to the environment in waste from manufacturing and processing facilities, from spills and accidental releases, and from the disposal of xylene-containing products (ATSDR, 2007d; CCME, 2004b; Environment Canada, 2014). In the past, predominant sources of releases to the atmosphere included emissions from petroleum refineries and chemical manufacturing facilities of styrene-butadiene, rubber, solvents, paints, plastics, synthetic fabric polymers, and polyesters. As new emissions-free and low VOC technologies are being implemented, and changes in industrial and consumer use patterns and increases in fuel efficiency occur, releases of VOCs, including xylenes, are expected to continue their decline.

The general population is exposed to xylenes mainly through inhalation of indoor air (Environment Canada & Health Canada, 1993h). Cigarette smoking may significantly increase levels in indoor air and, in smokers, inhalation of cigarette smoke is expected to be a major contribution to the total source of xylene exposure (ATSDR, 2007d). In addition to smoking, xylene levels in air have been shown to be higher for homes with a garage on the property, with a higher number of occupants, with recent renovations, and in which fragrances and paint remover have been recently used (Wheeler et al., 2013). Additional exposure may result from the use of consumer products containing xylenes, from the use of gasoline-powered engines, such as lawn mowers and outboard motors, and from ambient air, water, soil, drinking water, and food (ATSDR, 2007d; IARC, 1999b; Wheeler et al., 2013). As xylenes are present as a mixture in gasoline and commercial products, the general population is expected to be primarily exposed to xylenes as a mixture, not to the separate xylene isomers (ATSDR, 2007d).

Xylene is rapidly absorbed by all routes of exposure and distributed throughout the body following exposure, primarily into adipose tissues and those tissues with higher lipid content, such as the liver and the brain (ATSDR, 2007d; EPA, 2003; Health Canada, 1986d). Elimination of xylene from blood and most tissue compartments following inhalation is generally rapid, and in humans has a half-life ranging from about 1 to 20 hours (ATSDR, 2007d). The major route of excretion of absorbed xylene in the blood and body is excretion of metabolites in urine, with minor elimination by exhalation of unchanged chemical from the lungs (ATSDR, 2007d). Xylene levels in the blood are the most accurate biomarker of xylene exposure and reflect recent exposure (ATSDR, 2007d; IARC, 1999b).

Adverse health effects have been observed in humans and laboratory animals following xylene exposure via inhalation, ingestion, and dermal routes. In humans, xylene can be irritating to the eyes, nose, throat, lungs, and skin, and has been associated with symptoms of headaches, dizziness, reduced coordination, and feelings of intoxication (ATSDR, 2007d; CCOHS, 2013b). Acute inhalation exposure has been associated with reversible neurological symptoms whereas chronic exposure is associated with impaired neurological function, including cognitive and neuromuscular performance, as well as hearing deficits and dermatitis in humans (ATSDR, 2007d; IARC, 1999b). In humans, acute exposure to xylenes by ingestion has been associated with stomach discomfort, and changes in liver and kidney function; ingestion of petroleum solvents can be fatal (ATSDR, 2007d; IPCS, 1997). Exposure to high levels of mixed xylenes (and other solvents) in humans during pregnancy has been associated with fetal toxicity and developmental effects in children at levels associated with potential maternal toxicity, such as in solvent abuse (ATSDR, 2007d; EPA, 2003; IPCS, 1997). Xylene is not classifiable as to its carcinogenicity in humans according to Environment Canada and Health Canada (Group IV), the International Agency for Research on Cancer (Group 3) and the U.S. Environmental Protection Agency (Group D) (Environment Canada & Health Canada, 1993h; EPA, 2003; IARC, 1999b).

Under the Canadian Environmental Protection Act, Health Canada and Environment Canada concluded that xylenes are not entering the environment in quantities or under conditions that may constitute a danger to human life or health (Environment Canada & Health Canada, 1993h). Xylenes also part of a larger class of compounds called VOCs that, as a group, are environmental and health concerns because of their contribution to the formation of smog. The Government of Canada has taken and proposed a number of actions to address VOC emissions resulting from the use of consumer and commercial products in Canada (Canada, 2009a; Canada, 2009b; Environment Canada, 2002; Environment Canada, 2013b).

The current guideline for Canadian drinking water quality establishes an aesthetic objective for xylene based on its odour threshold (Health Canada, 1986d; Health Canada, 2012e). This guideline was deemed protective of short-term exposure, but a health-based value had not been established (Health Canada, 1986d). Recently, Health Canada released for public comment a revised guideline technical document by the Federal-Provincial-Territorial Committee on Drinking Water, based on the most current available scientific information on xylenes (Health Canada, 2014e). A final guideline technical document is expected to be available in the summer of 2015.

Xylenes were analyzed in the whole blood of Canadian Health Measures Survey (CHMS) participants aged 12 to 79 years in cycle 3 (2012-2013). Data are presented as µg/L blood for o-xylene and the sum of m-xylene and p-xylene. Finding a measurable amount of xylenes in blood can be an indicator of recent exposure to xylene and does not necessarily mean that an adverse health effect will occur. These data provide baseline levels for blood xylenes in the Canadian population.

Xylenes were also analyzed in indoor air from households of CHMS participants in cycle 2 (2009-2011) (Statistics Canada, 2012; Wheeler et al., 2013) and cycle 3 (2012-2013) and in tap water from households in cycle 3. Further details on the indoor air and tap water studies are available in the Canadian Health Measures Survey (CHMS) Data User Guide: Cycle 3 (Statistics Canada, 2015). Indoor air and tap water data are available through Statistics Canada's Research Data Centres or upon request by contacting Statistics Canada at info@statcan.gc.ca.

m-Xylene & p-xylene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 96 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2326	14.53	0.062 (0.050 - 0.079)	<LOD	0.063 (0.047 - 0.080)	0.20 (0.14 - 0.26)	0.30 (0.20 - 0.39)
Males	12-79	3 (2012-2013)	1172	13.31	0.065 (0.051 - 0.082)	<LOD	0.062 (0.045 - 0.080)	0.21 (0.15 - 0.28)	0.34Table 96 footnote E (0.19 - 0.49)
Females	12-79	3 (2012-2013)	1154	15.77	0.060 (0.047 - 0.078)	<LOD	0.064 (0.046 - 0.082)	0.19 (0.12 - 0.26)	0.27 (0.18 - 0.36)
Total	12-19	3 (2012-2013)	701	16.83	0.049 (0.037 - 0.065)	<LOD	0.055 (0.039 - 0.071)	0.14Table 96 footnote E (0.086 - 0.19)	0.18 (0.14 - 0.23)
Total	20-39	3 (2012-2013)	500	14.00	0.058 (0.045 - 0.074)	<LOD	0.057Table 96 footnote E (0.026 - 0.088)	0.16 (0.11 - 0.22)	0.25 (0.17 - 0.32)
Total	40-59	3 (2012-2013)	559	11.99	0.074 (0.056 - 0.096)	<LOD	0.068 (0.052 - 0.084)	0.28Table 96 footnote E (0.17 - 0.39)	0.42 (0.29 - 0.54)
Total	60-79	3 (2012-2013)	566	14.66	0.060 (0.045 - 0.079)	<LOD	0.061 (0.043 - 0.078)	0.18 (0.15 - 0.21)	0.25Table 96 footnote E (0.12 - 0.37)
Table 96 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 96 footnote a referrer Table 96 footnote E Use data with caution. Return to table 96 footnote E referrer

o-Xylene - Geometric means and selected percentiles of whole blood concentrations (μg/L) for the Canadian population aged 12-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	%<LODTable 97 footnote a	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	12-79	3 (2012-2013)	2336	41.05	--	<LOD	0.022Table 97 footnote E (0.010 - 0.034)	0.087 (0.061 - 0.11)	0.11 (0.083 - 0.14)
Males	12-79	3 (2012-2013)	1164	40.55	--	<LOD	0.022Table 97 footnote E (0.0097 - 0.033)	0.088 (0.061 - 0.11)	0.12 (0.075 - 0.16)
Females	12-79	3 (2012-2013)	1172	41.55	--	<LOD	0.022Table 97 footnote E (0.011 - 0.034)	0.081 (0.052 - 0.11)	0.11 (0.082 - 0.14)
Total	12-19	3 (2012-2013)	692	43.93	--	<LOD	Table 97 footnote F	0.057 (0.041 - 0.072)	0.075 (0.053 - 0.098)
Total	20-39	3 (2012-2013)	515	42.14	--	<LOD	0.020Table 97 footnote E (0.0095 - 0.030)	0.077Table 97 footnote E (0.036 - 0.12)	0.11Table 97 footnote E (0.053 - 0.17)
Total	40-59	3 (2012-2013)	565	38.94	0.022Table 97 footnote E (0.014 - 0.034)	<LOD	0.029Table 97 footnote E (0.012 - 0.045)	0.099 (0.075 - 0.12)	0.13 (0.095 - 0.17)
Total	60-79	3 (2012-2013)	564	38.65	0.016Table 97 footnote E (0.010 - 0.023)	<LOD	0.016Table 97 footnote E (<LOD - 0.027)	0.076 (0.055 - 0.098)	0.10Table 97 footnote E (0.030 - 0.17)
Table 97 footnote a If >40% of samples were below the LOD, the percentile distribution is reported but means were not calculated. Return to table 97 footnote a referrer Table 97 footnote E Use data with caution. Return to table 97 footnote E referrer Table 97 footnote F Data is too unreliable to be published. Return to table 97 footnote F referrer

References

Abrahamsson, K., Ekdahl, A., Collen, J., & Pedersen, M. (1995). Marine algae - A source of trichloroethylene and perchloroethylene. Limnology and Oceanography, 40(7), 1321-1326.

ACGIH (American Conference of Governmental Industrial Hygienists) (2005). Biological exposure indice (BEI): Polycyclic aromatic hydrocarbons (PAHs). ACGIH, Cincinnati, OH.

Ackley, K.L., B'Hymer, C., Sutton, K.L., & Caruso, J.A. (1999). Speciation of arsenic in fish tissue using microwave-assisted extraction followed by HPLC-ICP-MS. Journal of Analytical Atomic Spectrometry, 14(5), 845-850.

Adams, S.V., & Newcomb, P.A. (2014). Cadmium blood and urine concentrations as measures of exposure: NHANES 1999-2010. Journal of Exposure Science and Environmental Epidemiology, 24(2), 163-170.

AFN (Assembly of First Nations) (2013).  First Nations Biomonitoring Initiative: National results (2011). Assembly of First Nations, Ottawa, ON. Retrieved July 29, 2013.

Aggazzotti, G., Fantuzzi, G., Righi, E., & Predieri, G. (1998). Blood and breath analyses as biological indicators of exposure to trihalomethanes in indoor swimming pools. Science of the Total Environment, 217(1-2), 155-163.

Amzal, B., Julin, B., Vahter, M., Wolk, A., Johanson, G., & Akesson, A. (2009). Population toxicokinetic modeling of cadmium for health risk assessment. Environmental Health Perspectives, 117(8), 1293-1301.

Arbuckle, T.E., Davis, K., Marro, L., Fisher, M., Legrand, M., LeBlanc, A., Gaudreau, E., Foster, W.G., Choeurng, V., & Fraser, W.D. (2014). Phthalate and bisphenol A exposure among pregnant women in Canada - Results from the MIREC study. Environment International, 68, 55-65.

Arbuckle, T.E., Fraser, W.D., Fisher, M., Davis, K., Liang, C.L., Lupien, N., Bastien, S., Velez, M.P., von Dadelszen, P., Hemmings, D.G., et al. (2013). Cohort Profile: The Maternal-Infant Research on Environmental Chemicals Research Platform. Paediatric and Perinatal Epidemiology, 27(4), 415-425.

Arnold, S.M., Angerer, J., Boogaard, P.J., Hughes, M.F., O'Lone, R.B., Robison, S.H., & Schnatter, A.R. (2013). The use of biomonitoring data in exposure and human health risk assessment: Benzene case study. Critical Reviews in Toxicology, 43(2), 119-153.

ATSDR (Agency for Toxic Substances and Disease Registry) (1989).  Toxicological profile for bromodichloromethane. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (1995).  Toxicological profile for polycyclic aromatic hydrocarbons. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved February 17, 2012.

ATSDR (Agency for Toxic Substances and Disease Registry) (1997a).  Toxicological profile for tetrachloroethylene (PERC). U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (1997b).  Toxicological profile for trichloroethylene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (1999a).  Toxicological profile for mercury. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved March 30, 2012.

ATSDR (Agency for Toxic Substances and Disease Registry) (1999b).  ToxFAQs: Bromodichloromethane. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2000).  Toxicological profile for toluene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2003).  Toxicological profile for fluorides, hydrogen fluoride, and fluorine. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2005a).  Toxicological profile for naphthalene, 1-methylnaphthalene, and 2-methylnaphthalene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2005b).  Toxicological profile for bromoform and chlorodibromomethane. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2007a).  Toxicological profile for arsenic. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 30, 2012.

ATSDR (Agency for Toxic Substances and Disease Registry) (2007b).  Toxicological profile for lead. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved March 20, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2007c).  Toxicological profile for benzene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2007d).  Toxicological profile for xylene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2010a).  Toxicological profile for ethylbenzene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 21, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2010b).  Toxicological profile for styrene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

ATSDR (Agency for Toxic Substances and Disease Registry) (2011).  Addendum to the toxicological profile for styrene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved June 30, 2014.

ATSDR (Agency for Toxic Substances and Disease Registry) (2012a).  Toxicological profile for acrylamide. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved March 20, 2014.

ATSDR (Agency for Toxic Substances and Disease Registry) (2012b).  Toxicological profile for cadmium. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved August 15, 2014.

ATSDR (Agency for Toxic Substances and Disease Registry) (2012c).  ToxFAQs: Styrene. U.S. Department of Health and Human Services, Atlanta, GA. Retrieved April 10, 2015.

Aylward, L.L., Lorber, M., & Hays, S.M. (2011). Urinary DEHP metabolites and fasting time in NHANES. Journal of Exposure Science and Environmental Epidemiology, 21(6), 615-624.

Bagchi, D., Balmoori, J., Bagchi, M., Ye, X., Williams, C.B., & Stohs, S.J. (2002). Comparative effects of TCDD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice. Toxicology, 175(1-3), 73-82.

Barr, D.B., Wilder, L.C., Caudill, S.P., Gonzalez, A.J., Needham, L.L., & Pirkle, J.L. (2005). Urinary creatinine concentrations in the U.S. population: Implications for urinary biologic monitoring measurements. Environmental Health Perspectives, 113(2), 192-200.

Bates, M.N., Fawcett, J., Garrett, N., Cutress, T., & Kjellstrom, T. (2004). Health effects of dental amalgam exposure: A retrospective cohort study. International Journal of Epidemiology, 33(4), 894-902.

Batista, B.L., Souza, J.M.O., De Souza, S.S., & Barbosa Jr., F. (2011). Speciation of arsenic in rice and estimation of daily intake of different arsenic species by Brazilians through rice consumption. Journal of Hazardous Materials, 191(1-3), 342-348.

Batterman, S., Jia, C., & Hatzivasilis, G. (2007). Migration of volatile organic compounds from attached garages to residences: A major exposure source. Environmental Research, 104(2), 224-240.

Becker, K., Schulz, C., Kaus, S., Seiwert, M., & Seifert, B. (2003). German Environmental Survey 1998 (GerES III): Environmental pollutants in the urine of the German population. International Journal of Hygiene and Environmental Health, 206(1), 15-24.

Belfield, K.D., Hagan, D.J., Van Stryland, E.W., Schafer, K.J., & Negres, R.A. (1999). New two-photon absorbing fluorene derivatives: Synthesis and nonlinear optical characterization. Organic Letters, 1(10), 1575-1578.

Bellinger, D.C., Daniel, D., Trachtenberg, F., Tavares, M., & McKinlay, S. (2007). Dental amalgam restorations and children's neuropsychological function: The New England Children's Amalgam Trial. Environmental Health Perspectives, 115(3), 440-446.

Ben-Jonathan, N., Hugo, E.R., & Brandebourg, T.D. (2009). Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. Molecular and Cellular Endocrinology, 304(1), 49-54.

Benowitz, N.L. (1996). Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiologic Reviews, 18(2), 188-204.

Benowitz, N.L., & Jacob, P. (1994). Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clinical Pharmacology and Therapeutics, 56(5), 483-493.

Bernius, M., Inbasekaran, M., Woo, E., Wu, W., & Wujkowski, L. (2000). Light-emitting diodes based on fluorene polymers. Thin Solid Films, 363(1-2), 55-57.

Boeniger, M.F., Lowry, L.K., & Rosenberg, J. (1993). Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: A review. American Industrial Hygiene Association Journal, 54(10), 615-627.

Boogaard, P.J., & van Sittert, N.J. (1995). Biological monitoring of exposure to benzene: A comparison between S-Phenylmercapturic acid, trans,trans-muconic acid, and phenol. Occupational and Environmental Medicine, 52(9), 611-620.

Borges, H.T. (1994). Toxicity summary for chrysene. Oak Ridge Reservation and Environmental Restoration Program, Oak Ridge, TN.

Bouchard, M., & Viau, C. (1996). Urinary excretion kinetics of pyrene and benzo(a)pyrene metabolites following intravenous administration of the parent compounds or the metabolites. Toxicology and Applied Pharmacology, 139(2), 301-309.

Bouchard, M., Normandin, L., Gagnon, F., Viau, C., Dumas, P., Gaudreau, É, & Tremblay, C. (2009). Repeated measures of validated and novel biomarkers of exposure to polycyclic aromatic hydrocarbons in individuals living near an aluminum plant in Quebec, Canada. Journal of Toxicology and Environmental Health, Part A, 72(23), 1534-1549.

Bouchard, M., Pinsonneault, L., Tremblay, C., & Weber, J. (2001). Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons in subjects living in the vicinity of a creosote impregnation plant. International Archives of Occupational and Environmental Health, 74(7), 505-513.

Bowen, S.E., & Hannigan, J.H. (2006). Developmental toxicity of prenatal exposure to toluene. The AAPS Journal, 8(2), E419-E424.

Braun, J.M., Kalkbrenner, A.E., Calafat, A.M., Yolton, K., Ye, X., Dietrich, K.N., & Lanphear, B.P. (2011). Impact of early-life bisphenol A exposure on behavior and executive function in children. Pediatrics, 128(5), 873-882.

Brisson, B., Ayotte, P., Normandin, L., Gaudreau, E., Bienvenu, J.F., Fennell, T.R., Blanchet, C., Phaneuf, D., Lapointe, C., Bonvalot, Y., Gagne, M., Courteau, M., Snyder, R.W., & Bouchard, M. (2014). Journal of Exposure Science & Environmental Epidemiology, 24(2), 215-221.

Brown, K.M., von Weymarn, L.B., & Murphy, S.E. (2005). Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. Chemical Research in Toxicology, 18(12), 1792-1798.

Bryan, S.N., St-Denis, M., & Wojitas, D. (2007). Canadian Health Measures Survey: Operations and logistics. Health Reports, Special Issue Supp. 18, 53-70.

Busby Jr., W.F., Stevens, E.K., Martin, C.N., Chow, F.L., & Garner, R.C. (1989). Comparative lung tumorigenicity of parent and mononitro-polynuclear aromatic hydrocarbons in the BLU:Ha newborn mouse assay. Toxicology and Applied Pharmacology, 99(3), 555-563.

Bushnik, T., Levallois, P., D'Amour, M., Anderson, T.J., & McAlister, F.A. (2014). Association between blood lead and blood pressure: Results from the Canadian Health Measures Survey (2007 to 2011). Health Reports, 25(7), 12-22.

CADTH (Canadian Agency for Drugs and Technologies in Health) (2012).  Composite resin and amalgam dental filling materials: A Review of Safety, Clinical Effectiveness and Cost-effectiveness. CADTH, Ottawa, ON. Retrieved August 14, 2014.

Calafat, A.M., Ye, X., Wong, L., Reidy, J.A., & Needham, L.L. (2007). Urinary concentrations of triclosan in the U.S. population: 2003-2004. Environmental Health Perspectives, 116(3), 303-307.

Canada (1970-71-72). Statistics Act. c. 15, s. 1. Retrieved August 7, 2012.

Canada (1985).  Food and Drugs Act. RSC 1985, c. F-27. Retrieved March 23, 2015.

Canada (1997).  Benzene in Gasoline Regulations. SOR/97-493. Retrieved March 23, 2015.

Canada (1998).  Glazed Ceramics and Glassware Regulations. SOR/98-176. Retrieved March 24, 2015.

Canada (1999).  Canadian Environmental Protection Act, 1999. SC 1999, c. 33. Retrieved March 24, 2015.

Canada (2000). Order adding toxic substances to Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part II: Official Regulations, 134(7).

Canada (2005).  Surface Coating Materials Regulations. SOR/2005-109. Retrieved March 24, 2015.

Canada (2006).  Pest Control Products Act. SC 2002, c. 28. Retrieved March 24, 2015.

Canada (2009a).  Volatile Organic Compound (VOC) Concentration Limits for Architectural Coatings Regulations. SOR/2009-264. Retrieved March 24, 2015.

Canada (2009b).  Volatile Organic Compound (VOC) Concentration Limits for Automotive Refinishing Products Regulations. SOR/2009-197. Retrieved March 24, 2015.

Canada (2010a).  Order adding toxic substances to Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part I: Notices and Proposed Regulations, 144(44). Retrieved March 24, 2015.

Canada (2010b).  Canada Consumer Product Safety Act. SC 2010, c. 21. Retrieved March 24, 2015.

Canada (2010c).  Cribs, Cradles and Bassinets Regulations. SOR/2010-261. Retrieved March 24, 2015.

Canada (2010d).  Consumer Products Containing Lead (Contact with Mouth) Regulations. SOR/2010-273. Retrieved March 24, 2015.

Canada (2010e).  Order adding toxic substances to Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part II: Official Regulations, 144(10). Retrieved March 24, 2015.

Canada (2010f).  Chemical substances: Naphthalene. Retrieved June 11, 2012.

Canada (2011a).  Order adding a toxic substance to Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part II: Official Regulations, 145(5). Retrieved March 24, 2015.

Canada (2011b).  Toys Regulations. SOR/2011-17. Retrieved March 24, 2015.

Canada (2011c).  Regulations Respecting Products Containing Certain Substances Listed in Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part I: Notices and Proposed Regulations, 145(9). Retrieved March 24, 2015.

Canada (2011d).  Regulations amending the tetrachloroethylene (use in dry cleaning and reporting requirements) regulations (miscellaneous program). Canada Gazette, Part II: Official Regulations, 145(21). Retrieved March 24, 2015.

Canada (2011e).  Tetrachloroethylene (Use in Dry Cleaning and Reporting Requirements) Regulations. SOR/2003-79. Retrieved March 24, 2015.

Canada (2012a).  Regulations amending the Food and Drug Regulations (1652 - Schedule F). Canada Gazette, Part II: Official Regulations, 146(6). Retrieved March 24, 2015.

Canada (2012b).  Notice requiring the preparation and implementation of pollution prevention plans with respect to bisphenol A in industrial effluents. Canada Gazette, Part I: Notices and Proposed Regulations, 146(15). Retrieved March 24, 2015.

Canada (2012c).  Food and Drug Regulations. C.R.C., c. 870. Retrieved March 24, 2015.

Canada (2012d).  Order adding a toxic substance to Schedule 1 to the Canadian Environmental Protection Act, 1999. Canada Gazette, Part II: Official Regulations, 146(21). Retrieved March 24, 2015.

Capleton, A.C., & Levy, L.S. (2005). An overview of occupational benzene exposures and occupational exposure limits in Europe and North America. Chemico-Biological Interactions, 153-154, 43-53.

Carwile, J.L., & Michels, K.B. (2011). Urinary bisphenol A and obesity: NHANES 2003-2006. Environmental Research, 111, 825-830.

Castaño-Vinyals, G., D'Errico, A., Malats, N., & Kogevinas, M. (2004). Biomarkers of exposure to polycyclic aromatic hydrocarbons from environmental air pollution. Occupational and Environmental Medicine, 61(4), e12.

Caux, C., O'Brien, C., & Viau, C. (2002). Determination of firefighter exposure to polycyclic aromatic hydrocarbons and benzene during fire fighting using measurement of biological indicators. Applied Occupational and Environmental Hygiene, 17(5), 379-386.

CCME (Canadian Council of Ministers of the Environment) (1997).  Canadian soil quality guidelines for the protection of environmental and human health - Arsenic (inorganic). Winnipeg, MB. Retrieved April 30, 2012.

CCME (Canadian Council of Ministers of the Environment) (1999a).  Canadian soil quality guidelines for the protection of environmental and human health - Cadmium. Winnipeg, MB. Retrieved January 24, 2012.

CCME (Canadian Council of Ministers of the Environment) (1999b).  Canadian soil quality guidelines for the protection of environmental and human health - Mercury (inorganic). Winnipeg, MB. Retrieved March 30, 2012.

CCME (Canadian Council of Ministers of the Environment) (1999c).  Canadian water quality guidelines for the protection of aquatic life - Halogenated methanes. Winnipeg, MB. Retrieved June 25, 2014.

CCME (Canadian Council of Ministers of the Environment) (2000a).  Canada-wide standards for mercury emissions. Quebec City, QC. Retrieved March 30, 2012.

CCME (Canadian Council of Ministers of the Environment) (2000b).  Canada-wide standards for benzene - phase 1. Quebec City, QC. Retrieved June 9, 2012.

CCME (Canadian Council of Ministers of the Environment) (2001).  Canada-wide standards for benzene - phase 2. Quebec City, QC. Retrieved June 9, 2012.

CCME (Canadian Council of Ministers of the Environment) (2002).  Canadian water quality guidelines for the protection of aquatic life - Inorganic fluorides. Winnipeg, MB. Retrieved July 13, 2011.

CCME (Canadian Council of Ministers of the Environment) (2004a).  Canadian soil quality guidelines for the protection of environmental and human health - Toluene. Winnipeg, MB. Retrieved June 9, 2014.

CCME (Canadian Council of Ministers of the Environment) (2004b).  Canadian soil quality guidelines for the protection of environmental and human health - Xylenes. Winnipeg, MB. Retrieved June 26, 2014.

CCME (Canadian Council of Ministers of the Environment) (2005).  Canada-wide standards for mercury (mercury emissions, mercury-containing lamps, and mercury for dental amalgam waste): A report on progress. Winnipeg, MB. Retrieved March 30, 2012.

CCME (Canadian Council of Ministers of the Environment) (2006).  Canada-wide standards for mercury emissions from coal-fired electric power generation plants. Winnipeg, MB. Retrieved March 30, 2012.

CCME (Canadian Council of Ministers of the Environment) (2007).  Canada-wide standards for mercury - A report on compliance and evaluation (mercury from dental amalgam waste), a report on progress (mercury emissions and mercury-containing lamps). Winnipeg, MB. Retrieved April 2, 2012.

CCME (Canadian Council of Ministers of the Environment) (2012).  Canada-wide standards for benzene - 2010 final report. Winnipeg, MB. Retrieved May 15, 2014.

CCOHS (Canadian Centre for Occupational Health and Safety) (2013a).  Chemical profile: Toluene. Retrieved June 9, 2014.

CCOHS (Canadian Centre for Occupational Health and Safety) (2013b).  Chemical profile: Xylene (mixed isomers). Retrieved June 10, 2014.

CDC (Centers for Disease Control and Prevention) (2004).  The Health Consequences of Smoking: A Report of the Surgeon General. Department of Health and Human Services, Washington, DC. Retrieved April 12, 2012.

CDC (Centers for Disease Control and Prevention) (2009).  Fourth national report on human exposure to environmental chemicals. Department of Health and Human Services, Atlanta, GA. Retrieved July 11, 2011.

CEOH (Federal-Provincial Committee on Environmental and Occupational Health) (1994). Update of evidence for low-level effects of lead and blood-lead intervention levels and strategies - final report of the working group. Minister of Health, Ottawa, ON.

CFIA (Canadian Food Inspection Agency) (2013).  Food safety action plan report 2010/2011 (Chemistry). Ottawa, ON. Retrieved August 14, 2014.

Chang, R.L., Levin, W., Wood, A.W., Yagi, H., Tada, M., Vyas, K.P., Jerina, D.M., & Conney, A.H. (1983). Tumorigenicity of enantiomers of chrysene 1,2-dihydrodiol and of the diastereomeric bay-region chrysene 1,2-diol-3,4-epoxides on mouse skin and in newborn mice. Cancer Research, 43(1), 192-196.

Chen, C., Chuang, Y., Lin, T., & Wu, H. (1985). Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: High-arsenic well water and cancers. Cancer Research, 45, 5895-5899.

Chien, Y., & Yeh, C. (2012). Excretion kinetics of urinary 3-hydroxybenzo[a]pyrene following dietary exposure to benzo[a]pyrene in humans. Archives of Toxicology, 86(1), 45-53.

Clark, N.A., Teschke, K., Rideout, K., & Copes, R. (2007). Trace element levels in adults from the west coast of Canada and associations with age, gender, diet, activities, and levels of other trace elements. Chemosphere, 70(1), 155-164.

Cohen, S.M., Arnold, L.L., Eldan, M., Lewis, A.S., & Beck, B.D. (2006). Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Critical Reviews in Toxicology, 36(2), 99-133.

Conklin, S.D., & Chen, P.E. (2012). Quantification of four arsenic species in fruit juices by ion-chromatography-inductively coupled plasma-mass spectrometry. Food Additives & Contaminants: Part A, 29(8), 1272-1279.

Cotton, F.A., & Wilkinson, G. (1988). Advanced inorganic chemistry. John Wiley & Sons, New York, NY.

Crooks, P.A., & Dwoskin, L.P. (1997). Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochemical Pharmacology, 54(7), 743-753.

Curvall, M., Elwin, C.E., Kazemi-Vala, E., Warholm, C., & Enzell, C.R. (1990). The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. European Journal of Clinical Pharmacology, 38(3), 281-287.

Day, B., Langlois, R., Tremblay, M., & Knoppers, B. (2007). Canadian Health Measures Survey: Sampling strategy overview. Health Reports, Special Issue Supp. 18, 31-35.

Dekant, W., & Völkel, W. (2008). Human exposure to bisphenol A by biomonitoring: Methods, results and assessment of environmental exposures. Toxicology and Applied Pharmacology, 228(1), 114-134.

DeRouen, T.A., Martin, M.D., Leroux, B.G., Townes, B.D., Woods, J.S., Leitão, J., Castro-Caldas, A., Luis, H., Bernardo, M., Rosenbaum, G., & Martins, I.P. (2006). Neurobehavioral effects of dental amalgam in children: A randomized clinical trial. Journal of the American Medical Association, 295(15), 1784-1792.

Donald, J.M., Hooper, K., & Hopenhayn-Rich, C. (1991). Reproductive and developmental toxicity of toluene: A review. Environmental Health Perspectives, 94, 237-244.

EFSA (European Food Safety Authority) (2007). Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food on a request from the Commission related to 2,2-bis(4-hydroxyphenyl)propane (bisphenol A), question number EFSA-Q-2005-100. European Food Safety Authority Journal, 428, 1-75.

EFSA (European Food Safety Authority) (2008). Toxicokinetics of bisphenol A. Scientific opinion of the panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request from the commission on the toxicokinetics of bisphenol A. European Food Safety Authority Journal, 759, 1-10.

Emsley, J. (2001). Nature's building blocks: An A-Z guide to the elements. Oxford University Press, Oxford.

Environment Canada & Health Canada (1992). Priority substances list assessment report: Toluene. Minister of Supply and Services Canada, Ottawa, ON. Retrieved June 9, 2014.

Environment Canada & Health Canada (1993a). Priority substances list assessment report: Arsenic and its compounds. Minister of Supply and Services Canada, Ottawa, ON. Retrieved March 20, 2015.

Environment Canada & Health Canada (1993b). Priority substances list assessment report: Inorganic fluorides. Minister of Supply and Services Canada, Ottawa, ON. Retrieved August 30, 2011.

Environment Canada & Health Canada (1993c). Priority substances list assessment report: Benzene. Minister of Supply and Services Canada, Ottawa, ON. Retrieved March 20, 2015.

Environment Canada & Health Canada (1993d). Priority substances list assessment report: Styrene. Minister of Supply and Services Canada, Ottawa, ON. Retrieved June 30, 2014.

Environment Canada & Health Canada (1993e). Priority substances list assessment report: Tetrachloroethylene. Minister of Supply and Services Canada, Ottawa, ON. Retrieved July 4, 2014.

Environment Canada & Health Canada (1993f). Priority substances list assessment report: Trichloroethylene. Minister of Supply and Services Canada, Ottawa, ON. Retrieved July 2, 2014.

Environment Canada & Health Canada (1993g). Priority substances list assessment report: Chlorinated wastewater effluents. Minister of Supply and Services Canada, Ottawa, ON. Retrieved June 25, 2014.

Environment Canada & Health Canada (1993h). Priority substances list assessment report: Xylenes. Minister of Supply and Services Canada, Ottawa, ON. Retrieved June 10, 2014.

Environment Canada & Health Canada (1994a). Priority substances list assessment report: Cadmium and its compounds. Minister of Supply and Services Canada, Ottawa, ON. Retrieved January 24, 2012.

Environment Canada & Health Canada (1994b). Priority substances list assessment report: Polycyclic aromatic hydrocarbons. Minister of Supply and Services Canada, Ottawa, ON. Retrieved February 17, 2012.

Environment Canada & Health Canada (2000). Priority substances list assessment report: Chloroform. Minister of Supply and Services Canada, Ottawa, ON. Retrieved June 25, 2014.

Environment Canada & Health Canada (2008a).  Screening assessment for the Challenge: Phenol, 4,4'-(1-methylethylidene)bis-(Bisphenol A). Ottawa, ON. Retrieved March 20, 2015.

Environment Canada & Health Canada (2008b).  Proposed risk management approach for phenol, 4,4'-(1-methylethylidene) bis (bisphenol A). Ottawa, ON. Retrieved May 24, 2012.

Environment Canada & Health Canada (2008c).  Screening assessment for the Challenge: Naphthalene. Ottawa, ON. Retrieved May 14, 2012.

Environment Canada & Health Canada (2009a).  Proposed risk management approach for 2-propenamide (acrylamide). Ottawa, ON. Retrieved March 20, 2014.

Environment Canada & Health Canada (2009b).  Screening assessment for the Challenge: 2-Propenamide (acrylamide). Ottawa, ON. Retrieved March 20, 2014.

Environment Canada & Health Canada (2010).  Risk management strategy for mercury. Ottawa, ON. Retrieved March 30, 2012.

Environment Canada & Health Canada (2012a).  Risk management scope for triclosan. Ottawa, ON. Retrieved May 25, 2012.

Environment Canada & Health Canada (2012b).  Preliminary assessment: Triclosan. Ottawa, ON. Retrieved May 25, 2012.

Environment Canada & Health Canada (2014a).  Draft screening assessment report: Ethylbenzene. Ottawa, ON. Retrieved April 21, 2015.

Environment Canada & Health Canada (2014b).  Risk management scope: Benzene, ethyl-. Ottawa, ON. Retrieved April 21, 2015.

Environment Canada (2002).  Guidelines for volatile organic compounds in consumer products. Minister of the Environment, Ottawa, ON. Retrieved July 7, 2014.

Environment Canada (2008). A case against arsenic-based pesticides. Minister of the Environment, Ottawa, ON.

Environment Canada (2010a).  List of toxic substances managed under CEPA (Schedule I): Inorganic arsenic compounds. Minister of the Environment, Ottawa, ON. Retrieved March 24, 2015.

Environment Canada (2010b).  List of toxic substances managed under CEPA (Schedule I): Lead. Minister of the Environment, Ottawa, ON. Retrieved March 24, 2015.

Environment Canada (2010c).  Mercury and the environment. Minister of the Environment, Ottawa, ON. Retrieved March 24, 2015.

Environment Canada (2010d). List of toxic substances managed under CEPA (Schedule I):  Polycyclic aromatic hydrocarbons. Minister of the Environment, Ottawa, ON. Retrieved March 24, 2015.

Environment Canada (2013a).  Toxic substances list - Schedule I: Inorganic cadmium compounds. Minister of the Environment, Ottawa, ON. Retrieved March 20, 2015.

Environment Canada (2013b).  Consultation document: Revisions to the proposed volatile organic compound (VOC) concentration limits for certain products regulations. Minister of the Environment, Ottawa, ON. Retrieved July 7, 2014.

Environment Canada (2013c).  Overview of solvent degreasing regulations. Ottawa, ON. Retrieved July 2, 2014.

Environment Canada (2013d).  Solvent degreasing. Ottawa, ON. Retrieved July 2, 2014.

Environment Canada (2013e).  Trichloroethylene. Ottawa, ON. Retrieved July 2, 2014.

Environment Canada (2014).  Guidance document on the benzene in gasoline regulations. Minister of the Environment, Ottawa, ON. Retrieved June 10, 2014.

EPA (U.S. Environmental Protection Agency) (1980).  Ambient water quality criteria for fluoranthene. U.S. Environmental Protection Agency, Washington, DC. Retrieved March 24, 2015.

EPA (U.S. Environmental Protection Agency) (1998).  Integrated Risk Information System (IRIS): Arsenic, inorganic. Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH. Retrieved April 30, 2012.

EPA (U.S. Environmental Protection Agency) (2002).  Toxicological review of benzene (noncancer effects) - In support of summary information on the Integrated Risk Information System (IRIS). U.S. Environmental Protection Agency, Washington, DC. Retrieved June 8, 2012.

EPA (U.S. Environmental Protection Agency) (2003).  Toxicological review of xylenes. U.S. Environmental Protection Agency, Washington, DC. Retrieved June 10, 2014.

EPA (U.S. Environmental Protection Agency) (2005).  Integrated Risk Information System (IRIS): Toluene. Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH. Retrieved June 9, 2014.

EPA (U.S. Environmental Protection Agency) (2006).  Air quality criteria for lead - Volume I and II. U.S. Environmental Protection Agency, Washington, DC. Retrieved March 27, 2012.

EPA (U.S. Environmental Protection Agency) (2008a).  Cancer assessment document: Evaluation of the carcinogenic potential of triclosan. Office of Prevention, Pesticides and Toxic Substances, Washington, DC. Retrieved April 21, 2015.

EPA (U.S. Environmental Protection Agency) (2008b).  Reregistration eligibility decision (RED) for naphthalene: List C Case No 3058. Retrieved March 26, 2015.

EPA (U.S. Environmental Protection Agency) (2010).  Integrated Risk Information System (IRIS): Acrylamide. Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH. Retrieved March 20, 2014.

EPA (U.S. Environmental Protection Agency) (2011).  Information on the Integrated Risk Information System (IRIS): Trichloroethylene. Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH. Retrieved July 2, 2014.

EPA (U.S. Environmental Protection Agency) (2012).  Integrated Risk Information Systems (IRIS): Tetrachloroethylene (Perchloroethylene). Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH. Retrieved July 4, 2014.

EPA (U.S. Environmental Protection Agency) (2013).  Priority pollutants. Office of Water, Washington, D.C. Retrieved August 18, 2014.

EU (European Union) (2010).  Updated European Union risk assessment report: 4,4'-Isopropylidenediphenol (bisphenol A), CAS No: 80-05-7. European Chemicals Bureau, Luxembourg. Retrieved December 14, 2012.

Factor-Litvak, P., Hasselgren, G., Jocobs, D., Begg, M., Kline, J., Geier, J., Mervish, N., Schoenholtz, S., & Graziano, J. (2003). Mercury derived from dental amalgams and neuropsychologic function. Environmental Health Perspectives, 111(5), 719-723.

Fang, J., Stingley, R.L., Beland, F.A., Harrouk, W., Lumpkins, D.L., & Howard, P. (2010). Occurrence, efficacy, mtabolism, and toxicity of triclosan. Journal of Environmental Science and Health, Part C, 28(3), 147-171.

FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization) (2006).  Evaluation of certain food contaminants. Sixty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization, Geneva. Retrieved March 20, 2014.

Faust, R.A. (1993a). Toxicity profile for fluoranthene. Oak Ridge National Laboratory, Oak Ridge, TN.

Faust, R.A. (1993b). Toxicity summary for phenanthrene. Oak Ridge Reservation and Environmental Restoration Program, Oak Ridge, TN.

Faust, R.A. (1993c). Toxicity summary for pyrene. Oak Ridge Reservation and Environmental Restoration Program, Oak Ridge, TN.

Faust, R.A. (1994). Toxicity profile for benzo[a]pyrene. Oak Ridge National Laboratory, Oak Ridge, TN.

Fawell, J., Bailey, K., Chilton, J., Dahi, E., Fewtrell, L., & Magara, Y. (2006). Fluoride in drinking-water. World Health Organization, London.

FDA (U.S. Food and Drug Administration) (2008). Draft assessment of bisphenol A for use in food contact applications. U.S. Department of Health and Human Services, Washington, DC. Retrieved May 25, 2012.

Friberg, L. (1985). Cadmium and health: A toxicological and epidemiological appraisal. CRC Press, Boca Raton, FL.

Geens, T., Goeyens, L., & Covaci, A. (2011). Are potential sources for human exposure to bisphenol-A overlooked? International Journal of Hygiene and Environmental Health, 214(5), 339-347.

Genualdi, S., Nyman, P., & Begley, T. (2014). Updated evaluation of the migration of styrene monomer and oligomers from polystyrene food-contact materials to foods and food simulants. Food Additives & Contaminants: Part A, 31(4), 723-733.

Gospe, S.M., & Zhou S.S. (2000). Prenatal exposure to toluene results in abnormal neurogenesis and migration in rat somatosensory cortex. Pediatric Research, 47, 362-368.

Guillén, M. D., & Sopelana, P. (2003). Polycyclic aromatic hydrocarbons in diverse foods. In J.P.F. D'Mello (Ed.), Food Safety: Contaminants and Toxins. CAB International, Oxon, UK.

Haines, D.A., Arbuckle, T.E., Lye, E., Legrand, M., Fisher, M., Langlois, R., & Fraser, W. (2011). Reporting results of human biomonitoring of environmental chemicals to study participants: A comparison of approaches followed in two Canadian studies. Journal of Epidemiology and Community Health, 65(3), 191-198.

HBM Commission (Human Biomonitoring Commission of the German Federal Environmental Agency) (2003). Substance Monograph: Arsenic - Reference value in urine. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2003. 46, 12, 1098-1106 (in German).

Health Canada (1986a). Guidelines for Canadian drinking water quality: Guideline technical document - Cadmium. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (1986b). Guidelines for Canadian drinking water quality: Guideline technical document - Mercury. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (1986c). Guidelines for Canadian drinking water quality: Guideline technical document - Benzo[a]pyrene. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (1986d). Guidelines for Canadian drinking water quality: Guideline technical document - Toluene, ethylbenzene and the xylenes. Minister of Health, Ottawa, ON. Retrieved June 6, 2014.

Health Canada (1992). Guidelines for Canadian drinking water quality: Guideline technical document - Lead. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (1996a). The safety of dental amalgam. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (1996b). Guidelines for Canadian drinking water quality: Guideline technical document - Tetrachloroethylene. Minister of Health, Ottawa, ON. Retrieved July 4, 2014.

Health Canada (2004). Mercury - Your health and the environment. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (2005a). Fact sheet on chromated copper arsenate (CCA) treated wood. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2005b). Guidelines for Canadian drinking water quality: Supporting documentation - Trichloroethylene. Minister of Health, Ottawa, ON. Retrieved July 2, 2014.

Health Canada (2006a). Guidelines for Canadian drinking water quality: Guideline technical document - Arsenic. Minister of Health, Ottawa, ON. Retrieved April 22, 2015.

Health Canada (2006b). The National Strategy: Moving Forward - The 2006 progress report on tobacco control. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2006c). Guidelines for Canadian drinking water quality: Guideline technical document - Trihalomethanes. Minister of Health, Ottawa, ON. Retrieved June 25, 2014.

Health Canada (2007a). Human health risk assessment of mercury in fish and health benefits of fish consumption. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (2007b). Ethylbenzene and health. Minister of Health. Ottawa, ON. Retrieved April 21, 2015.

Health Canada (2008a). Food and nutrition: Health Canada reviews epidemiological studies on dietary acrylamide intake and the risk of endometrial, ovarian and/or breast cancer. Minister of Health, Ottawa, ON. Retrieved March 20, 2014.

Health Canada (2008b). Health risk assessment of bisphenol A from food packaging applications. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2008c). Mercury in Fish - Consumption advice: Making informed choices about fish. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (2009a). Food and nutrition: Information. Acrylamide - What you can do to reduce exposure. Minister of Health, Ottawa, ON. Retrieved March 20, 2014.

Health Canada (2009b). Food and nutrition: Health Canada updates its risk management strategy for acrylamide in food. Minister of Health, Ottawa, ON. Retrieved March 20, 2014.

Health Canada (2009c). Notice regarding Canada's legislated safety requirements related to heavy metal content in surface coating materials applied to children's toys. Minister of Health, Ottawa, ON.

Health Canada (2009d). Lead Information Package - Some Commonly Asked Questions About Lead and Human Health. Minister of Health, Ottawa, ON. Retrieved April 27, 2015.

Health Canada (2009e). Guidance on controlling corrosion in drinking water distribution systems. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2009f). Guidelines for Canadian drinking water quality: Guideline technical document - Benzene. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2010a). Report on Human Biomonitoring of Environmental Chemicals in Canada: Results of the Canadian Health Measures Survey Cycle 1 (2007-2009). Minister of Health, Ottawa, ON. Retrieved September 1, 2011.

Health Canada (2010b). Bisphenol A. Minister of Health, Ottawa, ON. Retrieved June 2, 2012.

Health Canada (2010c). Guidelines for Canadian drinking water quality: Guideline technical document - Fluoride. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2010d). It's your health - Fluoride and human health. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2010e). Dietary reference intakes. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2010f).  Report on the findings of the oral health component of the Canadian Health Measures Survey 2007-2009. Minister of Health, Ottawa. Retrieved March 24, 2015.

Health Canada (2010g). Smokeless tobacco products: A chemical and toxicity analysis. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2010h). Naphthalene. Re-evaluation decision RVD2010-04. Minister of Health, Ottawa, ON. Retrieved March 26, 2015.

Health Canada (2010i).  Regina Indoor Air Quality Study (2007): Data summary for volatile organic compound sampling. Minister of Health, Ottawa, ON. Retrieved April 21, 2015.

Health Canada (2011a). Draft proposal for cadmium guideline in children's jewellery. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2011b). Food Directorate updated approach for managing dietary exposure to lead. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2011c). Eating well with Canada's food guide. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (2011d). Carcinogens in tobacco smoke. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2011e). Residential indoor air quality guideline: Toluene. Minister of Health, Ottawa, ON. Retrieved June 9, 2014.

Health Canada (2012a). Analyses of volatile organic compounds in whole blood by solid phase microextraction and GC-MS/MS. Exposure and Biomonitoring Division, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, ON

Health Canada (2012b). Food and nutrition: Health Canada's revised exposure assessment of acrylamide in food. Minister of Health, Ottawa, ON. Retrieved August 6, 2014.

Health Canada (2012c). Natural health products ingredients database. Minister of Health, Ottawa, ON. Retrieved August 3, 2012.

Health Canada (2012d). Health Canada's updated assessment of bisphenol A (BPA) exposure from food sources. Minister of Health, Ottawa, ON. Retrieved March 23, 2015.

Health Canada (2012e). Guidelines for Canadian drinking water quality - Summary table. Minister of Health, Ottawa, ON. Retrieved August 25, 2014.

Health Canada (2012f). Canadian standards (maximum levels) for various chemical contaminants in foods. Minister of Health, Ottawa, ON. Retrieved March 23, 2015.

Health Canada (2012g). New labelling and packaging requirements for naphthalene-containing mothballs. Minister of Health, Ottawa, ON. Retrieved June 11, 2012.

Health Canada (2012h). Toluene in indoor air. Ottawa, ON. Retrieved June 9, 2014.

Health Canada (2013a). Second Report on Human Biomonitoring of Environmental Chemicals in Canada: Results of the Canadian Health Measures Survey Cycle 2 (2009-2011). Minister of Health, Ottawa, ON. Retrieved May 30, 2013.

Health Canada (2013b). Food and nutrition: Technical consultation - Health Canada call for data to assess the effectiveness of acrylamide reduction strategies in food. Minister of Health, Ottawa, ON. Retrieved August 6, 2014.

Health Canada (2013c). Food and nutrition: Notice of modification to the list of permitted food enzymes to enable the use of the enzyme asparaginase, obtained from Aspergillus oryzae (pCaHj621/BECh2#10), in green coffee. Minister of Health, Ottawa, ON. Retrieved April 21, 2015.

Health Canada (2013d). Drug product database online query. Minister of Health, Ottawa, ON. Retrieved June 12, 2014.

Health Canada (2013e). Canadian Total Diet Study. Minister of Health, Ottawa, ON. Retrieved March 27, 2014.

Health Canada (2013f). Final human health state of the science report on lead. Health Canada, Ottawa, ON. Retrieved June 13, 2013.

Health Canada (2013g).  It's your health - Lead and human health. Minister of Health, Ottawa, ON. Retrieved August 15, 2014.

Health Canada (2013h). Risk management strategy for lead. Health Canada, Ottawa, ON. Retrieved June 13, 2013.

Health Canada (2013i). Residential indoor air quality guideline: Naphthalene. Minister of Health, Ottawa, ON. Retrieved August 19, 2014.

Health Canada (2013j). Guidance for benzene in residential indoor air: Science assessment document. Minister of Health, Ottawa, ON. Retrieved May 15, 2014.

Health Canada (2014a). Determination of N-terminal hemoglobin adducts of acrylamide and glycidamide in whole blood by LC/MS/MS. Ontario Food Laboratory, Regions and Programs Bureau, Health Canada, Ottawa, ON.

Health Canada (2014b). List of prohibited and restricted cosmetic ingredients ("Hotlist"). Retrieved July 4, 2014.

Health Canada (2014c). Pesticide product information database. Retrieved April 21, 2015.

Health Canada (2014d). Proposed changes to the tolerances for arsenic and lead in fruit juice, fruit nectar, beverages when ready-to-serve, and water in sealed containers. Minister of Health, Ottawa, ON. Retrieved March 24, 2015.

Health Canada (2014e). Guidelines for Canadian drinking water quality: Document for public comment - Toluene, ethylbenzene and xylenes in drinking water. Ottawa, ON. Retrieved June 26, 2014.

Health Canada (2014f). Guidelines for Canadian drinking water quality: Document for public comment - Tetrachloroethylene in drinking water. Ottawa, ON. Retrieved September 2, 2014

Héroux, M.E., Clark, N., van Ryswyk, K., Mallick, R., Gilbert, N.L., Harrison, I., Rispler, K., Wang, D., Anastassopoulos, A., Guay, M., et al. (2010). Predictors of indoor air concentrations in smoking and non-smoking residences. International Journal of Environmental Research and Public Health, 7(8), 3080-3099.

Héroux, M.E., Gauvin, D., Gilbert, N.L., Guay, M., Dupuis, G., Legris, M., & Lévesque, B. (2008). Housing characteristics and indoor concentrations of selected volatile organic compounds (VOCs) in Quebec City, Canada. Indoor and Built Environment, 17(2), 128-137.

Hopf, N.B., Carreón, T., & Talaska, G. (2009). Biological markers of carcinogenic exposure in the aluminum smelter industry - A systematic review. Journal of Occupational and Environmental Hygiene, 6(9), 562-581.

HSDB (Hazardous Substances Data Bank) (2009).  Nicotine. National Library of Medicine, Bethesda, MD. Retrieved April 12, 2012.

Huang, J.H., Fecher, P., Ilgen, G., Hu, K.N., & Yang, J. (2012). Speciation of arsenite and arsenate in rice grain - Verification of nitric acid based extraction method and mass sample survey. Food Chemistry, 130(2), 453-459.

IARC (International Agency for Research on Cancer) (1987).  IARC monographs on the evaluation of carcinogenic risks to humans - Overall evaluations of carcinogenicity: An updating of IARC monographs volumes 1 to 42. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1991).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 52: Chlorinated drinking-water; chlorination by-products; some other halogenated compounds; cobalt and cobalt compounds. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1993).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 58: Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1995).  IARC monographs on the evaluation of carcinogenic risks to humans - Volume 63: Dry cleaning, some chlorinated solvents and other industrial chemicals. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1999a).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 60: Some industrial chemicals. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1999b).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 71: Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (1999c).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 73: Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2000).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 77: Some industrial chemicals. World Health Organization, Lyon. Retrieved April 21, 2015.

IARC (International Agency for Research on Cancer) (2002).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 82: Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2004).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 83: Tobacco smoke and involuntary smoking. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2006).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 87: Inorganic and organic lead compounds. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2007).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 89: Smokeless tobacco and some tobacco-specific N-nitrosamines. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2010).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 92: Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2012a).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 100C: Arsenic, metals, fibres, and dusts. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2012b).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 100F: Chemical agents and related occupations. World Health Organization, Lyon. Retrieved March 23, 2015.

IARC (International Agency for Research on Cancer) (2014).  IARC monographs on the evaluation of carcinogenic risks to humans - volume 106: Trichloroethylene, tetrachloroethylene, and some chlorinated agents. World Health Organization, Lyon. Retrieved March 20, 2015.

IMERC (Interstate Mercury Education and Reduction Clearinghouse) (2010).  Fact sheet - Mercury use in dental amalgam. Northeast Waste Management Officials' Association, Boston, MA. Retrieved April 3, 2012.

INSPQ (Institut national de santé publique du Québec) (2004).  Étude sur l'établissement de valeurs de référence d'éléments traces et de métaux dans le sang, le sérum et l'urine de la population de la grande région de Québec. INSPQ, Quebec City, QC. Retrieved July 11, 2011.

INSPQ (Institut national de santé publique du Québec) (2008). Analytical method for the determination of urine creatinine on Hitachi 917 (C-530), condensed version for the CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2009a). Analytical method for the determination of arsenic species in urine by ultra performance liquid chromatography coupled to argon plasma induced mass spectrometry (HPLC-ICP-MS) (M-585), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2009b). Analytical method for the determination of fluoride in urine (M-186), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2009c). Analytical method for the determination of inorganic mercury in urine with the FIMS 100 module from Perkin Elmer (M-568), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2009d). Analytical method for the determination of cotinine in urine by HPLC-MS-MS robotic workstation method (C-550), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2010). Analytical method for the determination of metals in blood by inductively coupled plasma mass spectrometry (ICP-MS), DRC II (M-572-D), condensed version for the CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2011). Analytical method for the determination of methylmercury in blood by Waters Acquity high-pressure liquid chromatography coupled with Varian 820-MS inductively coupled plasma mass spectrometry (HPLC-ICP-MS) (M-595-A), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2014a). Analytical method for the determination of bisphenol A and triclosan in urine by GC-MS-MS (E-475), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2014b). Analytical method for the determination of hydroxy polycyclic aromatic hydroxyhydrocarbons (PAHs) in urine by GC-MS-MS (E-465-A), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

INSPQ (Institut national de santé publique du Québec) (2014c). Analytical method for the determination of benzene metabolites in urine by UPLC-MS-MS (E-477), condensed version for CHMS. Laboratoire de toxicologie, Québec, QC.

IOM (Institute of Medicine) (1997). Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. The National Academies Press, Washington, DC.

IPCS (International Programme on Chemical Safety) (1997).  Environmental Health Criteria 190: Xylenes. World Health Organization, Geneva. Retrieved June 10, 2014.

IPCS (International Programme on Chemical Safety) (2000).  Environmental Health Criteria 216: Disinfectants and disinfectant by-products. World Health Organization, Geneva. Retrieved June 25, 2014.

IPCS (International Programme on Chemical Safety) (2003).  Concise international chemical assessment document 50 - Elemental mercury and inorganic mercury compounds: Human health aspects. World Health Organization, Geneva. Retrieved August 25, 2014.

Iwase, A., Aiba, M., & Kira, S. (1991). Respiratory nicotine absorption in non-smoking females during passive smoking. International Archives of Occupational and Environmental Health, 63(2), 139-143.

Jacob, J., & Seidel, A. (2002). Biomonitoring of polycyclic aromatic hydrocarbons in human urine. Journal of Chromatography B, 778(1), 31-47.

Jacob, J., Grimmer, G., & Dettbarn, G. (1999). Profile of urinary phenanthrene metabolites in smokers and non-smokers: Biomarkers. Biomarkers, 4(5), 319-327.

Jones, R.D., Jampani, H.B., Newman, J.L., & Lee, A.S. (2000). Triclosan: A review of effectiveness and safety in health care settings. American Journal of Infection Control, 28(2), 184-196.

Jongeneelen, F.J., Anzion, R.B.M., Leijdekkers, C.M., Bos, R.P., & Henderson, P.T. (1985). 1-Hydroxypyrene in human urine after exposure to coal tar and a coal tar derived product. International Archives of Occupational and Environmental Health, 57(1), 47-55.

Jules, G.E., Pratap, S., Ramesh, A., & Hood, D.B. (2012). In utero exposure to benzo(a)pyrene predisposes offspring to cardiovascular dysfunction in later-life. Toxicology, 295(1), 56-67.

Kang, D.H., Choi, D.H., Won, D., Yang, W., Schleibinger, H., & David, J. (2012). Household materials as emission sources of naphthalene in Canadian homes and their contribution to indoor air. Atmospheric Environment, 50, 79-87.

Kao, J., Patterson, F.K., & Hall, J. (1985). Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: An in vitro study with benzo[a]pyrene and testosterone. Toxicology and Applied Pharmacology, 81(3), 502-516.

Karaconji, I.B. (2005). Facts about nicotine toxicity. Archives of Industrial Hygiene and Toxicology, 56(4), 363-371.

Labrecque F., & Quigley, A. (2014). Sampling documentation for cycle 3 of the Canadian Health Measures Survey. Statistics Canada, Household Survey Methods Division, internal document.

Laird, B.D., Goncharov, A.B., & Chan, H.M. (2013). Body burden of metals and persistent organic pollutants among Inuit in the Canadian Arctic. Environment International, 59, 33-40.

Lanphear, B.P., Hornung, R., Khoury, J., Yolton, K., Baghurst, P., Bellinger, D.C., Canfield, R.L., Dietrich, K.N., Bornschein, R., Greene, T., et al. (2005). Low-level environmental lead exposure and children's intellectual function: An international pooled analysis. Environmental Health Perspectives, 113(7), 894-899.

Lauwerys, R.R., Bernard, A.M., Roels, H.A., & Buchet, J.P. (1994). Cadmium: Exposure markers as predictors of nephrotoxic effects. Clinical Chemistry, 40(7), 1391-1394.

Legrand, M., Feeley, M., Tikhonov, C., Schoen, D., & Li-Muller, A. (2010). Methylmercury blood guidance values for Canada. Canadian Journal of Public Health, 101(1), 28-31.

Leufroy, A., Noel, L., Dufailly, V., Beauchemin, D., & Guerin, T. (2011). Determination of seven arsenic species in seafood by ion exchange chromatography coupled to inductively coupled plasma-mass spectrometry following microwave assisted extraction: method validation and occurrence data. Talanta, 83(3), 770-779.

Lye, E., Legrand, M., Clarke, J., & Probert, A. (2013). Blood total mercury concentrations in the Canadian population: Canadian Health Measures Survey cycle 1, 2007-2009. Canadian Journal of Public Health, 104(3), e246-251.

Mackay, K.M., & Mackay, R.A. (1989). Introduction to modern inorganic chemistry. Prentice Hall, Englewood Cliffs, NJ.

Mage, D.T., Allen, R.H., Gondy, G., Smith, W., Barr, D.B., & Needham, L.L. (2004). Estimating pesticide dose from urinary pesticide concentration data by creatinine correction in the Third National Health and Nutrition Examination Survey (NHANES-III). Journal of Exposure Analysis and Environmental Epidemiology, 14(6), 457-465.

Maibach, H.I. (1969). Percutaneous penetration of Irgasan® CH 3565 in a soap solution. University of California Medical Center, Department of Dermatology, San Francisco, CA.

McHale, C.M., Zhang, L., & Smith, M.T. (2012). Current understanding of the mechanism of benzene-induced leukemia in humans: Implications for risk assessment. Carcinogenesis, 33(2), 240-252.

Meek, M.E., & Klaunig, J.E. (2010). Proposed mode of action of benzene-induced leukemia: Interpreting available data and identifying critical data gaps for risk assessment. Chemico-Biological Interactions, 184(1-2), 279-285.

Meeker, J.D., Barr, D.B., Serdar, B., Rappaport, S.M., & Hauser, R. (2007). Utility of urinary 1-naphthol and 2-naphthol levels to assess environmental carbaryl and naphthalene exposure in an epidemiology study. Journal of Exposure Sciences and Environmental Epidemiology, 17(4), 314-320.

Mielke, H., Partosch, F., & Gundert-Remy, U. (2011). The contribution of dermal exposure to the internal exposure of bisphenol A in man. Toxicology Letters, 204, 190-198.

Mitchell, C.E., & Tu, K.W. (1979). Distribution, retention, and elimination of pyrene in rats after inhalation. Journal of Toxicology and Environmental Health, 5(6), 1171-1179.

Mondal, R., Miyaki, N., Becerril, H.A., Norton, J.E., Parmer, J., Mayer, A.C., Tang, M.L., Brédas, J., McGehee, M.D., & Bao, Z. (2009). Synthesis of acenaphthyl and phenanthrene based fused-aromatic thienopyrazine co-polymers for photovoltaic and thin film transistor applications. Chemistry of Materials, 21(15), 3618-3628.

Morrow, H. (2000). Cadmium and cadmium alloys. Kirk-Othmer Encyclopedia of Chemical Technology. John Wiley & Sons, Inc., Mississauga, ON.

Nethery, E., Wheeler, A.J., Fisher, M., Sjodin, A., Li, Z., Romanoff, L.C., Foster, W., & Arbuckle, T.E. (2012). Urinary polycyclic aromatic hydrocarbons as a biomarker of exposure to PAHs in air: A pilot study among pregnant women. Journal of Exposure Sciences and Environmental Epidemiology, 22(1), 70-81.

Newbold, R.R., Padilla-Banks, E., & Jefferson, W.N. (2009). Environmental estrogens and obesity. Molecular and Cellular Endocrinology, 304(1), 84-89.

Nicolae, A., Ames, H., & Quinonez, C. (2013). Dental amalgam and urinary mercury concentrations: A descriptive study. BMC Oral Health, 13(44), 1-12.

NRC (National Research Council) (2006).  Fluoride in drinking water: A scientific review of EPA's Standards. Committee on Fluoride in Drinking Water, National Academies Press, Washington, DC. Retrieved March 26, 2015.

NSF International (2013).  NSF/ANSI Standard 60: Drinking Water Treatment Additives - health effects. NSF International, Ann Arbor, MI. Retrieved March 26, 2015.

NSF International (2014).  Health Canada survey on provincial adoption of ANSI/NSF Standard 60 and 61; NSF 372; NSF 223. NSF International, Ann Arbor, MI. Retrieved July 24, 2014.

NTP (National Toxicology Program) (2002).  Report on Carcinogens Background Document for Naphthalene. US Department of Health and Human Services, Research Triangle Park, NC. Retrieved March 24, 2015.

NTP (National Toxicology Program) (2005).  NTP-CERHR monograph on the potential human reproductive and developmental effects of acrylamide. U.S. Department of Health and Human Services, Research Triangle Park, NC. Retrieved April 21, 2015.

NTP (National Toxicology Program) (2007).  NTP-CERHR expert panel report on the reproductive and developmental toxicity of bisphenol-A. Department of Health and Human Services, Research Triangle Park, NC. Retrieved March 26, 2015.

NTP (National Toxicology Program) (2011).  Report on carcinogens. Department of Health and Human Services, Research Triangle Park, NC. Retrieved January 23, 2012.

Pearson, M., Lu, C., Schmotzer, B., Waller, L., & Riederer, A. (2009). Evaluation of physiological measures for correcting variation in urinary output: Implications for assessing environmental chemical exposure in children. Journal of Exposure Science and Environmental Epidemiology, 19(3), 336-342.

Qu, Q., Shore, R., Li, G., Su, L., Jin, X., Melikian, A.A., Roy, N., Chen, L.C., Wirgin, I., Cohen, et al. (2005). Biomarkers of benzene: Urinary metabolites in relation to individual genotype and personal exposure. Chemico-Biological Interactions, 153-154, 85-95.

Queckenberg, C., Meins, J., Wachall, B., Doroshyenko, O., Tomalik-Scharte, D., Bastian, B., Abdel-Tawab, M., & Fuhr, U. (2010). Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrobial Agents and Chemotherapy, 54(1), 570-572.

Rao, J., Wu, C., & Yue, K. (1992). Some recent work on resampling methods for complex surveys. Survey Methodology, 18(2), 209-217.

Rasmussen, P.E., Beauchemin, S., Chénier, M., Levesque, C., MacLean, L.C.W., Marro, L., Jones-Otazo, H., Petrovic, S., McDonald, L.T., & Gardner, H.D. (2011). Canadian house dust study: Lead bioaccessibility and speciation. Environmental Science & Technology, 45(11), 4959-4965.

Rasmussen, P.E., Beauchemin, S., Maclean, L.C.W., Chénier, M., Levesque, C., & Gardner, H.D. (2014). Impact of humidity on speciation and bioaccessibility of Pb, Zn, Co and Se in house dust. Journal of Analytical Atomic Spectrometry, 29(7), 1206-1217.

Rasmussen, P.E., Levesque, C., Chénier, M., Gardner, H.D., Jones-Otazo, H., & Petrovic, S. (2013). Canadian House Dust Study: Population-based concentrations, loads and loading rates of arsenic, cadmium, chromium, copper, nickel, lead, and zinc inside urban homes. Science of the Total Environment, 443, 520-529.

Rasmussen, P.E., Subramanian, K.S., & Jessiman, B.J. (2001). A multi-element profile of house dust in relation to exterior dust and soils in the city of Ottawa, Canada. Science of the Total Environment, 267(1), 125-140.

Remer, T., Neubert, A., & Maser-Gluth, C. (2002). Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. American Journal of Clinical Nutrition, 75(3), 561-569.

Rencz, A.N., Garrett, R.G., Adcock, S.W., & Bonham-Carter, G.F. (2006). Geochemical background in soil and till. No. Open File 5084. Geological Survey of Canada, Ottawa, ON.

Repace, J., Zhang, B., Bondy, S.J., Benowitz, N., & Ferrence, R. (2013). Air quality, mortality, and economic benefits of a smoke-free workplace law for non-smoking Ontario bar workers. Indoor Air, 23(2), 93-104.

Richardson, E., Pigott, W., Craig, C., Lawson. M., & Mackie, C. (2011).  North Hamilton child blood lead study public health report. Hamilton Public Health Services, Hamilton, ON. Retrieved May 22, 2012.

Richardson, G.M. (2014). Mercury exposure and risks from dental amalgam in Canada: The Canadian Health Measures Survey 2007-2009. Human and Ecological Risk Assessment: An International Journal, 20(2), 433-447.

Rihs, H., Pesch, B., Kappler, M., Rabstein, S., Rossbach, B., Angerer, J., Scherenberg, M., Adams, A., Wilhelm, M., Seidel, A., et al. (2005). Occupational exposure to polycyclic aromatic hydrocarbons in German industries: Association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphisms. Toxicology Letters, 157(3), 241-255.

Rothenberg, S.J., Khan, F., Manalo, M., Jiang, J., Cuellar, R., Reyes, S., Acosta, S., Jauregui, M., Diaz, M., Sanchez, M., et al. (2000). Maternal bone lead contribution to blood lead during and after pregnancy. Environmental Research, 82(1), 81-90.

Rust, K.F., & Rao, J.N.K. (1996). Variance estimation for complex surveys using replication techniques. Statistical Methods in Medical Research, 5(3), 283-310.

Ruttens, A., Blanpain, A.C., De Temmerman, L., & Waegeneers, N. (2012). Arsenic speciation in food in Belgium: Part 1: Fish, molluscs and crustaceans. Journal of Geochemical Exploration, 121, 55-61.

Sandborgh-Englund, G., Adolfsson-Erici, M., Odham, G., & Ekstrand, J. (2006). Pharmacokinetics of triclosan following oral ingestion in humans. Journal of Toxicology and Environmental Health, Part A, 69(20), 1861-1873.

Sandborgh-Englund, G., Elinder, C., Johanson, G., Lind, B., Skare, I., & Ekstrand, J. (1998). The absorption, blood levels, and excretion of mercury after a single dose of mercury vapor in humans. Toxicology and Applied Pharmacology, 150(1), 146-153.

SCCP (Scientific Committee on Consumer Products) (2009). Opinion on triclosan (COLIPA No. P32). Health & Consumer Protection Directorate-General, European Commission, Brussels.

Schwerdtle, T., Walter, I., Mackwin, I., & Hartwig, A. (2003). Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis, 24(5), 967-974.

Seaton, M.J., & Vesell, E.S. (1993). Variables affecting nicotine metabolism. Pharmacology & Therapeutics, 60(3), 461-500.

Smith, M.T. (2010). Advances in understanding benzene health effects and susceptibility. Annual Review of Public Health, 31, 133-148.

Song, Y., Hauser, R., Hu, F.B., Franke, A.A., Liu, S., & Sun, Q. (2014). Urinary concentrations of bisphenol A and phthalate metabolites and weight change: A prospective investigation in US women. International Journal of Obesity, 1-6.

Soto, A.M., Vandenberg, L.N., Maffini, M.V., & Sonnenschein, C. (2008). Does breast cancer start in the womb? Basic & Clinical Pharmacology & Toxicology, 102(2), 125-133.

SRNT Subcommittee on Biochemical Verification (2002). Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4, 149-159.

Statistics Canada (2012).  Canadian Health Measures Survey: Cycle 2 Data Tables. No. 82-626-X. Ministry of Industry, Ottawa, ON. Retrieved August 29, 2014.

Statistics Canada (2013a). Canadian Health Measures Survey (CHMS) Content summary for cycles 1 to 8. Ottawa, ON. Available upon request (infostats@statcan.gc.ca).

Statistics Canada (2013b).  Blood lead concentrations in Canadians, 2009 to 2011. Health Fact Sheets. Catalogue no. 82-625-X. Retrieved March 24, 2015.

Statistics Canada (2015). Canadian Health Measures Survey (CHMS) data user guide: Cycle 3. Ottawa, ON. Available upon request (infostats@statcan.gc.ca).

Stierlin, H. (1972). GP 41 353: Scouting studies to ascertain the cutaneous resorption of GP 41 353 in humans after topical application in a crème excipient. Ciba Geigy Ltd, Basel.

Storer, J.S., DeLeon, I., Millikan, L.E., Laseter, J.L., & Griffing, C. (1984). Human absorption of crude coal tar products. Archives of Dermatology, 120(7), 874-877.

Strickland, P., Kang, D., & Sithisarankul, P. (1996). Polycyclic aromatic hydrocarbon metabolites in urine as biomarkers of exposure and effect. Environmental Health Perspectives, 104 (Supplement 5), 927-932.

Teass, A., Biagini, R., DeBord, G., & DeLon Hull, R. (2003). Application of biological monitoring methods. NIOSH Manual of Analytical Methods, NIOSH Publication Number 2003-154(3).

Trail Health and Environment Committee (2011).  Annual fall blood lead testing results. Trail, BC. Retrieved August 18, 2014.

TRL (Toxicity Research Laboratories) (1989). 13-week mouse oral subchronic toxicity study on pyrene. TRL Study No. 042-012. Toxicity Research Laboratories, Ltd., Muskegon, MI.

Tseng, W. (1977). Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environmental Health Perspectives, 19, 109-119.

Turkall, R.M., Skowronski, G.A., Kadry, A.M., & Abdel-Rahman, M.S. (1994). A comparative study of the kinetics and bioavailability of pure and soil-adsorbed naphthalene in dermally exposed male rats. Archives of Environmental Contamination and Toxicology, 26(4), 504-509.

UNEP (United Nations Environment Programme) (2002).  Global Mercury Assessment. UNEP Chemicals, Geneva. Retrieved April 2, 2012.

UNEP (United Nations Environment Programme) (2007).  Montreal Protocol on Substances that Deplete the Ozone Layer. Ozone Secretariat, UNEP. Retrieved July 4, 2014.

UNEP (United Nations Environment Programme) (2013).  Minimata Convention on Mercury. United Nations. Retrieved August 26, 2014.

Urban, M., Kavvadias, D., Riedel, K., Scherer, G., & Tricker, A.R. (2006). Urinary mercapturic acids and a hemoglobin adduct for the dosimetry of acrylamide exposure in smokers and nonsmokers. Inhalation Toxicology, 18(10), 831-839. Retrieved on March 26, 2015.

USGS (U.S. Geological Survey) (2012).  Mineral Commodity Summaries 2012. Reston, VA. Retrieved April 16, 2012.

Viau, C., Carrier, G., Vyskocil, A., & Dodd, C. (1995). Urinary excretion kinetics of 1-hydroxypyrene in volunteers exposed to pyrene by the oral and dermal route. Science of the Total Environment, 163(1-3), 179-186.

Walsh, P.M., & Epstein, J.B. (2000). The oral effects of smokeless tobacco. Journal of the Canadian Dental Association, 66(1), 22-25.

Weisel, C.P. (2010). Benzene exposure: An overview of monitoring methods and their findings. Chemico-Biological Interactions, 184(1), 58-66.

Wheeler, A., Dobbin, N., Héroux, M., Fisher, M., Sun, L., Khoury, C., Hauser, R., Walker, M., Ramsay, T., Bienvenu, J., et al. (2014). Urinary and breast milk biomarkers to assess exposure to naphthalene in pregnant women: An investigation of personal and indoor air sources. Environmental Health, 13(1), 1-12.

Wheeler, A.J., Wong, S.L., & Khoury, C. (2013). Predictors of indoor BTEX concentrations in Canadian residences. Health Reports, 24(5), 11-17.

WHO (World Health Organization) (1990).  Environmental Health Criteria 101: Methylmercury. WHO, Geneva. Retrieved April 4, 2012.

WHO (World Health Organization) (1998).  Environmental Health Criteria 202: Selected non-heterocyclic polycyclic aromatic hydrocarbons. WHO, Geneva. Retrieved June 11, 2012.

WHO (World Health Organization) (2000).  Air quality guidelines for Europe, second edition. WHO, Geneva. Retrieved March 27, 2012.

WHO (World Health Organization) (2001).  Environmental Health Criteria 224: Arsenic and arsenic compounds. WHO, Geneva. Retrieved January 4, 2012.

WHO (World Health Organization) (2004).  Trihalomethanes in drinking-water: Background document for development of WHO guidelines for drinking-water quality. WHO, Geneva. Retrieved June 25, 2014.

WHO (World Health Organization) (2006).  Sixty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives: Evaluation of certain food contaminants. World Health Organization, Geneva. Retrieved August 17, 2012.

WHO (World Health Organization) (2010a).  Gender, women, and the tobacco epidemic. WHO, Geneva. Retrieved August 25, 2014.

WHO (World Health Organization) (2010b).  WHO guidelines for indoor air quality: Selected pollutants. The WHO European Center for Environment and Health, Bonn, Germany. Retrieved April 10, 2015.

WHO (World Health Organization) (2011a).  Toxicological and health aspects of bisphenol A: Report of joint FAO/WHO expert meeting and stakeholder meeting on bisphenol A. World Health Organization, Geneva. Retrieved August 2, 2012.

WHO (World Health Organization) (2011b).  Guidelines for drinking-water quality, fourth edition. WHO, Geneva. Retrieved March 9, 2012.

WHO (World Health Organization) (2011c).  Lead in drinking-water: Background document for development of WHO guidelines for drinking-water quality. WHO, Geneva. Retrieved May 22, 2012.

Wislocki, P.G., Bagan, E.S., Lu, A.Y.H., Dooley, K.L., Fu, P., Han-Hsu, H., Beland, F.A., & Kadlubar, F.F. (1986). Tumorigenicity of nitrated derivatives of pyrene, benz[a]anthracene, chrysene and benzo[a]pyrene in the newborn mouse assay. Carcinogenesis, 7(8), 1317-1322.

Wong, S.L., Malaison, E., Hammond, D., & Leatherdale, S.T. (2013). Secondhand smoke exposure among Canadians: Cotinine and self-report measures from the Canadian Health Measures Survey 2007-2009. Nicotine & Tobacco Research, 15(3), 693-700.

Wong, S.L., Shields, M., Leatherdale, S., Malaison, E., & Hammond, D. (2012). Assessment of validity of self-reported smoking status. Health Reports, 23(1), 1-7.

Wu, M.M., Kuo, T.L., Hwang, Y.H., & Chen, C.J. (1989). Dose-response relation between arsenic concentration in well water and mortality from cancer and vascular diseases. American Journal of Epidemiology, 130, 1123-1132.

Wu, W., Guo, F., Li, J., He, J., & Hua, J. (2010). New fluoranthene-based cyanine dye for dye-sensitized solar cells. Synthetic Metals, 160(9), 1008-1014.

Yang, J.J., Roy, T.A., & Mackerer, C.R. (1986). Percutaneous absorption of benzo[a]pyrene in the rat: Comparison of in vivo and in vitro results. Toxicology and Industrial Health, 2(4), 409-416.

Ye, X., Kuklenyik, Z., Needham, L., & Calafat, A. (2005). Quantification of urinary conjugates of bisphenol A, 2,5-dichlorophenol, and 2-hydroxy-4-methoxybenzophenone in humans by online solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 383(4), 638-644.

Yücel, M., Takagi, M., Walterfang, M., & Lubman, D.I. (2008). Toluene misuse and long-term harms: A systematic review of the neuropsychological and neuroimaging literature. Neuroscience and Biobehavioral Reviews, 32(5), 910-926.

Zalko, D., Jacques, C., Duplan, H., Bruel, S., & Perdu, E. (2011). Viable skin efficiently absorbs and metabolizes bisphenol A. Chemosphere, 82, 424-430.

Zhu, J., Wong, S.L., & Cakmak, S. (2013). Nationally representative levels of selected volatile organic compounds in Canadian residential indoor air: Population-based survey. Environmental Science & Technology, 47(23), 13276-13283.

Appendix A: Limits of Detection

Laboratory analyses of environmental chemicals and creatinine were performed at analytical laboratories within Health Canada and l'Institut national de santé publique du Québec (INSPQ). Laboratories developed standardized operating procedures for the analytical methods used to measure environmental chemicals or their metabolites in biological samples. The limit of detection (LOD) is defined as the lowest concentration of the analyte whose analytical response is measured to be greater than the noise level with 99% confidence and evaluated using EPA methodology (EPA, 2015) ^{Appendix A footnote 1}.

Limits of Detection

	Cycle 1	Cycle 2	Cycle 3
Metals and Trace Elements in Blood
Cadmium	0.04 µg/L	0.04 µg/L	0.08 µg/L
Lead	0.02 µg/dL	0.1 µg/dL	0.2 µg/dL
Methylmercury	---	---	0.2 µg Hg/L
Total mercury	0.1 µg/L	0.1 µg/L	0.4 µg/L
Metals and Trace Elements in Urine
Arsenate	---	0.8 µg As/LAppendix A footnote b	0.8 µg As/L
Arsenite	---	0.8 µg As/LAppendix A footnote b	0.8 µg As/L
Arsenocholine	---	---	0.8 µg As/L
Arsenocholine and arsenobetaine	---	0.8 µg As/LAppendix A footnote b	0.8 µg As/L
Dimethylarsinic acid	---	0.8 µg As/LAppendix A footnote b	0.8 µg As/L
Monomethylarsonic acid	---	0.8 µg As/LAppendix A footnote b	0.8 µg As/L
Fluoride	---	20 µg/L	10 µg/L
Inorganic mercury	0.1 µg/L	---	0.2 µg/L
Benzene Metabolites
S-Phenylmercapturic acid	---	0.08 µg/L	0.08 µg/L
trans,trans-Muconic acid	---	0.8 µg/L	0.6 µg/L
Environmental Phenols
Bisphenol A	0.2 µg/L	0.2 µg/L	0.2 µg/L
Triclosan	---	3 µg/L	5 µg/L
Nicotine Metabolite
Cotinine	1 µg/L	1 µg/L	1 µg/L
Volatile Organic Compounds
Benzene	---	---	0.007 µg/L
Bromodichloromethane	---	---	0.01 µg/L
Dibromochloromethane	---	---	0.007 µg/L
Ethylbenzene	---	---	0.01 µg/L
m-Xylene and p-xylene	---	---	0.02 µg/L
o-Xylene	---	---	0.009 µg/L
Styrene	---	---	0.01 µg/L
Tetrachloroethylene (Perchloroethylene)	---	---	0.02 µg/L
Toluene	---	---	0.01 µg/L
Tribromomethane (Bromoform)	---	---	0.01 µg/L
Trichloroethylene	---	---	0.03 µg/L
Trichloromethane (Chloroform)	---	---	0.01 µg/L
Acrylamide
Acrylamide haemoglobin adduct	---	---	10 pmol/g haemoglobin
Glycidamide haemoglobin adduct	---	---	20 pmol/g haemoglobin
Polycyclic Aromatic Hydrocarbon Metabolites
Benzo[a]pyrene Metabolite
3-Hydroxybenzo[a]pyrene	---	0.002 µg/L	0.003 µg/L
Chrysene Metabolites
2-Hydroxychrysene	---	0.004 µg/L	0.005 µg/L
3-Hydroxychrysene	---	0.003 µg/L	0.003 µg/L
4-Hydroxychrysene	---	0.003 µg/L	0.002 µg/L
6-Hydroxychrysene	---	0.006 µg/L	0.002 µg/L
Fluoranthene Metabolite
3-Hydroxyfluoranthene	---	0.008 µg/L	0.008 µg/L
Fluorene Metabolites
2-Hydroxyfluorene	---	0.003 µg/L	0.006 µg/L
3-Hydroxyfluorene	---	0.001 µg/L	0.002 µg/L
9-Hydroxyfluorene	---	0.003 µg/L	0.004 µg/L
Naphthalene Metabolites
1-Hydroxynapththalene	---	0.1 µg/L	0.02 µg/L
2-Hydroxynapththalene	---	0.05 µg/L	0.03 µg/L
Phenanthrene Metabolites
1-Hydroxyphenanthrene	---	0.005 µg/L	0.002 µg/L
2-Hydroxyphenanthrene	---	0.003 µg/L	0.002 µg/L
3-Hydroxyphenanthrene	---	0.003 µg/L	0.002 µg/L
4-Hydroxyphenanthrene	---	0.001 µg/L	0.003 µg/L
9-Hydroxyphenanthrene	---	0.004 µg/L	0.004 µg/L
Pyrene Metabolite
1-Hydroxypyrene	---	0.002 µg/L	0.003 µg/L
Adjustment Factor
Creatinine	3 mg/dL	4 mg/dL	5 mg/dL
Appendix A footnote a EPA (U.S. Environmental Protection Agency) (2015). Definition and procedure for the determination of the method detection limit - Revision 1.11, Federal Regulation 40 CFR 136 Appendix B. United States Environmental Protection Agency, Washington, DC. Return to Appendix A footnote a referrer Appendix A footnote b In the Second Report on Human Biomonitoring of Environmental Chemicals in Canada, all speciated arsenic was reported as µg of arsenic species per litre (e.g. µg arsenate/L). For this reason, the values presented in this report may differ from those in the Second Report. Return to the first Appendix A footnote b referrer

Appendix B: Conversion Factors

Units of measurement are important. Results are reported here using standard units; however, units can be converted using the conversion factors presented below for comparison of data with other data sets.

Definition of Units

Unit	Abbreviation	Value
litre	L
decilitre	dL	10-1 L
millilitre	mL	10-3 L
microlitre	µL	10-6 L
gram	g
milligram	mg	10-3 g
microgram	µg	10-6 g
nanogram	ng	10-9 g
picogram	pg	10-12 g

Data can be converted from µg/L to µmol/L using the molecular weight (MW) of the chemical using the formula:

Y µmol/L = X µg/L x conversion factor (CF), where the CF is equivalent to 1/MW.

Conversion Factors

	MW (g/mol)	CF (µg/L → µmol/L)
Metals and Trace Elements
Arsenate	---	0.01335Appendix B footnote a
Arsenite	---	0.01335Appendix B footnote a
Arsenocholine	---	0.01335Appendix B footnote a
Arsenocholine and arsenobetaine	---	0.01335Appendix B footnote a
Dimethylarsinic acid	---	0.01335Appendix B footnote a
Monomethylarsonic acid	---	0.01335Appendix B footnote a
Cadmium	112.41	0.00896
Fluoride	19.00	0.05263
Lead	207.20	0.04826Appendix B footnote b
Methylmercury	---	0.00499Appendix B footnote c
Mercury	200.59	0.00499
Benzene Metabolites
trans,trans-Muconic acid	142.11	0.00704
S-Phenylmercapturic acid	239.29	0.00418
Environmental Phenols
Bisphenol A	228.29	0.00438
Triclosan	289.54	0.00345
Nicotine Metabolite
Cotinine	176.22	0.00567
Volatile Organic Compounds
Benzene	78.11	0.01280
Bromodichloromethane	163.83	0.00610
Dibromochloromethane	208.28	0.00480
Ethylbenzene	106.17	0.00942
m-Xylene and p-xylene	106.17	0.00942
o-Xylene	106.17	0.00942
Styrene	104.15	0.00960
Tetrachloroethylene (Perchloroethylene)	165.83	0.00603
Toluene	92.14	0.01085
Tribromomethane (Bromoform)	252.73	0.00396
Trichloroethylene	131.39	0.00761
Trichloromethane (Chloroform)	119.38	0.00838
Acrylamide
Acrylamide haemoglobin adduct	---	NAAppendix B footnote d
Glycidamide haemoglobin adduct	---	NAAppendix B footnote d
Polycyclic Aromatic Hydrocarbon Metabolites
Benzo[a]pyrene Metabolite
3-Hydroxybenzo[a]pyrene	268.31	0.00373
Chrysene Metabolites
2-Hydroxychrysene	244.29	0.00409
3-Hydroxychrysene	244.29	0.00409
4-Hydroxychrysene	244.29	0.00409
6-Hydroxychrysene	244.29	0.00409
Fluoranthene Metabolite
3-Hydroxyfluoranthene	218.25	0.00458
Fluorene Metabolites
2-Hydroxyfluorene	182.22	0.00549
3-Hydroxyfluorene	182.22	0.00549
9-Hydroxyfluorene	182.22	0.00549
Naphthalene Metabolites
1-Hydroxynapththalene	144.17	0.00694
2-Hydroxynapththalene	144.17	0.00694
Phenanthrene Metabolites
1-Hydroxyphenanthrene	194.23	0.00515
2-Hydroxyphenanthrene	194.23	0.00515
3-Hydroxyphenanthrene	194.23	0.00515
4-Hydroxyphenanthrene	194.23	0.00515
9-Hydroxyphenanthrene	194.23	0.00515
Pyrene Metabolite
1-Hydroxypyrene	218.25	0.00458
Adjustment Factor
Creatinine	113.12	88.4Appendix B footnote e
Appendix B footnote a For converting arsenic species from µg As/L to µmol As/L Return to the first Appendix B footnote a referrer Appendix B footnote b For converting Pb from µg/dL to µmol/L Return to Appendix B footnote b referrer Appendix B footnote c For converting methylmercury from µg Hg/L to µmol Hg/L Return to Appendix B footnote c referrer Appendix B footnote d Not applicable Return to the first Appendix B footnote d referrer Appendix B footnote e For converting creatinine from mg/dL to µmol/L Return to Appendix B footnote e referrer

Appendix C: Creatinine

Creatinine - Geometric means and selected percentiles of urine concentrations (mg/dL) for the Canadian population aged 6-79 years by age group, Canadian Health Measures Survey cycle 1 (2007-2009).

Group	Age (years)	Cycle	n	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	6-79	1 (2007-2009)	5515	83 (78 - 89)	27 (23 - 30)	93 (86 - 99)	210 (200 - 220)	250 (240 - 260)
Males	6-79	1 (2007-2009)	2663	100 (97 - 110)	36 (28 - 43)	110 (100 - 110)	230 (220 - 240)	270 (250 - 280)
Females	6-79	1 (2007-2009)	2852	68 (62 - 74)	22 (18 - 25)	75 (66 - 84)	180 (160 - 190)	210 (200 - 230)
Total	6-11	1 (2007-2009)	1042	66 (60 - 72)	24 (18 - 29)	74 (67 - 81)	140 (130 - 150)	170 (160 - 180)
Total	12-19	1 (2007-2009)	992	120 (110 - 130)	39 (30 - 47)	130 (120 - 140)	250 (230 - 280)	300 (260 - 330)
Total	20-39	1 (2007-2009)	1172	90 (81 - 100)	29 (22 - 36)	99 (91 - 110)	230 (210 - 240)	280 (250 - 300)
Total	40-59	1 (2007-2009)	1221	78 (73 - 84)	24 (19 - 28)	86 (76 - 96)	210 (190 - 230)	240 (230 - 250)
Total	60-79	1 (2007-2009)	1088	72 (68 - 75)	26 (22 - 31)	81 (77 - 85)	150 (140 - 160)	190 (170 - 220)

Creatinine - Geometric means and selected percentiles of urine concentrations (mg/dL) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 2 (2009-2011).

Group	Age (years)	Cycle	n	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	2 (2009-2011)	6299	100 (100 - 110)	35 (33 - 38)	110 (110 - 120)	240 (230 - 260)	280 (270 - 300)
Males	3-79	2 (2009-2011)	3031	120 (120 - 130)	47 (42 - 53)	130 (120 - 150)	260 (240 - 280)	310 (280 - 340)
Females	3-79	2 (2009-2011)	3268	89 (85 - 94)	30 (27 - 32)	100 (96 - 100)	200 (180 - 230)	250 (240 - 270)
Total	3-5	2 (2009-2011)	572	59 (55 - 63)	26 (24 - 29)	61 (55 - 67)	110 (110 - 120)	140 (110 - 160)
Total	6-11	2 (2009-2011)	1059	88 (83 - 94)	37 (33 - 42)	98 (94 - 100)	170 (160 - 170)	190 (170 - 210)
Total	12-19	2 (2009-2011)	1042	130 (120 - 150)	52 (36 - 68)	150 (140 - 160)	270 (260 - 280)	300 (270 - 340)
Total	20-39	2 (2009-2011)	1322	120 (110 - 130)	37 (25 - 48)	140 (130 - 160)	260 (250 - 280)	330 (270 - 380)
Total	40-59	2 (2009-2011)	1223	100 (96 - 110)	33 (27 - 40)	110 (100 - 120)	240 (220 - 260)	280 (260 - 310)
Total	60-79	2 (2009-2011)	1081	85 (80 - 89)	32 (26 - 37)	96 (90 - 100)	180 (170 - 200)	230 (210 - 260)

Creatinine - Geometric means and selected percentiles of urine concentrations (mg/dL) for the Canadian population aged 3-79 years by age group, Canadian Health Measures Survey cycle 3 (2012-2013).

Group	Age (years)	Cycle	n	GM (95% CI)	10th (95% CI)	50th (95% CI)	90th (95% CI)	95th (95% CI)
Total	3-79	3 (2012-2013)	5704	97 (93 - 100)	33 (29 - 37)	100 (100 - 110)	240 (220 - 250)	280 (250 - 300)
Males	3-79	3 (2012-2013)	2847	110 (110 - 120)	40 (35 - 46)	120 (110 - 130)	260 (230 - 280)	300 (260 - 340)
Females	3-79	3 (2012-2013)	2857	83 (76 - 90)	26 (21 - 30)	93 (81 - 110)	210 (190 - 240)	250 (220 - 270)
Total	3-5	3 (2012-2013)	521	51 (45 - 58)	19 (14 - 24)	58 (51 - 65)	110 (99 - 110)	120 (110 - 120)
Total	6-11	3 (2012-2013)	1013	84 (77 - 92)	35 (28 - 42)	93 (82 - 100)	160 (150 - 180)	200 (170 - 230)
Total	12-19	3 (2012-2013)	998	130 (120 - 150)	52 (37 - 66)	150 (140 - 160)	280 (260 - 300)	320 (290 - 360)
Total	20-39	3 (2012-2013)	1048	110 (98 - 120)	36 (26 - 45)	110 (97 - 130)	270 (220 - 320)	330 (290 - 380)
Total	40-59	3 (2012-2013)	1080	95 (86 - 110)	34 (24 - 44)	110 (98 - 110)	220 (200 - 250)	250 (230 - 280)
Total	60-79	3 (2012-2013)	1044	84 (76 - 91)	26 (19 - 32)	96 (89 - 100)	190 (170 - 210)	230 (210 - 240)